Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
Chromosomale, Spontanaborten, Paraffin - eingebetteten, Gewebe, Aborte, Metaphasen, Zentromer - spezifischen, DNA - Sonden, Chromosomen, Kernsuspensionen, Chromosomenaberrationen, Kernsuspensionen, Paraffin - eingebettetem, Abortmaterial, genetischen Beratung, Eltern
DerPathologe.80190120.ger.abstr_task2
Sentence: Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant .
[ "Chromosomale", "Aberrationen", "sind", "eine", "wichtige", "Ursache", "von", "Spontanaborten", ".", "Zum", "Nachweis", "genetischer", "Stoerungen", "im", "Paraffin", "-", "eingebetteten", "Gewebe", "wurden", "26", "Aborte", "mit", "bekanntem", "zytogenetischem", "Befund", "an", "Metaphasen", "(", "konventionelle", "Zytogenetik", "/", "KZG", ";", "25", "numerische", "und", "eine", "strukturelle", "Aberration", ")", "retrospektiv", "mit", "der", "sog", ".", "Interphasezytogenetik", "(", "IZG", ")", "mit", "Zentromer", "-", "spezifischen", "DNA", "-", "Sonden", "(", "fuer", "#", "X", ",", "#", "Y", ",", "#", "10", "#", "18", "und", "#", "13/#21", ")", ",", "analysiert", ".", "Durch", "Zuordnung", "der", "IZG", "-", "Signalverteilungen", "(", "Chromosomen", "#", "X", ",", "#", "Y", "und", "#", "18", ")", "zu", "den", "KZG", "-", "Befunden", "wurden", "Grenzwerte", "fuer", "die", "IZG", "-", "Diagnose", "von", "Aneusomien", "ermittelt", "(", "fuer", "Zugewinn", ">", "=", "15", "%", "Kerne", "mit", "+1", "Signal", ";", "fuer", "Deletion", ">", "=", "40", "%", "der", "Kerne", "mit", "-1", "Signal", ")", ".", "Die", "Ergebnisse", "in", "Schnittpraeparaten", "(", "6", "µm", "dick", ")", "und", "parallel", "untersuchten", "Kernsuspensionen", "korrelierten", "statistisch", "hoch", "signifikant", "(", "p", "0,0001", ")", ".", "KZG-", "und", "IZG", "-", "Diagnosen", "stimmten", "in", "18", "von", "20", "auswertbaren", "Faellen", "ueberein", "(", "90", "%", ";", "kein", "falsch", "-", "positiver", "Befund", ")", ".", "Korrelationen", "zwischen", "zytogenetischen", "und", "histomorphologischen", "Befunden", "fanden", "sich", "nicht", ".", "Mit", "der", "IZG", "lassen", "sich", "numerische", "Chromosomenaberrationen", "an", "Schnitten", "und", "Kernsuspensionen", "von", "Paraffin", "-", "eingebettetem", "Abortmaterial", "zuverlaessig", "nachweisen", ",", "was", "die", "Moeglichkeit", "zur", "genetischen", "Beratung", "der", "Eltern", "eroeffnet", ".", "Die", "ermittelten", "Grenzwerte", "fuer", "den", "Nachweis", "von", "Aneusomien", "sind", "auch", "fuer", "tumorzytogenetische", "Untersuchungen", "mit", "der", "IZG", "-", "Technik", "relevant", "." ]
[ "umlsterm" ]
narrative ability is a Outcome_Mental, autism spectrum disorder : is a Participant_Condition, Autism is a Participant_Condition, computational linguistic tool is a Intervention_Educational, Latent Semantic Analysis ( LSA ) is a Intervention_Educational, high - functioning is a Participant_Condition, narratives is a Outcome_Mental, narrative ability . is a Outcome_Mental
65994_task0
Sentence: Quantifying narrative ability in autism spectrum disorder : a computational linguistic analysis of narrative coherence . Autism is a neurodevelopmental disorder characterized by serious difficulties with the social use of language , along with impaired social functioning and ritualistic/repetitive behaviors ( American Psychiatric Association in Diagnostic and statistical manual of mental disorders : DSM-5 , 5th edn . American Psychiatric Association , Arlington , 2013 ) . While substantial heterogeneity exists in symptom expression , impairments in language discourse skills , including narrative ( or storytelling ) , are universally observed in autism ( Tager-Flusberg et al . in Handbook on autism and pervasive developmental disorders , 3rd edn . Wiley , New York , pp 335-364 , 2005 ) . This study applied a computational linguistic tool , Latent Semantic Analysis ( LSA ) , to objectively characterize narrative performance in high-functioning individuals with autism and typically-developing controls , across two different narrative contexts that differ in the interpersonal and cognitive demands placed on the narrator . Results indicated that high-functioning individuals with autism produced narratives comparable in semantic content to those produced by controls when narrating from a picture book , but produced narratives diminished in semantic quality in a more demanding narrative recall task . This pattern is similar to that detected from analyses of hand-coded picture book narratives in prior research , and extends findings to an additional narrative context that proves particularly challenging for individuals with autism . Results are discussed in terms of the utility of LSA as a quantitative , objective , and efficient measure of narrative ability . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Participant_Condition, Outcome_Mental
[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental" ]
Quantifying narrative ability in autism spectrum disorder : a computational linguistic analysis of narrative coherence . Autism is a neurodevelopmental disorder characterized by serious difficulties with the social use of language , along with impaired social functioning and ritualistic/repetitive behaviors ( American Psychiatric Association in Diagnostic and statistical manual of mental disorders : DSM-5 , 5th edn . American Psychiatric Association , Arlington , 2013 ) . While substantial heterogeneity exists in symptom expression , impairments in language discourse skills , including narrative ( or storytelling ) , are universally observed in autism ( Tager-Flusberg et al . in Handbook on autism and pervasive developmental disorders , 3rd edn . Wiley , New York , pp 335-364 , 2005 ) . This study applied a computational linguistic tool , Latent Semantic Analysis ( LSA ) , to objectively characterize narrative performance in high-functioning individuals with autism and typically-developing controls , across two different narrative contexts that differ in the interpersonal and cognitive demands placed on the narrator . Results indicated that high-functioning individuals with autism produced narratives comparable in semantic content to those produced by controls when narrating from a picture book , but produced narratives diminished in semantic quality in a more demanding narrative recall task . This pattern is similar to that detected from analyses of hand-coded picture book narratives in prior research , and extends findings to an additional narrative context that proves particularly challenging for individuals with autism . Results are discussed in terms of the utility of LSA as a quantitative , objective , and efficient measure of narrative ability .
[ "Quantifying", "narrative", "ability", "in", "autism", "spectrum", "disorder", ":", "a", "computational", "linguistic", "analysis", "of", "narrative", "coherence", ".", "Autism", "is", "a", "neurodevelopmental", "disorder", "characterized", "by", "serious", "difficulties", "with", "the", "social", "use", "of", "language", ",", "along", "with", "impaired", "social", "functioning", "and", "ritualistic", "/", "repetitive", "behaviors", "(", "American", "Psychiatric", "Association", "in", "Diagnostic", "and", "statistical", "manual", "of", "mental", "disorders", ":", "DSM-5", ",", "5th", "edn", ".", "American", "Psychiatric", "Association", ",", "Arlington", ",", "2013", ")", ".", "While", "substantial", "heterogeneity", "exists", "in", "symptom", "expression", ",", "impairments", "in", "language", "discourse", "skills", ",", "including", "narrative", "(", "or", "storytelling", ")", ",", "are", "universally", "observed", "in", "autism", "(", "Tager", "-", "Flusberg", "et", "al", ".", "in", "Handbook", "on", "autism", "and", "pervasive", "developmental", "disorders", ",", "3rd", "edn", ".", "Wiley", ",", "New", "York", ",", "pp", "335", "-", "364", ",", "2005", ")", ".", "This", "study", "applied", "a", "computational", "linguistic", "tool", ",", "Latent", "Semantic", "Analysis", "(", "LSA", ")", ",", "to", "objectively", "characterize", "narrative", "performance", "in", "high", "-", "functioning", "individuals", "with", "autism", "and", "typically", "-", "developing", "controls", ",", "across", "two", "different", "narrative", "contexts", "that", "differ", "in", "the", "interpersonal", "and", "cognitive", "demands", "placed", "on", "the", "narrator", ".", "Results", "indicated", "that", "high", "-", "functioning", "individuals", "with", "autism", "produced", "narratives", "comparable", "in", "semantic", "content", "to", "those", "produced", "by", "controls", "when", "narrating", "from", "a", "picture", "book", ",", "but", "produced", "narratives", "diminished", "in", "semantic", "quality", "in", "a", "more", "demanding", "narrative", "recall", "task", ".", "This", "pattern", "is", "similar", "to", "that", "detected", "from", "analyses", "of", "hand", "-", "coded", "picture", "book", "narratives", "in", "prior", "research", ",", "and", "extends", "findings", "to", "an", "additional", "narrative", "context", "that", "proves", "particularly", "challenging", "for", "individuals", "with", "autism", ".", "Results", "are", "discussed", "in", "terms", "of", "the", "utility", "of", "LSA", "as", "a", "quantitative", ",", "objective", ",", "and", "efficient", "measure", "of", "narrative", "ability", "." ]
[ "Intervention_Educational", "Participant_Condition", "Outcome_Mental" ]
narrative ability is a Outcome_Mental, autism spectrum disorder : is a Participant_Condition, Autism is a Participant_Condition, computational linguistic tool is a Intervention_Educational, Latent Semantic Analysis ( LSA ) is a Intervention_Educational, high - functioning is a Participant_Condition, narratives is a Outcome_Mental, narrative ability . is a Outcome_Mental
65994_task1
Sentence: Quantifying narrative ability in autism spectrum disorder : a computational linguistic analysis of narrative coherence . Autism is a neurodevelopmental disorder characterized by serious difficulties with the social use of language , along with impaired social functioning and ritualistic/repetitive behaviors ( American Psychiatric Association in Diagnostic and statistical manual of mental disorders : DSM-5 , 5th edn . American Psychiatric Association , Arlington , 2013 ) . While substantial heterogeneity exists in symptom expression , impairments in language discourse skills , including narrative ( or storytelling ) , are universally observed in autism ( Tager-Flusberg et al . in Handbook on autism and pervasive developmental disorders , 3rd edn . Wiley , New York , pp 335-364 , 2005 ) . This study applied a computational linguistic tool , Latent Semantic Analysis ( LSA ) , to objectively characterize narrative performance in high-functioning individuals with autism and typically-developing controls , across two different narrative contexts that differ in the interpersonal and cognitive demands placed on the narrator . Results indicated that high-functioning individuals with autism produced narratives comparable in semantic content to those produced by controls when narrating from a picture book , but produced narratives diminished in semantic quality in a more demanding narrative recall task . This pattern is similar to that detected from analyses of hand-coded picture book narratives in prior research , and extends findings to an additional narrative context that proves particularly challenging for individuals with autism . Results are discussed in terms of the utility of LSA as a quantitative , objective , and efficient measure of narrative ability . Instructions: please typing these entity words according to sentence: narrative ability, autism spectrum disorder :, Autism, computational linguistic tool, Latent Semantic Analysis ( LSA ), high - functioning, narratives, narrative ability . Options: Intervention_Educational, Participant_Condition, Outcome_Mental
[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental" ]
Quantifying narrative ability in autism spectrum disorder : a computational linguistic analysis of narrative coherence . Autism is a neurodevelopmental disorder characterized by serious difficulties with the social use of language , along with impaired social functioning and ritualistic/repetitive behaviors ( American Psychiatric Association in Diagnostic and statistical manual of mental disorders : DSM-5 , 5th edn . American Psychiatric Association , Arlington , 2013 ) . While substantial heterogeneity exists in symptom expression , impairments in language discourse skills , including narrative ( or storytelling ) , are universally observed in autism ( Tager-Flusberg et al . in Handbook on autism and pervasive developmental disorders , 3rd edn . Wiley , New York , pp 335-364 , 2005 ) . This study applied a computational linguistic tool , Latent Semantic Analysis ( LSA ) , to objectively characterize narrative performance in high-functioning individuals with autism and typically-developing controls , across two different narrative contexts that differ in the interpersonal and cognitive demands placed on the narrator . Results indicated that high-functioning individuals with autism produced narratives comparable in semantic content to those produced by controls when narrating from a picture book , but produced narratives diminished in semantic quality in a more demanding narrative recall task . This pattern is similar to that detected from analyses of hand-coded picture book narratives in prior research , and extends findings to an additional narrative context that proves particularly challenging for individuals with autism . Results are discussed in terms of the utility of LSA as a quantitative , objective , and efficient measure of narrative ability .
[ "Quantifying", "narrative", "ability", "in", "autism", "spectrum", "disorder", ":", "a", "computational", "linguistic", "analysis", "of", "narrative", "coherence", ".", "Autism", "is", "a", "neurodevelopmental", "disorder", "characterized", "by", "serious", "difficulties", "with", "the", "social", "use", "of", "language", ",", "along", "with", "impaired", "social", "functioning", "and", "ritualistic", "/", "repetitive", "behaviors", "(", "American", "Psychiatric", "Association", "in", "Diagnostic", "and", "statistical", "manual", "of", "mental", "disorders", ":", "DSM-5", ",", "5th", "edn", ".", "American", "Psychiatric", "Association", ",", "Arlington", ",", "2013", ")", ".", "While", "substantial", "heterogeneity", "exists", "in", "symptom", "expression", ",", "impairments", "in", "language", "discourse", "skills", ",", "including", "narrative", "(", "or", "storytelling", ")", ",", "are", "universally", "observed", "in", "autism", "(", "Tager", "-", "Flusberg", "et", "al", ".", "in", "Handbook", "on", "autism", "and", "pervasive", "developmental", "disorders", ",", "3rd", "edn", ".", "Wiley", ",", "New", "York", ",", "pp", "335", "-", "364", ",", "2005", ")", ".", "This", "study", "applied", "a", "computational", "linguistic", "tool", ",", "Latent", "Semantic", "Analysis", "(", "LSA", ")", ",", "to", "objectively", "characterize", "narrative", "performance", "in", "high", "-", "functioning", "individuals", "with", "autism", "and", "typically", "-", "developing", "controls", ",", "across", "two", "different", "narrative", "contexts", "that", "differ", "in", "the", "interpersonal", "and", "cognitive", "demands", "placed", "on", "the", "narrator", ".", "Results", "indicated", "that", "high", "-", "functioning", "individuals", "with", "autism", "produced", "narratives", "comparable", "in", "semantic", "content", "to", "those", "produced", "by", "controls", "when", "narrating", "from", "a", "picture", "book", ",", "but", "produced", "narratives", "diminished", "in", "semantic", "quality", "in", "a", "more", "demanding", "narrative", "recall", "task", ".", "This", "pattern", "is", "similar", "to", "that", "detected", "from", "analyses", "of", "hand", "-", "coded", "picture", "book", "narratives", "in", "prior", "research", ",", "and", "extends", "findings", "to", "an", "additional", "narrative", "context", "that", "proves", "particularly", "challenging", "for", "individuals", "with", "autism", ".", "Results", "are", "discussed", "in", "terms", "of", "the", "utility", "of", "LSA", "as", "a", "quantitative", ",", "objective", ",", "and", "efficient", "measure", "of", "narrative", "ability", "." ]
[ "Intervention_Educational", "Participant_Condition", "Outcome_Mental" ]
narrative ability, autism spectrum disorder :, Autism, computational linguistic tool, Latent Semantic Analysis ( LSA ), high - functioning, narratives, narrative ability .
65994_task2
Sentence: Quantifying narrative ability in autism spectrum disorder : a computational linguistic analysis of narrative coherence . Autism is a neurodevelopmental disorder characterized by serious difficulties with the social use of language , along with impaired social functioning and ritualistic/repetitive behaviors ( American Psychiatric Association in Diagnostic and statistical manual of mental disorders : DSM-5 , 5th edn . American Psychiatric Association , Arlington , 2013 ) . While substantial heterogeneity exists in symptom expression , impairments in language discourse skills , including narrative ( or storytelling ) , are universally observed in autism ( Tager-Flusberg et al . in Handbook on autism and pervasive developmental disorders , 3rd edn . Wiley , New York , pp 335-364 , 2005 ) . This study applied a computational linguistic tool , Latent Semantic Analysis ( LSA ) , to objectively characterize narrative performance in high-functioning individuals with autism and typically-developing controls , across two different narrative contexts that differ in the interpersonal and cognitive demands placed on the narrator . Results indicated that high-functioning individuals with autism produced narratives comparable in semantic content to those produced by controls when narrating from a picture book , but produced narratives diminished in semantic quality in a more demanding narrative recall task . This pattern is similar to that detected from analyses of hand-coded picture book narratives in prior research , and extends findings to an additional narrative context that proves particularly challenging for individuals with autism . Results are discussed in terms of the utility of LSA as a quantitative , objective , and efficient measure of narrative ability . Instructions: please extract entity words from the input sentence
[ "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental" ]
Quantifying narrative ability in autism spectrum disorder : a computational linguistic analysis of narrative coherence . Autism is a neurodevelopmental disorder characterized by serious difficulties with the social use of language , along with impaired social functioning and ritualistic/repetitive behaviors ( American Psychiatric Association in Diagnostic and statistical manual of mental disorders : DSM-5 , 5th edn . American Psychiatric Association , Arlington , 2013 ) . While substantial heterogeneity exists in symptom expression , impairments in language discourse skills , including narrative ( or storytelling ) , are universally observed in autism ( Tager-Flusberg et al . in Handbook on autism and pervasive developmental disorders , 3rd edn . Wiley , New York , pp 335-364 , 2005 ) . This study applied a computational linguistic tool , Latent Semantic Analysis ( LSA ) , to objectively characterize narrative performance in high-functioning individuals with autism and typically-developing controls , across two different narrative contexts that differ in the interpersonal and cognitive demands placed on the narrator . Results indicated that high-functioning individuals with autism produced narratives comparable in semantic content to those produced by controls when narrating from a picture book , but produced narratives diminished in semantic quality in a more demanding narrative recall task . This pattern is similar to that detected from analyses of hand-coded picture book narratives in prior research , and extends findings to an additional narrative context that proves particularly challenging for individuals with autism . Results are discussed in terms of the utility of LSA as a quantitative , objective , and efficient measure of narrative ability .
[ "Quantifying", "narrative", "ability", "in", "autism", "spectrum", "disorder", ":", "a", "computational", "linguistic", "analysis", "of", "narrative", "coherence", ".", "Autism", "is", "a", "neurodevelopmental", "disorder", "characterized", "by", "serious", "difficulties", "with", "the", "social", "use", "of", "language", ",", "along", "with", "impaired", "social", "functioning", "and", "ritualistic", "/", "repetitive", "behaviors", "(", "American", "Psychiatric", "Association", "in", "Diagnostic", "and", "statistical", "manual", "of", "mental", "disorders", ":", "DSM-5", ",", "5th", "edn", ".", "American", "Psychiatric", "Association", ",", "Arlington", ",", "2013", ")", ".", "While", "substantial", "heterogeneity", "exists", "in", "symptom", "expression", ",", "impairments", "in", "language", "discourse", "skills", ",", "including", "narrative", "(", "or", "storytelling", ")", ",", "are", "universally", "observed", "in", "autism", "(", "Tager", "-", "Flusberg", "et", "al", ".", "in", "Handbook", "on", "autism", "and", "pervasive", "developmental", "disorders", ",", "3rd", "edn", ".", "Wiley", ",", "New", "York", ",", "pp", "335", "-", "364", ",", "2005", ")", ".", "This", "study", "applied", "a", "computational", "linguistic", "tool", ",", "Latent", "Semantic", "Analysis", "(", "LSA", ")", ",", "to", "objectively", "characterize", "narrative", "performance", "in", "high", "-", "functioning", "individuals", "with", "autism", "and", "typically", "-", "developing", "controls", ",", "across", "two", "different", "narrative", "contexts", "that", "differ", "in", "the", "interpersonal", "and", "cognitive", "demands", "placed", "on", "the", "narrator", ".", "Results", "indicated", "that", "high", "-", "functioning", "individuals", "with", "autism", "produced", "narratives", "comparable", "in", "semantic", "content", "to", "those", "produced", "by", "controls", "when", "narrating", "from", "a", "picture", "book", ",", "but", "produced", "narratives", "diminished", "in", "semantic", "quality", "in", "a", "more", "demanding", "narrative", "recall", "task", ".", "This", "pattern", "is", "similar", "to", "that", "detected", "from", "analyses", "of", "hand", "-", "coded", "picture", "book", "narratives", "in", "prior", "research", ",", "and", "extends", "findings", "to", "an", "additional", "narrative", "context", "that", "proves", "particularly", "challenging", "for", "individuals", "with", "autism", ".", "Results", "are", "discussed", "in", "terms", "of", "the", "utility", "of", "LSA", "as", "a", "quantitative", ",", "objective", ",", "and", "efficient", "measure", "of", "narrative", "ability", "." ]
[ "Intervention_Educational", "Participant_Condition", "Outcome_Mental" ]
standard is an umlsterm, treatment is an umlsterm, myocardial infarction is an umlsterm, time is an umlsterm, mortality is an umlsterm, therapy is an umlsterm, symptoms is an umlsterm, time is an umlsterm, time is an umlsterm, diagnosis is an umlsterm, myocardial infarction is an umlsterm, therapy is an umlsterm, risk is an umlsterm, patients is an umlsterm, symptoms is an umlsterm, time is an umlsterm, PTCA is an umlsterm, time is an umlsterm
IntensiveMedizin.00370053.eng.abstr_task0
Sentence: Intravenous thrombolysis has become a standard in treatment of acute myocardial infarction . Efficacy of thrombolysis is strictly time dependent . It has been shown in several studies that the most benefit in terms of myocardial salvage and short- and long-term mortality is achieved with initiation of therapy within the first 60-90 minutes after onset of symptoms . Nearly exlusively , prehospital initiation of thrombolysis makes it possible to take advantage of this early time window . Moreover , randomized studies yielded a better outcome when a time gain of > =90 minutes was achieved . Since it has been shown that prehospital diagnosis of an acute myocardial infarction is reliable and out-of-hospital initiation of therapy has no additional specific risk , patients seen within the first 60-90 minutes after onset of symptoms or for whom a relevant time gain > =90 minutes can be expected are ideal candidates for , and therefore should receive , prehospital thrombolysis . In places where acute intervention ( e.g. , PTCA ) is available , protocols should be developed which take the specific time windows into consideration . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Intravenous thrombolysis has become a standard in treatment of acute myocardial infarction . Efficacy of thrombolysis is strictly time dependent . It has been shown in several studies that the most benefit in terms of myocardial salvage and short- and long-term mortality is achieved with initiation of therapy within the first 60-90 minutes after onset of symptoms . Nearly exlusively , prehospital initiation of thrombolysis makes it possible to take advantage of this early time window . Moreover , randomized studies yielded a better outcome when a time gain of > =90 minutes was achieved . Since it has been shown that prehospital diagnosis of an acute myocardial infarction is reliable and out-of-hospital initiation of therapy has no additional specific risk , patients seen within the first 60-90 minutes after onset of symptoms or for whom a relevant time gain > =90 minutes can be expected are ideal candidates for , and therefore should receive , prehospital thrombolysis . In places where acute intervention ( e.g. , PTCA ) is available , protocols should be developed which take the specific time windows into consideration .
[ "Intravenous", "thrombolysis", "has", "become", "a", "standard", "in", "treatment", "of", "acute", "myocardial", "infarction", ".", "Efficacy", "of", "thrombolysis", "is", "strictly", "time", "dependent", ".", "It", "has", "been", "shown", "in", "several", "studies", "that", "the", "most", "benefit", "in", "terms", "of", "myocardial", "salvage", "and", "short-", "and", "long", "-", "term", "mortality", "is", "achieved", "with", "initiation", "of", "therapy", "within", "the", "first", "60", "-", "90", "minutes", "after", "onset", "of", "symptoms", ".", "Nearly", "exlusively", ",", "prehospital", "initiation", "of", "thrombolysis", "makes", "it", "possible", "to", "take", "advantage", "of", "this", "early", "time", "window", ".", "Moreover", ",", "randomized", "studies", "yielded", "a", "better", "outcome", "when", "a", "time", "gain", "of", ">", "=", "90", "minutes", "was", "achieved", ".", "Since", "it", "has", "been", "shown", "that", "prehospital", "diagnosis", "of", "an", "acute", "myocardial", "infarction", "is", "reliable", "and", "out", "-", "of", "-", "hospital", "initiation", "of", "therapy", "has", "no", "additional", "specific", "risk", ",", "patients", "seen", "within", "the", "first", "60", "-", "90", "minutes", "after", "onset", "of", "symptoms", "or", "for", "whom", "a", "relevant", "time", "gain", ">", "=", "90", "minutes", "can", "be", "expected", "are", "ideal", "candidates", "for", ",", "and", "therefore", "should", "receive", ",", "prehospital", "thrombolysis", ".", "In", "places", "where", "acute", "intervention", "(", "e.g", ".", ",", "PTCA", ")", "is", "available", ",", "protocols", "should", "be", "developed", "which", "take", "the", "specific", "time", "windows", "into", "consideration", "." ]
[ "umlsterm" ]
standard is an umlsterm, treatment is an umlsterm, myocardial infarction is an umlsterm, time is an umlsterm, mortality is an umlsterm, therapy is an umlsterm, symptoms is an umlsterm, time is an umlsterm, time is an umlsterm, diagnosis is an umlsterm, myocardial infarction is an umlsterm, therapy is an umlsterm, risk is an umlsterm, patients is an umlsterm, symptoms is an umlsterm, time is an umlsterm, PTCA is an umlsterm, time is an umlsterm
IntensiveMedizin.00370053.eng.abstr_task1
Sentence: Intravenous thrombolysis has become a standard in treatment of acute myocardial infarction . Efficacy of thrombolysis is strictly time dependent . It has been shown in several studies that the most benefit in terms of myocardial salvage and short- and long-term mortality is achieved with initiation of therapy within the first 60-90 minutes after onset of symptoms . Nearly exlusively , prehospital initiation of thrombolysis makes it possible to take advantage of this early time window . Moreover , randomized studies yielded a better outcome when a time gain of > =90 minutes was achieved . Since it has been shown that prehospital diagnosis of an acute myocardial infarction is reliable and out-of-hospital initiation of therapy has no additional specific risk , patients seen within the first 60-90 minutes after onset of symptoms or for whom a relevant time gain > =90 minutes can be expected are ideal candidates for , and therefore should receive , prehospital thrombolysis . In places where acute intervention ( e.g. , PTCA ) is available , protocols should be developed which take the specific time windows into consideration . Instructions: please typing these entity words according to sentence: standard, treatment, myocardial infarction, time, mortality, therapy, symptoms, time, time, diagnosis, myocardial infarction, therapy, risk, patients, symptoms, time, PTCA, time Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Intravenous thrombolysis has become a standard in treatment of acute myocardial infarction . Efficacy of thrombolysis is strictly time dependent . It has been shown in several studies that the most benefit in terms of myocardial salvage and short- and long-term mortality is achieved with initiation of therapy within the first 60-90 minutes after onset of symptoms . Nearly exlusively , prehospital initiation of thrombolysis makes it possible to take advantage of this early time window . Moreover , randomized studies yielded a better outcome when a time gain of > =90 minutes was achieved . Since it has been shown that prehospital diagnosis of an acute myocardial infarction is reliable and out-of-hospital initiation of therapy has no additional specific risk , patients seen within the first 60-90 minutes after onset of symptoms or for whom a relevant time gain > =90 minutes can be expected are ideal candidates for , and therefore should receive , prehospital thrombolysis . In places where acute intervention ( e.g. , PTCA ) is available , protocols should be developed which take the specific time windows into consideration .
[ "Intravenous", "thrombolysis", "has", "become", "a", "standard", "in", "treatment", "of", "acute", "myocardial", "infarction", ".", "Efficacy", "of", "thrombolysis", "is", "strictly", "time", "dependent", ".", "It", "has", "been", "shown", "in", "several", "studies", "that", "the", "most", "benefit", "in", "terms", "of", "myocardial", "salvage", "and", "short-", "and", "long", "-", "term", "mortality", "is", "achieved", "with", "initiation", "of", "therapy", "within", "the", "first", "60", "-", "90", "minutes", "after", "onset", "of", "symptoms", ".", "Nearly", "exlusively", ",", "prehospital", "initiation", "of", "thrombolysis", "makes", "it", "possible", "to", "take", "advantage", "of", "this", "early", "time", "window", ".", "Moreover", ",", "randomized", "studies", "yielded", "a", "better", "outcome", "when", "a", "time", "gain", "of", ">", "=", "90", "minutes", "was", "achieved", ".", "Since", "it", "has", "been", "shown", "that", "prehospital", "diagnosis", "of", "an", "acute", "myocardial", "infarction", "is", "reliable", "and", "out", "-", "of", "-", "hospital", "initiation", "of", "therapy", "has", "no", "additional", "specific", "risk", ",", "patients", "seen", "within", "the", "first", "60", "-", "90", "minutes", "after", "onset", "of", "symptoms", "or", "for", "whom", "a", "relevant", "time", "gain", ">", "=", "90", "minutes", "can", "be", "expected", "are", "ideal", "candidates", "for", ",", "and", "therefore", "should", "receive", ",", "prehospital", "thrombolysis", ".", "In", "places", "where", "acute", "intervention", "(", "e.g", ".", ",", "PTCA", ")", "is", "available", ",", "protocols", "should", "be", "developed", "which", "take", "the", "specific", "time", "windows", "into", "consideration", "." ]
[ "umlsterm" ]
standard, treatment, myocardial infarction, time, mortality, therapy, symptoms, time, time, diagnosis, myocardial infarction, therapy, risk, patients, symptoms, time, PTCA, time
IntensiveMedizin.00370053.eng.abstr_task2
Sentence: Intravenous thrombolysis has become a standard in treatment of acute myocardial infarction . Efficacy of thrombolysis is strictly time dependent . It has been shown in several studies that the most benefit in terms of myocardial salvage and short- and long-term mortality is achieved with initiation of therapy within the first 60-90 minutes after onset of symptoms . Nearly exlusively , prehospital initiation of thrombolysis makes it possible to take advantage of this early time window . Moreover , randomized studies yielded a better outcome when a time gain of > =90 minutes was achieved . Since it has been shown that prehospital diagnosis of an acute myocardial infarction is reliable and out-of-hospital initiation of therapy has no additional specific risk , patients seen within the first 60-90 minutes after onset of symptoms or for whom a relevant time gain > =90 minutes can be expected are ideal candidates for , and therefore should receive , prehospital thrombolysis . In places where acute intervention ( e.g. , PTCA ) is available , protocols should be developed which take the specific time windows into consideration . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Intravenous thrombolysis has become a standard in treatment of acute myocardial infarction . Efficacy of thrombolysis is strictly time dependent . It has been shown in several studies that the most benefit in terms of myocardial salvage and short- and long-term mortality is achieved with initiation of therapy within the first 60-90 minutes after onset of symptoms . Nearly exlusively , prehospital initiation of thrombolysis makes it possible to take advantage of this early time window . Moreover , randomized studies yielded a better outcome when a time gain of > =90 minutes was achieved . Since it has been shown that prehospital diagnosis of an acute myocardial infarction is reliable and out-of-hospital initiation of therapy has no additional specific risk , patients seen within the first 60-90 minutes after onset of symptoms or for whom a relevant time gain > =90 minutes can be expected are ideal candidates for , and therefore should receive , prehospital thrombolysis . In places where acute intervention ( e.g. , PTCA ) is available , protocols should be developed which take the specific time windows into consideration .
[ "Intravenous", "thrombolysis", "has", "become", "a", "standard", "in", "treatment", "of", "acute", "myocardial", "infarction", ".", "Efficacy", "of", "thrombolysis", "is", "strictly", "time", "dependent", ".", "It", "has", "been", "shown", "in", "several", "studies", "that", "the", "most", "benefit", "in", "terms", "of", "myocardial", "salvage", "and", "short-", "and", "long", "-", "term", "mortality", "is", "achieved", "with", "initiation", "of", "therapy", "within", "the", "first", "60", "-", "90", "minutes", "after", "onset", "of", "symptoms", ".", "Nearly", "exlusively", ",", "prehospital", "initiation", "of", "thrombolysis", "makes", "it", "possible", "to", "take", "advantage", "of", "this", "early", "time", "window", ".", "Moreover", ",", "randomized", "studies", "yielded", "a", "better", "outcome", "when", "a", "time", "gain", "of", ">", "=", "90", "minutes", "was", "achieved", ".", "Since", "it", "has", "been", "shown", "that", "prehospital", "diagnosis", "of", "an", "acute", "myocardial", "infarction", "is", "reliable", "and", "out", "-", "of", "-", "hospital", "initiation", "of", "therapy", "has", "no", "additional", "specific", "risk", ",", "patients", "seen", "within", "the", "first", "60", "-", "90", "minutes", "after", "onset", "of", "symptoms", "or", "for", "whom", "a", "relevant", "time", "gain", ">", "=", "90", "minutes", "can", "be", "expected", "are", "ideal", "candidates", "for", ",", "and", "therefore", "should", "receive", ",", "prehospital", "thrombolysis", ".", "In", "places", "where", "acute", "intervention", "(", "e.g", ".", ",", "PTCA", ")", "is", "available", ",", "protocols", "should", "be", "developed", "which", "take", "the", "specific", "time", "windows", "into", "consideration", "." ]
[ "umlsterm" ]
moderate to vigorous aerobic exercise is a Intervention_Physical, sleep need of sedentary young adults . is a Participant_Condition, Exercise is a Intervention_Physical, sedentary adults is a Participant_Condition
56953_task0
Sentence: The effects of moderate to vigorous aerobic exercise on the sleep need of sedentary young adults . Exercise has been recommended for enhancing sleep ; a claim linked to the belief that sleep need - defined by sleep duration and depth - is increased post-exercise to allow tissue recovery . Objective studies investigating exercise-sleep responses have produced mixed outcomes , and the disparity in results between studies may be due to differences in individual characteristics and/or exercise protocol , emphasising the importance of carefully controlled trials . We investigated the role of exercise on the sleep need of sedentary adults , after controlling for exercise mode , timing and duration . Twelve healthy volunteers ( 25.2 ± 4.0 years , 9 females , [ Vdot ] O ( 2 ) max 35.4 ± 8.8 ml· kg ( -1 ) · min ( -1 ) ) were randomised to no-exercise or to a bout of treadmill exercise at 45 % , 55 % , 65 % or 75 % [ Vdot ] O ( 2 ) max in a crossover design . Sleep on no-exercise and exercise nights were assessed by polysomnography . Participants spent a greater proportion of sleep in light sleep ( stage 1 + stage 2 ) after exercise at both 65 % and 75 % [ Vdot ] O ( 2 ) max ( P < 0.05 ) than the no-exercise condition . There was a trend of a reduced proportion of rapid eye movement sleep with increased exercise intensity ( P = 0.067 ) . No other changes were observed in any other sleep variables . Two findings emerged : vigorous exercise did not increase sleep need ; however , this level of exercise increased light sleep . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition
[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The effects of moderate to vigorous aerobic exercise on the sleep need of sedentary young adults . Exercise has been recommended for enhancing sleep ; a claim linked to the belief that sleep need - defined by sleep duration and depth - is increased post-exercise to allow tissue recovery . Objective studies investigating exercise-sleep responses have produced mixed outcomes , and the disparity in results between studies may be due to differences in individual characteristics and/or exercise protocol , emphasising the importance of carefully controlled trials . We investigated the role of exercise on the sleep need of sedentary adults , after controlling for exercise mode , timing and duration . Twelve healthy volunteers ( 25.2 ± 4.0 years , 9 females , [ Vdot ] O ( 2 ) max 35.4 ± 8.8 ml· kg ( -1 ) · min ( -1 ) ) were randomised to no-exercise or to a bout of treadmill exercise at 45 % , 55 % , 65 % or 75 % [ Vdot ] O ( 2 ) max in a crossover design . Sleep on no-exercise and exercise nights were assessed by polysomnography . Participants spent a greater proportion of sleep in light sleep ( stage 1 + stage 2 ) after exercise at both 65 % and 75 % [ Vdot ] O ( 2 ) max ( P < 0.05 ) than the no-exercise condition . There was a trend of a reduced proportion of rapid eye movement sleep with increased exercise intensity ( P = 0.067 ) . No other changes were observed in any other sleep variables . Two findings emerged : vigorous exercise did not increase sleep need ; however , this level of exercise increased light sleep .
[ "The", "effects", "of", "moderate", "to", "vigorous", "aerobic", "exercise", "on", "the", "sleep", "need", "of", "sedentary", "young", "adults", ".", "Exercise", "has", "been", "recommended", "for", "enhancing", "sleep", ";", "a", "claim", "linked", "to", "the", "belief", "that", "sleep", "need", "-", "defined", "by", "sleep", "duration", "and", "depth", "-", "is", "increased", "post", "-", "exercise", "to", "allow", "tissue", "recovery", ".", "Objective", "studies", "investigating", "exercise", "-", "sleep", "responses", "have", "produced", "mixed", "outcomes", ",", "and", "the", "disparity", "in", "results", "between", "studies", "may", "be", "due", "to", "differences", "in", "individual", "characteristics", "and", "/", "or", "exercise", "protocol", ",", "emphasising", "the", "importance", "of", "carefully", "controlled", "trials", ".", "We", "investigated", "the", "role", "of", "exercise", "on", "the", "sleep", "need", "of", "sedentary", "adults", ",", "after", "controlling", "for", "exercise", "mode", ",", "timing", "and", "duration", ".", "Twelve", "healthy", "volunteers", "(", "25.2", "±", "4.0", "years", ",", "9", "females", ",", "[", "Vdot", "]", "O", "(", "2", ")", "max", "35.4", "±", "8.8", "ml", "·", "kg", "(", "-1", ")", "·", "min", "(", "-1", ")", ")", "were", "randomised", "to", "no", "-", "exercise", "or", "to", "a", "bout", "of", "treadmill", "exercise", "at", "45", "%", ",", "55", "%", ",", "65", "%", "or", "75", "%", "[", "Vdot", "]", "O", "(", "2", ")", "max", "in", "a", "crossover", "design", ".", "Sleep", "on", "no", "-", "exercise", "and", "exercise", "nights", "were", "assessed", "by", "polysomnography", ".", "Participants", "spent", "a", "greater", "proportion", "of", "sleep", "in", "light", "sleep", "(", "stage", "1", "+", "stage", "2", ")", "after", "exercise", "at", "both", "65", "%", "and", "75", "%", "[", "Vdot", "]", "O", "(", "2", ")", "max", "(", "P", "<", "0.05", ")", "than", "the", "no", "-", "exercise", "condition", ".", "There", "was", "a", "trend", "of", "a", "reduced", "proportion", "of", "rapid", "eye", "movement", "sleep", "with", "increased", "exercise", "intensity", "(", "P", "=", "0.067", ")", ".", "No", "other", "changes", "were", "observed", "in", "any", "other", "sleep", "variables", ".", "Two", "findings", "emerged", ":", "vigorous", "exercise", "did", "not", "increase", "sleep", "need", ";", "however", ",", "this", "level", "of", "exercise", "increased", "light", "sleep", "." ]
[ "Participant_Condition", "Intervention_Physical" ]
moderate to vigorous aerobic exercise is a Intervention_Physical, sleep need of sedentary young adults . is a Participant_Condition, Exercise is a Intervention_Physical, sedentary adults is a Participant_Condition
56953_task1
Sentence: The effects of moderate to vigorous aerobic exercise on the sleep need of sedentary young adults . Exercise has been recommended for enhancing sleep ; a claim linked to the belief that sleep need - defined by sleep duration and depth - is increased post-exercise to allow tissue recovery . Objective studies investigating exercise-sleep responses have produced mixed outcomes , and the disparity in results between studies may be due to differences in individual characteristics and/or exercise protocol , emphasising the importance of carefully controlled trials . We investigated the role of exercise on the sleep need of sedentary adults , after controlling for exercise mode , timing and duration . Twelve healthy volunteers ( 25.2 ± 4.0 years , 9 females , [ Vdot ] O ( 2 ) max 35.4 ± 8.8 ml· kg ( -1 ) · min ( -1 ) ) were randomised to no-exercise or to a bout of treadmill exercise at 45 % , 55 % , 65 % or 75 % [ Vdot ] O ( 2 ) max in a crossover design . Sleep on no-exercise and exercise nights were assessed by polysomnography . Participants spent a greater proportion of sleep in light sleep ( stage 1 + stage 2 ) after exercise at both 65 % and 75 % [ Vdot ] O ( 2 ) max ( P < 0.05 ) than the no-exercise condition . There was a trend of a reduced proportion of rapid eye movement sleep with increased exercise intensity ( P = 0.067 ) . No other changes were observed in any other sleep variables . Two findings emerged : vigorous exercise did not increase sleep need ; however , this level of exercise increased light sleep . Instructions: please typing these entity words according to sentence: moderate to vigorous aerobic exercise, sleep need of sedentary young adults ., Exercise, sedentary adults Options: Intervention_Physical, Participant_Condition
[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The effects of moderate to vigorous aerobic exercise on the sleep need of sedentary young adults . Exercise has been recommended for enhancing sleep ; a claim linked to the belief that sleep need - defined by sleep duration and depth - is increased post-exercise to allow tissue recovery . Objective studies investigating exercise-sleep responses have produced mixed outcomes , and the disparity in results between studies may be due to differences in individual characteristics and/or exercise protocol , emphasising the importance of carefully controlled trials . We investigated the role of exercise on the sleep need of sedentary adults , after controlling for exercise mode , timing and duration . Twelve healthy volunteers ( 25.2 ± 4.0 years , 9 females , [ Vdot ] O ( 2 ) max 35.4 ± 8.8 ml· kg ( -1 ) · min ( -1 ) ) were randomised to no-exercise or to a bout of treadmill exercise at 45 % , 55 % , 65 % or 75 % [ Vdot ] O ( 2 ) max in a crossover design . Sleep on no-exercise and exercise nights were assessed by polysomnography . Participants spent a greater proportion of sleep in light sleep ( stage 1 + stage 2 ) after exercise at both 65 % and 75 % [ Vdot ] O ( 2 ) max ( P < 0.05 ) than the no-exercise condition . There was a trend of a reduced proportion of rapid eye movement sleep with increased exercise intensity ( P = 0.067 ) . No other changes were observed in any other sleep variables . Two findings emerged : vigorous exercise did not increase sleep need ; however , this level of exercise increased light sleep .
[ "The", "effects", "of", "moderate", "to", "vigorous", "aerobic", "exercise", "on", "the", "sleep", "need", "of", "sedentary", "young", "adults", ".", "Exercise", "has", "been", "recommended", "for", "enhancing", "sleep", ";", "a", "claim", "linked", "to", "the", "belief", "that", "sleep", "need", "-", "defined", "by", "sleep", "duration", "and", "depth", "-", "is", "increased", "post", "-", "exercise", "to", "allow", "tissue", "recovery", ".", "Objective", "studies", "investigating", "exercise", "-", "sleep", "responses", "have", "produced", "mixed", "outcomes", ",", "and", "the", "disparity", "in", "results", "between", "studies", "may", "be", "due", "to", "differences", "in", "individual", "characteristics", "and", "/", "or", "exercise", "protocol", ",", "emphasising", "the", "importance", "of", "carefully", "controlled", "trials", ".", "We", "investigated", "the", "role", "of", "exercise", "on", "the", "sleep", "need", "of", "sedentary", "adults", ",", "after", "controlling", "for", "exercise", "mode", ",", "timing", "and", "duration", ".", "Twelve", "healthy", "volunteers", "(", "25.2", "±", "4.0", "years", ",", "9", "females", ",", "[", "Vdot", "]", "O", "(", "2", ")", "max", "35.4", "±", "8.8", "ml", "·", "kg", "(", "-1", ")", "·", "min", "(", "-1", ")", ")", "were", "randomised", "to", "no", "-", "exercise", "or", "to", "a", "bout", "of", "treadmill", "exercise", "at", "45", "%", ",", "55", "%", ",", "65", "%", "or", "75", "%", "[", "Vdot", "]", "O", "(", "2", ")", "max", "in", "a", "crossover", "design", ".", "Sleep", "on", "no", "-", "exercise", "and", "exercise", "nights", "were", "assessed", "by", "polysomnography", ".", "Participants", "spent", "a", "greater", "proportion", "of", "sleep", "in", "light", "sleep", "(", "stage", "1", "+", "stage", "2", ")", "after", "exercise", "at", "both", "65", "%", "and", "75", "%", "[", "Vdot", "]", "O", "(", "2", ")", "max", "(", "P", "<", "0.05", ")", "than", "the", "no", "-", "exercise", "condition", ".", "There", "was", "a", "trend", "of", "a", "reduced", "proportion", "of", "rapid", "eye", "movement", "sleep", "with", "increased", "exercise", "intensity", "(", "P", "=", "0.067", ")", ".", "No", "other", "changes", "were", "observed", "in", "any", "other", "sleep", "variables", ".", "Two", "findings", "emerged", ":", "vigorous", "exercise", "did", "not", "increase", "sleep", "need", ";", "however", ",", "this", "level", "of", "exercise", "increased", "light", "sleep", "." ]
[ "Participant_Condition", "Intervention_Physical" ]
moderate to vigorous aerobic exercise, sleep need of sedentary young adults ., Exercise, sedentary adults
56953_task2
Sentence: The effects of moderate to vigorous aerobic exercise on the sleep need of sedentary young adults . Exercise has been recommended for enhancing sleep ; a claim linked to the belief that sleep need - defined by sleep duration and depth - is increased post-exercise to allow tissue recovery . Objective studies investigating exercise-sleep responses have produced mixed outcomes , and the disparity in results between studies may be due to differences in individual characteristics and/or exercise protocol , emphasising the importance of carefully controlled trials . We investigated the role of exercise on the sleep need of sedentary adults , after controlling for exercise mode , timing and duration . Twelve healthy volunteers ( 25.2 ± 4.0 years , 9 females , [ Vdot ] O ( 2 ) max 35.4 ± 8.8 ml· kg ( -1 ) · min ( -1 ) ) were randomised to no-exercise or to a bout of treadmill exercise at 45 % , 55 % , 65 % or 75 % [ Vdot ] O ( 2 ) max in a crossover design . Sleep on no-exercise and exercise nights were assessed by polysomnography . Participants spent a greater proportion of sleep in light sleep ( stage 1 + stage 2 ) after exercise at both 65 % and 75 % [ Vdot ] O ( 2 ) max ( P < 0.05 ) than the no-exercise condition . There was a trend of a reduced proportion of rapid eye movement sleep with increased exercise intensity ( P = 0.067 ) . No other changes were observed in any other sleep variables . Two findings emerged : vigorous exercise did not increase sleep need ; however , this level of exercise increased light sleep . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The effects of moderate to vigorous aerobic exercise on the sleep need of sedentary young adults . Exercise has been recommended for enhancing sleep ; a claim linked to the belief that sleep need - defined by sleep duration and depth - is increased post-exercise to allow tissue recovery . Objective studies investigating exercise-sleep responses have produced mixed outcomes , and the disparity in results between studies may be due to differences in individual characteristics and/or exercise protocol , emphasising the importance of carefully controlled trials . We investigated the role of exercise on the sleep need of sedentary adults , after controlling for exercise mode , timing and duration . Twelve healthy volunteers ( 25.2 ± 4.0 years , 9 females , [ Vdot ] O ( 2 ) max 35.4 ± 8.8 ml· kg ( -1 ) · min ( -1 ) ) were randomised to no-exercise or to a bout of treadmill exercise at 45 % , 55 % , 65 % or 75 % [ Vdot ] O ( 2 ) max in a crossover design . Sleep on no-exercise and exercise nights were assessed by polysomnography . Participants spent a greater proportion of sleep in light sleep ( stage 1 + stage 2 ) after exercise at both 65 % and 75 % [ Vdot ] O ( 2 ) max ( P < 0.05 ) than the no-exercise condition . There was a trend of a reduced proportion of rapid eye movement sleep with increased exercise intensity ( P = 0.067 ) . No other changes were observed in any other sleep variables . Two findings emerged : vigorous exercise did not increase sleep need ; however , this level of exercise increased light sleep .
[ "The", "effects", "of", "moderate", "to", "vigorous", "aerobic", "exercise", "on", "the", "sleep", "need", "of", "sedentary", "young", "adults", ".", "Exercise", "has", "been", "recommended", "for", "enhancing", "sleep", ";", "a", "claim", "linked", "to", "the", "belief", "that", "sleep", "need", "-", "defined", "by", "sleep", "duration", "and", "depth", "-", "is", "increased", "post", "-", "exercise", "to", "allow", "tissue", "recovery", ".", "Objective", "studies", "investigating", "exercise", "-", "sleep", "responses", "have", "produced", "mixed", "outcomes", ",", "and", "the", "disparity", "in", "results", "between", "studies", "may", "be", "due", "to", "differences", "in", "individual", "characteristics", "and", "/", "or", "exercise", "protocol", ",", "emphasising", "the", "importance", "of", "carefully", "controlled", "trials", ".", "We", "investigated", "the", "role", "of", "exercise", "on", "the", "sleep", "need", "of", "sedentary", "adults", ",", "after", "controlling", "for", "exercise", "mode", ",", "timing", "and", "duration", ".", "Twelve", "healthy", "volunteers", "(", "25.2", "±", "4.0", "years", ",", "9", "females", ",", "[", "Vdot", "]", "O", "(", "2", ")", "max", "35.4", "±", "8.8", "ml", "·", "kg", "(", "-1", ")", "·", "min", "(", "-1", ")", ")", "were", "randomised", "to", "no", "-", "exercise", "or", "to", "a", "bout", "of", "treadmill", "exercise", "at", "45", "%", ",", "55", "%", ",", "65", "%", "or", "75", "%", "[", "Vdot", "]", "O", "(", "2", ")", "max", "in", "a", "crossover", "design", ".", "Sleep", "on", "no", "-", "exercise", "and", "exercise", "nights", "were", "assessed", "by", "polysomnography", ".", "Participants", "spent", "a", "greater", "proportion", "of", "sleep", "in", "light", "sleep", "(", "stage", "1", "+", "stage", "2", ")", "after", "exercise", "at", "both", "65", "%", "and", "75", "%", "[", "Vdot", "]", "O", "(", "2", ")", "max", "(", "P", "<", "0.05", ")", "than", "the", "no", "-", "exercise", "condition", ".", "There", "was", "a", "trend", "of", "a", "reduced", "proportion", "of", "rapid", "eye", "movement", "sleep", "with", "increased", "exercise", "intensity", "(", "P", "=", "0.067", ")", ".", "No", "other", "changes", "were", "observed", "in", "any", "other", "sleep", "variables", ".", "Two", "findings", "emerged", ":", "vigorous", "exercise", "did", "not", "increase", "sleep", "need", ";", "however", ",", "this", "level", "of", "exercise", "increased", "light", "sleep", "." ]
[ "Participant_Condition", "Intervention_Physical" ]
GBA is a Gene, GCase is a Gene, GBA is a Gene
629_task0
Sentence: Gaucher disease paradigm: From ERAD to comorbidity. Mutations in the GBA gene, encoding the lysosomal acid beta-glucocerebrosidase (GCase), lead to deficient activity of the enzyme in the lysosomes, to glucosylceramide accumulation and to development of Gaucher disease (GD). More than 280 mutations in the GBA gene have been directly associated with GD. Mutant GCase variants present variable levels of endoplasmic reticulum (ER) retention, due to their inability to correctly fold, and undergo ER-associated degradation (ERAD) in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity. In the present review, we discuss ERAD of mutant GCase variants and its possible consequences in GD patients and in carriers of GD mutations. Hum Mutat 33:1398-1407, 2012. © 2012 Wiley Periodicals, Inc. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Gaucher disease paradigm: From ERAD to comorbidity. Mutations in the GBA gene, encoding the lysosomal acid beta-glucocerebrosidase (GCase), lead to deficient activity of the enzyme in the lysosomes, to glucosylceramide accumulation and to development of Gaucher disease (GD). More than 280 mutations in the GBA gene have been directly associated with GD. Mutant GCase variants present variable levels of endoplasmic reticulum (ER) retention, due to their inability to correctly fold, and undergo ER-associated degradation (ERAD) in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity. In the present review, we discuss ERAD of mutant GCase variants and its possible consequences in GD patients and in carriers of GD mutations. Hum Mutat 33:1398-1407, 2012. © 2012 Wiley Periodicals, Inc.
[ "Gaucher", "disease", "paradigm", ":", "From", "ERAD", "to", "comorbidity", ".", "Mutations", "in", "the", "GBA", "gene", ",", "encoding", "the", "lysosomal", "acid", "beta", "-", "glucocerebrosidase", "(", "GCase", ")", ",", "lead", "to", "deficient", "activity", "of", "the", "enzyme", "in", "the", "lysosomes", ",", "to", "glucosylceramide", "accumulation", "and", "to", "development", "of", "Gaucher", "disease", "(", "GD", ")", ".", "More", "than", "280", "mutations", "in", "the", "GBA", "gene", "have", "been", "directly", "associated", "with", "GD", ".", "Mutant", "GCase", "variants", "present", "variable", "levels", "of", "endoplasmic", "reticulum", "(", "ER", ")", "retention", ",", "due", "to", "their", "inability", "to", "correctly", "fold", ",", "and", "undergo", "ER", "-", "associated", "degradation", "(", "ERAD", ")", "in", "the", "proteasomes", ".", "The", "degree", "of", "ER", "retention", "and", "proteasomal", "degradation", "is", "one", "of", "the", "factors", "that", "determine", "GD", "severity", ".", "In", "the", "present", "review", ",", "we", "discuss", "ERAD", "of", "mutant", "GCase", "variants", "and", "its", "possible", "consequences", "in", "GD", "patients", "and", "in", "carriers", "of", "GD", "mutations", ".", "Hum", "Mutat", "33:1398", "-", "1407", ",", "2012", ".", "©", "2012", "Wiley", "Periodicals", ",", "Inc", ".", "\n" ]
[ "Gene" ]
GBA is a Gene, GCase is a Gene, GBA is a Gene
629_task1
Sentence: Gaucher disease paradigm: From ERAD to comorbidity. Mutations in the GBA gene, encoding the lysosomal acid beta-glucocerebrosidase (GCase), lead to deficient activity of the enzyme in the lysosomes, to glucosylceramide accumulation and to development of Gaucher disease (GD). More than 280 mutations in the GBA gene have been directly associated with GD. Mutant GCase variants present variable levels of endoplasmic reticulum (ER) retention, due to their inability to correctly fold, and undergo ER-associated degradation (ERAD) in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity. In the present review, we discuss ERAD of mutant GCase variants and its possible consequences in GD patients and in carriers of GD mutations. Hum Mutat 33:1398-1407, 2012. © 2012 Wiley Periodicals, Inc. Instructions: please typing these entity words according to sentence: GBA, GCase, GBA Options: Gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Gaucher disease paradigm: From ERAD to comorbidity. Mutations in the GBA gene, encoding the lysosomal acid beta-glucocerebrosidase (GCase), lead to deficient activity of the enzyme in the lysosomes, to glucosylceramide accumulation and to development of Gaucher disease (GD). More than 280 mutations in the GBA gene have been directly associated with GD. Mutant GCase variants present variable levels of endoplasmic reticulum (ER) retention, due to their inability to correctly fold, and undergo ER-associated degradation (ERAD) in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity. In the present review, we discuss ERAD of mutant GCase variants and its possible consequences in GD patients and in carriers of GD mutations. Hum Mutat 33:1398-1407, 2012. © 2012 Wiley Periodicals, Inc.
[ "Gaucher", "disease", "paradigm", ":", "From", "ERAD", "to", "comorbidity", ".", "Mutations", "in", "the", "GBA", "gene", ",", "encoding", "the", "lysosomal", "acid", "beta", "-", "glucocerebrosidase", "(", "GCase", ")", ",", "lead", "to", "deficient", "activity", "of", "the", "enzyme", "in", "the", "lysosomes", ",", "to", "glucosylceramide", "accumulation", "and", "to", "development", "of", "Gaucher", "disease", "(", "GD", ")", ".", "More", "than", "280", "mutations", "in", "the", "GBA", "gene", "have", "been", "directly", "associated", "with", "GD", ".", "Mutant", "GCase", "variants", "present", "variable", "levels", "of", "endoplasmic", "reticulum", "(", "ER", ")", "retention", ",", "due", "to", "their", "inability", "to", "correctly", "fold", ",", "and", "undergo", "ER", "-", "associated", "degradation", "(", "ERAD", ")", "in", "the", "proteasomes", ".", "The", "degree", "of", "ER", "retention", "and", "proteasomal", "degradation", "is", "one", "of", "the", "factors", "that", "determine", "GD", "severity", ".", "In", "the", "present", "review", ",", "we", "discuss", "ERAD", "of", "mutant", "GCase", "variants", "and", "its", "possible", "consequences", "in", "GD", "patients", "and", "in", "carriers", "of", "GD", "mutations", ".", "Hum", "Mutat", "33:1398", "-", "1407", ",", "2012", ".", "©", "2012", "Wiley", "Periodicals", ",", "Inc", ".", "\n" ]
[ "Gene" ]
GBA, GCase, GBA
629_task2
Sentence: Gaucher disease paradigm: From ERAD to comorbidity. Mutations in the GBA gene, encoding the lysosomal acid beta-glucocerebrosidase (GCase), lead to deficient activity of the enzyme in the lysosomes, to glucosylceramide accumulation and to development of Gaucher disease (GD). More than 280 mutations in the GBA gene have been directly associated with GD. Mutant GCase variants present variable levels of endoplasmic reticulum (ER) retention, due to their inability to correctly fold, and undergo ER-associated degradation (ERAD) in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity. In the present review, we discuss ERAD of mutant GCase variants and its possible consequences in GD patients and in carriers of GD mutations. Hum Mutat 33:1398-1407, 2012. © 2012 Wiley Periodicals, Inc. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Gaucher disease paradigm: From ERAD to comorbidity. Mutations in the GBA gene, encoding the lysosomal acid beta-glucocerebrosidase (GCase), lead to deficient activity of the enzyme in the lysosomes, to glucosylceramide accumulation and to development of Gaucher disease (GD). More than 280 mutations in the GBA gene have been directly associated with GD. Mutant GCase variants present variable levels of endoplasmic reticulum (ER) retention, due to their inability to correctly fold, and undergo ER-associated degradation (ERAD) in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity. In the present review, we discuss ERAD of mutant GCase variants and its possible consequences in GD patients and in carriers of GD mutations. Hum Mutat 33:1398-1407, 2012. © 2012 Wiley Periodicals, Inc.
[ "Gaucher", "disease", "paradigm", ":", "From", "ERAD", "to", "comorbidity", ".", "Mutations", "in", "the", "GBA", "gene", ",", "encoding", "the", "lysosomal", "acid", "beta", "-", "glucocerebrosidase", "(", "GCase", ")", ",", "lead", "to", "deficient", "activity", "of", "the", "enzyme", "in", "the", "lysosomes", ",", "to", "glucosylceramide", "accumulation", "and", "to", "development", "of", "Gaucher", "disease", "(", "GD", ")", ".", "More", "than", "280", "mutations", "in", "the", "GBA", "gene", "have", "been", "directly", "associated", "with", "GD", ".", "Mutant", "GCase", "variants", "present", "variable", "levels", "of", "endoplasmic", "reticulum", "(", "ER", ")", "retention", ",", "due", "to", "their", "inability", "to", "correctly", "fold", ",", "and", "undergo", "ER", "-", "associated", "degradation", "(", "ERAD", ")", "in", "the", "proteasomes", ".", "The", "degree", "of", "ER", "retention", "and", "proteasomal", "degradation", "is", "one", "of", "the", "factors", "that", "determine", "GD", "severity", ".", "In", "the", "present", "review", ",", "we", "discuss", "ERAD", "of", "mutant", "GCase", "variants", "and", "its", "possible", "consequences", "in", "GD", "patients", "and", "in", "carriers", "of", "GD", "mutations", ".", "Hum", "Mutat", "33:1398", "-", "1407", ",", "2012", ".", "©", "2012", "Wiley", "Periodicals", ",", "Inc", ".", "\n" ]
[ "Gene" ]
Hector is a NOMBRE_SUJETO_ASISTENCIA, Bracero Iglesias is a NOMBRE_SUJETO_ASISTENCIA, 27649 is a ID_SUJETO_ASISTENCIA, 83 29464890 is a ID_ASEGURAMIENTO, Calle Hermosillo , 23 , 2 , 1 is a CALLE, Sevilla is a TERRITORIO, 41329 is a TERRITORIO, 14/03/1966 is a FECHAS, España is a PAIS, 50 años is a EDAD_SUJETO_ASISTENCIA, 20/05/2016 is a FECHAS, 41 41 23678 is a ID_TITULACION_PERSONAL_SANITARIO, 50 años is a EDAD_SUJETO_ASISTENCIA, Francisco Javier Torres Gómez is a NOMBRE_PERSONAL_SANITARIO, Plaza de la Encarnación 32 P1 2B is a CALLE, 41003 is a TERRITORIO, Sevilla is a TERRITORIO, España is a PAIS, javiertorresgomez@yahoo.es is a CORREO_ELECTRONICO
15_task0
Sentence: Datos del paciente. Nombre: Hector. Apellidos: Bracero Iglesias. NHC: 27649. NASS: 83 29464890. Domicilio: Calle Hermosillo, 23, 2, 1. Localidad/ Provincia: Sevilla. CP: 41329. Datos asistenciales. Fecha de nacimiento: 14/03/1966. País: España. Edad: 50 años Sexo:. Fecha de Ingreso: 20/05/2016. Médico: NºCol: 41 41 23678. Informe clínico del paciente: Paciente de 50 años con antecedente de litiasis renal de repetición que consultó por hematuria recidivante y sensación de malestar. El estudio citológico seriado de orinas demostró la presencia de células atípicas sospechosas de malignidad. Los estudios de imagen permitieron observar una lesión heterogénea que ocupaba la práctica totalidad de la pelvis renal derecha. Se realizó nefrectomía total y ureterectomía parcial observándose un riñón de 10.5 x 5 cm de dimensiones máximas que mostraba a nivel de pelvis renal una lesión irregular y heterogénea de tonalidad pardusca en cuyo seno destacaban áreas hemorrágicas y otras ligeramente amarillentas y brillantes de consistencia sumamente blanda al corte. Dicha lesión, relativamente bien delimitada, no invadía el parénquima ni el seno renal quedando limitada al sistema pielocalicial aunque comprimiendo con márgenes expansivos la corteza en uno de los polos renales. El estudio histológico demostró que la lesión estaba constituida por nidos tumorales bien delimitados sin evidencia de invasión del parénquima renal, englobando una matriz mucinosa central la cual constituía más del 50% del volumen tumoral. En el seno de dicha matriz se encontraron flotando células neoplásicas sueltas y nidos de menor tamaño que los situados a nivel periférico. Las células tumorales mostraban morfología poligonal con núcleos centrales sin nucleolo aparente y escasa atipia así como citoplasmas eosinófilos y claros. En las áreas delimitantes con la matriz mucinosa se observó una tímida diferenciación glandular coincidiendo con la observación de algunos nucleolos y un ligero aumento de atipia nuclear. Las células tumorales mostraron intensa inmunopositividad para EMA, CK 7 y leve para CK20; ello,junto a la morfología, confirmó la naturaleza urotelial de la neoplasia. Con todos los datos expuestos se realizó el diagnóstico de carcinoma de células transicionales de bajo grado, con intensa diferenciación mucinosa, de pelvis renal (carcinoma coloide). Remitido por: Dr. Francisco Javier Torres Gómez Plaza de la Encarnación 32 P1 2B 41003. Sevilla (España) javiertorresgomez@yahoo.es Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "B-PAIS", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Hector. Apellidos: Bracero Iglesias. NHC: 27649. NASS: 83 29464890. Domicilio: Calle Hermosillo, 23, 2, 1. Localidad/ Provincia: Sevilla. CP: 41329. Datos asistenciales. Fecha de nacimiento: 14/03/1966. País: España. Edad: 50 años Sexo:. Fecha de Ingreso: 20/05/2016. Médico: NºCol: 41 41 23678. Informe clínico del paciente: Paciente de 50 años con antecedente de litiasis renal de repetición que consultó por hematuria recidivante y sensación de malestar. El estudio citológico seriado de orinas demostró la presencia de células atípicas sospechosas de malignidad. Los estudios de imagen permitieron observar una lesión heterogénea que ocupaba la práctica totalidad de la pelvis renal derecha. Se realizó nefrectomía total y ureterectomía parcial observándose un riñón de 10.5 x 5 cm de dimensiones máximas que mostraba a nivel de pelvis renal una lesión irregular y heterogénea de tonalidad pardusca en cuyo seno destacaban áreas hemorrágicas y otras ligeramente amarillentas y brillantes de consistencia sumamente blanda al corte. Dicha lesión, relativamente bien delimitada, no invadía el parénquima ni el seno renal quedando limitada al sistema pielocalicial aunque comprimiendo con márgenes expansivos la corteza en uno de los polos renales. El estudio histológico demostró que la lesión estaba constituida por nidos tumorales bien delimitados sin evidencia de invasión del parénquima renal, englobando una matriz mucinosa central la cual constituía más del 50% del volumen tumoral. En el seno de dicha matriz se encontraron flotando células neoplásicas sueltas y nidos de menor tamaño que los situados a nivel periférico. Las células tumorales mostraban morfología poligonal con núcleos centrales sin nucleolo aparente y escasa atipia así como citoplasmas eosinófilos y claros. En las áreas delimitantes con la matriz mucinosa se observó una tímida diferenciación glandular coincidiendo con la observación de algunos nucleolos y un ligero aumento de atipia nuclear. Las células tumorales mostraron intensa inmunopositividad para EMA, CK 7 y leve para CK20; ello,junto a la morfología, confirmó la naturaleza urotelial de la neoplasia. Con todos los datos expuestos se realizó el diagnóstico de carcinoma de células transicionales de bajo grado, con intensa diferenciación mucinosa, de pelvis renal (carcinoma coloide). Remitido por: Dr. Francisco Javier Torres Gómez Plaza de la Encarnación 32 P1 2B 41003. Sevilla (España) javiertorresgomez@yahoo.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Hector", ".", "\n", "Apellidos", ":", "Bracero", "Iglesias", ".", "\n", "NHC", ":", "27649", ".", "\n", "NASS", ":", "83", "29464890", ".", "\n", "Domicilio", ":", "Calle", "Hermosillo", ",", "23", ",", "2", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Sevilla", ".", "\n", "CP", ":", "41329", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/03/1966", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "50", "años", "Sexo", ":", ".", "\n", "Fecha", "de", "Ingreso", ":", "20/05/2016", ".", "\n", "Médico", ":", " ", "NºCol", ":", "41", "41", "23678", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "de", "50", "años", "con", "antecedente", "de", "litiasis", "renal", "de", "repetición", "que", "consultó", "por", "hematuria", "recidivante", "y", "sensación", "de", "malestar", ".", "El", "estudio", "citológico", "seriado", "de", "orinas", "demostró", "la", "presencia", "de", "células", "atípicas", "sospechosas", "de", "malignidad", ".", "Los", "estudios", "de", "imagen", "permitieron", "observar", "una", "lesión", "heterogénea", "que", "ocupaba", "la", "práctica", "totalidad", "de", "la", "pelvis", "renal", "derecha", ".", "Se", "realizó", "nefrectomía", "total", "y", "ureterectomía", "parcial", "observándose", "un", "riñón", "de", "10.5", "x", "5", "cm", "de", "dimensiones", "máximas", "que", "mostraba", "a", "nivel", "de", "pelvis", "renal", "una", "lesión", "irregular", "y", "heterogénea", "de", "tonalidad", "pardusca", "en", "cuyo", "seno", "destacaban", "áreas", "hemorrágicas", "y", "otras", "ligeramente", "amarillentas", "y", "brillantes", "de", "consistencia", "sumamente", "blanda", "al", "corte", ".", "Dicha", "lesión", ",", "relativamente", "bien", "delimitada", ",", "no", "invadía", "el", "parénquima", "ni", "el", "seno", "renal", "quedando", "limitada", "al", "sistema", "pielocalicial", "aunque", "comprimiendo", "con", "márgenes", "expansivos", "la", "corteza", "en", "uno", "de", "los", "polos", "renales", ".", "El", "estudio", "histológico", "demostró", "que", "la", "lesión", "estaba", "constituida", "por", "nidos", "tumorales", "bien", "delimitados", "sin", "evidencia", "de", "invasión", "del", "parénquima", "renal", ",", "englobando", "una", "matriz", "mucinosa", "central", "la", "cual", "constituía", "más", "del", "50", "%", "del", "volumen", "tumoral", ".", "En", "el", "seno", "de", "dicha", "matriz", "se", "encontraron", "flotando", "células", "neoplásicas", "sueltas", "y", "nidos", "de", "menor", "tamaño", "que", "los", "situados", "a", "nivel", "periférico", ".", "Las", "células", "tumorales", "mostraban", "morfología", "poligonal", "con", "núcleos", "centrales", "sin", "nucleolo", "aparente", "y", "escasa", "atipia", "así", "como", "citoplasmas", "eosinófilos", "y", "claros", ".", "En", "las", "áreas", "delimitantes", "con", "la", "matriz", "mucinosa", "se", "observó", "una", "tímida", "diferenciación", "glandular", "coincidiendo", "con", "la", "observación", "de", "algunos", "nucleolos", "y", "un", "ligero", "aumento", "de", "atipia", "nuclear", ".", "Las", "células", "tumorales", "mostraron", "intensa", "inmunopositividad", "para", "EMA", ",", "CK", "7", "y", "leve", "para", "CK20", ";", "ello", ",", "junto", "a", "la", "morfología", ",", "confirmó", "la", "naturaleza", "urotelial", "de", "la", "neoplasia", ".", "\n", "Con", "todos", "los", "datos", "expuestos", "se", "realizó", "el", "diagnóstico", "de", "carcinoma", "de", "células", "transicionales", "de", "bajo", "grado", ",", "con", "intensa", "diferenciación", "mucinosa", ",", "de", "pelvis", "renal", "(", "carcinoma", "coloide", ")", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Francisco", "Javier", "Torres", "Gómez", "Plaza", "de", "la", "Encarnación", "32", "P1", "2B", "41003", ".", "Sevilla", "(", "España", ")", "javiertorresgomez@yahoo.es", "\n" ]
[ "CALLE", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA" ]
Hector is a NOMBRE_SUJETO_ASISTENCIA, Bracero Iglesias is a NOMBRE_SUJETO_ASISTENCIA, 27649 is a ID_SUJETO_ASISTENCIA, 83 29464890 is a ID_ASEGURAMIENTO, Calle Hermosillo , 23 , 2 , 1 is a CALLE, Sevilla is a TERRITORIO, 41329 is a TERRITORIO, 14/03/1966 is a FECHAS, España is a PAIS, 50 años is a EDAD_SUJETO_ASISTENCIA, 20/05/2016 is a FECHAS, 41 41 23678 is a ID_TITULACION_PERSONAL_SANITARIO, 50 años is a EDAD_SUJETO_ASISTENCIA, Francisco Javier Torres Gómez is a NOMBRE_PERSONAL_SANITARIO, Plaza de la Encarnación 32 P1 2B is a CALLE, 41003 is a TERRITORIO, Sevilla is a TERRITORIO, España is a PAIS, javiertorresgomez@yahoo.es is a CORREO_ELECTRONICO
15_task1
Sentence: Datos del paciente. Nombre: Hector. Apellidos: Bracero Iglesias. NHC: 27649. NASS: 83 29464890. Domicilio: Calle Hermosillo, 23, 2, 1. Localidad/ Provincia: Sevilla. CP: 41329. Datos asistenciales. Fecha de nacimiento: 14/03/1966. País: España. Edad: 50 años Sexo:. Fecha de Ingreso: 20/05/2016. Médico: NºCol: 41 41 23678. Informe clínico del paciente: Paciente de 50 años con antecedente de litiasis renal de repetición que consultó por hematuria recidivante y sensación de malestar. El estudio citológico seriado de orinas demostró la presencia de células atípicas sospechosas de malignidad. Los estudios de imagen permitieron observar una lesión heterogénea que ocupaba la práctica totalidad de la pelvis renal derecha. Se realizó nefrectomía total y ureterectomía parcial observándose un riñón de 10.5 x 5 cm de dimensiones máximas que mostraba a nivel de pelvis renal una lesión irregular y heterogénea de tonalidad pardusca en cuyo seno destacaban áreas hemorrágicas y otras ligeramente amarillentas y brillantes de consistencia sumamente blanda al corte. Dicha lesión, relativamente bien delimitada, no invadía el parénquima ni el seno renal quedando limitada al sistema pielocalicial aunque comprimiendo con márgenes expansivos la corteza en uno de los polos renales. El estudio histológico demostró que la lesión estaba constituida por nidos tumorales bien delimitados sin evidencia de invasión del parénquima renal, englobando una matriz mucinosa central la cual constituía más del 50% del volumen tumoral. En el seno de dicha matriz se encontraron flotando células neoplásicas sueltas y nidos de menor tamaño que los situados a nivel periférico. Las células tumorales mostraban morfología poligonal con núcleos centrales sin nucleolo aparente y escasa atipia así como citoplasmas eosinófilos y claros. En las áreas delimitantes con la matriz mucinosa se observó una tímida diferenciación glandular coincidiendo con la observación de algunos nucleolos y un ligero aumento de atipia nuclear. Las células tumorales mostraron intensa inmunopositividad para EMA, CK 7 y leve para CK20; ello,junto a la morfología, confirmó la naturaleza urotelial de la neoplasia. Con todos los datos expuestos se realizó el diagnóstico de carcinoma de células transicionales de bajo grado, con intensa diferenciación mucinosa, de pelvis renal (carcinoma coloide). Remitido por: Dr. Francisco Javier Torres Gómez Plaza de la Encarnación 32 P1 2B 41003. Sevilla (España) javiertorresgomez@yahoo.es Instructions: please typing these entity words according to sentence: Hector, Bracero Iglesias, 27649, 83 29464890, Calle Hermosillo , 23 , 2 , 1, Sevilla, 41329, 14/03/1966, España, 50 años, 20/05/2016, 41 41 23678, 50 años, Francisco Javier Torres Gómez, Plaza de la Encarnación 32 P1 2B, 41003, Sevilla, España, javiertorresgomez@yahoo.es Options: TERRITORIO, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "B-PAIS", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Hector. Apellidos: Bracero Iglesias. NHC: 27649. NASS: 83 29464890. Domicilio: Calle Hermosillo, 23, 2, 1. Localidad/ Provincia: Sevilla. CP: 41329. Datos asistenciales. Fecha de nacimiento: 14/03/1966. País: España. Edad: 50 años Sexo:. Fecha de Ingreso: 20/05/2016. Médico: NºCol: 41 41 23678. Informe clínico del paciente: Paciente de 50 años con antecedente de litiasis renal de repetición que consultó por hematuria recidivante y sensación de malestar. El estudio citológico seriado de orinas demostró la presencia de células atípicas sospechosas de malignidad. Los estudios de imagen permitieron observar una lesión heterogénea que ocupaba la práctica totalidad de la pelvis renal derecha. Se realizó nefrectomía total y ureterectomía parcial observándose un riñón de 10.5 x 5 cm de dimensiones máximas que mostraba a nivel de pelvis renal una lesión irregular y heterogénea de tonalidad pardusca en cuyo seno destacaban áreas hemorrágicas y otras ligeramente amarillentas y brillantes de consistencia sumamente blanda al corte. Dicha lesión, relativamente bien delimitada, no invadía el parénquima ni el seno renal quedando limitada al sistema pielocalicial aunque comprimiendo con márgenes expansivos la corteza en uno de los polos renales. El estudio histológico demostró que la lesión estaba constituida por nidos tumorales bien delimitados sin evidencia de invasión del parénquima renal, englobando una matriz mucinosa central la cual constituía más del 50% del volumen tumoral. En el seno de dicha matriz se encontraron flotando células neoplásicas sueltas y nidos de menor tamaño que los situados a nivel periférico. Las células tumorales mostraban morfología poligonal con núcleos centrales sin nucleolo aparente y escasa atipia así como citoplasmas eosinófilos y claros. En las áreas delimitantes con la matriz mucinosa se observó una tímida diferenciación glandular coincidiendo con la observación de algunos nucleolos y un ligero aumento de atipia nuclear. Las células tumorales mostraron intensa inmunopositividad para EMA, CK 7 y leve para CK20; ello,junto a la morfología, confirmó la naturaleza urotelial de la neoplasia. Con todos los datos expuestos se realizó el diagnóstico de carcinoma de células transicionales de bajo grado, con intensa diferenciación mucinosa, de pelvis renal (carcinoma coloide). Remitido por: Dr. Francisco Javier Torres Gómez Plaza de la Encarnación 32 P1 2B 41003. Sevilla (España) javiertorresgomez@yahoo.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Hector", ".", "\n", "Apellidos", ":", "Bracero", "Iglesias", ".", "\n", "NHC", ":", "27649", ".", "\n", "NASS", ":", "83", "29464890", ".", "\n", "Domicilio", ":", "Calle", "Hermosillo", ",", "23", ",", "2", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Sevilla", ".", "\n", "CP", ":", "41329", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/03/1966", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "50", "años", "Sexo", ":", ".", "\n", "Fecha", "de", "Ingreso", ":", "20/05/2016", ".", "\n", "Médico", ":", " ", "NºCol", ":", "41", "41", "23678", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "de", "50", "años", "con", "antecedente", "de", "litiasis", "renal", "de", "repetición", "que", "consultó", "por", "hematuria", "recidivante", "y", "sensación", "de", "malestar", ".", "El", "estudio", "citológico", "seriado", "de", "orinas", "demostró", "la", "presencia", "de", "células", "atípicas", "sospechosas", "de", "malignidad", ".", "Los", "estudios", "de", "imagen", "permitieron", "observar", "una", "lesión", "heterogénea", "que", "ocupaba", "la", "práctica", "totalidad", "de", "la", "pelvis", "renal", "derecha", ".", "Se", "realizó", "nefrectomía", "total", "y", "ureterectomía", "parcial", "observándose", "un", "riñón", "de", "10.5", "x", "5", "cm", "de", "dimensiones", "máximas", "que", "mostraba", "a", "nivel", "de", "pelvis", "renal", "una", "lesión", "irregular", "y", "heterogénea", "de", "tonalidad", "pardusca", "en", "cuyo", "seno", "destacaban", "áreas", "hemorrágicas", "y", "otras", "ligeramente", "amarillentas", "y", "brillantes", "de", "consistencia", "sumamente", "blanda", "al", "corte", ".", "Dicha", "lesión", ",", "relativamente", "bien", "delimitada", ",", "no", "invadía", "el", "parénquima", "ni", "el", "seno", "renal", "quedando", "limitada", "al", "sistema", "pielocalicial", "aunque", "comprimiendo", "con", "márgenes", "expansivos", "la", "corteza", "en", "uno", "de", "los", "polos", "renales", ".", "El", "estudio", "histológico", "demostró", "que", "la", "lesión", "estaba", "constituida", "por", "nidos", "tumorales", "bien", "delimitados", "sin", "evidencia", "de", "invasión", "del", "parénquima", "renal", ",", "englobando", "una", "matriz", "mucinosa", "central", "la", "cual", "constituía", "más", "del", "50", "%", "del", "volumen", "tumoral", ".", "En", "el", "seno", "de", "dicha", "matriz", "se", "encontraron", "flotando", "células", "neoplásicas", "sueltas", "y", "nidos", "de", "menor", "tamaño", "que", "los", "situados", "a", "nivel", "periférico", ".", "Las", "células", "tumorales", "mostraban", "morfología", "poligonal", "con", "núcleos", "centrales", "sin", "nucleolo", "aparente", "y", "escasa", "atipia", "así", "como", "citoplasmas", "eosinófilos", "y", "claros", ".", "En", "las", "áreas", "delimitantes", "con", "la", "matriz", "mucinosa", "se", "observó", "una", "tímida", "diferenciación", "glandular", "coincidiendo", "con", "la", "observación", "de", "algunos", "nucleolos", "y", "un", "ligero", "aumento", "de", "atipia", "nuclear", ".", "Las", "células", "tumorales", "mostraron", "intensa", "inmunopositividad", "para", "EMA", ",", "CK", "7", "y", "leve", "para", "CK20", ";", "ello", ",", "junto", "a", "la", "morfología", ",", "confirmó", "la", "naturaleza", "urotelial", "de", "la", "neoplasia", ".", "\n", "Con", "todos", "los", "datos", "expuestos", "se", "realizó", "el", "diagnóstico", "de", "carcinoma", "de", "células", "transicionales", "de", "bajo", "grado", ",", "con", "intensa", "diferenciación", "mucinosa", ",", "de", "pelvis", "renal", "(", "carcinoma", "coloide", ")", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Francisco", "Javier", "Torres", "Gómez", "Plaza", "de", "la", "Encarnación", "32", "P1", "2B", "41003", ".", "Sevilla", "(", "España", ")", "javiertorresgomez@yahoo.es", "\n" ]
[ "CALLE", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA" ]
Hector, Bracero Iglesias, 27649, 83 29464890, Calle Hermosillo , 23 , 2 , 1, Sevilla, 41329, 14/03/1966, España, 50 años, 20/05/2016, 41 41 23678, 50 años, Francisco Javier Torres Gómez, Plaza de la Encarnación 32 P1 2B, 41003, Sevilla, España, javiertorresgomez@yahoo.es
15_task2
Sentence: Datos del paciente. Nombre: Hector. Apellidos: Bracero Iglesias. NHC: 27649. NASS: 83 29464890. Domicilio: Calle Hermosillo, 23, 2, 1. Localidad/ Provincia: Sevilla. CP: 41329. Datos asistenciales. Fecha de nacimiento: 14/03/1966. País: España. Edad: 50 años Sexo:. Fecha de Ingreso: 20/05/2016. Médico: NºCol: 41 41 23678. Informe clínico del paciente: Paciente de 50 años con antecedente de litiasis renal de repetición que consultó por hematuria recidivante y sensación de malestar. El estudio citológico seriado de orinas demostró la presencia de células atípicas sospechosas de malignidad. Los estudios de imagen permitieron observar una lesión heterogénea que ocupaba la práctica totalidad de la pelvis renal derecha. Se realizó nefrectomía total y ureterectomía parcial observándose un riñón de 10.5 x 5 cm de dimensiones máximas que mostraba a nivel de pelvis renal una lesión irregular y heterogénea de tonalidad pardusca en cuyo seno destacaban áreas hemorrágicas y otras ligeramente amarillentas y brillantes de consistencia sumamente blanda al corte. Dicha lesión, relativamente bien delimitada, no invadía el parénquima ni el seno renal quedando limitada al sistema pielocalicial aunque comprimiendo con márgenes expansivos la corteza en uno de los polos renales. El estudio histológico demostró que la lesión estaba constituida por nidos tumorales bien delimitados sin evidencia de invasión del parénquima renal, englobando una matriz mucinosa central la cual constituía más del 50% del volumen tumoral. En el seno de dicha matriz se encontraron flotando células neoplásicas sueltas y nidos de menor tamaño que los situados a nivel periférico. Las células tumorales mostraban morfología poligonal con núcleos centrales sin nucleolo aparente y escasa atipia así como citoplasmas eosinófilos y claros. En las áreas delimitantes con la matriz mucinosa se observó una tímida diferenciación glandular coincidiendo con la observación de algunos nucleolos y un ligero aumento de atipia nuclear. Las células tumorales mostraron intensa inmunopositividad para EMA, CK 7 y leve para CK20; ello,junto a la morfología, confirmó la naturaleza urotelial de la neoplasia. Con todos los datos expuestos se realizó el diagnóstico de carcinoma de células transicionales de bajo grado, con intensa diferenciación mucinosa, de pelvis renal (carcinoma coloide). Remitido por: Dr. Francisco Javier Torres Gómez Plaza de la Encarnación 32 P1 2B 41003. Sevilla (España) javiertorresgomez@yahoo.es Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "O", "B-TERRITORIO", "O", "B-PAIS", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Hector. Apellidos: Bracero Iglesias. NHC: 27649. NASS: 83 29464890. Domicilio: Calle Hermosillo, 23, 2, 1. Localidad/ Provincia: Sevilla. CP: 41329. Datos asistenciales. Fecha de nacimiento: 14/03/1966. País: España. Edad: 50 años Sexo:. Fecha de Ingreso: 20/05/2016. Médico: NºCol: 41 41 23678. Informe clínico del paciente: Paciente de 50 años con antecedente de litiasis renal de repetición que consultó por hematuria recidivante y sensación de malestar. El estudio citológico seriado de orinas demostró la presencia de células atípicas sospechosas de malignidad. Los estudios de imagen permitieron observar una lesión heterogénea que ocupaba la práctica totalidad de la pelvis renal derecha. Se realizó nefrectomía total y ureterectomía parcial observándose un riñón de 10.5 x 5 cm de dimensiones máximas que mostraba a nivel de pelvis renal una lesión irregular y heterogénea de tonalidad pardusca en cuyo seno destacaban áreas hemorrágicas y otras ligeramente amarillentas y brillantes de consistencia sumamente blanda al corte. Dicha lesión, relativamente bien delimitada, no invadía el parénquima ni el seno renal quedando limitada al sistema pielocalicial aunque comprimiendo con márgenes expansivos la corteza en uno de los polos renales. El estudio histológico demostró que la lesión estaba constituida por nidos tumorales bien delimitados sin evidencia de invasión del parénquima renal, englobando una matriz mucinosa central la cual constituía más del 50% del volumen tumoral. En el seno de dicha matriz se encontraron flotando células neoplásicas sueltas y nidos de menor tamaño que los situados a nivel periférico. Las células tumorales mostraban morfología poligonal con núcleos centrales sin nucleolo aparente y escasa atipia así como citoplasmas eosinófilos y claros. En las áreas delimitantes con la matriz mucinosa se observó una tímida diferenciación glandular coincidiendo con la observación de algunos nucleolos y un ligero aumento de atipia nuclear. Las células tumorales mostraron intensa inmunopositividad para EMA, CK 7 y leve para CK20; ello,junto a la morfología, confirmó la naturaleza urotelial de la neoplasia. Con todos los datos expuestos se realizó el diagnóstico de carcinoma de células transicionales de bajo grado, con intensa diferenciación mucinosa, de pelvis renal (carcinoma coloide). Remitido por: Dr. Francisco Javier Torres Gómez Plaza de la Encarnación 32 P1 2B 41003. Sevilla (España) javiertorresgomez@yahoo.es
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", " ", "Hector", ".", "\n", "Apellidos", ":", "Bracero", "Iglesias", ".", "\n", "NHC", ":", "27649", ".", "\n", "NASS", ":", "83", "29464890", ".", "\n", "Domicilio", ":", "Calle", "Hermosillo", ",", "23", ",", "2", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Sevilla", ".", "\n", "CP", ":", "41329", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "14/03/1966", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "50", "años", "Sexo", ":", ".", "\n", "Fecha", "de", "Ingreso", ":", "20/05/2016", ".", "\n", "Médico", ":", " ", "NºCol", ":", "41", "41", "23678", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Paciente", "de", "50", "años", "con", "antecedente", "de", "litiasis", "renal", "de", "repetición", "que", "consultó", "por", "hematuria", "recidivante", "y", "sensación", "de", "malestar", ".", "El", "estudio", "citológico", "seriado", "de", "orinas", "demostró", "la", "presencia", "de", "células", "atípicas", "sospechosas", "de", "malignidad", ".", "Los", "estudios", "de", "imagen", "permitieron", "observar", "una", "lesión", "heterogénea", "que", "ocupaba", "la", "práctica", "totalidad", "de", "la", "pelvis", "renal", "derecha", ".", "Se", "realizó", "nefrectomía", "total", "y", "ureterectomía", "parcial", "observándose", "un", "riñón", "de", "10.5", "x", "5", "cm", "de", "dimensiones", "máximas", "que", "mostraba", "a", "nivel", "de", "pelvis", "renal", "una", "lesión", "irregular", "y", "heterogénea", "de", "tonalidad", "pardusca", "en", "cuyo", "seno", "destacaban", "áreas", "hemorrágicas", "y", "otras", "ligeramente", "amarillentas", "y", "brillantes", "de", "consistencia", "sumamente", "blanda", "al", "corte", ".", "Dicha", "lesión", ",", "relativamente", "bien", "delimitada", ",", "no", "invadía", "el", "parénquima", "ni", "el", "seno", "renal", "quedando", "limitada", "al", "sistema", "pielocalicial", "aunque", "comprimiendo", "con", "márgenes", "expansivos", "la", "corteza", "en", "uno", "de", "los", "polos", "renales", ".", "El", "estudio", "histológico", "demostró", "que", "la", "lesión", "estaba", "constituida", "por", "nidos", "tumorales", "bien", "delimitados", "sin", "evidencia", "de", "invasión", "del", "parénquima", "renal", ",", "englobando", "una", "matriz", "mucinosa", "central", "la", "cual", "constituía", "más", "del", "50", "%", "del", "volumen", "tumoral", ".", "En", "el", "seno", "de", "dicha", "matriz", "se", "encontraron", "flotando", "células", "neoplásicas", "sueltas", "y", "nidos", "de", "menor", "tamaño", "que", "los", "situados", "a", "nivel", "periférico", ".", "Las", "células", "tumorales", "mostraban", "morfología", "poligonal", "con", "núcleos", "centrales", "sin", "nucleolo", "aparente", "y", "escasa", "atipia", "así", "como", "citoplasmas", "eosinófilos", "y", "claros", ".", "En", "las", "áreas", "delimitantes", "con", "la", "matriz", "mucinosa", "se", "observó", "una", "tímida", "diferenciación", "glandular", "coincidiendo", "con", "la", "observación", "de", "algunos", "nucleolos", "y", "un", "ligero", "aumento", "de", "atipia", "nuclear", ".", "Las", "células", "tumorales", "mostraron", "intensa", "inmunopositividad", "para", "EMA", ",", "CK", "7", "y", "leve", "para", "CK20", ";", "ello", ",", "junto", "a", "la", "morfología", ",", "confirmó", "la", "naturaleza", "urotelial", "de", "la", "neoplasia", ".", "\n", "Con", "todos", "los", "datos", "expuestos", "se", "realizó", "el", "diagnóstico", "de", "carcinoma", "de", "células", "transicionales", "de", "bajo", "grado", ",", "con", "intensa", "diferenciación", "mucinosa", ",", "de", "pelvis", "renal", "(", "carcinoma", "coloide", ")", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Francisco", "Javier", "Torres", "Gómez", "Plaza", "de", "la", "Encarnación", "32", "P1", "2B", "41003", ".", "Sevilla", "(", "España", ")", "javiertorresgomez@yahoo.es", "\n" ]
[ "CALLE", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA" ]
barbiturates is a GROUP, tranquilizers is a GROUP, alcohol is a DRUG, Diphenoxylate HCl is a DRUG, atropine sulfate is a DRUG, MAO inhibitors is a GROUP, diphenoxylate hydrochloride is a DRUG, diphenoxylate is a DRUG
Diphenoxylate_ddi_task0
Sentence: Known drug interactions include barbiturates, tranquilizers, and alcohol. Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG
[ "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Known drug interactions include barbiturates, tranquilizers, and alcohol. Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.
[ "Known", "drug", "interactions", "include", "barbiturates", ",", "tranquilizers", ",", "and", "alcohol", ".", "Diphenoxylate", "HCl", "and", "atropine", "sulfate", "may", "interact", "with", "MAO", "inhibitors", "In", "studies", "with", "male", "rats", ",", "diphenoxylate", "hydrochloride", "was", "found", "to", "inhibit", "the", "hepatic", "microsomal", "enzyme", "system", "at", "a", "dose", "of", "2", "mg", "/", "kg", "/", "day", ".", "Therefore", ",", "diphenoxylate", "has", "the", "potential", "to", "prolong", "the", "biological", "half", "-", "lives", "of", "drugs", "for", "which", "the", "rate", "of", "elimination", "is", "dependent", "on", "the", "microsomal", "drug", "metabolizing", "enzyme", "system", "." ]
[ "DRUG", "GROUP" ]
barbiturates is a GROUP, tranquilizers is a GROUP, alcohol is a DRUG, Diphenoxylate HCl is a DRUG, atropine sulfate is a DRUG, MAO inhibitors is a GROUP, diphenoxylate hydrochloride is a DRUG, diphenoxylate is a DRUG
Diphenoxylate_ddi_task1
Sentence: Known drug interactions include barbiturates, tranquilizers, and alcohol. Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system. Instructions: please typing these entity words according to sentence: barbiturates, tranquilizers, alcohol, Diphenoxylate HCl, atropine sulfate, MAO inhibitors, diphenoxylate hydrochloride, diphenoxylate Options: GROUP, DRUG
[ "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Known drug interactions include barbiturates, tranquilizers, and alcohol. Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.
[ "Known", "drug", "interactions", "include", "barbiturates", ",", "tranquilizers", ",", "and", "alcohol", ".", "Diphenoxylate", "HCl", "and", "atropine", "sulfate", "may", "interact", "with", "MAO", "inhibitors", "In", "studies", "with", "male", "rats", ",", "diphenoxylate", "hydrochloride", "was", "found", "to", "inhibit", "the", "hepatic", "microsomal", "enzyme", "system", "at", "a", "dose", "of", "2", "mg", "/", "kg", "/", "day", ".", "Therefore", ",", "diphenoxylate", "has", "the", "potential", "to", "prolong", "the", "biological", "half", "-", "lives", "of", "drugs", "for", "which", "the", "rate", "of", "elimination", "is", "dependent", "on", "the", "microsomal", "drug", "metabolizing", "enzyme", "system", "." ]
[ "DRUG", "GROUP" ]
barbiturates, tranquilizers, alcohol, Diphenoxylate HCl, atropine sulfate, MAO inhibitors, diphenoxylate hydrochloride, diphenoxylate
Diphenoxylate_ddi_task2
Sentence: Known drug interactions include barbiturates, tranquilizers, and alcohol. Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Known drug interactions include barbiturates, tranquilizers, and alcohol. Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.
[ "Known", "drug", "interactions", "include", "barbiturates", ",", "tranquilizers", ",", "and", "alcohol", ".", "Diphenoxylate", "HCl", "and", "atropine", "sulfate", "may", "interact", "with", "MAO", "inhibitors", "In", "studies", "with", "male", "rats", ",", "diphenoxylate", "hydrochloride", "was", "found", "to", "inhibit", "the", "hepatic", "microsomal", "enzyme", "system", "at", "a", "dose", "of", "2", "mg", "/", "kg", "/", "day", ".", "Therefore", ",", "diphenoxylate", "has", "the", "potential", "to", "prolong", "the", "biological", "half", "-", "lives", "of", "drugs", "for", "which", "the", "rate", "of", "elimination", "is", "dependent", "on", "the", "microsomal", "drug", "metabolizing", "enzyme", "system", "." ]
[ "DRUG", "GROUP" ]
Trichosporon is an umlsterm, human is an umlsterm, infections is an umlsterm, test is an umlsterm, criteria is an umlsterm, evaluation is an umlsterm, strains is an umlsterm, inkin is an umlsterm, Trichosporon is an umlsterm, yeast is an umlsterm, inkin is an umlsterm, nail is an umlsterm, inkin is an umlsterm, skin is an umlsterm, anogenital region is an umlsterm, mycoses is an umlsterm, mycoses is an umlsterm, therapy is an umlsterm, onychomycosis is an umlsterm, skin is an umlsterm, increasing incidence is an umlsterm, mycoses is an umlsterm
DerHautarzt.60470913.eng.abstr_task0
Sentence: Based on molecular data , the genus Trichosporon was recently reclassified . Six human pathogenic species , which are closely related to specific types of infections can be differentiated . By means of commercial test systems and simple key criteria according to Gueho et al. [ 15 ] , 44 isolates that had been identified as Tr . cutaneum between 7/92 and 1/96 , were reclassified . The evaluation of clinical data also included 66 isolates that had not been preserved , and 27 strains of Tr . inkin . Trichosporon species were found in 4.8% of all yeast isolates ( 3.8% Tr . cutaneum , 1% Tr . inkin ) . Nearly every other isolate of Tr . cutaneum was cultivated from nail material , while Tr . inkin was mainly isolated from skin in the anogenital region . In 38 cases , reclassification revealed Tr . mucoides ; Tr . ovoides and Tr . asteroides were identified in 3 cases each , while Tr . asahii , an especially remarkable pathogen in systemic mycoses , was not found . Clinically , isolates of Tr . mucoides were predominant in toenail mycoses which might be considered in the therapy of onychomycosis . Furthermore , isolates from the skin should be evaluated with respect to the increasing incidence of systemic Trichopsoron mycoses . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Based on molecular data , the genus Trichosporon was recently reclassified . Six human pathogenic species , which are closely related to specific types of infections can be differentiated . By means of commercial test systems and simple key criteria according to Gueho et al. [ 15 ] , 44 isolates that had been identified as Tr . cutaneum between 7/92 and 1/96 , were reclassified . The evaluation of clinical data also included 66 isolates that had not been preserved , and 27 strains of Tr . inkin . Trichosporon species were found in 4.8% of all yeast isolates ( 3.8% Tr . cutaneum , 1% Tr . inkin ) . Nearly every other isolate of Tr . cutaneum was cultivated from nail material , while Tr . inkin was mainly isolated from skin in the anogenital region . In 38 cases , reclassification revealed Tr . mucoides ; Tr . ovoides and Tr . asteroides were identified in 3 cases each , while Tr . asahii , an especially remarkable pathogen in systemic mycoses , was not found . Clinically , isolates of Tr . mucoides were predominant in toenail mycoses which might be considered in the therapy of onychomycosis . Furthermore , isolates from the skin should be evaluated with respect to the increasing incidence of systemic Trichopsoron mycoses .
[ "Based", "on", "molecular", "data", ",", "the", "genus", "Trichosporon", "was", "recently", "reclassified", ".", "Six", "human", "pathogenic", "species", ",", "which", "are", "closely", "related", "to", "specific", "types", "of", "infections", "can", "be", "differentiated", ".", "By", "means", "of", "commercial", "test", "systems", "and", "simple", "key", "criteria", "according", "to", "Gueho", "et", "al", ".", "[", "15", "]", ",", "44", "isolates", "that", "had", "been", "identified", "as", "Tr", ".", "cutaneum", "between", "7/92", "and", "1/96", ",", "were", "reclassified", ".", "The", "evaluation", "of", "clinical", "data", "also", "included", "66", "isolates", "that", "had", "not", "been", "preserved", ",", "and", "27", "strains", "of", "Tr", ".", "inkin", ".", "Trichosporon", "species", "were", "found", "in", "4.8", "%", "of", "all", "yeast", "isolates", "(", "3.8", "%", "Tr", ".", "cutaneum", ",", "1", "%", "Tr", ".", "inkin", ")", ".", "Nearly", "every", "other", "isolate", "of", "Tr", ".", "cutaneum", "was", "cultivated", "from", "nail", "material", ",", "while", "Tr", ".", "inkin", "was", "mainly", "isolated", "from", "skin", "in", "the", "anogenital", "region", ".", "In", "38", "cases", ",", "reclassification", "revealed", "Tr", ".", "mucoides", ";", "Tr", ".", "ovoides", "and", "Tr", ".", "asteroides", "were", "identified", "in", "3", "cases", "each", ",", "while", "Tr", ".", "asahii", ",", "an", "especially", "remarkable", "pathogen", "in", "systemic", "mycoses", ",", "was", "not", "found", ".", "Clinically", ",", "isolates", "of", "Tr", ".", "mucoides", "were", "predominant", "in", "toenail", "mycoses", "which", "might", "be", "considered", "in", "the", "therapy", "of", "onychomycosis", ".", "Furthermore", ",", "isolates", "from", "the", "skin", "should", "be", "evaluated", "with", "respect", "to", "the", "increasing", "incidence", "of", "systemic", "Trichopsoron", "mycoses", "." ]
[ "umlsterm" ]
Trichosporon is an umlsterm, human is an umlsterm, infections is an umlsterm, test is an umlsterm, criteria is an umlsterm, evaluation is an umlsterm, strains is an umlsterm, inkin is an umlsterm, Trichosporon is an umlsterm, yeast is an umlsterm, inkin is an umlsterm, nail is an umlsterm, inkin is an umlsterm, skin is an umlsterm, anogenital region is an umlsterm, mycoses is an umlsterm, mycoses is an umlsterm, therapy is an umlsterm, onychomycosis is an umlsterm, skin is an umlsterm, increasing incidence is an umlsterm, mycoses is an umlsterm
DerHautarzt.60470913.eng.abstr_task1
Sentence: Based on molecular data , the genus Trichosporon was recently reclassified . Six human pathogenic species , which are closely related to specific types of infections can be differentiated . By means of commercial test systems and simple key criteria according to Gueho et al. [ 15 ] , 44 isolates that had been identified as Tr . cutaneum between 7/92 and 1/96 , were reclassified . The evaluation of clinical data also included 66 isolates that had not been preserved , and 27 strains of Tr . inkin . Trichosporon species were found in 4.8% of all yeast isolates ( 3.8% Tr . cutaneum , 1% Tr . inkin ) . Nearly every other isolate of Tr . cutaneum was cultivated from nail material , while Tr . inkin was mainly isolated from skin in the anogenital region . In 38 cases , reclassification revealed Tr . mucoides ; Tr . ovoides and Tr . asteroides were identified in 3 cases each , while Tr . asahii , an especially remarkable pathogen in systemic mycoses , was not found . Clinically , isolates of Tr . mucoides were predominant in toenail mycoses which might be considered in the therapy of onychomycosis . Furthermore , isolates from the skin should be evaluated with respect to the increasing incidence of systemic Trichopsoron mycoses . Instructions: please typing these entity words according to sentence: Trichosporon, human, infections, test, criteria, evaluation, strains, inkin, Trichosporon, yeast, inkin, nail, inkin, skin, anogenital region, mycoses, mycoses, therapy, onychomycosis, skin, increasing incidence, mycoses Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Based on molecular data , the genus Trichosporon was recently reclassified . Six human pathogenic species , which are closely related to specific types of infections can be differentiated . By means of commercial test systems and simple key criteria according to Gueho et al. [ 15 ] , 44 isolates that had been identified as Tr . cutaneum between 7/92 and 1/96 , were reclassified . The evaluation of clinical data also included 66 isolates that had not been preserved , and 27 strains of Tr . inkin . Trichosporon species were found in 4.8% of all yeast isolates ( 3.8% Tr . cutaneum , 1% Tr . inkin ) . Nearly every other isolate of Tr . cutaneum was cultivated from nail material , while Tr . inkin was mainly isolated from skin in the anogenital region . In 38 cases , reclassification revealed Tr . mucoides ; Tr . ovoides and Tr . asteroides were identified in 3 cases each , while Tr . asahii , an especially remarkable pathogen in systemic mycoses , was not found . Clinically , isolates of Tr . mucoides were predominant in toenail mycoses which might be considered in the therapy of onychomycosis . Furthermore , isolates from the skin should be evaluated with respect to the increasing incidence of systemic Trichopsoron mycoses .
[ "Based", "on", "molecular", "data", ",", "the", "genus", "Trichosporon", "was", "recently", "reclassified", ".", "Six", "human", "pathogenic", "species", ",", "which", "are", "closely", "related", "to", "specific", "types", "of", "infections", "can", "be", "differentiated", ".", "By", "means", "of", "commercial", "test", "systems", "and", "simple", "key", "criteria", "according", "to", "Gueho", "et", "al", ".", "[", "15", "]", ",", "44", "isolates", "that", "had", "been", "identified", "as", "Tr", ".", "cutaneum", "between", "7/92", "and", "1/96", ",", "were", "reclassified", ".", "The", "evaluation", "of", "clinical", "data", "also", "included", "66", "isolates", "that", "had", "not", "been", "preserved", ",", "and", "27", "strains", "of", "Tr", ".", "inkin", ".", "Trichosporon", "species", "were", "found", "in", "4.8", "%", "of", "all", "yeast", "isolates", "(", "3.8", "%", "Tr", ".", "cutaneum", ",", "1", "%", "Tr", ".", "inkin", ")", ".", "Nearly", "every", "other", "isolate", "of", "Tr", ".", "cutaneum", "was", "cultivated", "from", "nail", "material", ",", "while", "Tr", ".", "inkin", "was", "mainly", "isolated", "from", "skin", "in", "the", "anogenital", "region", ".", "In", "38", "cases", ",", "reclassification", "revealed", "Tr", ".", "mucoides", ";", "Tr", ".", "ovoides", "and", "Tr", ".", "asteroides", "were", "identified", "in", "3", "cases", "each", ",", "while", "Tr", ".", "asahii", ",", "an", "especially", "remarkable", "pathogen", "in", "systemic", "mycoses", ",", "was", "not", "found", ".", "Clinically", ",", "isolates", "of", "Tr", ".", "mucoides", "were", "predominant", "in", "toenail", "mycoses", "which", "might", "be", "considered", "in", "the", "therapy", "of", "onychomycosis", ".", "Furthermore", ",", "isolates", "from", "the", "skin", "should", "be", "evaluated", "with", "respect", "to", "the", "increasing", "incidence", "of", "systemic", "Trichopsoron", "mycoses", "." ]
[ "umlsterm" ]
Trichosporon, human, infections, test, criteria, evaluation, strains, inkin, Trichosporon, yeast, inkin, nail, inkin, skin, anogenital region, mycoses, mycoses, therapy, onychomycosis, skin, increasing incidence, mycoses
DerHautarzt.60470913.eng.abstr_task2
Sentence: Based on molecular data , the genus Trichosporon was recently reclassified . Six human pathogenic species , which are closely related to specific types of infections can be differentiated . By means of commercial test systems and simple key criteria according to Gueho et al. [ 15 ] , 44 isolates that had been identified as Tr . cutaneum between 7/92 and 1/96 , were reclassified . The evaluation of clinical data also included 66 isolates that had not been preserved , and 27 strains of Tr . inkin . Trichosporon species were found in 4.8% of all yeast isolates ( 3.8% Tr . cutaneum , 1% Tr . inkin ) . Nearly every other isolate of Tr . cutaneum was cultivated from nail material , while Tr . inkin was mainly isolated from skin in the anogenital region . In 38 cases , reclassification revealed Tr . mucoides ; Tr . ovoides and Tr . asteroides were identified in 3 cases each , while Tr . asahii , an especially remarkable pathogen in systemic mycoses , was not found . Clinically , isolates of Tr . mucoides were predominant in toenail mycoses which might be considered in the therapy of onychomycosis . Furthermore , isolates from the skin should be evaluated with respect to the increasing incidence of systemic Trichopsoron mycoses . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Based on molecular data , the genus Trichosporon was recently reclassified . Six human pathogenic species , which are closely related to specific types of infections can be differentiated . By means of commercial test systems and simple key criteria according to Gueho et al. [ 15 ] , 44 isolates that had been identified as Tr . cutaneum between 7/92 and 1/96 , were reclassified . The evaluation of clinical data also included 66 isolates that had not been preserved , and 27 strains of Tr . inkin . Trichosporon species were found in 4.8% of all yeast isolates ( 3.8% Tr . cutaneum , 1% Tr . inkin ) . Nearly every other isolate of Tr . cutaneum was cultivated from nail material , while Tr . inkin was mainly isolated from skin in the anogenital region . In 38 cases , reclassification revealed Tr . mucoides ; Tr . ovoides and Tr . asteroides were identified in 3 cases each , while Tr . asahii , an especially remarkable pathogen in systemic mycoses , was not found . Clinically , isolates of Tr . mucoides were predominant in toenail mycoses which might be considered in the therapy of onychomycosis . Furthermore , isolates from the skin should be evaluated with respect to the increasing incidence of systemic Trichopsoron mycoses .
[ "Based", "on", "molecular", "data", ",", "the", "genus", "Trichosporon", "was", "recently", "reclassified", ".", "Six", "human", "pathogenic", "species", ",", "which", "are", "closely", "related", "to", "specific", "types", "of", "infections", "can", "be", "differentiated", ".", "By", "means", "of", "commercial", "test", "systems", "and", "simple", "key", "criteria", "according", "to", "Gueho", "et", "al", ".", "[", "15", "]", ",", "44", "isolates", "that", "had", "been", "identified", "as", "Tr", ".", "cutaneum", "between", "7/92", "and", "1/96", ",", "were", "reclassified", ".", "The", "evaluation", "of", "clinical", "data", "also", "included", "66", "isolates", "that", "had", "not", "been", "preserved", ",", "and", "27", "strains", "of", "Tr", ".", "inkin", ".", "Trichosporon", "species", "were", "found", "in", "4.8", "%", "of", "all", "yeast", "isolates", "(", "3.8", "%", "Tr", ".", "cutaneum", ",", "1", "%", "Tr", ".", "inkin", ")", ".", "Nearly", "every", "other", "isolate", "of", "Tr", ".", "cutaneum", "was", "cultivated", "from", "nail", "material", ",", "while", "Tr", ".", "inkin", "was", "mainly", "isolated", "from", "skin", "in", "the", "anogenital", "region", ".", "In", "38", "cases", ",", "reclassification", "revealed", "Tr", ".", "mucoides", ";", "Tr", ".", "ovoides", "and", "Tr", ".", "asteroides", "were", "identified", "in", "3", "cases", "each", ",", "while", "Tr", ".", "asahii", ",", "an", "especially", "remarkable", "pathogen", "in", "systemic", "mycoses", ",", "was", "not", "found", ".", "Clinically", ",", "isolates", "of", "Tr", ".", "mucoides", "were", "predominant", "in", "toenail", "mycoses", "which", "might", "be", "considered", "in", "the", "therapy", "of", "onychomycosis", ".", "Furthermore", ",", "isolates", "from", "the", "skin", "should", "be", "evaluated", "with", "respect", "to", "the", "increasing", "incidence", "of", "systemic", "Trichopsoron", "mycoses", "." ]
[ "umlsterm" ]
Distraktionsosteogenese is an umlsterm, Verwendung is an umlsterm, Methode is an umlsterm, Unterkiefers is an umlsterm, Schaf is an umlsterm, Osteotomie is an umlsterm, Unterkiefer is an umlsterm, Steuereinheit is an umlsterm, Halsregion is an umlsterm, Geraet is an umlsterm, Methode is an umlsterm, Unterkiefer is an umlsterm, Zeit is an umlsterm, Geraet is an umlsterm, Distraktionsosteogenese is an umlsterm, Unterkiefers is an umlsterm
MundKieferGesichtschirurgie.9003s140.ger.abstr_task0
Sentence: Die Distraktionsosteogenese unter Verwendung von externen oder intraoralen Distraktoren ist eine anerkannte Methode zur Verlaengerung des menschlichen Unterkiefers . In dieser praeklinischen Studie am Schaf wird ein vollstaendig implantierbarer Distraktor zur mandibularen Verlaengerung praesentiert . Nach Durchfuehrung einer Osteotomie im Unterkiefer wurden der elektromagnetische Distraktor fixiert und die Energie und Steuereinheit subkutan in die Halsregion implantiert . Nach einer Einheilungszeit von 5 Tagen wurde das Geraet mit einem Magneten transkutan eingeschaltet und ermoeglichte in kalibrierten Schritten von 0,04 mm/h eine gesamte Verlaengerung von 1,0 mm pro Tag . Mit dieser Methode war es moeglich , den Unterkiefer ohne transmukoese Aktivierung automatisch ueber eine Zeit von 14 Tagen zu verlaengern . In unserer Studie wurde dieses neu entwickelte Geraet erfolgreich fuer die Distraktionsosteogenese verwendet und ermoeglichte eine maximale Verlaengerung des Unterkiefers von 13,6 mm . Weitere Untersuchungen sind notwendig , um einen Fortschritt zur klinischen Anwendung in naher Zukunft zu erzielen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Distraktionsosteogenese unter Verwendung von externen oder intraoralen Distraktoren ist eine anerkannte Methode zur Verlaengerung des menschlichen Unterkiefers . In dieser praeklinischen Studie am Schaf wird ein vollstaendig implantierbarer Distraktor zur mandibularen Verlaengerung praesentiert . Nach Durchfuehrung einer Osteotomie im Unterkiefer wurden der elektromagnetische Distraktor fixiert und die Energie und Steuereinheit subkutan in die Halsregion implantiert . Nach einer Einheilungszeit von 5 Tagen wurde das Geraet mit einem Magneten transkutan eingeschaltet und ermoeglichte in kalibrierten Schritten von 0,04 mm/h eine gesamte Verlaengerung von 1,0 mm pro Tag . Mit dieser Methode war es moeglich , den Unterkiefer ohne transmukoese Aktivierung automatisch ueber eine Zeit von 14 Tagen zu verlaengern . In unserer Studie wurde dieses neu entwickelte Geraet erfolgreich fuer die Distraktionsosteogenese verwendet und ermoeglichte eine maximale Verlaengerung des Unterkiefers von 13,6 mm . Weitere Untersuchungen sind notwendig , um einen Fortschritt zur klinischen Anwendung in naher Zukunft zu erzielen .
[ "Die", "Distraktionsosteogenese", "unter", "Verwendung", "von", "externen", "oder", "intraoralen", "Distraktoren", "ist", "eine", "anerkannte", "Methode", "zur", "Verlaengerung", "des", "menschlichen", "Unterkiefers", ".", "In", "dieser", "praeklinischen", "Studie", "am", "Schaf", "wird", "ein", "vollstaendig", "implantierbarer", "Distraktor", "zur", "mandibularen", "Verlaengerung", "praesentiert", ".", "Nach", "Durchfuehrung", "einer", "Osteotomie", "im", "Unterkiefer", "wurden", "der", "elektromagnetische", "Distraktor", "fixiert", "und", "die", "Energie", "und", "Steuereinheit", "subkutan", "in", "die", "Halsregion", "implantiert", ".", "Nach", "einer", "Einheilungszeit", "von", "5", "Tagen", "wurde", "das", "Geraet", "mit", "einem", "Magneten", "transkutan", "eingeschaltet", "und", "ermoeglichte", "in", "kalibrierten", "Schritten", "von", "0,04", "mm", "/", "h", "eine", "gesamte", "Verlaengerung", "von", "1,0", "mm", "pro", "Tag", ".", "Mit", "dieser", "Methode", "war", "es", "moeglich", ",", "den", "Unterkiefer", "ohne", "transmukoese", "Aktivierung", "automatisch", "ueber", "eine", "Zeit", "von", "14", "Tagen", "zu", "verlaengern", ".", "In", "unserer", "Studie", "wurde", "dieses", "neu", "entwickelte", "Geraet", "erfolgreich", "fuer", "die", "Distraktionsosteogenese", "verwendet", "und", "ermoeglichte", "eine", "maximale", "Verlaengerung", "des", "Unterkiefers", "von", "13,6", "mm", ".", "Weitere", "Untersuchungen", "sind", "notwendig", ",", "um", "einen", "Fortschritt", "zur", "klinischen", "Anwendung", "in", "naher", "Zukunft", "zu", "erzielen", "." ]
[ "umlsterm" ]
Distraktionsosteogenese is an umlsterm, Verwendung is an umlsterm, Methode is an umlsterm, Unterkiefers is an umlsterm, Schaf is an umlsterm, Osteotomie is an umlsterm, Unterkiefer is an umlsterm, Steuereinheit is an umlsterm, Halsregion is an umlsterm, Geraet is an umlsterm, Methode is an umlsterm, Unterkiefer is an umlsterm, Zeit is an umlsterm, Geraet is an umlsterm, Distraktionsosteogenese is an umlsterm, Unterkiefers is an umlsterm
MundKieferGesichtschirurgie.9003s140.ger.abstr_task1
Sentence: Die Distraktionsosteogenese unter Verwendung von externen oder intraoralen Distraktoren ist eine anerkannte Methode zur Verlaengerung des menschlichen Unterkiefers . In dieser praeklinischen Studie am Schaf wird ein vollstaendig implantierbarer Distraktor zur mandibularen Verlaengerung praesentiert . Nach Durchfuehrung einer Osteotomie im Unterkiefer wurden der elektromagnetische Distraktor fixiert und die Energie und Steuereinheit subkutan in die Halsregion implantiert . Nach einer Einheilungszeit von 5 Tagen wurde das Geraet mit einem Magneten transkutan eingeschaltet und ermoeglichte in kalibrierten Schritten von 0,04 mm/h eine gesamte Verlaengerung von 1,0 mm pro Tag . Mit dieser Methode war es moeglich , den Unterkiefer ohne transmukoese Aktivierung automatisch ueber eine Zeit von 14 Tagen zu verlaengern . In unserer Studie wurde dieses neu entwickelte Geraet erfolgreich fuer die Distraktionsosteogenese verwendet und ermoeglichte eine maximale Verlaengerung des Unterkiefers von 13,6 mm . Weitere Untersuchungen sind notwendig , um einen Fortschritt zur klinischen Anwendung in naher Zukunft zu erzielen . Instructions: please typing these entity words according to sentence: Distraktionsosteogenese, Verwendung, Methode, Unterkiefers, Schaf, Osteotomie, Unterkiefer, Steuereinheit, Halsregion, Geraet, Methode, Unterkiefer, Zeit, Geraet, Distraktionsosteogenese, Unterkiefers Options: umlsterm
[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Distraktionsosteogenese unter Verwendung von externen oder intraoralen Distraktoren ist eine anerkannte Methode zur Verlaengerung des menschlichen Unterkiefers . In dieser praeklinischen Studie am Schaf wird ein vollstaendig implantierbarer Distraktor zur mandibularen Verlaengerung praesentiert . Nach Durchfuehrung einer Osteotomie im Unterkiefer wurden der elektromagnetische Distraktor fixiert und die Energie und Steuereinheit subkutan in die Halsregion implantiert . Nach einer Einheilungszeit von 5 Tagen wurde das Geraet mit einem Magneten transkutan eingeschaltet und ermoeglichte in kalibrierten Schritten von 0,04 mm/h eine gesamte Verlaengerung von 1,0 mm pro Tag . Mit dieser Methode war es moeglich , den Unterkiefer ohne transmukoese Aktivierung automatisch ueber eine Zeit von 14 Tagen zu verlaengern . In unserer Studie wurde dieses neu entwickelte Geraet erfolgreich fuer die Distraktionsosteogenese verwendet und ermoeglichte eine maximale Verlaengerung des Unterkiefers von 13,6 mm . Weitere Untersuchungen sind notwendig , um einen Fortschritt zur klinischen Anwendung in naher Zukunft zu erzielen .
[ "Die", "Distraktionsosteogenese", "unter", "Verwendung", "von", "externen", "oder", "intraoralen", "Distraktoren", "ist", "eine", "anerkannte", "Methode", "zur", "Verlaengerung", "des", "menschlichen", "Unterkiefers", ".", "In", "dieser", "praeklinischen", "Studie", "am", "Schaf", "wird", "ein", "vollstaendig", "implantierbarer", "Distraktor", "zur", "mandibularen", "Verlaengerung", "praesentiert", ".", "Nach", "Durchfuehrung", "einer", "Osteotomie", "im", "Unterkiefer", "wurden", "der", "elektromagnetische", "Distraktor", "fixiert", "und", "die", "Energie", "und", "Steuereinheit", "subkutan", "in", "die", "Halsregion", "implantiert", ".", "Nach", "einer", "Einheilungszeit", "von", "5", "Tagen", "wurde", "das", "Geraet", "mit", "einem", "Magneten", "transkutan", "eingeschaltet", "und", "ermoeglichte", "in", "kalibrierten", "Schritten", "von", "0,04", "mm", "/", "h", "eine", "gesamte", "Verlaengerung", "von", "1,0", "mm", "pro", "Tag", ".", "Mit", "dieser", "Methode", "war", "es", "moeglich", ",", "den", "Unterkiefer", "ohne", "transmukoese", "Aktivierung", "automatisch", "ueber", "eine", "Zeit", "von", "14", "Tagen", "zu", "verlaengern", ".", "In", "unserer", "Studie", "wurde", "dieses", "neu", "entwickelte", "Geraet", "erfolgreich", "fuer", "die", "Distraktionsosteogenese", "verwendet", "und", "ermoeglichte", "eine", "maximale", "Verlaengerung", "des", "Unterkiefers", "von", "13,6", "mm", ".", "Weitere", "Untersuchungen", "sind", "notwendig", ",", "um", "einen", "Fortschritt", "zur", "klinischen", "Anwendung", "in", "naher", "Zukunft", "zu", "erzielen", "." ]
[ "umlsterm" ]
Distraktionsosteogenese, Verwendung, Methode, Unterkiefers, Schaf, Osteotomie, Unterkiefer, Steuereinheit, Halsregion, Geraet, Methode, Unterkiefer, Zeit, Geraet, Distraktionsosteogenese, Unterkiefers
MundKieferGesichtschirurgie.9003s140.ger.abstr_task2
Sentence: Die Distraktionsosteogenese unter Verwendung von externen oder intraoralen Distraktoren ist eine anerkannte Methode zur Verlaengerung des menschlichen Unterkiefers . In dieser praeklinischen Studie am Schaf wird ein vollstaendig implantierbarer Distraktor zur mandibularen Verlaengerung praesentiert . Nach Durchfuehrung einer Osteotomie im Unterkiefer wurden der elektromagnetische Distraktor fixiert und die Energie und Steuereinheit subkutan in die Halsregion implantiert . Nach einer Einheilungszeit von 5 Tagen wurde das Geraet mit einem Magneten transkutan eingeschaltet und ermoeglichte in kalibrierten Schritten von 0,04 mm/h eine gesamte Verlaengerung von 1,0 mm pro Tag . Mit dieser Methode war es moeglich , den Unterkiefer ohne transmukoese Aktivierung automatisch ueber eine Zeit von 14 Tagen zu verlaengern . In unserer Studie wurde dieses neu entwickelte Geraet erfolgreich fuer die Distraktionsosteogenese verwendet und ermoeglichte eine maximale Verlaengerung des Unterkiefers von 13,6 mm . Weitere Untersuchungen sind notwendig , um einen Fortschritt zur klinischen Anwendung in naher Zukunft zu erzielen . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Distraktionsosteogenese unter Verwendung von externen oder intraoralen Distraktoren ist eine anerkannte Methode zur Verlaengerung des menschlichen Unterkiefers . In dieser praeklinischen Studie am Schaf wird ein vollstaendig implantierbarer Distraktor zur mandibularen Verlaengerung praesentiert . Nach Durchfuehrung einer Osteotomie im Unterkiefer wurden der elektromagnetische Distraktor fixiert und die Energie und Steuereinheit subkutan in die Halsregion implantiert . Nach einer Einheilungszeit von 5 Tagen wurde das Geraet mit einem Magneten transkutan eingeschaltet und ermoeglichte in kalibrierten Schritten von 0,04 mm/h eine gesamte Verlaengerung von 1,0 mm pro Tag . Mit dieser Methode war es moeglich , den Unterkiefer ohne transmukoese Aktivierung automatisch ueber eine Zeit von 14 Tagen zu verlaengern . In unserer Studie wurde dieses neu entwickelte Geraet erfolgreich fuer die Distraktionsosteogenese verwendet und ermoeglichte eine maximale Verlaengerung des Unterkiefers von 13,6 mm . Weitere Untersuchungen sind notwendig , um einen Fortschritt zur klinischen Anwendung in naher Zukunft zu erzielen .
[ "Die", "Distraktionsosteogenese", "unter", "Verwendung", "von", "externen", "oder", "intraoralen", "Distraktoren", "ist", "eine", "anerkannte", "Methode", "zur", "Verlaengerung", "des", "menschlichen", "Unterkiefers", ".", "In", "dieser", "praeklinischen", "Studie", "am", "Schaf", "wird", "ein", "vollstaendig", "implantierbarer", "Distraktor", "zur", "mandibularen", "Verlaengerung", "praesentiert", ".", "Nach", "Durchfuehrung", "einer", "Osteotomie", "im", "Unterkiefer", "wurden", "der", "elektromagnetische", "Distraktor", "fixiert", "und", "die", "Energie", "und", "Steuereinheit", "subkutan", "in", "die", "Halsregion", "implantiert", ".", "Nach", "einer", "Einheilungszeit", "von", "5", "Tagen", "wurde", "das", "Geraet", "mit", "einem", "Magneten", "transkutan", "eingeschaltet", "und", "ermoeglichte", "in", "kalibrierten", "Schritten", "von", "0,04", "mm", "/", "h", "eine", "gesamte", "Verlaengerung", "von", "1,0", "mm", "pro", "Tag", ".", "Mit", "dieser", "Methode", "war", "es", "moeglich", ",", "den", "Unterkiefer", "ohne", "transmukoese", "Aktivierung", "automatisch", "ueber", "eine", "Zeit", "von", "14", "Tagen", "zu", "verlaengern", ".", "In", "unserer", "Studie", "wurde", "dieses", "neu", "entwickelte", "Geraet", "erfolgreich", "fuer", "die", "Distraktionsosteogenese", "verwendet", "und", "ermoeglichte", "eine", "maximale", "Verlaengerung", "des", "Unterkiefers", "von", "13,6", "mm", ".", "Weitere", "Untersuchungen", "sind", "notwendig", ",", "um", "einen", "Fortschritt", "zur", "klinischen", "Anwendung", "in", "naher", "Zukunft", "zu", "erzielen", "." ]
[ "umlsterm" ]
Uebelkeit is an umlsterm, Erbrechen is an umlsterm, Risikofaktoren is an umlsterm, Patienten is an umlsterm
DerSchmerz.70110241.ger.abstr_task0
Sentence: Uebelkeit und Erbrechen ( PONV ) sind nach wie vor ein Problem der postoperativen Phase . Viele Risikofaktoren sind bekannt , jedoch sind die Bedeutung der unterschiedlichen postoperativen analgetischen Regimes und die Erwartungshaltung der Patienten wenig untermauert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Uebelkeit und Erbrechen ( PONV ) sind nach wie vor ein Problem der postoperativen Phase . Viele Risikofaktoren sind bekannt , jedoch sind die Bedeutung der unterschiedlichen postoperativen analgetischen Regimes und die Erwartungshaltung der Patienten wenig untermauert .
[ "Uebelkeit", "und", "Erbrechen", "(", "PONV", ")", "sind", "nach", "wie", "vor", "ein", "Problem", "der", "postoperativen", "Phase", ".", "Viele", "Risikofaktoren", "sind", "bekannt", ",", "jedoch", "sind", "die", "Bedeutung", "der", "unterschiedlichen", "postoperativen", "analgetischen", "Regimes", "und", "die", "Erwartungshaltung", "der", "Patienten", "wenig", "untermauert", "." ]
[ "umlsterm" ]
Uebelkeit is an umlsterm, Erbrechen is an umlsterm, Risikofaktoren is an umlsterm, Patienten is an umlsterm
DerSchmerz.70110241.ger.abstr_task1
Sentence: Uebelkeit und Erbrechen ( PONV ) sind nach wie vor ein Problem der postoperativen Phase . Viele Risikofaktoren sind bekannt , jedoch sind die Bedeutung der unterschiedlichen postoperativen analgetischen Regimes und die Erwartungshaltung der Patienten wenig untermauert . Instructions: please typing these entity words according to sentence: Uebelkeit, Erbrechen, Risikofaktoren, Patienten Options: umlsterm
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Uebelkeit und Erbrechen ( PONV ) sind nach wie vor ein Problem der postoperativen Phase . Viele Risikofaktoren sind bekannt , jedoch sind die Bedeutung der unterschiedlichen postoperativen analgetischen Regimes und die Erwartungshaltung der Patienten wenig untermauert .
[ "Uebelkeit", "und", "Erbrechen", "(", "PONV", ")", "sind", "nach", "wie", "vor", "ein", "Problem", "der", "postoperativen", "Phase", ".", "Viele", "Risikofaktoren", "sind", "bekannt", ",", "jedoch", "sind", "die", "Bedeutung", "der", "unterschiedlichen", "postoperativen", "analgetischen", "Regimes", "und", "die", "Erwartungshaltung", "der", "Patienten", "wenig", "untermauert", "." ]
[ "umlsterm" ]
Uebelkeit, Erbrechen, Risikofaktoren, Patienten
DerSchmerz.70110241.ger.abstr_task2
Sentence: Uebelkeit und Erbrechen ( PONV ) sind nach wie vor ein Problem der postoperativen Phase . Viele Risikofaktoren sind bekannt , jedoch sind die Bedeutung der unterschiedlichen postoperativen analgetischen Regimes und die Erwartungshaltung der Patienten wenig untermauert . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Uebelkeit und Erbrechen ( PONV ) sind nach wie vor ein Problem der postoperativen Phase . Viele Risikofaktoren sind bekannt , jedoch sind die Bedeutung der unterschiedlichen postoperativen analgetischen Regimes und die Erwartungshaltung der Patienten wenig untermauert .
[ "Uebelkeit", "und", "Erbrechen", "(", "PONV", ")", "sind", "nach", "wie", "vor", "ein", "Problem", "der", "postoperativen", "Phase", ".", "Viele", "Risikofaktoren", "sind", "bekannt", ",", "jedoch", "sind", "die", "Bedeutung", "der", "unterschiedlichen", "postoperativen", "analgetischen", "Regimes", "und", "die", "Erwartungshaltung", "der", "Patienten", "wenig", "untermauert", "." ]
[ "umlsterm" ]
citoqueratina-7 is a PROTEINAS, citoqueratina-20 is a PROTEINAS, citoquetatina is a PROTEINAS, Cisplatino is a NORMALIZABLES, Gemcitabina is a NORMALIZABLES, Paclitaxel is a NORMALIZABLES, Carboplatino is a NORMALIZABLES, creatinina is a NORMALIZABLES
422_task0
Sentence: Varón de 60 años de edad que acude a consulta en enero de 2009 por episodios de hematuria macroscópica ocasional de dos años de evolución. Transcurridos 10 meses desde el primer episodio empezó con polaquiuria y disuria, por lo que 2 meses después se realizó estudio ecográfico en el que se evidenciaba un engrosamiento de la pared vesical derecha que condicionaba ureterohidronefrosis. Se realizó estudio de extensión mediante TAC toraco-abdominal y gammagrafía ósea no apreciándose lesiones sugestivas de metástasis y confirmando los hallazgos ecográficos. En febrero de 2009, recibió tratamiento quirúrgico mediante RTU vesical con diagnóstico de carcinoma plasmocitoide de vejiga con invasión de la capa muscular propia y presencia de focos de embolización linfovascular, por lo que se le indicó una cisto-prostatectomía radical con derivación ileal que se practicó sin incidencias el 27 de marzo de 2009. El informe anatomopatológico reveló una neoformación epitelial atípica de crecimiento difuso con algunos nidos o cordones, constituidos por células de pequeño tamaño, citoplasma escaso y núcleo grande, pleomórfico y polilobulado. Además se observaron algunas áreas donde los núcleos eran más pleomórficos, polilobulados, grandes y muy hipercromáticos, respecto al resto de la población tumoral. Las figuras de mitosis tanto típicas y atípicas así como de apoptosis eran frecuentes. Las células neoplásicas infiltraban la pared vesical alcanzando la capa muscular propia. El estudio inmunohistoquímico citoplasmático fue positivo en un 100% para la citoqueratina-7 y en un 70% para la citoqueratina-20 y la citoquetatina de alto peso molecular con carácter difuso. El diagnóstico definitivo fue de carcinoma de urotelio poco diferenciado, de alto grado, variante de células plasmocitoides. A continuación, el paciente fue remitido al departamento de Oncología iniciando tratamiento quimioterápico adyuvante con Cisplatino y Gemcitabina (4 ciclos) que concluyó en agosto de 2009. En marzo de 2010, en exploración de control y estando el paciente asintomático, se objetivaron lesiones sugestivas de metástasis en columna, por lo que se realizó RM de columna en la que se informó de posibles metástasis a nivel de D3, D8, D9, D10 y L1. Se realizó gammagrafía ósea y PET-TAC que no fueron concluyentes, por lo que se recomiendó control evolutivo en tres meses. En dicho control se objetivó crecimiento de las lesiones óseas ya conocidas que se biopsiaron, no siendo concluyentes de malignidad. En septiembre de 2010 se repitió el PET-TAC no objetivándose signos de captación ósea patológica, pero sí ganglionar múltiple en región axilar izquierda, perivascular mediastínica, subcarinal y mamaria interna, así como a nivel retroperitoneal. Se realizó de nuevo punción con aguja fina vertebral que se informó como lesión metastásica compatible con tumor urotelial plasmocitoide. Además se realizó biopsia de ganglios mamarios que también se informaron como compatibles con lesiones metástasicas originarias del tumor urotelial plasmocitoide. En ese momento se inició una nueva línea de tratamiento quimioterápico con Paclitaxel y Carboplatino, en pauta trisemanal con un total de 6 ciclos, que concluyó en enero de 2011. A mitad de tratamiento quimioterápico se realizó nuevo TAC de control en el que la enfermedad permanecía estabilizada. El 17 de febrero de 2011, en TAC de reevaluación se objetivó ureterohidronefrosis moderada-severa derecha a expensas de imagen nodular que protruía en la luz ureteral sugestiva de nueva lesión tumoral. Además presentaba atrofia funcional del riñón contralateral con aumento de la creatinina plasmática hasta 2,9 ng/mL. Se decidió la colocación de una nefrostomía percutánea derecha con colocación de un catéter ureteral doble J por vía anterógrada. Durante este ingreso sufrió un IAM inferoposterior y de ventrículo derecho tratado mediante angioplastia primaria de manera eficaz. Finalmente, a mediados de marzo de 2011 falleció el paciente. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Varón de 60 años de edad que acude a consulta en enero de 2009 por episodios de hematuria macroscópica ocasional de dos años de evolución. Transcurridos 10 meses desde el primer episodio empezó con polaquiuria y disuria, por lo que 2 meses después se realizó estudio ecográfico en el que se evidenciaba un engrosamiento de la pared vesical derecha que condicionaba ureterohidronefrosis. Se realizó estudio de extensión mediante TAC toraco-abdominal y gammagrafía ósea no apreciándose lesiones sugestivas de metástasis y confirmando los hallazgos ecográficos. En febrero de 2009, recibió tratamiento quirúrgico mediante RTU vesical con diagnóstico de carcinoma plasmocitoide de vejiga con invasión de la capa muscular propia y presencia de focos de embolización linfovascular, por lo que se le indicó una cisto-prostatectomía radical con derivación ileal que se practicó sin incidencias el 27 de marzo de 2009. El informe anatomopatológico reveló una neoformación epitelial atípica de crecimiento difuso con algunos nidos o cordones, constituidos por células de pequeño tamaño, citoplasma escaso y núcleo grande, pleomórfico y polilobulado. Además se observaron algunas áreas donde los núcleos eran más pleomórficos, polilobulados, grandes y muy hipercromáticos, respecto al resto de la población tumoral. Las figuras de mitosis tanto típicas y atípicas así como de apoptosis eran frecuentes. Las células neoplásicas infiltraban la pared vesical alcanzando la capa muscular propia. El estudio inmunohistoquímico citoplasmático fue positivo en un 100% para la citoqueratina-7 y en un 70% para la citoqueratina-20 y la citoquetatina de alto peso molecular con carácter difuso. El diagnóstico definitivo fue de carcinoma de urotelio poco diferenciado, de alto grado, variante de células plasmocitoides. A continuación, el paciente fue remitido al departamento de Oncología iniciando tratamiento quimioterápico adyuvante con Cisplatino y Gemcitabina (4 ciclos) que concluyó en agosto de 2009. En marzo de 2010, en exploración de control y estando el paciente asintomático, se objetivaron lesiones sugestivas de metástasis en columna, por lo que se realizó RM de columna en la que se informó de posibles metástasis a nivel de D3, D8, D9, D10 y L1. Se realizó gammagrafía ósea y PET-TAC que no fueron concluyentes, por lo que se recomiendó control evolutivo en tres meses. En dicho control se objetivó crecimiento de las lesiones óseas ya conocidas que se biopsiaron, no siendo concluyentes de malignidad. En septiembre de 2010 se repitió el PET-TAC no objetivándose signos de captación ósea patológica, pero sí ganglionar múltiple en región axilar izquierda, perivascular mediastínica, subcarinal y mamaria interna, así como a nivel retroperitoneal. Se realizó de nuevo punción con aguja fina vertebral que se informó como lesión metastásica compatible con tumor urotelial plasmocitoide. Además se realizó biopsia de ganglios mamarios que también se informaron como compatibles con lesiones metástasicas originarias del tumor urotelial plasmocitoide. En ese momento se inició una nueva línea de tratamiento quimioterápico con Paclitaxel y Carboplatino, en pauta trisemanal con un total de 6 ciclos, que concluyó en enero de 2011. A mitad de tratamiento quimioterápico se realizó nuevo TAC de control en el que la enfermedad permanecía estabilizada. El 17 de febrero de 2011, en TAC de reevaluación se objetivó ureterohidronefrosis moderada-severa derecha a expensas de imagen nodular que protruía en la luz ureteral sugestiva de nueva lesión tumoral. Además presentaba atrofia funcional del riñón contralateral con aumento de la creatinina plasmática hasta 2,9 ng/mL. Se decidió la colocación de una nefrostomía percutánea derecha con colocación de un catéter ureteral doble J por vía anterógrada. Durante este ingreso sufrió un IAM inferoposterior y de ventrículo derecho tratado mediante angioplastia primaria de manera eficaz. Finalmente, a mediados de marzo de 2011 falleció el paciente.
[ "Varón", "de", "60", "años", "de", "edad", "que", "acude", "a", "consulta", "en", "enero", "de", "2009", "por", "episodios", "de", "hematuria", "macroscópica", "ocasional", "de", "dos", "años", "de", "evolución", ".", "Transcurridos", "10", "meses", "desde", "el", "primer", "episodio", "empezó", "con", "polaquiuria", "y", "disuria", ",", "por", "lo", "que", "2", "meses", "después", "se", "realizó", "estudio", "ecográfico", "en", "el", "que", "se", "evidenciaba", "un", "engrosamiento", "de", "la", "pared", "vesical", "derecha", "que", "condicionaba", "ureterohidronefrosis", ".", "Se", "realizó", "estudio", "de", "extensión", "mediante", "TAC", "toraco", "-", "abdominal", "y", "gammagrafía", "ósea", "no", "apreciándose", "lesiones", "sugestivas", "de", "metástasis", "y", "confirmando", "los", "hallazgos", "ecográficos", ".", "En", "febrero", "de", "2009", ",", "recibió", "tratamiento", "quirúrgico", "mediante", "RTU", "vesical", "con", "diagnóstico", "de", "carcinoma", "plasmocitoide", "de", "vejiga", "con", "invasión", "de", "la", "capa", "muscular", "propia", "y", "presencia", "de", "focos", "de", "embolización", "linfovascular", ",", "por", "lo", "que", "se", "le", "indicó", "una", "cisto", "-", "prostatectomía", "radical", "con", "derivación", "ileal", "que", "se", "practicó", "sin", "incidencias", "el", "27", "de", "marzo", "de", "2009", ".", "\n", "El", "informe", "anatomopatológico", "reveló", "una", "neoformación", "epitelial", "atípica", "de", "crecimiento", "difuso", "con", "algunos", "nidos", "o", "cordones", ",", "constituidos", "por", "células", "de", "pequeño", "tamaño", ",", "citoplasma", "escaso", "y", "núcleo", "grande", ",", "pleomórfico", "y", "polilobulado", ".", "Además", "se", "observaron", "algunas", "áreas", "donde", "los", "núcleos", "eran", "más", "pleomórficos", ",", "polilobulados", ",", "grandes", "y", "muy", "hipercromáticos", ",", "respecto", "al", "resto", "de", "la", "población", "tumoral", ".", "Las", "figuras", "de", "mitosis", "tanto", "típicas", "y", "atípicas", "así", "como", "de", "apoptosis", "eran", "frecuentes", ".", "Las", "células", "neoplásicas", "infiltraban", "la", "pared", "vesical", "alcanzando", "la", "capa", "muscular", "propia", ".", "El", "estudio", "inmunohistoquímico", "citoplasmático", "fue", "positivo", "en", "un", "100", "%", "para", "la", "citoqueratina-7", "y", "en", "un", "70", "%", "para", "la", "citoqueratina-20", "y", "la", "citoquetatina", "de", "alto", "peso", "molecular", "con", "carácter", "difuso", ".", "El", "diagnóstico", "definitivo", "fue", "de", "carcinoma", "de", "urotelio", "poco", "diferenciado", ",", "de", "alto", "grado", ",", "variante", "de", "células", "plasmocitoides", ".", "\n\n", "A", "continuación", ",", "el", "paciente", "fue", "remitido", "al", "departamento", "de", "Oncología", "iniciando", "tratamiento", "quimioterápico", "adyuvante", "con", "Cisplatino", "y", "Gemcitabina", "(", "4", "ciclos", ")", "que", "concluyó", "en", "agosto", "de", "2009", ".", "\n", "En", "marzo", "de", "2010", ",", "en", "exploración", "de", "control", "y", "estando", "el", "paciente", "asintomático", ",", "se", "objetivaron", "lesiones", "sugestivas", "de", "metástasis", "en", "columna", ",", "por", "lo", "que", "se", "realizó", "RM", "de", "columna", "en", "la", "que", "se", "informó", "de", "posibles", "metástasis", "a", "nivel", "de", "D3", ",", "D8", ",", "D9", ",", "D10", "y", "L1", ".", "Se", "realizó", "gammagrafía", "ósea", "y", "PET", "-", "TAC", "que", "no", "fueron", "concluyentes", ",", "por", "lo", "que", "se", "recomiendó", "control", "evolutivo", "en", "tres", "meses", ".", "En", "dicho", "control", "se", "objetivó", "crecimiento", "de", "las", "lesiones", "óseas", "ya", "conocidas", "que", "se", "biopsiaron", ",", "no", "siendo", "concluyentes", "de", "malignidad", ".", "\n", "En", "septiembre", "de", "2010", "se", "repitió", "el", "PET", "-", "TAC", "no", "objetivándose", "signos", "de", "captación", "ósea", "patológica", ",", "pero", "sí", "ganglionar", "múltiple", "en", "región", "axilar", "izquierda", ",", "perivascular", "mediastínica", ",", "subcarinal", "y", "mamaria", "interna", ",", "así", "como", "a", "nivel", "retroperitoneal", ".", "Se", "realizó", "de", "nuevo", "punción", "con", "aguja", "fina", "vertebral", "que", "se", "informó", "como", "lesión", "metastásica", "compatible", "con", "tumor", "urotelial", "plasmocitoide", ".", "Además", "se", "realizó", "biopsia", "de", "ganglios", "mamarios", "que", "también", "se", "informaron", "como", "compatibles", "con", "lesiones", "metástasicas", "originarias", "del", "tumor", "urotelial", "plasmocitoide", ".", "\n", "En", "ese", "momento", "se", "inició", "una", "nueva", "línea", "de", "tratamiento", "quimioterápico", "con", "Paclitaxel", "y", "Carboplatino", ",", "en", "pauta", "trisemanal", "con", "un", "total", "de", "6", "ciclos", ",", "que", "concluyó", "en", "enero", "de", "2011", ".", "A", "mitad", "de", "tratamiento", "quimioterápico", "se", "realizó", "nuevo", "TAC", "de", "control", "en", "el", "que", "la", "enfermedad", "permanecía", "estabilizada", ".", "\n", "El", "17", "de", "febrero", "de", "2011", ",", "en", "TAC", "de", "reevaluación", "se", "objetivó", "ureterohidronefrosis", "moderada", "-", "severa", "derecha", "a", "expensas", "de", "imagen", "nodular", "que", "protruía", "en", "la", "luz", "ureteral", "sugestiva", "de", "nueva", "lesión", "tumoral", ".", "Además", "presentaba", "atrofia", "funcional", "del", "riñón", "contralateral", "con", "aumento", "de", "la", "creatinina", "plasmática", "hasta", "2,9", "ng", "/", "mL.", "Se", "decidió", "la", "colocación", "de", "una", "nefrostomía", "percutánea", "derecha", "con", "colocación", "de", "un", "catéter", "ureteral", "doble", "J", "por", "vía", "anterógrada", ".", "Durante", "este", "ingreso", "sufrió", "un", "IAM", "inferoposterior", "y", "de", "ventrículo", "derecho", "tratado", "mediante", "angioplastia", "primaria", "de", "manera", "eficaz", ".", "\n", "Finalmente", ",", "a", "mediados", "de", "marzo", "de", "2011", "falleció", "el", "paciente", ".", "\n\n" ]
[ "PROTEINAS", "NORMALIZABLES" ]
citoqueratina-7 is a PROTEINAS, citoqueratina-20 is a PROTEINAS, citoquetatina is a PROTEINAS, Cisplatino is a NORMALIZABLES, Gemcitabina is a NORMALIZABLES, Paclitaxel is a NORMALIZABLES, Carboplatino is a NORMALIZABLES, creatinina is a NORMALIZABLES
422_task1
Sentence: Varón de 60 años de edad que acude a consulta en enero de 2009 por episodios de hematuria macroscópica ocasional de dos años de evolución. Transcurridos 10 meses desde el primer episodio empezó con polaquiuria y disuria, por lo que 2 meses después se realizó estudio ecográfico en el que se evidenciaba un engrosamiento de la pared vesical derecha que condicionaba ureterohidronefrosis. Se realizó estudio de extensión mediante TAC toraco-abdominal y gammagrafía ósea no apreciándose lesiones sugestivas de metástasis y confirmando los hallazgos ecográficos. En febrero de 2009, recibió tratamiento quirúrgico mediante RTU vesical con diagnóstico de carcinoma plasmocitoide de vejiga con invasión de la capa muscular propia y presencia de focos de embolización linfovascular, por lo que se le indicó una cisto-prostatectomía radical con derivación ileal que se practicó sin incidencias el 27 de marzo de 2009. El informe anatomopatológico reveló una neoformación epitelial atípica de crecimiento difuso con algunos nidos o cordones, constituidos por células de pequeño tamaño, citoplasma escaso y núcleo grande, pleomórfico y polilobulado. Además se observaron algunas áreas donde los núcleos eran más pleomórficos, polilobulados, grandes y muy hipercromáticos, respecto al resto de la población tumoral. Las figuras de mitosis tanto típicas y atípicas así como de apoptosis eran frecuentes. Las células neoplásicas infiltraban la pared vesical alcanzando la capa muscular propia. El estudio inmunohistoquímico citoplasmático fue positivo en un 100% para la citoqueratina-7 y en un 70% para la citoqueratina-20 y la citoquetatina de alto peso molecular con carácter difuso. El diagnóstico definitivo fue de carcinoma de urotelio poco diferenciado, de alto grado, variante de células plasmocitoides. A continuación, el paciente fue remitido al departamento de Oncología iniciando tratamiento quimioterápico adyuvante con Cisplatino y Gemcitabina (4 ciclos) que concluyó en agosto de 2009. En marzo de 2010, en exploración de control y estando el paciente asintomático, se objetivaron lesiones sugestivas de metástasis en columna, por lo que se realizó RM de columna en la que se informó de posibles metástasis a nivel de D3, D8, D9, D10 y L1. Se realizó gammagrafía ósea y PET-TAC que no fueron concluyentes, por lo que se recomiendó control evolutivo en tres meses. En dicho control se objetivó crecimiento de las lesiones óseas ya conocidas que se biopsiaron, no siendo concluyentes de malignidad. En septiembre de 2010 se repitió el PET-TAC no objetivándose signos de captación ósea patológica, pero sí ganglionar múltiple en región axilar izquierda, perivascular mediastínica, subcarinal y mamaria interna, así como a nivel retroperitoneal. Se realizó de nuevo punción con aguja fina vertebral que se informó como lesión metastásica compatible con tumor urotelial plasmocitoide. Además se realizó biopsia de ganglios mamarios que también se informaron como compatibles con lesiones metástasicas originarias del tumor urotelial plasmocitoide. En ese momento se inició una nueva línea de tratamiento quimioterápico con Paclitaxel y Carboplatino, en pauta trisemanal con un total de 6 ciclos, que concluyó en enero de 2011. A mitad de tratamiento quimioterápico se realizó nuevo TAC de control en el que la enfermedad permanecía estabilizada. El 17 de febrero de 2011, en TAC de reevaluación se objetivó ureterohidronefrosis moderada-severa derecha a expensas de imagen nodular que protruía en la luz ureteral sugestiva de nueva lesión tumoral. Además presentaba atrofia funcional del riñón contralateral con aumento de la creatinina plasmática hasta 2,9 ng/mL. Se decidió la colocación de una nefrostomía percutánea derecha con colocación de un catéter ureteral doble J por vía anterógrada. Durante este ingreso sufrió un IAM inferoposterior y de ventrículo derecho tratado mediante angioplastia primaria de manera eficaz. Finalmente, a mediados de marzo de 2011 falleció el paciente. Instructions: please typing these entity words according to sentence: citoqueratina-7, citoqueratina-20, citoquetatina, Cisplatino, Gemcitabina, Paclitaxel, Carboplatino, creatinina Options: NORMALIZABLES, PROTEINAS
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Varón de 60 años de edad que acude a consulta en enero de 2009 por episodios de hematuria macroscópica ocasional de dos años de evolución. Transcurridos 10 meses desde el primer episodio empezó con polaquiuria y disuria, por lo que 2 meses después se realizó estudio ecográfico en el que se evidenciaba un engrosamiento de la pared vesical derecha que condicionaba ureterohidronefrosis. Se realizó estudio de extensión mediante TAC toraco-abdominal y gammagrafía ósea no apreciándose lesiones sugestivas de metástasis y confirmando los hallazgos ecográficos. En febrero de 2009, recibió tratamiento quirúrgico mediante RTU vesical con diagnóstico de carcinoma plasmocitoide de vejiga con invasión de la capa muscular propia y presencia de focos de embolización linfovascular, por lo que se le indicó una cisto-prostatectomía radical con derivación ileal que se practicó sin incidencias el 27 de marzo de 2009. El informe anatomopatológico reveló una neoformación epitelial atípica de crecimiento difuso con algunos nidos o cordones, constituidos por células de pequeño tamaño, citoplasma escaso y núcleo grande, pleomórfico y polilobulado. Además se observaron algunas áreas donde los núcleos eran más pleomórficos, polilobulados, grandes y muy hipercromáticos, respecto al resto de la población tumoral. Las figuras de mitosis tanto típicas y atípicas así como de apoptosis eran frecuentes. Las células neoplásicas infiltraban la pared vesical alcanzando la capa muscular propia. El estudio inmunohistoquímico citoplasmático fue positivo en un 100% para la citoqueratina-7 y en un 70% para la citoqueratina-20 y la citoquetatina de alto peso molecular con carácter difuso. El diagnóstico definitivo fue de carcinoma de urotelio poco diferenciado, de alto grado, variante de células plasmocitoides. A continuación, el paciente fue remitido al departamento de Oncología iniciando tratamiento quimioterápico adyuvante con Cisplatino y Gemcitabina (4 ciclos) que concluyó en agosto de 2009. En marzo de 2010, en exploración de control y estando el paciente asintomático, se objetivaron lesiones sugestivas de metástasis en columna, por lo que se realizó RM de columna en la que se informó de posibles metástasis a nivel de D3, D8, D9, D10 y L1. Se realizó gammagrafía ósea y PET-TAC que no fueron concluyentes, por lo que se recomiendó control evolutivo en tres meses. En dicho control se objetivó crecimiento de las lesiones óseas ya conocidas que se biopsiaron, no siendo concluyentes de malignidad. En septiembre de 2010 se repitió el PET-TAC no objetivándose signos de captación ósea patológica, pero sí ganglionar múltiple en región axilar izquierda, perivascular mediastínica, subcarinal y mamaria interna, así como a nivel retroperitoneal. Se realizó de nuevo punción con aguja fina vertebral que se informó como lesión metastásica compatible con tumor urotelial plasmocitoide. Además se realizó biopsia de ganglios mamarios que también se informaron como compatibles con lesiones metástasicas originarias del tumor urotelial plasmocitoide. En ese momento se inició una nueva línea de tratamiento quimioterápico con Paclitaxel y Carboplatino, en pauta trisemanal con un total de 6 ciclos, que concluyó en enero de 2011. A mitad de tratamiento quimioterápico se realizó nuevo TAC de control en el que la enfermedad permanecía estabilizada. El 17 de febrero de 2011, en TAC de reevaluación se objetivó ureterohidronefrosis moderada-severa derecha a expensas de imagen nodular que protruía en la luz ureteral sugestiva de nueva lesión tumoral. Además presentaba atrofia funcional del riñón contralateral con aumento de la creatinina plasmática hasta 2,9 ng/mL. Se decidió la colocación de una nefrostomía percutánea derecha con colocación de un catéter ureteral doble J por vía anterógrada. Durante este ingreso sufrió un IAM inferoposterior y de ventrículo derecho tratado mediante angioplastia primaria de manera eficaz. Finalmente, a mediados de marzo de 2011 falleció el paciente.
[ "Varón", "de", "60", "años", "de", "edad", "que", "acude", "a", "consulta", "en", "enero", "de", "2009", "por", "episodios", "de", "hematuria", "macroscópica", "ocasional", "de", "dos", "años", "de", "evolución", ".", "Transcurridos", "10", "meses", "desde", "el", "primer", "episodio", "empezó", "con", "polaquiuria", "y", "disuria", ",", "por", "lo", "que", "2", "meses", "después", "se", "realizó", "estudio", "ecográfico", "en", "el", "que", "se", "evidenciaba", "un", "engrosamiento", "de", "la", "pared", "vesical", "derecha", "que", "condicionaba", "ureterohidronefrosis", ".", "Se", "realizó", "estudio", "de", "extensión", "mediante", "TAC", "toraco", "-", "abdominal", "y", "gammagrafía", "ósea", "no", "apreciándose", "lesiones", "sugestivas", "de", "metástasis", "y", "confirmando", "los", "hallazgos", "ecográficos", ".", "En", "febrero", "de", "2009", ",", "recibió", "tratamiento", "quirúrgico", "mediante", "RTU", "vesical", "con", "diagnóstico", "de", "carcinoma", "plasmocitoide", "de", "vejiga", "con", "invasión", "de", "la", "capa", "muscular", "propia", "y", "presencia", "de", "focos", "de", "embolización", "linfovascular", ",", "por", "lo", "que", "se", "le", "indicó", "una", "cisto", "-", "prostatectomía", "radical", "con", "derivación", "ileal", "que", "se", "practicó", "sin", "incidencias", "el", "27", "de", "marzo", "de", "2009", ".", "\n", "El", "informe", "anatomopatológico", "reveló", "una", "neoformación", "epitelial", "atípica", "de", "crecimiento", "difuso", "con", "algunos", "nidos", "o", "cordones", ",", "constituidos", "por", "células", "de", "pequeño", "tamaño", ",", "citoplasma", "escaso", "y", "núcleo", "grande", ",", "pleomórfico", "y", "polilobulado", ".", "Además", "se", "observaron", "algunas", "áreas", "donde", "los", "núcleos", "eran", "más", "pleomórficos", ",", "polilobulados", ",", "grandes", "y", "muy", "hipercromáticos", ",", "respecto", "al", "resto", "de", "la", "población", "tumoral", ".", "Las", "figuras", "de", "mitosis", "tanto", "típicas", "y", "atípicas", "así", "como", "de", "apoptosis", "eran", "frecuentes", ".", "Las", "células", "neoplásicas", "infiltraban", "la", "pared", "vesical", "alcanzando", "la", "capa", "muscular", "propia", ".", "El", "estudio", "inmunohistoquímico", "citoplasmático", "fue", "positivo", "en", "un", "100", "%", "para", "la", "citoqueratina-7", "y", "en", "un", "70", "%", "para", "la", "citoqueratina-20", "y", "la", "citoquetatina", "de", "alto", "peso", "molecular", "con", "carácter", "difuso", ".", "El", "diagnóstico", "definitivo", "fue", "de", "carcinoma", "de", "urotelio", "poco", "diferenciado", ",", "de", "alto", "grado", ",", "variante", "de", "células", "plasmocitoides", ".", "\n\n", "A", "continuación", ",", "el", "paciente", "fue", "remitido", "al", "departamento", "de", "Oncología", "iniciando", "tratamiento", "quimioterápico", "adyuvante", "con", "Cisplatino", "y", "Gemcitabina", "(", "4", "ciclos", ")", "que", "concluyó", "en", "agosto", "de", "2009", ".", "\n", "En", "marzo", "de", "2010", ",", "en", "exploración", "de", "control", "y", "estando", "el", "paciente", "asintomático", ",", "se", "objetivaron", "lesiones", "sugestivas", "de", "metástasis", "en", "columna", ",", "por", "lo", "que", "se", "realizó", "RM", "de", "columna", "en", "la", "que", "se", "informó", "de", "posibles", "metástasis", "a", "nivel", "de", "D3", ",", "D8", ",", "D9", ",", "D10", "y", "L1", ".", "Se", "realizó", "gammagrafía", "ósea", "y", "PET", "-", "TAC", "que", "no", "fueron", "concluyentes", ",", "por", "lo", "que", "se", "recomiendó", "control", "evolutivo", "en", "tres", "meses", ".", "En", "dicho", "control", "se", "objetivó", "crecimiento", "de", "las", "lesiones", "óseas", "ya", "conocidas", "que", "se", "biopsiaron", ",", "no", "siendo", "concluyentes", "de", "malignidad", ".", "\n", "En", "septiembre", "de", "2010", "se", "repitió", "el", "PET", "-", "TAC", "no", "objetivándose", "signos", "de", "captación", "ósea", "patológica", ",", "pero", "sí", "ganglionar", "múltiple", "en", "región", "axilar", "izquierda", ",", "perivascular", "mediastínica", ",", "subcarinal", "y", "mamaria", "interna", ",", "así", "como", "a", "nivel", "retroperitoneal", ".", "Se", "realizó", "de", "nuevo", "punción", "con", "aguja", "fina", "vertebral", "que", "se", "informó", "como", "lesión", "metastásica", "compatible", "con", "tumor", "urotelial", "plasmocitoide", ".", "Además", "se", "realizó", "biopsia", "de", "ganglios", "mamarios", "que", "también", "se", "informaron", "como", "compatibles", "con", "lesiones", "metástasicas", "originarias", "del", "tumor", "urotelial", "plasmocitoide", ".", "\n", "En", "ese", "momento", "se", "inició", "una", "nueva", "línea", "de", "tratamiento", "quimioterápico", "con", "Paclitaxel", "y", "Carboplatino", ",", "en", "pauta", "trisemanal", "con", "un", "total", "de", "6", "ciclos", ",", "que", "concluyó", "en", "enero", "de", "2011", ".", "A", "mitad", "de", "tratamiento", "quimioterápico", "se", "realizó", "nuevo", "TAC", "de", "control", "en", "el", "que", "la", "enfermedad", "permanecía", "estabilizada", ".", "\n", "El", "17", "de", "febrero", "de", "2011", ",", "en", "TAC", "de", "reevaluación", "se", "objetivó", "ureterohidronefrosis", "moderada", "-", "severa", "derecha", "a", "expensas", "de", "imagen", "nodular", "que", "protruía", "en", "la", "luz", "ureteral", "sugestiva", "de", "nueva", "lesión", "tumoral", ".", "Además", "presentaba", "atrofia", "funcional", "del", "riñón", "contralateral", "con", "aumento", "de", "la", "creatinina", "plasmática", "hasta", "2,9", "ng", "/", "mL.", "Se", "decidió", "la", "colocación", "de", "una", "nefrostomía", "percutánea", "derecha", "con", "colocación", "de", "un", "catéter", "ureteral", "doble", "J", "por", "vía", "anterógrada", ".", "Durante", "este", "ingreso", "sufrió", "un", "IAM", "inferoposterior", "y", "de", "ventrículo", "derecho", "tratado", "mediante", "angioplastia", "primaria", "de", "manera", "eficaz", ".", "\n", "Finalmente", ",", "a", "mediados", "de", "marzo", "de", "2011", "falleció", "el", "paciente", ".", "\n\n" ]
[ "PROTEINAS", "NORMALIZABLES" ]
citoqueratina-7, citoqueratina-20, citoquetatina, Cisplatino, Gemcitabina, Paclitaxel, Carboplatino, creatinina
422_task2
Sentence: Varón de 60 años de edad que acude a consulta en enero de 2009 por episodios de hematuria macroscópica ocasional de dos años de evolución. Transcurridos 10 meses desde el primer episodio empezó con polaquiuria y disuria, por lo que 2 meses después se realizó estudio ecográfico en el que se evidenciaba un engrosamiento de la pared vesical derecha que condicionaba ureterohidronefrosis. Se realizó estudio de extensión mediante TAC toraco-abdominal y gammagrafía ósea no apreciándose lesiones sugestivas de metástasis y confirmando los hallazgos ecográficos. En febrero de 2009, recibió tratamiento quirúrgico mediante RTU vesical con diagnóstico de carcinoma plasmocitoide de vejiga con invasión de la capa muscular propia y presencia de focos de embolización linfovascular, por lo que se le indicó una cisto-prostatectomía radical con derivación ileal que se practicó sin incidencias el 27 de marzo de 2009. El informe anatomopatológico reveló una neoformación epitelial atípica de crecimiento difuso con algunos nidos o cordones, constituidos por células de pequeño tamaño, citoplasma escaso y núcleo grande, pleomórfico y polilobulado. Además se observaron algunas áreas donde los núcleos eran más pleomórficos, polilobulados, grandes y muy hipercromáticos, respecto al resto de la población tumoral. Las figuras de mitosis tanto típicas y atípicas así como de apoptosis eran frecuentes. Las células neoplásicas infiltraban la pared vesical alcanzando la capa muscular propia. El estudio inmunohistoquímico citoplasmático fue positivo en un 100% para la citoqueratina-7 y en un 70% para la citoqueratina-20 y la citoquetatina de alto peso molecular con carácter difuso. El diagnóstico definitivo fue de carcinoma de urotelio poco diferenciado, de alto grado, variante de células plasmocitoides. A continuación, el paciente fue remitido al departamento de Oncología iniciando tratamiento quimioterápico adyuvante con Cisplatino y Gemcitabina (4 ciclos) que concluyó en agosto de 2009. En marzo de 2010, en exploración de control y estando el paciente asintomático, se objetivaron lesiones sugestivas de metástasis en columna, por lo que se realizó RM de columna en la que se informó de posibles metástasis a nivel de D3, D8, D9, D10 y L1. Se realizó gammagrafía ósea y PET-TAC que no fueron concluyentes, por lo que se recomiendó control evolutivo en tres meses. En dicho control se objetivó crecimiento de las lesiones óseas ya conocidas que se biopsiaron, no siendo concluyentes de malignidad. En septiembre de 2010 se repitió el PET-TAC no objetivándose signos de captación ósea patológica, pero sí ganglionar múltiple en región axilar izquierda, perivascular mediastínica, subcarinal y mamaria interna, así como a nivel retroperitoneal. Se realizó de nuevo punción con aguja fina vertebral que se informó como lesión metastásica compatible con tumor urotelial plasmocitoide. Además se realizó biopsia de ganglios mamarios que también se informaron como compatibles con lesiones metástasicas originarias del tumor urotelial plasmocitoide. En ese momento se inició una nueva línea de tratamiento quimioterápico con Paclitaxel y Carboplatino, en pauta trisemanal con un total de 6 ciclos, que concluyó en enero de 2011. A mitad de tratamiento quimioterápico se realizó nuevo TAC de control en el que la enfermedad permanecía estabilizada. El 17 de febrero de 2011, en TAC de reevaluación se objetivó ureterohidronefrosis moderada-severa derecha a expensas de imagen nodular que protruía en la luz ureteral sugestiva de nueva lesión tumoral. Además presentaba atrofia funcional del riñón contralateral con aumento de la creatinina plasmática hasta 2,9 ng/mL. Se decidió la colocación de una nefrostomía percutánea derecha con colocación de un catéter ureteral doble J por vía anterógrada. Durante este ingreso sufrió un IAM inferoposterior y de ventrículo derecho tratado mediante angioplastia primaria de manera eficaz. Finalmente, a mediados de marzo de 2011 falleció el paciente. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Varón de 60 años de edad que acude a consulta en enero de 2009 por episodios de hematuria macroscópica ocasional de dos años de evolución. Transcurridos 10 meses desde el primer episodio empezó con polaquiuria y disuria, por lo que 2 meses después se realizó estudio ecográfico en el que se evidenciaba un engrosamiento de la pared vesical derecha que condicionaba ureterohidronefrosis. Se realizó estudio de extensión mediante TAC toraco-abdominal y gammagrafía ósea no apreciándose lesiones sugestivas de metástasis y confirmando los hallazgos ecográficos. En febrero de 2009, recibió tratamiento quirúrgico mediante RTU vesical con diagnóstico de carcinoma plasmocitoide de vejiga con invasión de la capa muscular propia y presencia de focos de embolización linfovascular, por lo que se le indicó una cisto-prostatectomía radical con derivación ileal que se practicó sin incidencias el 27 de marzo de 2009. El informe anatomopatológico reveló una neoformación epitelial atípica de crecimiento difuso con algunos nidos o cordones, constituidos por células de pequeño tamaño, citoplasma escaso y núcleo grande, pleomórfico y polilobulado. Además se observaron algunas áreas donde los núcleos eran más pleomórficos, polilobulados, grandes y muy hipercromáticos, respecto al resto de la población tumoral. Las figuras de mitosis tanto típicas y atípicas así como de apoptosis eran frecuentes. Las células neoplásicas infiltraban la pared vesical alcanzando la capa muscular propia. El estudio inmunohistoquímico citoplasmático fue positivo en un 100% para la citoqueratina-7 y en un 70% para la citoqueratina-20 y la citoquetatina de alto peso molecular con carácter difuso. El diagnóstico definitivo fue de carcinoma de urotelio poco diferenciado, de alto grado, variante de células plasmocitoides. A continuación, el paciente fue remitido al departamento de Oncología iniciando tratamiento quimioterápico adyuvante con Cisplatino y Gemcitabina (4 ciclos) que concluyó en agosto de 2009. En marzo de 2010, en exploración de control y estando el paciente asintomático, se objetivaron lesiones sugestivas de metástasis en columna, por lo que se realizó RM de columna en la que se informó de posibles metástasis a nivel de D3, D8, D9, D10 y L1. Se realizó gammagrafía ósea y PET-TAC que no fueron concluyentes, por lo que se recomiendó control evolutivo en tres meses. En dicho control se objetivó crecimiento de las lesiones óseas ya conocidas que se biopsiaron, no siendo concluyentes de malignidad. En septiembre de 2010 se repitió el PET-TAC no objetivándose signos de captación ósea patológica, pero sí ganglionar múltiple en región axilar izquierda, perivascular mediastínica, subcarinal y mamaria interna, así como a nivel retroperitoneal. Se realizó de nuevo punción con aguja fina vertebral que se informó como lesión metastásica compatible con tumor urotelial plasmocitoide. Además se realizó biopsia de ganglios mamarios que también se informaron como compatibles con lesiones metástasicas originarias del tumor urotelial plasmocitoide. En ese momento se inició una nueva línea de tratamiento quimioterápico con Paclitaxel y Carboplatino, en pauta trisemanal con un total de 6 ciclos, que concluyó en enero de 2011. A mitad de tratamiento quimioterápico se realizó nuevo TAC de control en el que la enfermedad permanecía estabilizada. El 17 de febrero de 2011, en TAC de reevaluación se objetivó ureterohidronefrosis moderada-severa derecha a expensas de imagen nodular que protruía en la luz ureteral sugestiva de nueva lesión tumoral. Además presentaba atrofia funcional del riñón contralateral con aumento de la creatinina plasmática hasta 2,9 ng/mL. Se decidió la colocación de una nefrostomía percutánea derecha con colocación de un catéter ureteral doble J por vía anterógrada. Durante este ingreso sufrió un IAM inferoposterior y de ventrículo derecho tratado mediante angioplastia primaria de manera eficaz. Finalmente, a mediados de marzo de 2011 falleció el paciente.
[ "Varón", "de", "60", "años", "de", "edad", "que", "acude", "a", "consulta", "en", "enero", "de", "2009", "por", "episodios", "de", "hematuria", "macroscópica", "ocasional", "de", "dos", "años", "de", "evolución", ".", "Transcurridos", "10", "meses", "desde", "el", "primer", "episodio", "empezó", "con", "polaquiuria", "y", "disuria", ",", "por", "lo", "que", "2", "meses", "después", "se", "realizó", "estudio", "ecográfico", "en", "el", "que", "se", "evidenciaba", "un", "engrosamiento", "de", "la", "pared", "vesical", "derecha", "que", "condicionaba", "ureterohidronefrosis", ".", "Se", "realizó", "estudio", "de", "extensión", "mediante", "TAC", "toraco", "-", "abdominal", "y", "gammagrafía", "ósea", "no", "apreciándose", "lesiones", "sugestivas", "de", "metástasis", "y", "confirmando", "los", "hallazgos", "ecográficos", ".", "En", "febrero", "de", "2009", ",", "recibió", "tratamiento", "quirúrgico", "mediante", "RTU", "vesical", "con", "diagnóstico", "de", "carcinoma", "plasmocitoide", "de", "vejiga", "con", "invasión", "de", "la", "capa", "muscular", "propia", "y", "presencia", "de", "focos", "de", "embolización", "linfovascular", ",", "por", "lo", "que", "se", "le", "indicó", "una", "cisto", "-", "prostatectomía", "radical", "con", "derivación", "ileal", "que", "se", "practicó", "sin", "incidencias", "el", "27", "de", "marzo", "de", "2009", ".", "\n", "El", "informe", "anatomopatológico", "reveló", "una", "neoformación", "epitelial", "atípica", "de", "crecimiento", "difuso", "con", "algunos", "nidos", "o", "cordones", ",", "constituidos", "por", "células", "de", "pequeño", "tamaño", ",", "citoplasma", "escaso", "y", "núcleo", "grande", ",", "pleomórfico", "y", "polilobulado", ".", "Además", "se", "observaron", "algunas", "áreas", "donde", "los", "núcleos", "eran", "más", "pleomórficos", ",", "polilobulados", ",", "grandes", "y", "muy", "hipercromáticos", ",", "respecto", "al", "resto", "de", "la", "población", "tumoral", ".", "Las", "figuras", "de", "mitosis", "tanto", "típicas", "y", "atípicas", "así", "como", "de", "apoptosis", "eran", "frecuentes", ".", "Las", "células", "neoplásicas", "infiltraban", "la", "pared", "vesical", "alcanzando", "la", "capa", "muscular", "propia", ".", "El", "estudio", "inmunohistoquímico", "citoplasmático", "fue", "positivo", "en", "un", "100", "%", "para", "la", "citoqueratina-7", "y", "en", "un", "70", "%", "para", "la", "citoqueratina-20", "y", "la", "citoquetatina", "de", "alto", "peso", "molecular", "con", "carácter", "difuso", ".", "El", "diagnóstico", "definitivo", "fue", "de", "carcinoma", "de", "urotelio", "poco", "diferenciado", ",", "de", "alto", "grado", ",", "variante", "de", "células", "plasmocitoides", ".", "\n\n", "A", "continuación", ",", "el", "paciente", "fue", "remitido", "al", "departamento", "de", "Oncología", "iniciando", "tratamiento", "quimioterápico", "adyuvante", "con", "Cisplatino", "y", "Gemcitabina", "(", "4", "ciclos", ")", "que", "concluyó", "en", "agosto", "de", "2009", ".", "\n", "En", "marzo", "de", "2010", ",", "en", "exploración", "de", "control", "y", "estando", "el", "paciente", "asintomático", ",", "se", "objetivaron", "lesiones", "sugestivas", "de", "metástasis", "en", "columna", ",", "por", "lo", "que", "se", "realizó", "RM", "de", "columna", "en", "la", "que", "se", "informó", "de", "posibles", "metástasis", "a", "nivel", "de", "D3", ",", "D8", ",", "D9", ",", "D10", "y", "L1", ".", "Se", "realizó", "gammagrafía", "ósea", "y", "PET", "-", "TAC", "que", "no", "fueron", "concluyentes", ",", "por", "lo", "que", "se", "recomiendó", "control", "evolutivo", "en", "tres", "meses", ".", "En", "dicho", "control", "se", "objetivó", "crecimiento", "de", "las", "lesiones", "óseas", "ya", "conocidas", "que", "se", "biopsiaron", ",", "no", "siendo", "concluyentes", "de", "malignidad", ".", "\n", "En", "septiembre", "de", "2010", "se", "repitió", "el", "PET", "-", "TAC", "no", "objetivándose", "signos", "de", "captación", "ósea", "patológica", ",", "pero", "sí", "ganglionar", "múltiple", "en", "región", "axilar", "izquierda", ",", "perivascular", "mediastínica", ",", "subcarinal", "y", "mamaria", "interna", ",", "así", "como", "a", "nivel", "retroperitoneal", ".", "Se", "realizó", "de", "nuevo", "punción", "con", "aguja", "fina", "vertebral", "que", "se", "informó", "como", "lesión", "metastásica", "compatible", "con", "tumor", "urotelial", "plasmocitoide", ".", "Además", "se", "realizó", "biopsia", "de", "ganglios", "mamarios", "que", "también", "se", "informaron", "como", "compatibles", "con", "lesiones", "metástasicas", "originarias", "del", "tumor", "urotelial", "plasmocitoide", ".", "\n", "En", "ese", "momento", "se", "inició", "una", "nueva", "línea", "de", "tratamiento", "quimioterápico", "con", "Paclitaxel", "y", "Carboplatino", ",", "en", "pauta", "trisemanal", "con", "un", "total", "de", "6", "ciclos", ",", "que", "concluyó", "en", "enero", "de", "2011", ".", "A", "mitad", "de", "tratamiento", "quimioterápico", "se", "realizó", "nuevo", "TAC", "de", "control", "en", "el", "que", "la", "enfermedad", "permanecía", "estabilizada", ".", "\n", "El", "17", "de", "febrero", "de", "2011", ",", "en", "TAC", "de", "reevaluación", "se", "objetivó", "ureterohidronefrosis", "moderada", "-", "severa", "derecha", "a", "expensas", "de", "imagen", "nodular", "que", "protruía", "en", "la", "luz", "ureteral", "sugestiva", "de", "nueva", "lesión", "tumoral", ".", "Además", "presentaba", "atrofia", "funcional", "del", "riñón", "contralateral", "con", "aumento", "de", "la", "creatinina", "plasmática", "hasta", "2,9", "ng", "/", "mL.", "Se", "decidió", "la", "colocación", "de", "una", "nefrostomía", "percutánea", "derecha", "con", "colocación", "de", "un", "catéter", "ureteral", "doble", "J", "por", "vía", "anterógrada", ".", "Durante", "este", "ingreso", "sufrió", "un", "IAM", "inferoposterior", "y", "de", "ventrículo", "derecho", "tratado", "mediante", "angioplastia", "primaria", "de", "manera", "eficaz", ".", "\n", "Finalmente", ",", "a", "mediados", "de", "marzo", "de", "2011", "falleció", "el", "paciente", ".", "\n\n" ]
[ "PROTEINAS", "NORMALIZABLES" ]
Cardiovascular safety is a Outcome_Other, gastrointestinal tolerability is a Outcome_Other, etoricoxib is a Intervention_Pharmacological, diclofenac is a Intervention_Pharmacological, cardiovascular ( CV ) and other safety and efficacy parameters is a Outcome_Other, OA patients is a Participant_Condition, RA patients is a Participant_Condition, thrombotic CV events is a Outcome_Physical, Other safety and efficacy parameters is a Outcome_Other, 23 504 is a Participant_Sample-size, thrombotic CV risk hazard ratio is a Outcome_Other, cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate is a Outcome_Adverse-effects, systolic blood pressure is a Outcome_Physical, renovascular AEs is a Outcome_Physical, GI / liver tolerability profile is a Outcome_Other
39218_task0
Sentence: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial ( The MEDAL study ) . OBJECTIVE To compare cardiovascular ( CV ) and other safety and efficacy parameters of etoricoxib 60 and 90 mg , and diclofenac 150 mg. METHODS This double-blind study randomized OA patients to etoricoxib 90 mg , then to 60 mg once daily vs diclofenac 75 mg twice daily ; RA patients were randomized to etoricoxib 90 mg once daily or diclofenac 75 mg twice daily . The primary endpoint was non-inferiority of etoricoxib vs diclofenac for thrombotic CV events ( 95 % CI upper bound of hazard ratio < 1.30 ) . Other safety and efficacy parameters were evaluated in cohorts of patients based on etoricoxib dose and disease . RESULTS A total of 23 504 patients were randomized with mean treatment duration from 19.4 to 20.8 months . The thrombotic CV risk hazard ratio ( HR ) ( etoricoxib to diclofenac ) was 0.96 ( 95 % CI 0.81 , 1.15 ) , consistent with non-inferiority of etoricoxib to diclofenac . The cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort ; HR ( 95 % CI ) of 0.46 ( 0.39 , 0.54 ) , 0.52 ( 0.42 , 0.63 ) and 0.49 ( 0.39 , 0.62 ) for the 60 mg OA , 90 mg OA and RA cohorts . The maximum average change in systolic blood pressure ( BP ) with etoricoxib was 3.4-3.6 mmHg ( diastolic BP : 1.0-1.5 mmHg ) , while diclofenac produced a maximum average change of 0.9-1.9 mmHg ( diastolic BP : 0.0-0.5 mmHg ) . Both agents resulted in similar efficacy regardless of etoricoxib dose . CONCLUSION Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac . Compared with diclofenac , etoricoxib demonstrated a greater risk of renovascular AEs , but a more favourable GI/liver tolerability profile . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial ( The MEDAL study ) . OBJECTIVE To compare cardiovascular ( CV ) and other safety and efficacy parameters of etoricoxib 60 and 90 mg , and diclofenac 150 mg. METHODS This double-blind study randomized OA patients to etoricoxib 90 mg , then to 60 mg once daily vs diclofenac 75 mg twice daily ; RA patients were randomized to etoricoxib 90 mg once daily or diclofenac 75 mg twice daily . The primary endpoint was non-inferiority of etoricoxib vs diclofenac for thrombotic CV events ( 95 % CI upper bound of hazard ratio < 1.30 ) . Other safety and efficacy parameters were evaluated in cohorts of patients based on etoricoxib dose and disease . RESULTS A total of 23 504 patients were randomized with mean treatment duration from 19.4 to 20.8 months . The thrombotic CV risk hazard ratio ( HR ) ( etoricoxib to diclofenac ) was 0.96 ( 95 % CI 0.81 , 1.15 ) , consistent with non-inferiority of etoricoxib to diclofenac . The cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort ; HR ( 95 % CI ) of 0.46 ( 0.39 , 0.54 ) , 0.52 ( 0.42 , 0.63 ) and 0.49 ( 0.39 , 0.62 ) for the 60 mg OA , 90 mg OA and RA cohorts . The maximum average change in systolic blood pressure ( BP ) with etoricoxib was 3.4-3.6 mmHg ( diastolic BP : 1.0-1.5 mmHg ) , while diclofenac produced a maximum average change of 0.9-1.9 mmHg ( diastolic BP : 0.0-0.5 mmHg ) . Both agents resulted in similar efficacy regardless of etoricoxib dose . CONCLUSION Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac . Compared with diclofenac , etoricoxib demonstrated a greater risk of renovascular AEs , but a more favourable GI/liver tolerability profile .
[ "Cardiovascular", "safety", "and", "gastrointestinal", "tolerability", "of", "etoricoxib", "vs", "diclofenac", "in", "a", "randomized", "controlled", "clinical", "trial", "(", "The", "MEDAL", "study", ")", ".", "OBJECTIVE", "To", "compare", "cardiovascular", "(", "CV", ")", "and", "other", "safety", "and", "efficacy", "parameters", "of", "etoricoxib", "60", "and", "90", "mg", ",", "and", "diclofenac", "150", "mg", ".", "METHODS", "This", "double", "-", "blind", "study", "randomized", "OA", "patients", "to", "etoricoxib", "90", "mg", ",", "then", "to", "60", "mg", "once", "daily", "vs", "diclofenac", "75", "mg", "twice", "daily", ";", "RA", "patients", "were", "randomized", "to", "etoricoxib", "90", "mg", "once", "daily", "or", "diclofenac", "75", "mg", "twice", "daily", ".", "The", "primary", "endpoint", "was", "non", "-", "inferiority", "of", "etoricoxib", "vs", "diclofenac", "for", "thrombotic", "CV", "events", "(", "95", "%", "CI", "upper", "bound", "of", "hazard", "ratio", "<", "1.30", ")", ".", "Other", "safety", "and", "efficacy", "parameters", "were", "evaluated", "in", "cohorts", "of", "patients", "based", "on", "etoricoxib", "dose", "and", "disease", ".", "RESULTS", "A", "total", "of", "23", "504", "patients", "were", "randomized", "with", "mean", "treatment", "duration", "from", "19.4", "to", "20.8", "months", ".", "The", "thrombotic", "CV", "risk", "hazard", "ratio", "(", "HR", ")", "(", "etoricoxib", "to", "diclofenac", ")", "was", "0.96", "(", "95", "%", "CI", "0.81", ",", "1.15", ")", ",", "consistent", "with", "non", "-", "inferiority", "of", "etoricoxib", "to", "diclofenac", ".", "The", "cumulative", "gastrointestinal", "(", "GI", ")", "/liver", "adverse", "events", "(", "AEs", ")", "discontinuation", "rate", "was", "significantly", "lower", "for", "etoricoxib", "than", "diclofenac", "in", "each", "patient", "cohort", ";", "HR", "(", "95", "%", "CI", ")", "of", "0.46", "(", "0.39", ",", "0.54", ")", ",", "0.52", "(", "0.42", ",", "0.63", ")", "and", "0.49", "(", "0.39", ",", "0.62", ")", "for", "the", "60", "mg", "OA", ",", "90", "mg", "OA", "and", "RA", "cohorts", ".", "The", "maximum", "average", "change", "in", "systolic", "blood", "pressure", "(", "BP", ")", "with", "etoricoxib", "was", "3.4", "-", "3.6", "mmHg", "(", "diastolic", "BP", ":", "1.0", "-", "1.5", "mmHg", ")", ",", "while", "diclofenac", "produced", "a", "maximum", "average", "change", "of", "0.9", "-", "1.9", "mmHg", "(", "diastolic", "BP", ":", "0.0", "-", "0.5", "mmHg", ")", ".", "Both", "agents", "resulted", "in", "similar", "efficacy", "regardless", "of", "etoricoxib", "dose", ".", "CONCLUSION", "Long", "-", "term", "etoricoxib", "use", "is", "associated", "with", "a", "risk", "of", "thrombotic", "CV", "events", "comparable", "with", "that", "of", "diclofenac", ".", "Compared", "with", "diclofenac", ",", "etoricoxib", "demonstrated", "a", "greater", "risk", "of", "renovascular", "AEs", ",", "but", "a", "more", "favourable", "GI", "/", "liver", "tolerability", "profile", "." ]
[ "Outcome_Adverse-effects", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size" ]
Cardiovascular safety is a Outcome_Other, gastrointestinal tolerability is a Outcome_Other, etoricoxib is a Intervention_Pharmacological, diclofenac is a Intervention_Pharmacological, cardiovascular ( CV ) and other safety and efficacy parameters is a Outcome_Other, OA patients is a Participant_Condition, RA patients is a Participant_Condition, thrombotic CV events is a Outcome_Physical, Other safety and efficacy parameters is a Outcome_Other, 23 504 is a Participant_Sample-size, thrombotic CV risk hazard ratio is a Outcome_Other, cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate is a Outcome_Adverse-effects, systolic blood pressure is a Outcome_Physical, renovascular AEs is a Outcome_Physical, GI / liver tolerability profile is a Outcome_Other
39218_task1
Sentence: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial ( The MEDAL study ) . OBJECTIVE To compare cardiovascular ( CV ) and other safety and efficacy parameters of etoricoxib 60 and 90 mg , and diclofenac 150 mg. METHODS This double-blind study randomized OA patients to etoricoxib 90 mg , then to 60 mg once daily vs diclofenac 75 mg twice daily ; RA patients were randomized to etoricoxib 90 mg once daily or diclofenac 75 mg twice daily . The primary endpoint was non-inferiority of etoricoxib vs diclofenac for thrombotic CV events ( 95 % CI upper bound of hazard ratio < 1.30 ) . Other safety and efficacy parameters were evaluated in cohorts of patients based on etoricoxib dose and disease . RESULTS A total of 23 504 patients were randomized with mean treatment duration from 19.4 to 20.8 months . The thrombotic CV risk hazard ratio ( HR ) ( etoricoxib to diclofenac ) was 0.96 ( 95 % CI 0.81 , 1.15 ) , consistent with non-inferiority of etoricoxib to diclofenac . The cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort ; HR ( 95 % CI ) of 0.46 ( 0.39 , 0.54 ) , 0.52 ( 0.42 , 0.63 ) and 0.49 ( 0.39 , 0.62 ) for the 60 mg OA , 90 mg OA and RA cohorts . The maximum average change in systolic blood pressure ( BP ) with etoricoxib was 3.4-3.6 mmHg ( diastolic BP : 1.0-1.5 mmHg ) , while diclofenac produced a maximum average change of 0.9-1.9 mmHg ( diastolic BP : 0.0-0.5 mmHg ) . Both agents resulted in similar efficacy regardless of etoricoxib dose . CONCLUSION Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac . Compared with diclofenac , etoricoxib demonstrated a greater risk of renovascular AEs , but a more favourable GI/liver tolerability profile . Instructions: please typing these entity words according to sentence: Cardiovascular safety, gastrointestinal tolerability, etoricoxib, diclofenac, cardiovascular ( CV ) and other safety and efficacy parameters, OA patients, RA patients, thrombotic CV events, Other safety and efficacy parameters, 23 504, thrombotic CV risk hazard ratio, cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate, systolic blood pressure, renovascular AEs, GI / liver tolerability profile Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial ( The MEDAL study ) . OBJECTIVE To compare cardiovascular ( CV ) and other safety and efficacy parameters of etoricoxib 60 and 90 mg , and diclofenac 150 mg. METHODS This double-blind study randomized OA patients to etoricoxib 90 mg , then to 60 mg once daily vs diclofenac 75 mg twice daily ; RA patients were randomized to etoricoxib 90 mg once daily or diclofenac 75 mg twice daily . The primary endpoint was non-inferiority of etoricoxib vs diclofenac for thrombotic CV events ( 95 % CI upper bound of hazard ratio < 1.30 ) . Other safety and efficacy parameters were evaluated in cohorts of patients based on etoricoxib dose and disease . RESULTS A total of 23 504 patients were randomized with mean treatment duration from 19.4 to 20.8 months . The thrombotic CV risk hazard ratio ( HR ) ( etoricoxib to diclofenac ) was 0.96 ( 95 % CI 0.81 , 1.15 ) , consistent with non-inferiority of etoricoxib to diclofenac . The cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort ; HR ( 95 % CI ) of 0.46 ( 0.39 , 0.54 ) , 0.52 ( 0.42 , 0.63 ) and 0.49 ( 0.39 , 0.62 ) for the 60 mg OA , 90 mg OA and RA cohorts . The maximum average change in systolic blood pressure ( BP ) with etoricoxib was 3.4-3.6 mmHg ( diastolic BP : 1.0-1.5 mmHg ) , while diclofenac produced a maximum average change of 0.9-1.9 mmHg ( diastolic BP : 0.0-0.5 mmHg ) . Both agents resulted in similar efficacy regardless of etoricoxib dose . CONCLUSION Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac . Compared with diclofenac , etoricoxib demonstrated a greater risk of renovascular AEs , but a more favourable GI/liver tolerability profile .
[ "Cardiovascular", "safety", "and", "gastrointestinal", "tolerability", "of", "etoricoxib", "vs", "diclofenac", "in", "a", "randomized", "controlled", "clinical", "trial", "(", "The", "MEDAL", "study", ")", ".", "OBJECTIVE", "To", "compare", "cardiovascular", "(", "CV", ")", "and", "other", "safety", "and", "efficacy", "parameters", "of", "etoricoxib", "60", "and", "90", "mg", ",", "and", "diclofenac", "150", "mg", ".", "METHODS", "This", "double", "-", "blind", "study", "randomized", "OA", "patients", "to", "etoricoxib", "90", "mg", ",", "then", "to", "60", "mg", "once", "daily", "vs", "diclofenac", "75", "mg", "twice", "daily", ";", "RA", "patients", "were", "randomized", "to", "etoricoxib", "90", "mg", "once", "daily", "or", "diclofenac", "75", "mg", "twice", "daily", ".", "The", "primary", "endpoint", "was", "non", "-", "inferiority", "of", "etoricoxib", "vs", "diclofenac", "for", "thrombotic", "CV", "events", "(", "95", "%", "CI", "upper", "bound", "of", "hazard", "ratio", "<", "1.30", ")", ".", "Other", "safety", "and", "efficacy", "parameters", "were", "evaluated", "in", "cohorts", "of", "patients", "based", "on", "etoricoxib", "dose", "and", "disease", ".", "RESULTS", "A", "total", "of", "23", "504", "patients", "were", "randomized", "with", "mean", "treatment", "duration", "from", "19.4", "to", "20.8", "months", ".", "The", "thrombotic", "CV", "risk", "hazard", "ratio", "(", "HR", ")", "(", "etoricoxib", "to", "diclofenac", ")", "was", "0.96", "(", "95", "%", "CI", "0.81", ",", "1.15", ")", ",", "consistent", "with", "non", "-", "inferiority", "of", "etoricoxib", "to", "diclofenac", ".", "The", "cumulative", "gastrointestinal", "(", "GI", ")", "/liver", "adverse", "events", "(", "AEs", ")", "discontinuation", "rate", "was", "significantly", "lower", "for", "etoricoxib", "than", "diclofenac", "in", "each", "patient", "cohort", ";", "HR", "(", "95", "%", "CI", ")", "of", "0.46", "(", "0.39", ",", "0.54", ")", ",", "0.52", "(", "0.42", ",", "0.63", ")", "and", "0.49", "(", "0.39", ",", "0.62", ")", "for", "the", "60", "mg", "OA", ",", "90", "mg", "OA", "and", "RA", "cohorts", ".", "The", "maximum", "average", "change", "in", "systolic", "blood", "pressure", "(", "BP", ")", "with", "etoricoxib", "was", "3.4", "-", "3.6", "mmHg", "(", "diastolic", "BP", ":", "1.0", "-", "1.5", "mmHg", ")", ",", "while", "diclofenac", "produced", "a", "maximum", "average", "change", "of", "0.9", "-", "1.9", "mmHg", "(", "diastolic", "BP", ":", "0.0", "-", "0.5", "mmHg", ")", ".", "Both", "agents", "resulted", "in", "similar", "efficacy", "regardless", "of", "etoricoxib", "dose", ".", "CONCLUSION", "Long", "-", "term", "etoricoxib", "use", "is", "associated", "with", "a", "risk", "of", "thrombotic", "CV", "events", "comparable", "with", "that", "of", "diclofenac", ".", "Compared", "with", "diclofenac", ",", "etoricoxib", "demonstrated", "a", "greater", "risk", "of", "renovascular", "AEs", ",", "but", "a", "more", "favourable", "GI", "/", "liver", "tolerability", "profile", "." ]
[ "Outcome_Adverse-effects", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size" ]
Cardiovascular safety, gastrointestinal tolerability, etoricoxib, diclofenac, cardiovascular ( CV ) and other safety and efficacy parameters, OA patients, RA patients, thrombotic CV events, Other safety and efficacy parameters, 23 504, thrombotic CV risk hazard ratio, cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate, systolic blood pressure, renovascular AEs, GI / liver tolerability profile
39218_task2
Sentence: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial ( The MEDAL study ) . OBJECTIVE To compare cardiovascular ( CV ) and other safety and efficacy parameters of etoricoxib 60 and 90 mg , and diclofenac 150 mg. METHODS This double-blind study randomized OA patients to etoricoxib 90 mg , then to 60 mg once daily vs diclofenac 75 mg twice daily ; RA patients were randomized to etoricoxib 90 mg once daily or diclofenac 75 mg twice daily . The primary endpoint was non-inferiority of etoricoxib vs diclofenac for thrombotic CV events ( 95 % CI upper bound of hazard ratio < 1.30 ) . Other safety and efficacy parameters were evaluated in cohorts of patients based on etoricoxib dose and disease . RESULTS A total of 23 504 patients were randomized with mean treatment duration from 19.4 to 20.8 months . The thrombotic CV risk hazard ratio ( HR ) ( etoricoxib to diclofenac ) was 0.96 ( 95 % CI 0.81 , 1.15 ) , consistent with non-inferiority of etoricoxib to diclofenac . The cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort ; HR ( 95 % CI ) of 0.46 ( 0.39 , 0.54 ) , 0.52 ( 0.42 , 0.63 ) and 0.49 ( 0.39 , 0.62 ) for the 60 mg OA , 90 mg OA and RA cohorts . The maximum average change in systolic blood pressure ( BP ) with etoricoxib was 3.4-3.6 mmHg ( diastolic BP : 1.0-1.5 mmHg ) , while diclofenac produced a maximum average change of 0.9-1.9 mmHg ( diastolic BP : 0.0-0.5 mmHg ) . Both agents resulted in similar efficacy regardless of etoricoxib dose . CONCLUSION Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac . Compared with diclofenac , etoricoxib demonstrated a greater risk of renovascular AEs , but a more favourable GI/liver tolerability profile . Instructions: please extract entity words from the input sentence
[ "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial ( The MEDAL study ) . OBJECTIVE To compare cardiovascular ( CV ) and other safety and efficacy parameters of etoricoxib 60 and 90 mg , and diclofenac 150 mg. METHODS This double-blind study randomized OA patients to etoricoxib 90 mg , then to 60 mg once daily vs diclofenac 75 mg twice daily ; RA patients were randomized to etoricoxib 90 mg once daily or diclofenac 75 mg twice daily . The primary endpoint was non-inferiority of etoricoxib vs diclofenac for thrombotic CV events ( 95 % CI upper bound of hazard ratio < 1.30 ) . Other safety and efficacy parameters were evaluated in cohorts of patients based on etoricoxib dose and disease . RESULTS A total of 23 504 patients were randomized with mean treatment duration from 19.4 to 20.8 months . The thrombotic CV risk hazard ratio ( HR ) ( etoricoxib to diclofenac ) was 0.96 ( 95 % CI 0.81 , 1.15 ) , consistent with non-inferiority of etoricoxib to diclofenac . The cumulative gastrointestinal ( GI ) /liver adverse events ( AEs ) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort ; HR ( 95 % CI ) of 0.46 ( 0.39 , 0.54 ) , 0.52 ( 0.42 , 0.63 ) and 0.49 ( 0.39 , 0.62 ) for the 60 mg OA , 90 mg OA and RA cohorts . The maximum average change in systolic blood pressure ( BP ) with etoricoxib was 3.4-3.6 mmHg ( diastolic BP : 1.0-1.5 mmHg ) , while diclofenac produced a maximum average change of 0.9-1.9 mmHg ( diastolic BP : 0.0-0.5 mmHg ) . Both agents resulted in similar efficacy regardless of etoricoxib dose . CONCLUSION Long-term etoricoxib use is associated with a risk of thrombotic CV events comparable with that of diclofenac . Compared with diclofenac , etoricoxib demonstrated a greater risk of renovascular AEs , but a more favourable GI/liver tolerability profile .
[ "Cardiovascular", "safety", "and", "gastrointestinal", "tolerability", "of", "etoricoxib", "vs", "diclofenac", "in", "a", "randomized", "controlled", "clinical", "trial", "(", "The", "MEDAL", "study", ")", ".", "OBJECTIVE", "To", "compare", "cardiovascular", "(", "CV", ")", "and", "other", "safety", "and", "efficacy", "parameters", "of", "etoricoxib", "60", "and", "90", "mg", ",", "and", "diclofenac", "150", "mg", ".", "METHODS", "This", "double", "-", "blind", "study", "randomized", "OA", "patients", "to", "etoricoxib", "90", "mg", ",", "then", "to", "60", "mg", "once", "daily", "vs", "diclofenac", "75", "mg", "twice", "daily", ";", "RA", "patients", "were", "randomized", "to", "etoricoxib", "90", "mg", "once", "daily", "or", "diclofenac", "75", "mg", "twice", "daily", ".", "The", "primary", "endpoint", "was", "non", "-", "inferiority", "of", "etoricoxib", "vs", "diclofenac", "for", "thrombotic", "CV", "events", "(", "95", "%", "CI", "upper", "bound", "of", "hazard", "ratio", "<", "1.30", ")", ".", "Other", "safety", "and", "efficacy", "parameters", "were", "evaluated", "in", "cohorts", "of", "patients", "based", "on", "etoricoxib", "dose", "and", "disease", ".", "RESULTS", "A", "total", "of", "23", "504", "patients", "were", "randomized", "with", "mean", "treatment", "duration", "from", "19.4", "to", "20.8", "months", ".", "The", "thrombotic", "CV", "risk", "hazard", "ratio", "(", "HR", ")", "(", "etoricoxib", "to", "diclofenac", ")", "was", "0.96", "(", "95", "%", "CI", "0.81", ",", "1.15", ")", ",", "consistent", "with", "non", "-", "inferiority", "of", "etoricoxib", "to", "diclofenac", ".", "The", "cumulative", "gastrointestinal", "(", "GI", ")", "/liver", "adverse", "events", "(", "AEs", ")", "discontinuation", "rate", "was", "significantly", "lower", "for", "etoricoxib", "than", "diclofenac", "in", "each", "patient", "cohort", ";", "HR", "(", "95", "%", "CI", ")", "of", "0.46", "(", "0.39", ",", "0.54", ")", ",", "0.52", "(", "0.42", ",", "0.63", ")", "and", "0.49", "(", "0.39", ",", "0.62", ")", "for", "the", "60", "mg", "OA", ",", "90", "mg", "OA", "and", "RA", "cohorts", ".", "The", "maximum", "average", "change", "in", "systolic", "blood", "pressure", "(", "BP", ")", "with", "etoricoxib", "was", "3.4", "-", "3.6", "mmHg", "(", "diastolic", "BP", ":", "1.0", "-", "1.5", "mmHg", ")", ",", "while", "diclofenac", "produced", "a", "maximum", "average", "change", "of", "0.9", "-", "1.9", "mmHg", "(", "diastolic", "BP", ":", "0.0", "-", "0.5", "mmHg", ")", ".", "Both", "agents", "resulted", "in", "similar", "efficacy", "regardless", "of", "etoricoxib", "dose", ".", "CONCLUSION", "Long", "-", "term", "etoricoxib", "use", "is", "associated", "with", "a", "risk", "of", "thrombotic", "CV", "events", "comparable", "with", "that", "of", "diclofenac", ".", "Compared", "with", "diclofenac", ",", "etoricoxib", "demonstrated", "a", "greater", "risk", "of", "renovascular", "AEs", ",", "but", "a", "more", "favourable", "GI", "/", "liver", "tolerability", "profile", "." ]
[ "Outcome_Adverse-effects", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size" ]
Hh is a protein, Ptc is a protein, Ptc is a protein, Smo is a protein, Smo is a protein, Ci is a protein, Ci is a protein
1.0alpha7.train.189_task0
Sentence: The binding of Hh to Ptc alleviates the repressive action of Ptc on Smo and, when Smo is derepressed, Ci proteolysis is inhibited and Ci is converted into a transcriptional activator. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein
[ "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O" ]
The binding of Hh to Ptc alleviates the repressive action of Ptc on Smo and, when Smo is derepressed, Ci proteolysis is inhibited and Ci is converted into a transcriptional activator.
[ "The", "binding", "of", "Hh", "to", "Ptc", "alleviates", "the", "repressive", "action", "of", "Ptc", "on", "Smo", "and", ",", "when", "Smo", "is", "derepressed", ",", "Ci", "proteolysis", "is", "inhibited", "and", "Ci", "is", "converted", "into", "a", "transcriptional", "activator", "." ]
[ "protein" ]
Hh is a protein, Ptc is a protein, Ptc is a protein, Smo is a protein, Smo is a protein, Ci is a protein, Ci is a protein
1.0alpha7.train.189_task1
Sentence: The binding of Hh to Ptc alleviates the repressive action of Ptc on Smo and, when Smo is derepressed, Ci proteolysis is inhibited and Ci is converted into a transcriptional activator. Instructions: please typing these entity words according to sentence: Hh, Ptc, Ptc, Smo, Smo, Ci, Ci Options: protein
[ "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O" ]
The binding of Hh to Ptc alleviates the repressive action of Ptc on Smo and, when Smo is derepressed, Ci proteolysis is inhibited and Ci is converted into a transcriptional activator.
[ "The", "binding", "of", "Hh", "to", "Ptc", "alleviates", "the", "repressive", "action", "of", "Ptc", "on", "Smo", "and", ",", "when", "Smo", "is", "derepressed", ",", "Ci", "proteolysis", "is", "inhibited", "and", "Ci", "is", "converted", "into", "a", "transcriptional", "activator", "." ]
[ "protein" ]
Hh, Ptc, Ptc, Smo, Smo, Ci, Ci
1.0alpha7.train.189_task2
Sentence: The binding of Hh to Ptc alleviates the repressive action of Ptc on Smo and, when Smo is derepressed, Ci proteolysis is inhibited and Ci is converted into a transcriptional activator. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O" ]
The binding of Hh to Ptc alleviates the repressive action of Ptc on Smo and, when Smo is derepressed, Ci proteolysis is inhibited and Ci is converted into a transcriptional activator.
[ "The", "binding", "of", "Hh", "to", "Ptc", "alleviates", "the", "repressive", "action", "of", "Ptc", "on", "Smo", "and", ",", "when", "Smo", "is", "derepressed", ",", "Ci", "proteolysis", "is", "inhibited", "and", "Ci", "is", "converted", "into", "a", "transcriptional", "activator", "." ]
[ "protein" ]
herzerhaltende is an umlsterm, Neugeborenenalter is an umlsterm, Stenose is an umlsterm, Subaortenstenose is an umlsterm, Aortenkoarktation is an umlsterm, Sterblichkeit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Kinder is an umlsterm, Ueberlebenden is an umlsterm, Patienten is an umlsterm, Kinder is an umlsterm, Kinder is an umlsterm, Fontan - Operation is an umlsterm, wachsender is an umlsterm, Fontan - Operation is an umlsterm, Risiko is an umlsterm, Lebensqualitaet is an umlsterm
ZfuerKardiologie.70860505.ger.abstr_task0
Sentence: Die chirurgische Versorgung von Neugeborenen mit hypoplastischem Linksherz-Syndrom ( HLHS ) wird immer noch zurueckhaltend betrachtet . Die komplette herzerhaltende Palliation beinhaltet neben der Norwood-Operation im Neugeborenenalter auch die spaetere Kreislauftrennung nach Fontan . Unsere Erfahrungen mit den einzelnen operativen Teilschritten werden vorgestellt . 43 Saeuglinge mit anatomischem ( n = 33 ) oder funktionellem ( n = 10 ) HLHS erhielten von 1989 bis 1996 eine Norwood-Operation . Funktionelle HLHS waren : Mitralatresie mit doppeltem Ausgang aus der rechten Kammer und subaortaler Stenose ( n = 2 ) , atrioventrikulaerer Septumdefekt mit hypoplastischer linker Kammer , Subaortenstenose und Aortenkoarktation ( n = 1 hypoplastischer , subaortaler rechter Ventrikel ) , mit restriktivem Ventrikelseptumdefekt und Aortenhypoplasie ( n = 7 ) . Das mediane Operationsalter betrug 15 Tage ( 5 bis 182 Tage ) , das mittlere Gewicht war 3,3 kg ( 3,0 bis 4,9 kg ) . Die operative Sterblichkeit lag bei 32% ( n = 14 ) , wobei sie seit 1994 auf 16% ( 3 von 19 Patienten ) gesenkt werden konnte . 5 Patienten ( 12% ) verstarben 2 Wochen bis 6 Monate spaeter , 2 Kinder wurden herztransplantiert . Von den 22 lang Ueberlebenden erhielten bisher 19 Patienten im medianen Alter von 7 Monaten ( 2 bis 14 Monate ) die obere , bidirektionale kavopulmonale Anastomose als Hemi-Fontan . 2 Kinder verstarben ( 10% ) . Von den 17 Ueberlebenden erhielten bisher 12 nach einem mittleren Intervall von 12 Monaten die ergaenzende kavopulmonale Anastomose . Alle Kinder ueberlebten den Eingriff und sind damit fertig palliiert . Die laengste Nachbeobachtung nach kompletter Fontan-Operation liegt bisher bei 6 Jahren . Zusammenfassung : Die Ergebnisse der Norwood-Operation werden mit wachsender Erfahrung guenstiger . Die nachfolgende zweischrittige Fontan-Operation hat dann nur noch ein relativ geringes Risiko und fuehrt zu einer sehr guten Lebensqualitaet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die chirurgische Versorgung von Neugeborenen mit hypoplastischem Linksherz-Syndrom ( HLHS ) wird immer noch zurueckhaltend betrachtet . Die komplette herzerhaltende Palliation beinhaltet neben der Norwood-Operation im Neugeborenenalter auch die spaetere Kreislauftrennung nach Fontan . Unsere Erfahrungen mit den einzelnen operativen Teilschritten werden vorgestellt . 43 Saeuglinge mit anatomischem ( n = 33 ) oder funktionellem ( n = 10 ) HLHS erhielten von 1989 bis 1996 eine Norwood-Operation . Funktionelle HLHS waren : Mitralatresie mit doppeltem Ausgang aus der rechten Kammer und subaortaler Stenose ( n = 2 ) , atrioventrikulaerer Septumdefekt mit hypoplastischer linker Kammer , Subaortenstenose und Aortenkoarktation ( n = 1 hypoplastischer , subaortaler rechter Ventrikel ) , mit restriktivem Ventrikelseptumdefekt und Aortenhypoplasie ( n = 7 ) . Das mediane Operationsalter betrug 15 Tage ( 5 bis 182 Tage ) , das mittlere Gewicht war 3,3 kg ( 3,0 bis 4,9 kg ) . Die operative Sterblichkeit lag bei 32% ( n = 14 ) , wobei sie seit 1994 auf 16% ( 3 von 19 Patienten ) gesenkt werden konnte . 5 Patienten ( 12% ) verstarben 2 Wochen bis 6 Monate spaeter , 2 Kinder wurden herztransplantiert . Von den 22 lang Ueberlebenden erhielten bisher 19 Patienten im medianen Alter von 7 Monaten ( 2 bis 14 Monate ) die obere , bidirektionale kavopulmonale Anastomose als Hemi-Fontan . 2 Kinder verstarben ( 10% ) . Von den 17 Ueberlebenden erhielten bisher 12 nach einem mittleren Intervall von 12 Monaten die ergaenzende kavopulmonale Anastomose . Alle Kinder ueberlebten den Eingriff und sind damit fertig palliiert . Die laengste Nachbeobachtung nach kompletter Fontan-Operation liegt bisher bei 6 Jahren . Zusammenfassung : Die Ergebnisse der Norwood-Operation werden mit wachsender Erfahrung guenstiger . Die nachfolgende zweischrittige Fontan-Operation hat dann nur noch ein relativ geringes Risiko und fuehrt zu einer sehr guten Lebensqualitaet .
[ "Die", "chirurgische", "Versorgung", "von", "Neugeborenen", "mit", "hypoplastischem", "Linksherz", "-", "Syndrom", "(", "HLHS", ")", "wird", "immer", "noch", "zurueckhaltend", "betrachtet", ".", "Die", "komplette", "herzerhaltende", "Palliation", "beinhaltet", "neben", "der", "Norwood", "-", "Operation", "im", "Neugeborenenalter", "auch", "die", "spaetere", "Kreislauftrennung", "nach", "Fontan", ".", "Unsere", "Erfahrungen", "mit", "den", "einzelnen", "operativen", "Teilschritten", "werden", "vorgestellt", ".", "43", "Saeuglinge", "mit", "anatomischem", "(", "n", "=", "33", ")", "oder", "funktionellem", "(", "n", "=", "10", ")", "HLHS", "erhielten", "von", "1989", "bis", "1996", "eine", "Norwood", "-", "Operation", ".", "Funktionelle", "HLHS", "waren", ":", "Mitralatresie", "mit", "doppeltem", "Ausgang", "aus", "der", "rechten", "Kammer", "und", "subaortaler", "Stenose", "(", "n", "=", "2", ")", ",", "atrioventrikulaerer", "Septumdefekt", "mit", "hypoplastischer", "linker", "Kammer", ",", "Subaortenstenose", "und", "Aortenkoarktation", "(", "n", "=", "1", "hypoplastischer", ",", "subaortaler", "rechter", "Ventrikel", ")", ",", "mit", "restriktivem", "Ventrikelseptumdefekt", "und", "Aortenhypoplasie", "(", "n", "=", "7", ")", ".", "Das", "mediane", "Operationsalter", "betrug", "15", "Tage", "(", "5", "bis", "182", "Tage", ")", ",", "das", "mittlere", "Gewicht", "war", "3,3", "kg", "(", "3,0", "bis", "4,9", "kg", ")", ".", "Die", "operative", "Sterblichkeit", "lag", "bei", "32", "%", "(", "n", "=", "14", ")", ",", "wobei", "sie", "seit", "1994", "auf", "16", "%", "(", "3", "von", "19", "Patienten", ")", "gesenkt", "werden", "konnte", ".", "5", "Patienten", "(", "12", "%", ")", "verstarben", "2", "Wochen", "bis", "6", "Monate", "spaeter", ",", "2", "Kinder", "wurden", "herztransplantiert", ".", "Von", "den", "22", "lang", "Ueberlebenden", "erhielten", "bisher", "19", "Patienten", "im", "medianen", "Alter", "von", "7", "Monaten", "(", "2", "bis", "14", "Monate", ")", "die", "obere", ",", "bidirektionale", "kavopulmonale", "Anastomose", "als", "Hemi", "-", "Fontan", ".", "2", "Kinder", "verstarben", "(", "10", "%", ")", ".", "Von", "den", "17", "Ueberlebenden", "erhielten", "bisher", "12", "nach", "einem", "mittleren", "Intervall", "von", "12", "Monaten", "die", "ergaenzende", "kavopulmonale", "Anastomose", ".", "Alle", "Kinder", "ueberlebten", "den", "Eingriff", "und", "sind", "damit", "fertig", "palliiert", ".", "Die", "laengste", "Nachbeobachtung", "nach", "kompletter", "Fontan", "-", "Operation", "liegt", "bisher", "bei", "6", "Jahren", ".", "Zusammenfassung", ":", "Die", "Ergebnisse", "der", "Norwood", "-", "Operation", "werden", "mit", "wachsender", "Erfahrung", "guenstiger", ".", "Die", "nachfolgende", "zweischrittige", "Fontan", "-", "Operation", "hat", "dann", "nur", "noch", "ein", "relativ", "geringes", "Risiko", "und", "fuehrt", "zu", "einer", "sehr", "guten", "Lebensqualitaet", "." ]
[ "umlsterm" ]
herzerhaltende is an umlsterm, Neugeborenenalter is an umlsterm, Stenose is an umlsterm, Subaortenstenose is an umlsterm, Aortenkoarktation is an umlsterm, Sterblichkeit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Kinder is an umlsterm, Ueberlebenden is an umlsterm, Patienten is an umlsterm, Kinder is an umlsterm, Kinder is an umlsterm, Fontan - Operation is an umlsterm, wachsender is an umlsterm, Fontan - Operation is an umlsterm, Risiko is an umlsterm, Lebensqualitaet is an umlsterm
ZfuerKardiologie.70860505.ger.abstr_task1
Sentence: Die chirurgische Versorgung von Neugeborenen mit hypoplastischem Linksherz-Syndrom ( HLHS ) wird immer noch zurueckhaltend betrachtet . Die komplette herzerhaltende Palliation beinhaltet neben der Norwood-Operation im Neugeborenenalter auch die spaetere Kreislauftrennung nach Fontan . Unsere Erfahrungen mit den einzelnen operativen Teilschritten werden vorgestellt . 43 Saeuglinge mit anatomischem ( n = 33 ) oder funktionellem ( n = 10 ) HLHS erhielten von 1989 bis 1996 eine Norwood-Operation . Funktionelle HLHS waren : Mitralatresie mit doppeltem Ausgang aus der rechten Kammer und subaortaler Stenose ( n = 2 ) , atrioventrikulaerer Septumdefekt mit hypoplastischer linker Kammer , Subaortenstenose und Aortenkoarktation ( n = 1 hypoplastischer , subaortaler rechter Ventrikel ) , mit restriktivem Ventrikelseptumdefekt und Aortenhypoplasie ( n = 7 ) . Das mediane Operationsalter betrug 15 Tage ( 5 bis 182 Tage ) , das mittlere Gewicht war 3,3 kg ( 3,0 bis 4,9 kg ) . Die operative Sterblichkeit lag bei 32% ( n = 14 ) , wobei sie seit 1994 auf 16% ( 3 von 19 Patienten ) gesenkt werden konnte . 5 Patienten ( 12% ) verstarben 2 Wochen bis 6 Monate spaeter , 2 Kinder wurden herztransplantiert . Von den 22 lang Ueberlebenden erhielten bisher 19 Patienten im medianen Alter von 7 Monaten ( 2 bis 14 Monate ) die obere , bidirektionale kavopulmonale Anastomose als Hemi-Fontan . 2 Kinder verstarben ( 10% ) . Von den 17 Ueberlebenden erhielten bisher 12 nach einem mittleren Intervall von 12 Monaten die ergaenzende kavopulmonale Anastomose . Alle Kinder ueberlebten den Eingriff und sind damit fertig palliiert . Die laengste Nachbeobachtung nach kompletter Fontan-Operation liegt bisher bei 6 Jahren . Zusammenfassung : Die Ergebnisse der Norwood-Operation werden mit wachsender Erfahrung guenstiger . Die nachfolgende zweischrittige Fontan-Operation hat dann nur noch ein relativ geringes Risiko und fuehrt zu einer sehr guten Lebensqualitaet . Instructions: please typing these entity words according to sentence: herzerhaltende, Neugeborenenalter, Stenose, Subaortenstenose, Aortenkoarktation, Sterblichkeit, Patienten, Patienten, Kinder, Ueberlebenden, Patienten, Kinder, Kinder, Fontan - Operation, wachsender, Fontan - Operation, Risiko, Lebensqualitaet Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die chirurgische Versorgung von Neugeborenen mit hypoplastischem Linksherz-Syndrom ( HLHS ) wird immer noch zurueckhaltend betrachtet . Die komplette herzerhaltende Palliation beinhaltet neben der Norwood-Operation im Neugeborenenalter auch die spaetere Kreislauftrennung nach Fontan . Unsere Erfahrungen mit den einzelnen operativen Teilschritten werden vorgestellt . 43 Saeuglinge mit anatomischem ( n = 33 ) oder funktionellem ( n = 10 ) HLHS erhielten von 1989 bis 1996 eine Norwood-Operation . Funktionelle HLHS waren : Mitralatresie mit doppeltem Ausgang aus der rechten Kammer und subaortaler Stenose ( n = 2 ) , atrioventrikulaerer Septumdefekt mit hypoplastischer linker Kammer , Subaortenstenose und Aortenkoarktation ( n = 1 hypoplastischer , subaortaler rechter Ventrikel ) , mit restriktivem Ventrikelseptumdefekt und Aortenhypoplasie ( n = 7 ) . Das mediane Operationsalter betrug 15 Tage ( 5 bis 182 Tage ) , das mittlere Gewicht war 3,3 kg ( 3,0 bis 4,9 kg ) . Die operative Sterblichkeit lag bei 32% ( n = 14 ) , wobei sie seit 1994 auf 16% ( 3 von 19 Patienten ) gesenkt werden konnte . 5 Patienten ( 12% ) verstarben 2 Wochen bis 6 Monate spaeter , 2 Kinder wurden herztransplantiert . Von den 22 lang Ueberlebenden erhielten bisher 19 Patienten im medianen Alter von 7 Monaten ( 2 bis 14 Monate ) die obere , bidirektionale kavopulmonale Anastomose als Hemi-Fontan . 2 Kinder verstarben ( 10% ) . Von den 17 Ueberlebenden erhielten bisher 12 nach einem mittleren Intervall von 12 Monaten die ergaenzende kavopulmonale Anastomose . Alle Kinder ueberlebten den Eingriff und sind damit fertig palliiert . Die laengste Nachbeobachtung nach kompletter Fontan-Operation liegt bisher bei 6 Jahren . Zusammenfassung : Die Ergebnisse der Norwood-Operation werden mit wachsender Erfahrung guenstiger . Die nachfolgende zweischrittige Fontan-Operation hat dann nur noch ein relativ geringes Risiko und fuehrt zu einer sehr guten Lebensqualitaet .
[ "Die", "chirurgische", "Versorgung", "von", "Neugeborenen", "mit", "hypoplastischem", "Linksherz", "-", "Syndrom", "(", "HLHS", ")", "wird", "immer", "noch", "zurueckhaltend", "betrachtet", ".", "Die", "komplette", "herzerhaltende", "Palliation", "beinhaltet", "neben", "der", "Norwood", "-", "Operation", "im", "Neugeborenenalter", "auch", "die", "spaetere", "Kreislauftrennung", "nach", "Fontan", ".", "Unsere", "Erfahrungen", "mit", "den", "einzelnen", "operativen", "Teilschritten", "werden", "vorgestellt", ".", "43", "Saeuglinge", "mit", "anatomischem", "(", "n", "=", "33", ")", "oder", "funktionellem", "(", "n", "=", "10", ")", "HLHS", "erhielten", "von", "1989", "bis", "1996", "eine", "Norwood", "-", "Operation", ".", "Funktionelle", "HLHS", "waren", ":", "Mitralatresie", "mit", "doppeltem", "Ausgang", "aus", "der", "rechten", "Kammer", "und", "subaortaler", "Stenose", "(", "n", "=", "2", ")", ",", "atrioventrikulaerer", "Septumdefekt", "mit", "hypoplastischer", "linker", "Kammer", ",", "Subaortenstenose", "und", "Aortenkoarktation", "(", "n", "=", "1", "hypoplastischer", ",", "subaortaler", "rechter", "Ventrikel", ")", ",", "mit", "restriktivem", "Ventrikelseptumdefekt", "und", "Aortenhypoplasie", "(", "n", "=", "7", ")", ".", "Das", "mediane", "Operationsalter", "betrug", "15", "Tage", "(", "5", "bis", "182", "Tage", ")", ",", "das", "mittlere", "Gewicht", "war", "3,3", "kg", "(", "3,0", "bis", "4,9", "kg", ")", ".", "Die", "operative", "Sterblichkeit", "lag", "bei", "32", "%", "(", "n", "=", "14", ")", ",", "wobei", "sie", "seit", "1994", "auf", "16", "%", "(", "3", "von", "19", "Patienten", ")", "gesenkt", "werden", "konnte", ".", "5", "Patienten", "(", "12", "%", ")", "verstarben", "2", "Wochen", "bis", "6", "Monate", "spaeter", ",", "2", "Kinder", "wurden", "herztransplantiert", ".", "Von", "den", "22", "lang", "Ueberlebenden", "erhielten", "bisher", "19", "Patienten", "im", "medianen", "Alter", "von", "7", "Monaten", "(", "2", "bis", "14", "Monate", ")", "die", "obere", ",", "bidirektionale", "kavopulmonale", "Anastomose", "als", "Hemi", "-", "Fontan", ".", "2", "Kinder", "verstarben", "(", "10", "%", ")", ".", "Von", "den", "17", "Ueberlebenden", "erhielten", "bisher", "12", "nach", "einem", "mittleren", "Intervall", "von", "12", "Monaten", "die", "ergaenzende", "kavopulmonale", "Anastomose", ".", "Alle", "Kinder", "ueberlebten", "den", "Eingriff", "und", "sind", "damit", "fertig", "palliiert", ".", "Die", "laengste", "Nachbeobachtung", "nach", "kompletter", "Fontan", "-", "Operation", "liegt", "bisher", "bei", "6", "Jahren", ".", "Zusammenfassung", ":", "Die", "Ergebnisse", "der", "Norwood", "-", "Operation", "werden", "mit", "wachsender", "Erfahrung", "guenstiger", ".", "Die", "nachfolgende", "zweischrittige", "Fontan", "-", "Operation", "hat", "dann", "nur", "noch", "ein", "relativ", "geringes", "Risiko", "und", "fuehrt", "zu", "einer", "sehr", "guten", "Lebensqualitaet", "." ]
[ "umlsterm" ]
herzerhaltende, Neugeborenenalter, Stenose, Subaortenstenose, Aortenkoarktation, Sterblichkeit, Patienten, Patienten, Kinder, Ueberlebenden, Patienten, Kinder, Kinder, Fontan - Operation, wachsender, Fontan - Operation, Risiko, Lebensqualitaet
ZfuerKardiologie.70860505.ger.abstr_task2
Sentence: Die chirurgische Versorgung von Neugeborenen mit hypoplastischem Linksherz-Syndrom ( HLHS ) wird immer noch zurueckhaltend betrachtet . Die komplette herzerhaltende Palliation beinhaltet neben der Norwood-Operation im Neugeborenenalter auch die spaetere Kreislauftrennung nach Fontan . Unsere Erfahrungen mit den einzelnen operativen Teilschritten werden vorgestellt . 43 Saeuglinge mit anatomischem ( n = 33 ) oder funktionellem ( n = 10 ) HLHS erhielten von 1989 bis 1996 eine Norwood-Operation . Funktionelle HLHS waren : Mitralatresie mit doppeltem Ausgang aus der rechten Kammer und subaortaler Stenose ( n = 2 ) , atrioventrikulaerer Septumdefekt mit hypoplastischer linker Kammer , Subaortenstenose und Aortenkoarktation ( n = 1 hypoplastischer , subaortaler rechter Ventrikel ) , mit restriktivem Ventrikelseptumdefekt und Aortenhypoplasie ( n = 7 ) . Das mediane Operationsalter betrug 15 Tage ( 5 bis 182 Tage ) , das mittlere Gewicht war 3,3 kg ( 3,0 bis 4,9 kg ) . Die operative Sterblichkeit lag bei 32% ( n = 14 ) , wobei sie seit 1994 auf 16% ( 3 von 19 Patienten ) gesenkt werden konnte . 5 Patienten ( 12% ) verstarben 2 Wochen bis 6 Monate spaeter , 2 Kinder wurden herztransplantiert . Von den 22 lang Ueberlebenden erhielten bisher 19 Patienten im medianen Alter von 7 Monaten ( 2 bis 14 Monate ) die obere , bidirektionale kavopulmonale Anastomose als Hemi-Fontan . 2 Kinder verstarben ( 10% ) . Von den 17 Ueberlebenden erhielten bisher 12 nach einem mittleren Intervall von 12 Monaten die ergaenzende kavopulmonale Anastomose . Alle Kinder ueberlebten den Eingriff und sind damit fertig palliiert . Die laengste Nachbeobachtung nach kompletter Fontan-Operation liegt bisher bei 6 Jahren . Zusammenfassung : Die Ergebnisse der Norwood-Operation werden mit wachsender Erfahrung guenstiger . Die nachfolgende zweischrittige Fontan-Operation hat dann nur noch ein relativ geringes Risiko und fuehrt zu einer sehr guten Lebensqualitaet . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die chirurgische Versorgung von Neugeborenen mit hypoplastischem Linksherz-Syndrom ( HLHS ) wird immer noch zurueckhaltend betrachtet . Die komplette herzerhaltende Palliation beinhaltet neben der Norwood-Operation im Neugeborenenalter auch die spaetere Kreislauftrennung nach Fontan . Unsere Erfahrungen mit den einzelnen operativen Teilschritten werden vorgestellt . 43 Saeuglinge mit anatomischem ( n = 33 ) oder funktionellem ( n = 10 ) HLHS erhielten von 1989 bis 1996 eine Norwood-Operation . Funktionelle HLHS waren : Mitralatresie mit doppeltem Ausgang aus der rechten Kammer und subaortaler Stenose ( n = 2 ) , atrioventrikulaerer Septumdefekt mit hypoplastischer linker Kammer , Subaortenstenose und Aortenkoarktation ( n = 1 hypoplastischer , subaortaler rechter Ventrikel ) , mit restriktivem Ventrikelseptumdefekt und Aortenhypoplasie ( n = 7 ) . Das mediane Operationsalter betrug 15 Tage ( 5 bis 182 Tage ) , das mittlere Gewicht war 3,3 kg ( 3,0 bis 4,9 kg ) . Die operative Sterblichkeit lag bei 32% ( n = 14 ) , wobei sie seit 1994 auf 16% ( 3 von 19 Patienten ) gesenkt werden konnte . 5 Patienten ( 12% ) verstarben 2 Wochen bis 6 Monate spaeter , 2 Kinder wurden herztransplantiert . Von den 22 lang Ueberlebenden erhielten bisher 19 Patienten im medianen Alter von 7 Monaten ( 2 bis 14 Monate ) die obere , bidirektionale kavopulmonale Anastomose als Hemi-Fontan . 2 Kinder verstarben ( 10% ) . Von den 17 Ueberlebenden erhielten bisher 12 nach einem mittleren Intervall von 12 Monaten die ergaenzende kavopulmonale Anastomose . Alle Kinder ueberlebten den Eingriff und sind damit fertig palliiert . Die laengste Nachbeobachtung nach kompletter Fontan-Operation liegt bisher bei 6 Jahren . Zusammenfassung : Die Ergebnisse der Norwood-Operation werden mit wachsender Erfahrung guenstiger . Die nachfolgende zweischrittige Fontan-Operation hat dann nur noch ein relativ geringes Risiko und fuehrt zu einer sehr guten Lebensqualitaet .
[ "Die", "chirurgische", "Versorgung", "von", "Neugeborenen", "mit", "hypoplastischem", "Linksherz", "-", "Syndrom", "(", "HLHS", ")", "wird", "immer", "noch", "zurueckhaltend", "betrachtet", ".", "Die", "komplette", "herzerhaltende", "Palliation", "beinhaltet", "neben", "der", "Norwood", "-", "Operation", "im", "Neugeborenenalter", "auch", "die", "spaetere", "Kreislauftrennung", "nach", "Fontan", ".", "Unsere", "Erfahrungen", "mit", "den", "einzelnen", "operativen", "Teilschritten", "werden", "vorgestellt", ".", "43", "Saeuglinge", "mit", "anatomischem", "(", "n", "=", "33", ")", "oder", "funktionellem", "(", "n", "=", "10", ")", "HLHS", "erhielten", "von", "1989", "bis", "1996", "eine", "Norwood", "-", "Operation", ".", "Funktionelle", "HLHS", "waren", ":", "Mitralatresie", "mit", "doppeltem", "Ausgang", "aus", "der", "rechten", "Kammer", "und", "subaortaler", "Stenose", "(", "n", "=", "2", ")", ",", "atrioventrikulaerer", "Septumdefekt", "mit", "hypoplastischer", "linker", "Kammer", ",", "Subaortenstenose", "und", "Aortenkoarktation", "(", "n", "=", "1", "hypoplastischer", ",", "subaortaler", "rechter", "Ventrikel", ")", ",", "mit", "restriktivem", "Ventrikelseptumdefekt", "und", "Aortenhypoplasie", "(", "n", "=", "7", ")", ".", "Das", "mediane", "Operationsalter", "betrug", "15", "Tage", "(", "5", "bis", "182", "Tage", ")", ",", "das", "mittlere", "Gewicht", "war", "3,3", "kg", "(", "3,0", "bis", "4,9", "kg", ")", ".", "Die", "operative", "Sterblichkeit", "lag", "bei", "32", "%", "(", "n", "=", "14", ")", ",", "wobei", "sie", "seit", "1994", "auf", "16", "%", "(", "3", "von", "19", "Patienten", ")", "gesenkt", "werden", "konnte", ".", "5", "Patienten", "(", "12", "%", ")", "verstarben", "2", "Wochen", "bis", "6", "Monate", "spaeter", ",", "2", "Kinder", "wurden", "herztransplantiert", ".", "Von", "den", "22", "lang", "Ueberlebenden", "erhielten", "bisher", "19", "Patienten", "im", "medianen", "Alter", "von", "7", "Monaten", "(", "2", "bis", "14", "Monate", ")", "die", "obere", ",", "bidirektionale", "kavopulmonale", "Anastomose", "als", "Hemi", "-", "Fontan", ".", "2", "Kinder", "verstarben", "(", "10", "%", ")", ".", "Von", "den", "17", "Ueberlebenden", "erhielten", "bisher", "12", "nach", "einem", "mittleren", "Intervall", "von", "12", "Monaten", "die", "ergaenzende", "kavopulmonale", "Anastomose", ".", "Alle", "Kinder", "ueberlebten", "den", "Eingriff", "und", "sind", "damit", "fertig", "palliiert", ".", "Die", "laengste", "Nachbeobachtung", "nach", "kompletter", "Fontan", "-", "Operation", "liegt", "bisher", "bei", "6", "Jahren", ".", "Zusammenfassung", ":", "Die", "Ergebnisse", "der", "Norwood", "-", "Operation", "werden", "mit", "wachsender", "Erfahrung", "guenstiger", ".", "Die", "nachfolgende", "zweischrittige", "Fontan", "-", "Operation", "hat", "dann", "nur", "noch", "ein", "relativ", "geringes", "Risiko", "und", "fuehrt", "zu", "einer", "sehr", "guten", "Lebensqualitaet", "." ]
[ "umlsterm" ]
Three - dimensional echocardiography is an umlsterm, nuclear magnetic resonance is an umlsterm, techniques is an umlsterm, measurements is an umlsterm, labor is an umlsterm, time is an umlsterm, ventricular septal defects is an umlsterm, hypertrophic obstructive cardiomyopathy is an umlsterm, ability is an umlsterm, stress is an umlsterm
ZfuerKardiologie.0089s104.eng.abstr_task0
Sentence: Three-dimensional echocardiography has been realized in two different technical approaches : first as reconstruction of previously acquired multiple two-dimensional cross-sections , and recently as real-time 3D echo . Both approaches allow one to measure quantitative parameters of cardiac structures , such as mass and volume , with an accuracy far superior to 2D echo and equal to nuclear magnetic resonance techniques . However , such measurements are labor and time intensive . Other spatially complex cardiac structures such as valves , atrial and ventricular septal defects , or dynamic outflow tract obstruction in hypertrophic obstructive cardiomyopathy can be assessed adequately in both qualitative and quantitative fashion . Furthermore , the advent of real-time 3D echo with its ability to gather the full 3D data set within seconds promises to widen the potential applications of 3D echo , for example , including stress echo . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Three-dimensional echocardiography has been realized in two different technical approaches : first as reconstruction of previously acquired multiple two-dimensional cross-sections , and recently as real-time 3D echo . Both approaches allow one to measure quantitative parameters of cardiac structures , such as mass and volume , with an accuracy far superior to 2D echo and equal to nuclear magnetic resonance techniques . However , such measurements are labor and time intensive . Other spatially complex cardiac structures such as valves , atrial and ventricular septal defects , or dynamic outflow tract obstruction in hypertrophic obstructive cardiomyopathy can be assessed adequately in both qualitative and quantitative fashion . Furthermore , the advent of real-time 3D echo with its ability to gather the full 3D data set within seconds promises to widen the potential applications of 3D echo , for example , including stress echo .
[ "Three", "-", "dimensional", "echocardiography", "has", "been", "realized", "in", "two", "different", "technical", "approaches", ":", "first", "as", "reconstruction", "of", "previously", "acquired", "multiple", "two", "-", "dimensional", "cross", "-", "sections", ",", "and", "recently", "as", "real", "-", "time", "3D", "echo", ".", "Both", "approaches", "allow", "one", "to", "measure", "quantitative", "parameters", "of", "cardiac", "structures", ",", "such", "as", "mass", "and", "volume", ",", "with", "an", "accuracy", "far", "superior", "to", "2D", "echo", "and", "equal", "to", "nuclear", "magnetic", "resonance", "techniques", ".", "However", ",", "such", "measurements", "are", "labor", "and", "time", "intensive", ".", "Other", "spatially", "complex", "cardiac", "structures", "such", "as", "valves", ",", "atrial", "and", "ventricular", "septal", "defects", ",", "or", "dynamic", "outflow", "tract", "obstruction", "in", "hypertrophic", "obstructive", "cardiomyopathy", "can", "be", "assessed", "adequately", "in", "both", "qualitative", "and", "quantitative", "fashion", ".", "Furthermore", ",", "the", "advent", "of", "real", "-", "time", "3D", "echo", "with", "its", "ability", "to", "gather", "the", "full", "3D", "data", "set", "within", "seconds", "promises", "to", "widen", "the", "potential", "applications", "of", "3D", "echo", ",", "for", "example", ",", "including", "stress", "echo", "." ]
[ "umlsterm" ]
Three - dimensional echocardiography is an umlsterm, nuclear magnetic resonance is an umlsterm, techniques is an umlsterm, measurements is an umlsterm, labor is an umlsterm, time is an umlsterm, ventricular septal defects is an umlsterm, hypertrophic obstructive cardiomyopathy is an umlsterm, ability is an umlsterm, stress is an umlsterm
ZfuerKardiologie.0089s104.eng.abstr_task1
Sentence: Three-dimensional echocardiography has been realized in two different technical approaches : first as reconstruction of previously acquired multiple two-dimensional cross-sections , and recently as real-time 3D echo . Both approaches allow one to measure quantitative parameters of cardiac structures , such as mass and volume , with an accuracy far superior to 2D echo and equal to nuclear magnetic resonance techniques . However , such measurements are labor and time intensive . Other spatially complex cardiac structures such as valves , atrial and ventricular septal defects , or dynamic outflow tract obstruction in hypertrophic obstructive cardiomyopathy can be assessed adequately in both qualitative and quantitative fashion . Furthermore , the advent of real-time 3D echo with its ability to gather the full 3D data set within seconds promises to widen the potential applications of 3D echo , for example , including stress echo . Instructions: please typing these entity words according to sentence: Three - dimensional echocardiography, nuclear magnetic resonance, techniques, measurements, labor, time, ventricular septal defects, hypertrophic obstructive cardiomyopathy, ability, stress Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Three-dimensional echocardiography has been realized in two different technical approaches : first as reconstruction of previously acquired multiple two-dimensional cross-sections , and recently as real-time 3D echo . Both approaches allow one to measure quantitative parameters of cardiac structures , such as mass and volume , with an accuracy far superior to 2D echo and equal to nuclear magnetic resonance techniques . However , such measurements are labor and time intensive . Other spatially complex cardiac structures such as valves , atrial and ventricular septal defects , or dynamic outflow tract obstruction in hypertrophic obstructive cardiomyopathy can be assessed adequately in both qualitative and quantitative fashion . Furthermore , the advent of real-time 3D echo with its ability to gather the full 3D data set within seconds promises to widen the potential applications of 3D echo , for example , including stress echo .
[ "Three", "-", "dimensional", "echocardiography", "has", "been", "realized", "in", "two", "different", "technical", "approaches", ":", "first", "as", "reconstruction", "of", "previously", "acquired", "multiple", "two", "-", "dimensional", "cross", "-", "sections", ",", "and", "recently", "as", "real", "-", "time", "3D", "echo", ".", "Both", "approaches", "allow", "one", "to", "measure", "quantitative", "parameters", "of", "cardiac", "structures", ",", "such", "as", "mass", "and", "volume", ",", "with", "an", "accuracy", "far", "superior", "to", "2D", "echo", "and", "equal", "to", "nuclear", "magnetic", "resonance", "techniques", ".", "However", ",", "such", "measurements", "are", "labor", "and", "time", "intensive", ".", "Other", "spatially", "complex", "cardiac", "structures", "such", "as", "valves", ",", "atrial", "and", "ventricular", "septal", "defects", ",", "or", "dynamic", "outflow", "tract", "obstruction", "in", "hypertrophic", "obstructive", "cardiomyopathy", "can", "be", "assessed", "adequately", "in", "both", "qualitative", "and", "quantitative", "fashion", ".", "Furthermore", ",", "the", "advent", "of", "real", "-", "time", "3D", "echo", "with", "its", "ability", "to", "gather", "the", "full", "3D", "data", "set", "within", "seconds", "promises", "to", "widen", "the", "potential", "applications", "of", "3D", "echo", ",", "for", "example", ",", "including", "stress", "echo", "." ]
[ "umlsterm" ]
Three - dimensional echocardiography, nuclear magnetic resonance, techniques, measurements, labor, time, ventricular septal defects, hypertrophic obstructive cardiomyopathy, ability, stress
ZfuerKardiologie.0089s104.eng.abstr_task2
Sentence: Three-dimensional echocardiography has been realized in two different technical approaches : first as reconstruction of previously acquired multiple two-dimensional cross-sections , and recently as real-time 3D echo . Both approaches allow one to measure quantitative parameters of cardiac structures , such as mass and volume , with an accuracy far superior to 2D echo and equal to nuclear magnetic resonance techniques . However , such measurements are labor and time intensive . Other spatially complex cardiac structures such as valves , atrial and ventricular septal defects , or dynamic outflow tract obstruction in hypertrophic obstructive cardiomyopathy can be assessed adequately in both qualitative and quantitative fashion . Furthermore , the advent of real-time 3D echo with its ability to gather the full 3D data set within seconds promises to widen the potential applications of 3D echo , for example , including stress echo . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Three-dimensional echocardiography has been realized in two different technical approaches : first as reconstruction of previously acquired multiple two-dimensional cross-sections , and recently as real-time 3D echo . Both approaches allow one to measure quantitative parameters of cardiac structures , such as mass and volume , with an accuracy far superior to 2D echo and equal to nuclear magnetic resonance techniques . However , such measurements are labor and time intensive . Other spatially complex cardiac structures such as valves , atrial and ventricular septal defects , or dynamic outflow tract obstruction in hypertrophic obstructive cardiomyopathy can be assessed adequately in both qualitative and quantitative fashion . Furthermore , the advent of real-time 3D echo with its ability to gather the full 3D data set within seconds promises to widen the potential applications of 3D echo , for example , including stress echo .
[ "Three", "-", "dimensional", "echocardiography", "has", "been", "realized", "in", "two", "different", "technical", "approaches", ":", "first", "as", "reconstruction", "of", "previously", "acquired", "multiple", "two", "-", "dimensional", "cross", "-", "sections", ",", "and", "recently", "as", "real", "-", "time", "3D", "echo", ".", "Both", "approaches", "allow", "one", "to", "measure", "quantitative", "parameters", "of", "cardiac", "structures", ",", "such", "as", "mass", "and", "volume", ",", "with", "an", "accuracy", "far", "superior", "to", "2D", "echo", "and", "equal", "to", "nuclear", "magnetic", "resonance", "techniques", ".", "However", ",", "such", "measurements", "are", "labor", "and", "time", "intensive", ".", "Other", "spatially", "complex", "cardiac", "structures", "such", "as", "valves", ",", "atrial", "and", "ventricular", "septal", "defects", ",", "or", "dynamic", "outflow", "tract", "obstruction", "in", "hypertrophic", "obstructive", "cardiomyopathy", "can", "be", "assessed", "adequately", "in", "both", "qualitative", "and", "quantitative", "fashion", ".", "Furthermore", ",", "the", "advent", "of", "real", "-", "time", "3D", "echo", "with", "its", "ability", "to", "gather", "the", "full", "3D", "data", "set", "within", "seconds", "promises", "to", "widen", "the", "potential", "applications", "of", "3D", "echo", ",", "for", "example", ",", "including", "stress", "echo", "." ]
[ "umlsterm" ]
congenital or acquired is a Scope, bleeding tendency is a Condition, platelet count is a Measurement, < 50,000/ µL is a Value, hypersensitivity is a Condition, shrimps , lobsters or beetles is a Scope
NCT02954029_exc_task0
Sentence: congenital or acquired bleeding tendency platelet count <50,000/ µL hypersensitivity to shrimps, lobsters or beetles Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Condition, Measurement, Value
[ "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]
congenital or acquired bleeding tendency platelet count <50,000/ µL hypersensitivity to shrimps, lobsters or beetles
[ "congenital", "or", "acquired", "bleeding", "tendency", "\n", "platelet", "count", "<", "50,000/", "µL", "\n", "hypersensitivity", "to", "shrimps", ",", "lobsters", "or", "beetles", "\n" ]
[ "Scope", "Condition", "Measurement", "Value", "Qualifier" ]
congenital or acquired is a Scope, bleeding tendency is a Condition, platelet count is a Measurement, < 50,000/ µL is a Value, hypersensitivity is a Condition, shrimps , lobsters or beetles is a Scope
NCT02954029_exc_task1
Sentence: congenital or acquired bleeding tendency platelet count <50,000/ µL hypersensitivity to shrimps, lobsters or beetles Instructions: please typing these entity words according to sentence: congenital or acquired, bleeding tendency, platelet count, < 50,000/ µL, hypersensitivity, shrimps , lobsters or beetles Options: Scope, Condition, Measurement, Value
[ "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]
congenital or acquired bleeding tendency platelet count <50,000/ µL hypersensitivity to shrimps, lobsters or beetles
[ "congenital", "or", "acquired", "bleeding", "tendency", "\n", "platelet", "count", "<", "50,000/", "µL", "\n", "hypersensitivity", "to", "shrimps", ",", "lobsters", "or", "beetles", "\n" ]
[ "Scope", "Condition", "Measurement", "Value", "Qualifier" ]
congenital or acquired, bleeding tendency, platelet count, < 50,000/ µL, hypersensitivity, shrimps , lobsters or beetles
NCT02954029_exc_task2
Sentence: congenital or acquired bleeding tendency platelet count <50,000/ µL hypersensitivity to shrimps, lobsters or beetles Instructions: please extract entity words from the input sentence
[ "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O" ]
congenital or acquired bleeding tendency platelet count <50,000/ µL hypersensitivity to shrimps, lobsters or beetles
[ "congenital", "or", "acquired", "bleeding", "tendency", "\n", "platelet", "count", "<", "50,000/", "µL", "\n", "hypersensitivity", "to", "shrimps", ",", "lobsters", "or", "beetles", "\n" ]
[ "Scope", "Condition", "Measurement", "Value", "Qualifier" ]
value is an umlsterm, magnetic resonance imaging is an umlsterm, MRI is an umlsterm, faecal incontinence is an umlsterm
DerRadiologe.00400465.eng.abstr_task0
Sentence: Purpose . Within the recent years several studies have been performed to determine the value of endoanal magnetic resonance imaging ( MRI ) in faecal incontinence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Purpose . Within the recent years several studies have been performed to determine the value of endoanal magnetic resonance imaging ( MRI ) in faecal incontinence .
[ "Purpose", ".", "Within", "the", "recent", "years", "several", "studies", "have", "been", "performed", "to", "determine", "the", "value", "of", "endoanal", "magnetic", "resonance", "imaging", "(", "MRI", ")", "in", "faecal", "incontinence", "." ]
[ "umlsterm" ]
value is an umlsterm, magnetic resonance imaging is an umlsterm, MRI is an umlsterm, faecal incontinence is an umlsterm
DerRadiologe.00400465.eng.abstr_task1
Sentence: Purpose . Within the recent years several studies have been performed to determine the value of endoanal magnetic resonance imaging ( MRI ) in faecal incontinence . Instructions: please typing these entity words according to sentence: value, magnetic resonance imaging, MRI, faecal incontinence Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Purpose . Within the recent years several studies have been performed to determine the value of endoanal magnetic resonance imaging ( MRI ) in faecal incontinence .
[ "Purpose", ".", "Within", "the", "recent", "years", "several", "studies", "have", "been", "performed", "to", "determine", "the", "value", "of", "endoanal", "magnetic", "resonance", "imaging", "(", "MRI", ")", "in", "faecal", "incontinence", "." ]
[ "umlsterm" ]
value, magnetic resonance imaging, MRI, faecal incontinence
DerRadiologe.00400465.eng.abstr_task2
Sentence: Purpose . Within the recent years several studies have been performed to determine the value of endoanal magnetic resonance imaging ( MRI ) in faecal incontinence . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Purpose . Within the recent years several studies have been performed to determine the value of endoanal magnetic resonance imaging ( MRI ) in faecal incontinence .
[ "Purpose", ".", "Within", "the", "recent", "years", "several", "studies", "have", "been", "performed", "to", "determine", "the", "value", "of", "endoanal", "magnetic", "resonance", "imaging", "(", "MRI", ")", "in", "faecal", "incontinence", "." ]
[ "umlsterm" ]
CheR is a Protein, CheB is a Protein, CheB is a Protein, CheB is a Protein, CheR is a Protein
10_task0
Sentence: Efficient adaptational demethylation of chemoreceptors requires the same enzyme-docking site as efficient methylation. The mechanistic basis of sensory adaptation and gradient sensing in bacterial chemotaxis is reversible covalent modification of transmembrane chemoreceptors, methylation, and demethylation at specific glutamyl residues in their cytoplasmic domains. These reactions are catalyzed by a dedicated methyltransferase CheR and a dedicated methylesterase CheB. The esterase is also a deamidase that creates certain methyl-accepting glutamyls by hydrolysis of glutamine side chains. We investigated the action of CheB and its activated form, phospho-CheB, on a truncated form of the aspartate receptor of Escherichia coli that was missing the last 5 aa of the intact receptor. The deleted pentapeptide is conserved in several chemoreceptors in enteric and related bacteria. The truncated receptor was much less efficiently demethylated and deamidated than intact receptor, but essentially was unperturbed for kinase activation or transmembrane signaling. CheB bound specifically to an affinity column carrying the isolated pentapeptide, implying that in the intact receptor the pentapeptide serves as a docking site for the methylesterase/deamidase and that the truncated receptor was inefficiently modified because the enzyme could not dock. It is striking that the same pentapeptide serves as an activity-enhancing docking site for the methyltransferase CheR, the other enzyme involved in adaptational covalent modification of chemoreceptors. A shared docking site raises the tantalizing possibility that relative rates of methylation and demethylation could be influenced by competition between the two enzymes at that site. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Efficient adaptational demethylation of chemoreceptors requires the same enzyme-docking site as efficient methylation. The mechanistic basis of sensory adaptation and gradient sensing in bacterial chemotaxis is reversible covalent modification of transmembrane chemoreceptors, methylation, and demethylation at specific glutamyl residues in their cytoplasmic domains. These reactions are catalyzed by a dedicated methyltransferase CheR and a dedicated methylesterase CheB. The esterase is also a deamidase that creates certain methyl-accepting glutamyls by hydrolysis of glutamine side chains. We investigated the action of CheB and its activated form, phospho-CheB, on a truncated form of the aspartate receptor of Escherichia coli that was missing the last 5 aa of the intact receptor. The deleted pentapeptide is conserved in several chemoreceptors in enteric and related bacteria. The truncated receptor was much less efficiently demethylated and deamidated than intact receptor, but essentially was unperturbed for kinase activation or transmembrane signaling. CheB bound specifically to an affinity column carrying the isolated pentapeptide, implying that in the intact receptor the pentapeptide serves as a docking site for the methylesterase/deamidase and that the truncated receptor was inefficiently modified because the enzyme could not dock. It is striking that the same pentapeptide serves as an activity-enhancing docking site for the methyltransferase CheR, the other enzyme involved in adaptational covalent modification of chemoreceptors. A shared docking site raises the tantalizing possibility that relative rates of methylation and demethylation could be influenced by competition between the two enzymes at that site.
[ "Efficient", "adaptational", "demethylation", "of", "chemoreceptors", "requires", "the", "same", "enzyme", "-", "docking", "site", "as", "efficient", "methylation", ".", "\n", "The", "mechanistic", "basis", "of", "sensory", "adaptation", "and", "gradient", "sensing", "in", "bacterial", "chemotaxis", "is", "reversible", "covalent", "modification", "of", "transmembrane", "chemoreceptors", ",", "methylation", ",", "and", "demethylation", "at", "specific", "glutamyl", "residues", "in", "their", "cytoplasmic", "domains", ".", "These", "reactions", "are", "catalyzed", "by", "a", "dedicated", "methyltransferase", "CheR", "and", "a", "dedicated", "methylesterase", "CheB.", "The", "esterase", "is", "also", "a", "deamidase", "that", "creates", "certain", "methyl", "-", "accepting", "glutamyls", "by", "hydrolysis", "of", "glutamine", "side", "chains", ".", "We", "investigated", "the", "action", "of", "CheB", "and", "its", "activated", "form", ",", "phospho", "-", "CheB", ",", "on", "a", "truncated", "form", "of", "the", "aspartate", "receptor", "of", "Escherichia", "coli", "that", "was", "missing", "the", "last", "5", "aa", "of", "the", "intact", "receptor", ".", "The", "deleted", "pentapeptide", "is", "conserved", "in", "several", "chemoreceptors", "in", "enteric", "and", "related", "bacteria", ".", "The", "truncated", "receptor", "was", "much", "less", "efficiently", "demethylated", "and", "deamidated", "than", "intact", "receptor", ",", "but", "essentially", "was", "unperturbed", "for", "kinase", "activation", "or", "transmembrane", "signaling", ".", "CheB", "bound", "specifically", "to", "an", "affinity", "column", "carrying", "the", "isolated", "pentapeptide", ",", "implying", "that", "in", "the", "intact", "receptor", "the", "pentapeptide", "serves", "as", "a", "docking", "site", "for", "the", "methylesterase", "/", "deamidase", "and", "that", "the", "truncated", "receptor", "was", "inefficiently", "modified", "because", "the", "enzyme", "could", "not", "dock", ".", "It", "is", "striking", "that", "the", "same", "pentapeptide", "serves", "as", "an", "activity", "-", "enhancing", "docking", "site", "for", "the", "methyltransferase", "CheR", ",", "the", "other", "enzyme", "involved", "in", "adaptational", "covalent", "modification", "of", "chemoreceptors", ".", "A", "shared", "docking", "site", "raises", "the", "tantalizing", "possibility", "that", "relative", "rates", "of", "methylation", "and", "demethylation", "could", "be", "influenced", "by", "competition", "between", "the", "two", "enzymes", "at", "that", "site", ".", "\n" ]
[ "Protein" ]
CheR is a Protein, CheB is a Protein, CheB is a Protein, CheB is a Protein, CheR is a Protein
10_task1
Sentence: Efficient adaptational demethylation of chemoreceptors requires the same enzyme-docking site as efficient methylation. The mechanistic basis of sensory adaptation and gradient sensing in bacterial chemotaxis is reversible covalent modification of transmembrane chemoreceptors, methylation, and demethylation at specific glutamyl residues in their cytoplasmic domains. These reactions are catalyzed by a dedicated methyltransferase CheR and a dedicated methylesterase CheB. The esterase is also a deamidase that creates certain methyl-accepting glutamyls by hydrolysis of glutamine side chains. We investigated the action of CheB and its activated form, phospho-CheB, on a truncated form of the aspartate receptor of Escherichia coli that was missing the last 5 aa of the intact receptor. The deleted pentapeptide is conserved in several chemoreceptors in enteric and related bacteria. The truncated receptor was much less efficiently demethylated and deamidated than intact receptor, but essentially was unperturbed for kinase activation or transmembrane signaling. CheB bound specifically to an affinity column carrying the isolated pentapeptide, implying that in the intact receptor the pentapeptide serves as a docking site for the methylesterase/deamidase and that the truncated receptor was inefficiently modified because the enzyme could not dock. It is striking that the same pentapeptide serves as an activity-enhancing docking site for the methyltransferase CheR, the other enzyme involved in adaptational covalent modification of chemoreceptors. A shared docking site raises the tantalizing possibility that relative rates of methylation and demethylation could be influenced by competition between the two enzymes at that site. Instructions: please typing these entity words according to sentence: CheR, CheB, CheB, CheB, CheR Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Efficient adaptational demethylation of chemoreceptors requires the same enzyme-docking site as efficient methylation. The mechanistic basis of sensory adaptation and gradient sensing in bacterial chemotaxis is reversible covalent modification of transmembrane chemoreceptors, methylation, and demethylation at specific glutamyl residues in their cytoplasmic domains. These reactions are catalyzed by a dedicated methyltransferase CheR and a dedicated methylesterase CheB. The esterase is also a deamidase that creates certain methyl-accepting glutamyls by hydrolysis of glutamine side chains. We investigated the action of CheB and its activated form, phospho-CheB, on a truncated form of the aspartate receptor of Escherichia coli that was missing the last 5 aa of the intact receptor. The deleted pentapeptide is conserved in several chemoreceptors in enteric and related bacteria. The truncated receptor was much less efficiently demethylated and deamidated than intact receptor, but essentially was unperturbed for kinase activation or transmembrane signaling. CheB bound specifically to an affinity column carrying the isolated pentapeptide, implying that in the intact receptor the pentapeptide serves as a docking site for the methylesterase/deamidase and that the truncated receptor was inefficiently modified because the enzyme could not dock. It is striking that the same pentapeptide serves as an activity-enhancing docking site for the methyltransferase CheR, the other enzyme involved in adaptational covalent modification of chemoreceptors. A shared docking site raises the tantalizing possibility that relative rates of methylation and demethylation could be influenced by competition between the two enzymes at that site.
[ "Efficient", "adaptational", "demethylation", "of", "chemoreceptors", "requires", "the", "same", "enzyme", "-", "docking", "site", "as", "efficient", "methylation", ".", "\n", "The", "mechanistic", "basis", "of", "sensory", "adaptation", "and", "gradient", "sensing", "in", "bacterial", "chemotaxis", "is", "reversible", "covalent", "modification", "of", "transmembrane", "chemoreceptors", ",", "methylation", ",", "and", "demethylation", "at", "specific", "glutamyl", "residues", "in", "their", "cytoplasmic", "domains", ".", "These", "reactions", "are", "catalyzed", "by", "a", "dedicated", "methyltransferase", "CheR", "and", "a", "dedicated", "methylesterase", "CheB.", "The", "esterase", "is", "also", "a", "deamidase", "that", "creates", "certain", "methyl", "-", "accepting", "glutamyls", "by", "hydrolysis", "of", "glutamine", "side", "chains", ".", "We", "investigated", "the", "action", "of", "CheB", "and", "its", "activated", "form", ",", "phospho", "-", "CheB", ",", "on", "a", "truncated", "form", "of", "the", "aspartate", "receptor", "of", "Escherichia", "coli", "that", "was", "missing", "the", "last", "5", "aa", "of", "the", "intact", "receptor", ".", "The", "deleted", "pentapeptide", "is", "conserved", "in", "several", "chemoreceptors", "in", "enteric", "and", "related", "bacteria", ".", "The", "truncated", "receptor", "was", "much", "less", "efficiently", "demethylated", "and", "deamidated", "than", "intact", "receptor", ",", "but", "essentially", "was", "unperturbed", "for", "kinase", "activation", "or", "transmembrane", "signaling", ".", "CheB", "bound", "specifically", "to", "an", "affinity", "column", "carrying", "the", "isolated", "pentapeptide", ",", "implying", "that", "in", "the", "intact", "receptor", "the", "pentapeptide", "serves", "as", "a", "docking", "site", "for", "the", "methylesterase", "/", "deamidase", "and", "that", "the", "truncated", "receptor", "was", "inefficiently", "modified", "because", "the", "enzyme", "could", "not", "dock", ".", "It", "is", "striking", "that", "the", "same", "pentapeptide", "serves", "as", "an", "activity", "-", "enhancing", "docking", "site", "for", "the", "methyltransferase", "CheR", ",", "the", "other", "enzyme", "involved", "in", "adaptational", "covalent", "modification", "of", "chemoreceptors", ".", "A", "shared", "docking", "site", "raises", "the", "tantalizing", "possibility", "that", "relative", "rates", "of", "methylation", "and", "demethylation", "could", "be", "influenced", "by", "competition", "between", "the", "two", "enzymes", "at", "that", "site", ".", "\n" ]
[ "Protein" ]
CheR, CheB, CheB, CheB, CheR
10_task2
Sentence: Efficient adaptational demethylation of chemoreceptors requires the same enzyme-docking site as efficient methylation. The mechanistic basis of sensory adaptation and gradient sensing in bacterial chemotaxis is reversible covalent modification of transmembrane chemoreceptors, methylation, and demethylation at specific glutamyl residues in their cytoplasmic domains. These reactions are catalyzed by a dedicated methyltransferase CheR and a dedicated methylesterase CheB. The esterase is also a deamidase that creates certain methyl-accepting glutamyls by hydrolysis of glutamine side chains. We investigated the action of CheB and its activated form, phospho-CheB, on a truncated form of the aspartate receptor of Escherichia coli that was missing the last 5 aa of the intact receptor. The deleted pentapeptide is conserved in several chemoreceptors in enteric and related bacteria. The truncated receptor was much less efficiently demethylated and deamidated than intact receptor, but essentially was unperturbed for kinase activation or transmembrane signaling. CheB bound specifically to an affinity column carrying the isolated pentapeptide, implying that in the intact receptor the pentapeptide serves as a docking site for the methylesterase/deamidase and that the truncated receptor was inefficiently modified because the enzyme could not dock. It is striking that the same pentapeptide serves as an activity-enhancing docking site for the methyltransferase CheR, the other enzyme involved in adaptational covalent modification of chemoreceptors. A shared docking site raises the tantalizing possibility that relative rates of methylation and demethylation could be influenced by competition between the two enzymes at that site. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Efficient adaptational demethylation of chemoreceptors requires the same enzyme-docking site as efficient methylation. The mechanistic basis of sensory adaptation and gradient sensing in bacterial chemotaxis is reversible covalent modification of transmembrane chemoreceptors, methylation, and demethylation at specific glutamyl residues in their cytoplasmic domains. These reactions are catalyzed by a dedicated methyltransferase CheR and a dedicated methylesterase CheB. The esterase is also a deamidase that creates certain methyl-accepting glutamyls by hydrolysis of glutamine side chains. We investigated the action of CheB and its activated form, phospho-CheB, on a truncated form of the aspartate receptor of Escherichia coli that was missing the last 5 aa of the intact receptor. The deleted pentapeptide is conserved in several chemoreceptors in enteric and related bacteria. The truncated receptor was much less efficiently demethylated and deamidated than intact receptor, but essentially was unperturbed for kinase activation or transmembrane signaling. CheB bound specifically to an affinity column carrying the isolated pentapeptide, implying that in the intact receptor the pentapeptide serves as a docking site for the methylesterase/deamidase and that the truncated receptor was inefficiently modified because the enzyme could not dock. It is striking that the same pentapeptide serves as an activity-enhancing docking site for the methyltransferase CheR, the other enzyme involved in adaptational covalent modification of chemoreceptors. A shared docking site raises the tantalizing possibility that relative rates of methylation and demethylation could be influenced by competition between the two enzymes at that site.
[ "Efficient", "adaptational", "demethylation", "of", "chemoreceptors", "requires", "the", "same", "enzyme", "-", "docking", "site", "as", "efficient", "methylation", ".", "\n", "The", "mechanistic", "basis", "of", "sensory", "adaptation", "and", "gradient", "sensing", "in", "bacterial", "chemotaxis", "is", "reversible", "covalent", "modification", "of", "transmembrane", "chemoreceptors", ",", "methylation", ",", "and", "demethylation", "at", "specific", "glutamyl", "residues", "in", "their", "cytoplasmic", "domains", ".", "These", "reactions", "are", "catalyzed", "by", "a", "dedicated", "methyltransferase", "CheR", "and", "a", "dedicated", "methylesterase", "CheB.", "The", "esterase", "is", "also", "a", "deamidase", "that", "creates", "certain", "methyl", "-", "accepting", "glutamyls", "by", "hydrolysis", "of", "glutamine", "side", "chains", ".", "We", "investigated", "the", "action", "of", "CheB", "and", "its", "activated", "form", ",", "phospho", "-", "CheB", ",", "on", "a", "truncated", "form", "of", "the", "aspartate", "receptor", "of", "Escherichia", "coli", "that", "was", "missing", "the", "last", "5", "aa", "of", "the", "intact", "receptor", ".", "The", "deleted", "pentapeptide", "is", "conserved", "in", "several", "chemoreceptors", "in", "enteric", "and", "related", "bacteria", ".", "The", "truncated", "receptor", "was", "much", "less", "efficiently", "demethylated", "and", "deamidated", "than", "intact", "receptor", ",", "but", "essentially", "was", "unperturbed", "for", "kinase", "activation", "or", "transmembrane", "signaling", ".", "CheB", "bound", "specifically", "to", "an", "affinity", "column", "carrying", "the", "isolated", "pentapeptide", ",", "implying", "that", "in", "the", "intact", "receptor", "the", "pentapeptide", "serves", "as", "a", "docking", "site", "for", "the", "methylesterase", "/", "deamidase", "and", "that", "the", "truncated", "receptor", "was", "inefficiently", "modified", "because", "the", "enzyme", "could", "not", "dock", ".", "It", "is", "striking", "that", "the", "same", "pentapeptide", "serves", "as", "an", "activity", "-", "enhancing", "docking", "site", "for", "the", "methyltransferase", "CheR", ",", "the", "other", "enzyme", "involved", "in", "adaptational", "covalent", "modification", "of", "chemoreceptors", ".", "A", "shared", "docking", "site", "raises", "the", "tantalizing", "possibility", "that", "relative", "rates", "of", "methylation", "and", "demethylation", "could", "be", "influenced", "by", "competition", "between", "the", "two", "enzymes", "at", "that", "site", ".", "\n" ]
[ "Protein" ]
bench step exercise intervention is a Intervention_Physical, work ability is a Outcome_Physical, cardiovascular is a Outcome_Physical, Work ability is a Outcome_Physical, Bench step exercise is a Intervention_Physical, oxidative stress . is a Outcome_Physical, n=7 is a Participant_Sample-size, n=6 is a Participant_Sample-size, glucose metabolism and antioxidative capacity is a Outcome_Physical, work ability by reducing absences from work and improving the prognosis of work ability . is a Outcome_Physical
72447_task0
Sentence: Effects of bench step exercise intervention on work ability in terms of cardiovascular risk factors and oxidative stress : a randomized controlled study . Work ability is partly determined by physical and mental fitness . Bench step exercise can be practiced anywhere at any time . The aim of this study was to determine the effects of a bench step exercise on work ability by examining cardiovascular risk factors and oxidative stress . Thirteen volunteers working in a warehousing industry comprised the bench step exercise group ( n=7 ) and the control group ( n=6 ) . The participants in the step exercise group were encouraged to practice the step exercise at home for 16 weeks . The step exercise improved glucose metabolism and antioxidative capacity and increased work ability by reducing absences from work and improving the prognosis of work ability . The improvement in work ability was related to a reduction in oxidative stress . These results suggest that a bench step exercise may improve work ability by reducing cardiovascular risk factors and oxidative stress . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Physical, Participant_Sample-size
[ "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of bench step exercise intervention on work ability in terms of cardiovascular risk factors and oxidative stress : a randomized controlled study . Work ability is partly determined by physical and mental fitness . Bench step exercise can be practiced anywhere at any time . The aim of this study was to determine the effects of a bench step exercise on work ability by examining cardiovascular risk factors and oxidative stress . Thirteen volunteers working in a warehousing industry comprised the bench step exercise group ( n=7 ) and the control group ( n=6 ) . The participants in the step exercise group were encouraged to practice the step exercise at home for 16 weeks . The step exercise improved glucose metabolism and antioxidative capacity and increased work ability by reducing absences from work and improving the prognosis of work ability . The improvement in work ability was related to a reduction in oxidative stress . These results suggest that a bench step exercise may improve work ability by reducing cardiovascular risk factors and oxidative stress .
[ "Effects", "of", "bench", "step", "exercise", "intervention", "on", "work", "ability", "in", "terms", "of", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", ":", "a", "randomized", "controlled", "study", ".", "Work", "ability", "is", "partly", "determined", "by", "physical", "and", "mental", "fitness", ".", "Bench", "step", "exercise", "can", "be", "practiced", "anywhere", "at", "any", "time", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "effects", "of", "a", "bench", "step", "exercise", "on", "work", "ability", "by", "examining", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", ".", "Thirteen", "volunteers", "working", "in", "a", "warehousing", "industry", "comprised", "the", "bench", "step", "exercise", "group", "(", "n=7", ")", "and", "the", "control", "group", "(", "n=6", ")", ".", "The", "participants", "in", "the", "step", "exercise", "group", "were", "encouraged", "to", "practice", "the", "step", "exercise", "at", "home", "for", "16", "weeks", ".", "The", "step", "exercise", "improved", "glucose", "metabolism", "and", "antioxidative", "capacity", "and", "increased", "work", "ability", "by", "reducing", "absences", "from", "work", "and", "improving", "the", "prognosis", "of", "work", "ability", ".", "The", "improvement", "in", "work", "ability", "was", "related", "to", "a", "reduction", "in", "oxidative", "stress", ".", "These", "results", "suggest", "that", "a", "bench", "step", "exercise", "may", "improve", "work", "ability", "by", "reducing", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", "." ]
[ "Outcome_Physical", "Intervention_Physical", "Participant_Sample-size" ]
bench step exercise intervention is a Intervention_Physical, work ability is a Outcome_Physical, cardiovascular is a Outcome_Physical, Work ability is a Outcome_Physical, Bench step exercise is a Intervention_Physical, oxidative stress . is a Outcome_Physical, n=7 is a Participant_Sample-size, n=6 is a Participant_Sample-size, glucose metabolism and antioxidative capacity is a Outcome_Physical, work ability by reducing absences from work and improving the prognosis of work ability . is a Outcome_Physical
72447_task1
Sentence: Effects of bench step exercise intervention on work ability in terms of cardiovascular risk factors and oxidative stress : a randomized controlled study . Work ability is partly determined by physical and mental fitness . Bench step exercise can be practiced anywhere at any time . The aim of this study was to determine the effects of a bench step exercise on work ability by examining cardiovascular risk factors and oxidative stress . Thirteen volunteers working in a warehousing industry comprised the bench step exercise group ( n=7 ) and the control group ( n=6 ) . The participants in the step exercise group were encouraged to practice the step exercise at home for 16 weeks . The step exercise improved glucose metabolism and antioxidative capacity and increased work ability by reducing absences from work and improving the prognosis of work ability . The improvement in work ability was related to a reduction in oxidative stress . These results suggest that a bench step exercise may improve work ability by reducing cardiovascular risk factors and oxidative stress . Instructions: please typing these entity words according to sentence: bench step exercise intervention, work ability, cardiovascular, Work ability, Bench step exercise, oxidative stress ., n=7, n=6, glucose metabolism and antioxidative capacity, work ability by reducing absences from work and improving the prognosis of work ability . Options: Intervention_Physical, Outcome_Physical, Participant_Sample-size
[ "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of bench step exercise intervention on work ability in terms of cardiovascular risk factors and oxidative stress : a randomized controlled study . Work ability is partly determined by physical and mental fitness . Bench step exercise can be practiced anywhere at any time . The aim of this study was to determine the effects of a bench step exercise on work ability by examining cardiovascular risk factors and oxidative stress . Thirteen volunteers working in a warehousing industry comprised the bench step exercise group ( n=7 ) and the control group ( n=6 ) . The participants in the step exercise group were encouraged to practice the step exercise at home for 16 weeks . The step exercise improved glucose metabolism and antioxidative capacity and increased work ability by reducing absences from work and improving the prognosis of work ability . The improvement in work ability was related to a reduction in oxidative stress . These results suggest that a bench step exercise may improve work ability by reducing cardiovascular risk factors and oxidative stress .
[ "Effects", "of", "bench", "step", "exercise", "intervention", "on", "work", "ability", "in", "terms", "of", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", ":", "a", "randomized", "controlled", "study", ".", "Work", "ability", "is", "partly", "determined", "by", "physical", "and", "mental", "fitness", ".", "Bench", "step", "exercise", "can", "be", "practiced", "anywhere", "at", "any", "time", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "effects", "of", "a", "bench", "step", "exercise", "on", "work", "ability", "by", "examining", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", ".", "Thirteen", "volunteers", "working", "in", "a", "warehousing", "industry", "comprised", "the", "bench", "step", "exercise", "group", "(", "n=7", ")", "and", "the", "control", "group", "(", "n=6", ")", ".", "The", "participants", "in", "the", "step", "exercise", "group", "were", "encouraged", "to", "practice", "the", "step", "exercise", "at", "home", "for", "16", "weeks", ".", "The", "step", "exercise", "improved", "glucose", "metabolism", "and", "antioxidative", "capacity", "and", "increased", "work", "ability", "by", "reducing", "absences", "from", "work", "and", "improving", "the", "prognosis", "of", "work", "ability", ".", "The", "improvement", "in", "work", "ability", "was", "related", "to", "a", "reduction", "in", "oxidative", "stress", ".", "These", "results", "suggest", "that", "a", "bench", "step", "exercise", "may", "improve", "work", "ability", "by", "reducing", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", "." ]
[ "Outcome_Physical", "Intervention_Physical", "Participant_Sample-size" ]
bench step exercise intervention, work ability, cardiovascular, Work ability, Bench step exercise, oxidative stress ., n=7, n=6, glucose metabolism and antioxidative capacity, work ability by reducing absences from work and improving the prognosis of work ability .
72447_task2
Sentence: Effects of bench step exercise intervention on work ability in terms of cardiovascular risk factors and oxidative stress : a randomized controlled study . Work ability is partly determined by physical and mental fitness . Bench step exercise can be practiced anywhere at any time . The aim of this study was to determine the effects of a bench step exercise on work ability by examining cardiovascular risk factors and oxidative stress . Thirteen volunteers working in a warehousing industry comprised the bench step exercise group ( n=7 ) and the control group ( n=6 ) . The participants in the step exercise group were encouraged to practice the step exercise at home for 16 weeks . The step exercise improved glucose metabolism and antioxidative capacity and increased work ability by reducing absences from work and improving the prognosis of work ability . The improvement in work ability was related to a reduction in oxidative stress . These results suggest that a bench step exercise may improve work ability by reducing cardiovascular risk factors and oxidative stress . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of bench step exercise intervention on work ability in terms of cardiovascular risk factors and oxidative stress : a randomized controlled study . Work ability is partly determined by physical and mental fitness . Bench step exercise can be practiced anywhere at any time . The aim of this study was to determine the effects of a bench step exercise on work ability by examining cardiovascular risk factors and oxidative stress . Thirteen volunteers working in a warehousing industry comprised the bench step exercise group ( n=7 ) and the control group ( n=6 ) . The participants in the step exercise group were encouraged to practice the step exercise at home for 16 weeks . The step exercise improved glucose metabolism and antioxidative capacity and increased work ability by reducing absences from work and improving the prognosis of work ability . The improvement in work ability was related to a reduction in oxidative stress . These results suggest that a bench step exercise may improve work ability by reducing cardiovascular risk factors and oxidative stress .
[ "Effects", "of", "bench", "step", "exercise", "intervention", "on", "work", "ability", "in", "terms", "of", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", ":", "a", "randomized", "controlled", "study", ".", "Work", "ability", "is", "partly", "determined", "by", "physical", "and", "mental", "fitness", ".", "Bench", "step", "exercise", "can", "be", "practiced", "anywhere", "at", "any", "time", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "the", "effects", "of", "a", "bench", "step", "exercise", "on", "work", "ability", "by", "examining", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", ".", "Thirteen", "volunteers", "working", "in", "a", "warehousing", "industry", "comprised", "the", "bench", "step", "exercise", "group", "(", "n=7", ")", "and", "the", "control", "group", "(", "n=6", ")", ".", "The", "participants", "in", "the", "step", "exercise", "group", "were", "encouraged", "to", "practice", "the", "step", "exercise", "at", "home", "for", "16", "weeks", ".", "The", "step", "exercise", "improved", "glucose", "metabolism", "and", "antioxidative", "capacity", "and", "increased", "work", "ability", "by", "reducing", "absences", "from", "work", "and", "improving", "the", "prognosis", "of", "work", "ability", ".", "The", "improvement", "in", "work", "ability", "was", "related", "to", "a", "reduction", "in", "oxidative", "stress", ".", "These", "results", "suggest", "that", "a", "bench", "step", "exercise", "may", "improve", "work", "ability", "by", "reducing", "cardiovascular", "risk", "factors", "and", "oxidative", "stress", "." ]
[ "Outcome_Physical", "Intervention_Physical", "Participant_Sample-size" ]
NF - kappa B - independent suppression is an other_name, HIV is a virus, ascorbic acid is an other_organic_compound
65585_task0
Sentence: NF-kappa B-independent suppression of HIV expression by ascorbic acid. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, virus, other_name
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-virus", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O" ]
NF-kappa B-independent suppression of HIV expression by ascorbic acid.
[ "NF", "-", "kappa", "B", "-", "independent", "suppression", "of", "HIV", "expression", "by", "ascorbic", "acid", "." ]
[ "cell_type", "(OR other_name other_name)", "other_name", "protein_family_or_group", "", "inorganic", "cell_component", "amino_acid_monomer", "cell_line", "other_organic_compound", "protein_complex", "protein_molecule", "virus" ]
NF - kappa B - independent suppression is an other_name, HIV is a virus, ascorbic acid is an other_organic_compound
65585_task1
Sentence: NF-kappa B-independent suppression of HIV expression by ascorbic acid. Instructions: please typing these entity words according to sentence: NF - kappa B - independent suppression, HIV, ascorbic acid Options: other_organic_compound, virus, other_name
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-virus", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O" ]
NF-kappa B-independent suppression of HIV expression by ascorbic acid.
[ "NF", "-", "kappa", "B", "-", "independent", "suppression", "of", "HIV", "expression", "by", "ascorbic", "acid", "." ]
[ "cell_type", "(OR other_name other_name)", "other_name", "protein_family_or_group", "", "inorganic", "cell_component", "amino_acid_monomer", "cell_line", "other_organic_compound", "protein_complex", "protein_molecule", "virus" ]
NF - kappa B - independent suppression, HIV, ascorbic acid
65585_task2
Sentence: NF-kappa B-independent suppression of HIV expression by ascorbic acid. Instructions: please extract entity words from the input sentence
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-virus", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O" ]
NF-kappa B-independent suppression of HIV expression by ascorbic acid.
[ "NF", "-", "kappa", "B", "-", "independent", "suppression", "of", "HIV", "expression", "by", "ascorbic", "acid", "." ]
[ "cell_type", "(OR other_name other_name)", "other_name", "protein_family_or_group", "", "inorganic", "cell_component", "amino_acid_monomer", "cell_line", "other_organic_compound", "protein_complex", "protein_molecule", "virus" ]
ACE inhibitors is a GROUP, NSAIDs is a GROUP, Angiotensin Converting Enzyme ( ACE ) inhibitors is a GROUP, VIOXX is a BRAND, ACE inhibitor is a GROUP, benazepril is a DRUG, ACE inhibitor is a GROUP, VIOXX is a BRAND, ACE inhibitors is a GROUP, Aspirin is a BRAND, aspirin is a BRAND, VIOXX is a BRAND, VIOXX is a BRAND, aspirin is a BRAND, VIOXX is a BRAND, ibuprofen is a DRUG, aspirin is a BRAND, ibuprofen is a DRUG, VIOXX is a BRAND, aspirin is a BRAND, VIOXX is a BRAND, aspirin is a BRAND, VIOXX is a BRAND, VIOXX is a BRAND, aspirin is a BRAND, Cimetidine is a DRUG, cimetidine is a DRUG, rofecoxib is a DRUG, Digoxin is a DRUG, Rofecoxib is a DRUG, digoxin is a DRUG, Furosemide is a DRUG, NSAIDs is a GROUP, furosemide is a DRUG, thiazides is a GROUP, Ketoconazole is a DRUG, Ketoconazole is a DRUG, rofecoxib is a DRUG, Lithium is a DRUG, NSAIDs is a GROUP, lithium is a DRUG, lithium is a DRUG, lithium is a DRUG, VIOXX is a BRAND, lithium is a DRUG, lithium is a DRUG, Methotrexate is a DRUG, VIOXX is a BRAND, methotrexate is a DRUG, methotrexate is a DRUG, VIOXX is a BRAND, methotrexate is a DRUG, methotrexate is a DRUG, methotrexate is a DRUG, rofecoxib is a DRUG, methotrexate is a DRUG, methotrexate is a DRUG, VIOXX is a BRAND, methotrexate is a DRUG, Contraceptives is a GROUP, Rofecoxib is a DRUG, ethinyl estradiol is a DRUG, norethindrone is a DRUG, Prednisone is a DRUG, prednisolone is a DRUG, Rofecoxib is a DRUG, prednisolone is a DRUG, prednisone is a DRUG, Rifampin is a DRUG, VIOXX is a BRAND, rifampin is a DRUG, rofecoxib is a DRUG, VIOXX is a BRAND, VIOXX is a BRAND, Theophylline is a DRUG, VIOXX is a BRAND, theophylline is a DRUG, theophylline is a DRUG, theophylline is a DRUG, VIOXX is a BRAND, theophylline is a DRUG, rofecoxib is a DRUG, amitriptyline is a DRUG, tacrine is a DRUG, zileuton is a DRUG, Warfarin is a DRUG, VIOXX is a BRAND, warfarin is a DRUG, warfarin is a DRUG, rofecoxib is a DRUG, VIOXX is a BRAND, warfarin is a DRUG
Rofecoxib_ddi_task0
Sentence: ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors. In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone. This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors. Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone. In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone. Patients taking low-dose aspirin plus ibuprofen were not studied. At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood. Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis. Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis. Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted. Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose. Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. In post-marketing experience there have been reports of increases in plasma lithium levels. Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis. At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis. At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL). Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly. Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone. Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone. Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations. Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism. Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline. Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline. These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2. Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton). Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications. In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%. In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG, BRAND
[ "B-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-GROUP", "I-GROUP", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-GROUP", "I-GROUP", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O" ]
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors. In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone. This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors. Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone. In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone. Patients taking low-dose aspirin plus ibuprofen were not studied. At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood. Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis. Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis. Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted. Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose. Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. In post-marketing experience there have been reports of increases in plasma lithium levels. Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis. At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis. At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL). Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly. Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone. Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone. Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations. Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism. Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline. Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline. These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2. Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton). Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications. In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%. In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
[ "ACE", "inhibitors", ":", "Reports", "suggest", "that", "NSAIDs", "may", "diminish", "the", "antihypertensive", "effect", "of", "Angiotensin", "Converting", "Enzyme", "(", "ACE", ")", "inhibitors", ".", "In", "patients", "with", "mild", "to", "moderate", "hypertension", ",", "administration", "of", "25", "mg", "daily", "of", "VIOXX", "with", "the", "ACE", "inhibitor", "benazepril", ",", "10", "to", "40", "mg", "for", "4", "weeks", ",", "was", "associated", "with", "an", "average", "increase", "in", "mean", "arterial", "pressure", "of", "about", "3", "mm", "Hg", "compared", "to", "ACE", "inhibitor", "alone", ".", "This", "interaction", "should", "be", "given", "consideration", "in", "patients", "taking", "VIOXX", "concomitantly", "with", "ACE", "inhibitors", ".", "Aspirin", ":", "Concomitant", "administration", "of", "low", "-", "dose", "aspirin", "with", "VIOXX", "may", "result", "in", "an", "increased", "rate", "of", "GI", "ulceration", "or", "other", "complications", ",", "compared", "to", "use", "of", "VIOXX", "alone", ".", "In", "a", "12-week", "endoscopy", "study", "conducted", "in", "OA", "patients", "there", "was", "no", "difference", "in", "the", "cumulative", "incidence", "of", "endoscopic", "gastroduodenal", "ulcers", "in", "patients", "taking", "low", "-", "dose", "(", "81", "mg", ")", "enteric", "coated", "aspirin", "plus", "VIOXX", "25", "mg", "daily", ",", "as", "compared", "to", "those", "taking", "ibuprofen", "2400", "mg", "daily", "alone", ".", "Patients", "taking", "low", "-", "dose", "aspirin", "plus", "ibuprofen", "were", "not", "studied", ".", "At", "steady", "state", ",", "VIOXX", "50", "mg", "once", "daily", "had", "no", "effect", "on", "the", "anti", "-", "platelet", "activity", "of", "low", "-", "dose", "(", "81", "mg", "once", "daily", ")", "aspirin", ",", "as", "assessed", "by", "ex", "vivo", "platelet", "aggregation", "and", "serum", "TXB2", "generation", "in", "clotting", "blood", ".", "Because", "of", "its", "lack", "of", "platelet", "effects", ",", "VIOXX", "is", "not", "a", "substitute", "for", "aspirin", "for", "cardiovascular", "prophylaxis", ".", "Therefore", ",", "in", "patients", "taking", "VIOXX", ",", "antiplatelet", "therapies", "should", "not", "be", "discontinued", "and", "should", "be", "considered", "in", "patients", "with", "an", "indication", "for", "cardiovascular", "prophylaxis", ".", "Prospective", ",", "long", "-", "term", "studies", "on", "concomitant", "administration", "of", "VIOXX", "and", "aspirin", "have", "not", "been", "conducted", ".", "Cimetidine", ":", "Co", "-", "administration", "with", "high", "doses", "of", "cimetidine", "[", "800", "mg", "twice", "daily", "]", "increased", "the", "Cmax", "of", "rofecoxib", "by", "21", "%", ",", "the", "AUC0", "-", "120hr", "by", "23", "%", "and", "the", "t1/2", "by", "15", "%", ".", "These", "small", "changes", "are", "not", "clinically", "significant", "and", "no", "dose", "adjustment", "is", "necessary", ".", "Digoxin", ":", "Rofecoxib", "75", "mg", "once", "daily", "for", "11", "days", "does", "not", "alter", "the", "plasma", "concentration", "profile", "or", "renal", "elimination", "of", "digoxin", "after", "a", "single", "0.5", "mg", "oral", "dose", ".", "Furosemide", ":", "Clinical", "studies", ",", "as", "well", "as", "post", "-", "marketing", "observations", ",", "have", "shown", "that", "NSAIDs", "can", "reduce", "the", "natriuretic", "effect", "of", "furosemide", "and", "thiazides", "in", "some", "patients", ".", "This", "response", "has", "been", "attributed", "to", "inhibition", "of", "renal", "prostaglandin", "synthesis", ".", "Ketoconazole", ":", "Ketoconazole", "400", "mg", "daily", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "rofecoxib", ".", "Lithium", ":", "NSAIDs", "have", "produced", "an", "elevation", "of", "plasma", "lithium", "levels", "and", "a", "reduction", "in", "renal", "lithium", "clearance", ".", "In", "post", "-", "marketing", "experience", "there", "have", "been", "reports", "of", "increases", "in", "plasma", "lithium", "levels", ".", "Thus", ",", "when", "VIOXX", "and", "lithium", "are", "administered", "concurrently", ",", "subjects", "should", "be", "observed", "carefully", "for", "signs", "of", "lithium", "toxicity", ".", "Methotrexate", "VIOXX", "12.5", ",", "25", ",", "and", "50", "mg", ",", "each", "dose", "administered", "once", "daily", "for", "7", "days", ",", "had", "no", "effect", "on", "the", "plasma", "concentration", "of", "methotrexate", "as", "measured", "by", "AUC0", "-", "24hr", "in", "patients", "receiving", "single", "weekly", "methotrexate", "doses", "of", "7.5", "to", "20", "mg", "for", "rheumatoid", "arthritis", ".", "At", "higher", "than", "recommended", "doses", ",", "VIOXX", "75", "mg", "administered", "once", "daily", "for", "10", "days", "increased", "plasma", "concentrations", "by", "23", "%", "as", "measured", "by", "AUC0", "-", "24hr", "in", "patients", "receiving", "methotrexate", "7.5", "to", "15", "mg", "/", "week", "for", "rheumatoid", "arthritis", ".", "At", "24", "hours", "postdose", ",", "a", "similar", "proportion", "of", "patients", "treated", "with", "methotrexate", "alone", "(", "94", "%", ")", "and", "subsequently", "treated", "with", "methotrexate", "co", "-", "administered", "with", "75", "mg", "of", "rofecoxib", "(", "88", "%", ")", "had", "methotrexate", "plasma", "concentrations", "below", "the", "measurable", "limit", "(", "5", "ng", "/", "mL", ")", ".", "Standard", "monitoring", "of", "methotrexate", "-", "related", "toxicity", "should", "be", "continued", "if", "VIOXX", "and", "methotrexate", "are", "administered", "concomitantly", ".", "Oral", "Contraceptives", "Rofecoxib", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "ethinyl", "estradiol", "and", "norethindrone", ".", "Prednisone", "/", "prednisolone", ":", "Rofecoxib", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "prednisolone", "or", "prednisone", ".", "Rifampin", ":", "Co", "-", "administration", "of", "VIOXX", "with", "rifampin", "600", "mg", "daily", ",", "a", "potent", "inducer", "of", "hepatic", "metabolism", ",", "produced", "an", "approximate", "50", "%", "decrease", "in", "rofecoxib", "plasma", "concentrations", ".", "Therefore", ",", "a", "starting", "daily", "dose", "of", "25", "mg", "of", "VIOXX", "should", "be", "considered", "for", "the", "treatment", "of", "osteoarthritis", "when", "VIOXX", "is", "co", "-", "administered", "with", "potent", "inducers", "of", "hepatic", "metabolism", ".", "Theophylline", "VIOXX", "12.5", ",", "25", ",", "and", "50", "mg", "administered", "once", "daily", "for", "7", "days", "increased", "plasma", "theophylline", "concentrations", "(", "AUC(0-", ")", ")", "by", "38", "to", "60", "%", "in", "healthy", "subjects", "administered", "a", "single", "300-mg", "dose", "of", "theophylline", ".", "Adequate", "monitoring", "of", "theophylline", "plasma", "concentrations", "should", "be", "considered", "when", "therapy", "with", "VIOXX", "is", "initiated", "or", "changed", "in", "patients", "receiving", "theophylline", ".", "These", "data", "suggest", "that", "rofecoxib", "may", "produce", "a", "modest", "inhibition", "of", "cytochrome", "P450", "(", "CYP", ")", "1A2", ".", "Therefore", ",", "there", "is", "a", "potential", "for", "an", "interaction", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "1A2", "(", "e.g", ".", ",", "amitriptyline", ",", "tacrine", ",", "and", "zileuton", ")", ".", "Warfarin", ":", "Anticoagulant", "activity", "should", "be", "monitored", ",", "particularly", "in", "the", "first", "few", "days", "after", "initiating", "or", "changing", "VIOXX", "therapy", "in", "patients", "receiving", "warfarin", "or", "similar", "agents", ",", "since", "these", "patients", "are", "at", "an", "increased", "risk", "of", "bleeding", "complications", ".", "In", "single", "and", "multiple", "dose", "studies", "in", "healthy", "subjects", "receiving", "both", "warfarin", "and", "rofecoxib", ",", "prothrombin", "time", "(", "measured", "as", "INR", ")", "was", "increased", "by", "approximately", "8", "%", "to", "11", "%", ".", "In", "post", "-", "marketing", "experience", ",", "bleeding", "events", "have", "been", "reported", ",", "predominantly", "in", "the", "elderly", ",", "in", "association", "with", "increases", "in", "prothrombin", "time", "in", "patients", "receiving", "VIOXX", "concurrently", "with", "warfarin", "." ]
[ "GROUP", "DRUG", "BRAND" ]
ACE inhibitors is a GROUP, NSAIDs is a GROUP, Angiotensin Converting Enzyme ( ACE ) inhibitors is a GROUP, VIOXX is a BRAND, ACE inhibitor is a GROUP, benazepril is a DRUG, ACE inhibitor is a GROUP, VIOXX is a BRAND, ACE inhibitors is a GROUP, Aspirin is a BRAND, aspirin is a BRAND, VIOXX is a BRAND, VIOXX is a BRAND, aspirin is a BRAND, VIOXX is a BRAND, ibuprofen is a DRUG, aspirin is a BRAND, ibuprofen is a DRUG, VIOXX is a BRAND, aspirin is a BRAND, VIOXX is a BRAND, aspirin is a BRAND, VIOXX is a BRAND, VIOXX is a BRAND, aspirin is a BRAND, Cimetidine is a DRUG, cimetidine is a DRUG, rofecoxib is a DRUG, Digoxin is a DRUG, Rofecoxib is a DRUG, digoxin is a DRUG, Furosemide is a DRUG, NSAIDs is a GROUP, furosemide is a DRUG, thiazides is a GROUP, Ketoconazole is a DRUG, Ketoconazole is a DRUG, rofecoxib is a DRUG, Lithium is a DRUG, NSAIDs is a GROUP, lithium is a DRUG, lithium is a DRUG, lithium is a DRUG, VIOXX is a BRAND, lithium is a DRUG, lithium is a DRUG, Methotrexate is a DRUG, VIOXX is a BRAND, methotrexate is a DRUG, methotrexate is a DRUG, VIOXX is a BRAND, methotrexate is a DRUG, methotrexate is a DRUG, methotrexate is a DRUG, rofecoxib is a DRUG, methotrexate is a DRUG, methotrexate is a DRUG, VIOXX is a BRAND, methotrexate is a DRUG, Contraceptives is a GROUP, Rofecoxib is a DRUG, ethinyl estradiol is a DRUG, norethindrone is a DRUG, Prednisone is a DRUG, prednisolone is a DRUG, Rofecoxib is a DRUG, prednisolone is a DRUG, prednisone is a DRUG, Rifampin is a DRUG, VIOXX is a BRAND, rifampin is a DRUG, rofecoxib is a DRUG, VIOXX is a BRAND, VIOXX is a BRAND, Theophylline is a DRUG, VIOXX is a BRAND, theophylline is a DRUG, theophylline is a DRUG, theophylline is a DRUG, VIOXX is a BRAND, theophylline is a DRUG, rofecoxib is a DRUG, amitriptyline is a DRUG, tacrine is a DRUG, zileuton is a DRUG, Warfarin is a DRUG, VIOXX is a BRAND, warfarin is a DRUG, warfarin is a DRUG, rofecoxib is a DRUG, VIOXX is a BRAND, warfarin is a DRUG
Rofecoxib_ddi_task1
Sentence: ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors. In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone. This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors. Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone. In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone. Patients taking low-dose aspirin plus ibuprofen were not studied. At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood. Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis. Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis. Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted. Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose. Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. In post-marketing experience there have been reports of increases in plasma lithium levels. Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis. At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis. At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL). Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly. Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone. Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone. Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations. Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism. Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline. Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline. These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2. Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton). Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications. In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%. In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin. Instructions: please typing these entity words according to sentence: ACE inhibitors, NSAIDs, Angiotensin Converting Enzyme ( ACE ) inhibitors, VIOXX, ACE inhibitor, benazepril, ACE inhibitor, VIOXX, ACE inhibitors, Aspirin, aspirin, VIOXX, VIOXX, aspirin, VIOXX, ibuprofen, aspirin, ibuprofen, VIOXX, aspirin, VIOXX, aspirin, VIOXX, VIOXX, aspirin, Cimetidine, cimetidine, rofecoxib, Digoxin, Rofecoxib, digoxin, Furosemide, NSAIDs, furosemide, thiazides, Ketoconazole, Ketoconazole, rofecoxib, Lithium, NSAIDs, lithium, lithium, lithium, VIOXX, lithium, lithium, Methotrexate, VIOXX, methotrexate, methotrexate, VIOXX, methotrexate, methotrexate, methotrexate, rofecoxib, methotrexate, methotrexate, VIOXX, methotrexate, Contraceptives, Rofecoxib, ethinyl estradiol, norethindrone, Prednisone, prednisolone, Rofecoxib, prednisolone, prednisone, Rifampin, VIOXX, rifampin, rofecoxib, VIOXX, VIOXX, Theophylline, VIOXX, theophylline, theophylline, theophylline, VIOXX, theophylline, rofecoxib, amitriptyline, tacrine, zileuton, Warfarin, VIOXX, warfarin, warfarin, rofecoxib, VIOXX, warfarin Options: GROUP, DRUG, BRAND
[ "B-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-GROUP", "I-GROUP", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-GROUP", "I-GROUP", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O" ]
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors. In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone. This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors. Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone. In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone. Patients taking low-dose aspirin plus ibuprofen were not studied. At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood. Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis. Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis. Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted. Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose. Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. In post-marketing experience there have been reports of increases in plasma lithium levels. Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis. At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis. At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL). Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly. Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone. Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone. Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations. Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism. Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline. Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline. These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2. Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton). Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications. In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%. In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
[ "ACE", "inhibitors", ":", "Reports", "suggest", "that", "NSAIDs", "may", "diminish", "the", "antihypertensive", "effect", "of", "Angiotensin", "Converting", "Enzyme", "(", "ACE", ")", "inhibitors", ".", "In", "patients", "with", "mild", "to", "moderate", "hypertension", ",", "administration", "of", "25", "mg", "daily", "of", "VIOXX", "with", "the", "ACE", "inhibitor", "benazepril", ",", "10", "to", "40", "mg", "for", "4", "weeks", ",", "was", "associated", "with", "an", "average", "increase", "in", "mean", "arterial", "pressure", "of", "about", "3", "mm", "Hg", "compared", "to", "ACE", "inhibitor", "alone", ".", "This", "interaction", "should", "be", "given", "consideration", "in", "patients", "taking", "VIOXX", "concomitantly", "with", "ACE", "inhibitors", ".", "Aspirin", ":", "Concomitant", "administration", "of", "low", "-", "dose", "aspirin", "with", "VIOXX", "may", "result", "in", "an", "increased", "rate", "of", "GI", "ulceration", "or", "other", "complications", ",", "compared", "to", "use", "of", "VIOXX", "alone", ".", "In", "a", "12-week", "endoscopy", "study", "conducted", "in", "OA", "patients", "there", "was", "no", "difference", "in", "the", "cumulative", "incidence", "of", "endoscopic", "gastroduodenal", "ulcers", "in", "patients", "taking", "low", "-", "dose", "(", "81", "mg", ")", "enteric", "coated", "aspirin", "plus", "VIOXX", "25", "mg", "daily", ",", "as", "compared", "to", "those", "taking", "ibuprofen", "2400", "mg", "daily", "alone", ".", "Patients", "taking", "low", "-", "dose", "aspirin", "plus", "ibuprofen", "were", "not", "studied", ".", "At", "steady", "state", ",", "VIOXX", "50", "mg", "once", "daily", "had", "no", "effect", "on", "the", "anti", "-", "platelet", "activity", "of", "low", "-", "dose", "(", "81", "mg", "once", "daily", ")", "aspirin", ",", "as", "assessed", "by", "ex", "vivo", "platelet", "aggregation", "and", "serum", "TXB2", "generation", "in", "clotting", "blood", ".", "Because", "of", "its", "lack", "of", "platelet", "effects", ",", "VIOXX", "is", "not", "a", "substitute", "for", "aspirin", "for", "cardiovascular", "prophylaxis", ".", "Therefore", ",", "in", "patients", "taking", "VIOXX", ",", "antiplatelet", "therapies", "should", "not", "be", "discontinued", "and", "should", "be", "considered", "in", "patients", "with", "an", "indication", "for", "cardiovascular", "prophylaxis", ".", "Prospective", ",", "long", "-", "term", "studies", "on", "concomitant", "administration", "of", "VIOXX", "and", "aspirin", "have", "not", "been", "conducted", ".", "Cimetidine", ":", "Co", "-", "administration", "with", "high", "doses", "of", "cimetidine", "[", "800", "mg", "twice", "daily", "]", "increased", "the", "Cmax", "of", "rofecoxib", "by", "21", "%", ",", "the", "AUC0", "-", "120hr", "by", "23", "%", "and", "the", "t1/2", "by", "15", "%", ".", "These", "small", "changes", "are", "not", "clinically", "significant", "and", "no", "dose", "adjustment", "is", "necessary", ".", "Digoxin", ":", "Rofecoxib", "75", "mg", "once", "daily", "for", "11", "days", "does", "not", "alter", "the", "plasma", "concentration", "profile", "or", "renal", "elimination", "of", "digoxin", "after", "a", "single", "0.5", "mg", "oral", "dose", ".", "Furosemide", ":", "Clinical", "studies", ",", "as", "well", "as", "post", "-", "marketing", "observations", ",", "have", "shown", "that", "NSAIDs", "can", "reduce", "the", "natriuretic", "effect", "of", "furosemide", "and", "thiazides", "in", "some", "patients", ".", "This", "response", "has", "been", "attributed", "to", "inhibition", "of", "renal", "prostaglandin", "synthesis", ".", "Ketoconazole", ":", "Ketoconazole", "400", "mg", "daily", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "rofecoxib", ".", "Lithium", ":", "NSAIDs", "have", "produced", "an", "elevation", "of", "plasma", "lithium", "levels", "and", "a", "reduction", "in", "renal", "lithium", "clearance", ".", "In", "post", "-", "marketing", "experience", "there", "have", "been", "reports", "of", "increases", "in", "plasma", "lithium", "levels", ".", "Thus", ",", "when", "VIOXX", "and", "lithium", "are", "administered", "concurrently", ",", "subjects", "should", "be", "observed", "carefully", "for", "signs", "of", "lithium", "toxicity", ".", "Methotrexate", "VIOXX", "12.5", ",", "25", ",", "and", "50", "mg", ",", "each", "dose", "administered", "once", "daily", "for", "7", "days", ",", "had", "no", "effect", "on", "the", "plasma", "concentration", "of", "methotrexate", "as", "measured", "by", "AUC0", "-", "24hr", "in", "patients", "receiving", "single", "weekly", "methotrexate", "doses", "of", "7.5", "to", "20", "mg", "for", "rheumatoid", "arthritis", ".", "At", "higher", "than", "recommended", "doses", ",", "VIOXX", "75", "mg", "administered", "once", "daily", "for", "10", "days", "increased", "plasma", "concentrations", "by", "23", "%", "as", "measured", "by", "AUC0", "-", "24hr", "in", "patients", "receiving", "methotrexate", "7.5", "to", "15", "mg", "/", "week", "for", "rheumatoid", "arthritis", ".", "At", "24", "hours", "postdose", ",", "a", "similar", "proportion", "of", "patients", "treated", "with", "methotrexate", "alone", "(", "94", "%", ")", "and", "subsequently", "treated", "with", "methotrexate", "co", "-", "administered", "with", "75", "mg", "of", "rofecoxib", "(", "88", "%", ")", "had", "methotrexate", "plasma", "concentrations", "below", "the", "measurable", "limit", "(", "5", "ng", "/", "mL", ")", ".", "Standard", "monitoring", "of", "methotrexate", "-", "related", "toxicity", "should", "be", "continued", "if", "VIOXX", "and", "methotrexate", "are", "administered", "concomitantly", ".", "Oral", "Contraceptives", "Rofecoxib", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "ethinyl", "estradiol", "and", "norethindrone", ".", "Prednisone", "/", "prednisolone", ":", "Rofecoxib", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "prednisolone", "or", "prednisone", ".", "Rifampin", ":", "Co", "-", "administration", "of", "VIOXX", "with", "rifampin", "600", "mg", "daily", ",", "a", "potent", "inducer", "of", "hepatic", "metabolism", ",", "produced", "an", "approximate", "50", "%", "decrease", "in", "rofecoxib", "plasma", "concentrations", ".", "Therefore", ",", "a", "starting", "daily", "dose", "of", "25", "mg", "of", "VIOXX", "should", "be", "considered", "for", "the", "treatment", "of", "osteoarthritis", "when", "VIOXX", "is", "co", "-", "administered", "with", "potent", "inducers", "of", "hepatic", "metabolism", ".", "Theophylline", "VIOXX", "12.5", ",", "25", ",", "and", "50", "mg", "administered", "once", "daily", "for", "7", "days", "increased", "plasma", "theophylline", "concentrations", "(", "AUC(0-", ")", ")", "by", "38", "to", "60", "%", "in", "healthy", "subjects", "administered", "a", "single", "300-mg", "dose", "of", "theophylline", ".", "Adequate", "monitoring", "of", "theophylline", "plasma", "concentrations", "should", "be", "considered", "when", "therapy", "with", "VIOXX", "is", "initiated", "or", "changed", "in", "patients", "receiving", "theophylline", ".", "These", "data", "suggest", "that", "rofecoxib", "may", "produce", "a", "modest", "inhibition", "of", "cytochrome", "P450", "(", "CYP", ")", "1A2", ".", "Therefore", ",", "there", "is", "a", "potential", "for", "an", "interaction", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "1A2", "(", "e.g", ".", ",", "amitriptyline", ",", "tacrine", ",", "and", "zileuton", ")", ".", "Warfarin", ":", "Anticoagulant", "activity", "should", "be", "monitored", ",", "particularly", "in", "the", "first", "few", "days", "after", "initiating", "or", "changing", "VIOXX", "therapy", "in", "patients", "receiving", "warfarin", "or", "similar", "agents", ",", "since", "these", "patients", "are", "at", "an", "increased", "risk", "of", "bleeding", "complications", ".", "In", "single", "and", "multiple", "dose", "studies", "in", "healthy", "subjects", "receiving", "both", "warfarin", "and", "rofecoxib", ",", "prothrombin", "time", "(", "measured", "as", "INR", ")", "was", "increased", "by", "approximately", "8", "%", "to", "11", "%", ".", "In", "post", "-", "marketing", "experience", ",", "bleeding", "events", "have", "been", "reported", ",", "predominantly", "in", "the", "elderly", ",", "in", "association", "with", "increases", "in", "prothrombin", "time", "in", "patients", "receiving", "VIOXX", "concurrently", "with", "warfarin", "." ]
[ "GROUP", "DRUG", "BRAND" ]
ACE inhibitors, NSAIDs, Angiotensin Converting Enzyme ( ACE ) inhibitors, VIOXX, ACE inhibitor, benazepril, ACE inhibitor, VIOXX, ACE inhibitors, Aspirin, aspirin, VIOXX, VIOXX, aspirin, VIOXX, ibuprofen, aspirin, ibuprofen, VIOXX, aspirin, VIOXX, aspirin, VIOXX, VIOXX, aspirin, Cimetidine, cimetidine, rofecoxib, Digoxin, Rofecoxib, digoxin, Furosemide, NSAIDs, furosemide, thiazides, Ketoconazole, Ketoconazole, rofecoxib, Lithium, NSAIDs, lithium, lithium, lithium, VIOXX, lithium, lithium, Methotrexate, VIOXX, methotrexate, methotrexate, VIOXX, methotrexate, methotrexate, methotrexate, rofecoxib, methotrexate, methotrexate, VIOXX, methotrexate, Contraceptives, Rofecoxib, ethinyl estradiol, norethindrone, Prednisone, prednisolone, Rofecoxib, prednisolone, prednisone, Rifampin, VIOXX, rifampin, rofecoxib, VIOXX, VIOXX, Theophylline, VIOXX, theophylline, theophylline, theophylline, VIOXX, theophylline, rofecoxib, amitriptyline, tacrine, zileuton, Warfarin, VIOXX, warfarin, warfarin, rofecoxib, VIOXX, warfarin
Rofecoxib_ddi_task2
Sentence: ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors. In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone. This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors. Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone. In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone. Patients taking low-dose aspirin plus ibuprofen were not studied. At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood. Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis. Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis. Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted. Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose. Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. In post-marketing experience there have been reports of increases in plasma lithium levels. Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis. At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis. At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL). Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly. Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone. Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone. Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations. Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism. Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline. Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline. These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2. Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton). Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications. In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%. In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin. Instructions: please extract entity words from the input sentence
[ "B-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-GROUP", "I-GROUP", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-GROUP", "I-GROUP", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O" ]
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors. In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone. This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors. Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone. In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone. Patients taking low-dose aspirin plus ibuprofen were not studied. At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood. Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis. Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis. Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted. Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose. Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. In post-marketing experience there have been reports of increases in plasma lithium levels. Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis. At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis. At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL). Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly. Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone. Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone. Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations. Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism. Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline. Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline. These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2. Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton). Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications. In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%. In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
[ "ACE", "inhibitors", ":", "Reports", "suggest", "that", "NSAIDs", "may", "diminish", "the", "antihypertensive", "effect", "of", "Angiotensin", "Converting", "Enzyme", "(", "ACE", ")", "inhibitors", ".", "In", "patients", "with", "mild", "to", "moderate", "hypertension", ",", "administration", "of", "25", "mg", "daily", "of", "VIOXX", "with", "the", "ACE", "inhibitor", "benazepril", ",", "10", "to", "40", "mg", "for", "4", "weeks", ",", "was", "associated", "with", "an", "average", "increase", "in", "mean", "arterial", "pressure", "of", "about", "3", "mm", "Hg", "compared", "to", "ACE", "inhibitor", "alone", ".", "This", "interaction", "should", "be", "given", "consideration", "in", "patients", "taking", "VIOXX", "concomitantly", "with", "ACE", "inhibitors", ".", "Aspirin", ":", "Concomitant", "administration", "of", "low", "-", "dose", "aspirin", "with", "VIOXX", "may", "result", "in", "an", "increased", "rate", "of", "GI", "ulceration", "or", "other", "complications", ",", "compared", "to", "use", "of", "VIOXX", "alone", ".", "In", "a", "12-week", "endoscopy", "study", "conducted", "in", "OA", "patients", "there", "was", "no", "difference", "in", "the", "cumulative", "incidence", "of", "endoscopic", "gastroduodenal", "ulcers", "in", "patients", "taking", "low", "-", "dose", "(", "81", "mg", ")", "enteric", "coated", "aspirin", "plus", "VIOXX", "25", "mg", "daily", ",", "as", "compared", "to", "those", "taking", "ibuprofen", "2400", "mg", "daily", "alone", ".", "Patients", "taking", "low", "-", "dose", "aspirin", "plus", "ibuprofen", "were", "not", "studied", ".", "At", "steady", "state", ",", "VIOXX", "50", "mg", "once", "daily", "had", "no", "effect", "on", "the", "anti", "-", "platelet", "activity", "of", "low", "-", "dose", "(", "81", "mg", "once", "daily", ")", "aspirin", ",", "as", "assessed", "by", "ex", "vivo", "platelet", "aggregation", "and", "serum", "TXB2", "generation", "in", "clotting", "blood", ".", "Because", "of", "its", "lack", "of", "platelet", "effects", ",", "VIOXX", "is", "not", "a", "substitute", "for", "aspirin", "for", "cardiovascular", "prophylaxis", ".", "Therefore", ",", "in", "patients", "taking", "VIOXX", ",", "antiplatelet", "therapies", "should", "not", "be", "discontinued", "and", "should", "be", "considered", "in", "patients", "with", "an", "indication", "for", "cardiovascular", "prophylaxis", ".", "Prospective", ",", "long", "-", "term", "studies", "on", "concomitant", "administration", "of", "VIOXX", "and", "aspirin", "have", "not", "been", "conducted", ".", "Cimetidine", ":", "Co", "-", "administration", "with", "high", "doses", "of", "cimetidine", "[", "800", "mg", "twice", "daily", "]", "increased", "the", "Cmax", "of", "rofecoxib", "by", "21", "%", ",", "the", "AUC0", "-", "120hr", "by", "23", "%", "and", "the", "t1/2", "by", "15", "%", ".", "These", "small", "changes", "are", "not", "clinically", "significant", "and", "no", "dose", "adjustment", "is", "necessary", ".", "Digoxin", ":", "Rofecoxib", "75", "mg", "once", "daily", "for", "11", "days", "does", "not", "alter", "the", "plasma", "concentration", "profile", "or", "renal", "elimination", "of", "digoxin", "after", "a", "single", "0.5", "mg", "oral", "dose", ".", "Furosemide", ":", "Clinical", "studies", ",", "as", "well", "as", "post", "-", "marketing", "observations", ",", "have", "shown", "that", "NSAIDs", "can", "reduce", "the", "natriuretic", "effect", "of", "furosemide", "and", "thiazides", "in", "some", "patients", ".", "This", "response", "has", "been", "attributed", "to", "inhibition", "of", "renal", "prostaglandin", "synthesis", ".", "Ketoconazole", ":", "Ketoconazole", "400", "mg", "daily", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "rofecoxib", ".", "Lithium", ":", "NSAIDs", "have", "produced", "an", "elevation", "of", "plasma", "lithium", "levels", "and", "a", "reduction", "in", "renal", "lithium", "clearance", ".", "In", "post", "-", "marketing", "experience", "there", "have", "been", "reports", "of", "increases", "in", "plasma", "lithium", "levels", ".", "Thus", ",", "when", "VIOXX", "and", "lithium", "are", "administered", "concurrently", ",", "subjects", "should", "be", "observed", "carefully", "for", "signs", "of", "lithium", "toxicity", ".", "Methotrexate", "VIOXX", "12.5", ",", "25", ",", "and", "50", "mg", ",", "each", "dose", "administered", "once", "daily", "for", "7", "days", ",", "had", "no", "effect", "on", "the", "plasma", "concentration", "of", "methotrexate", "as", "measured", "by", "AUC0", "-", "24hr", "in", "patients", "receiving", "single", "weekly", "methotrexate", "doses", "of", "7.5", "to", "20", "mg", "for", "rheumatoid", "arthritis", ".", "At", "higher", "than", "recommended", "doses", ",", "VIOXX", "75", "mg", "administered", "once", "daily", "for", "10", "days", "increased", "plasma", "concentrations", "by", "23", "%", "as", "measured", "by", "AUC0", "-", "24hr", "in", "patients", "receiving", "methotrexate", "7.5", "to", "15", "mg", "/", "week", "for", "rheumatoid", "arthritis", ".", "At", "24", "hours", "postdose", ",", "a", "similar", "proportion", "of", "patients", "treated", "with", "methotrexate", "alone", "(", "94", "%", ")", "and", "subsequently", "treated", "with", "methotrexate", "co", "-", "administered", "with", "75", "mg", "of", "rofecoxib", "(", "88", "%", ")", "had", "methotrexate", "plasma", "concentrations", "below", "the", "measurable", "limit", "(", "5", "ng", "/", "mL", ")", ".", "Standard", "monitoring", "of", "methotrexate", "-", "related", "toxicity", "should", "be", "continued", "if", "VIOXX", "and", "methotrexate", "are", "administered", "concomitantly", ".", "Oral", "Contraceptives", "Rofecoxib", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "ethinyl", "estradiol", "and", "norethindrone", ".", "Prednisone", "/", "prednisolone", ":", "Rofecoxib", "did", "not", "have", "any", "clinically", "important", "effect", "on", "the", "pharmacokinetics", "of", "prednisolone", "or", "prednisone", ".", "Rifampin", ":", "Co", "-", "administration", "of", "VIOXX", "with", "rifampin", "600", "mg", "daily", ",", "a", "potent", "inducer", "of", "hepatic", "metabolism", ",", "produced", "an", "approximate", "50", "%", "decrease", "in", "rofecoxib", "plasma", "concentrations", ".", "Therefore", ",", "a", "starting", "daily", "dose", "of", "25", "mg", "of", "VIOXX", "should", "be", "considered", "for", "the", "treatment", "of", "osteoarthritis", "when", "VIOXX", "is", "co", "-", "administered", "with", "potent", "inducers", "of", "hepatic", "metabolism", ".", "Theophylline", "VIOXX", "12.5", ",", "25", ",", "and", "50", "mg", "administered", "once", "daily", "for", "7", "days", "increased", "plasma", "theophylline", "concentrations", "(", "AUC(0-", ")", ")", "by", "38", "to", "60", "%", "in", "healthy", "subjects", "administered", "a", "single", "300-mg", "dose", "of", "theophylline", ".", "Adequate", "monitoring", "of", "theophylline", "plasma", "concentrations", "should", "be", "considered", "when", "therapy", "with", "VIOXX", "is", "initiated", "or", "changed", "in", "patients", "receiving", "theophylline", ".", "These", "data", "suggest", "that", "rofecoxib", "may", "produce", "a", "modest", "inhibition", "of", "cytochrome", "P450", "(", "CYP", ")", "1A2", ".", "Therefore", ",", "there", "is", "a", "potential", "for", "an", "interaction", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "1A2", "(", "e.g", ".", ",", "amitriptyline", ",", "tacrine", ",", "and", "zileuton", ")", ".", "Warfarin", ":", "Anticoagulant", "activity", "should", "be", "monitored", ",", "particularly", "in", "the", "first", "few", "days", "after", "initiating", "or", "changing", "VIOXX", "therapy", "in", "patients", "receiving", "warfarin", "or", "similar", "agents", ",", "since", "these", "patients", "are", "at", "an", "increased", "risk", "of", "bleeding", "complications", ".", "In", "single", "and", "multiple", "dose", "studies", "in", "healthy", "subjects", "receiving", "both", "warfarin", "and", "rofecoxib", ",", "prothrombin", "time", "(", "measured", "as", "INR", ")", "was", "increased", "by", "approximately", "8", "%", "to", "11", "%", ".", "In", "post", "-", "marketing", "experience", ",", "bleeding", "events", "have", "been", "reported", ",", "predominantly", "in", "the", "elderly", ",", "in", "association", "with", "increases", "in", "prothrombin", "time", "in", "patients", "receiving", "VIOXX", "concurrently", "with", "warfarin", "." ]
[ "GROUP", "DRUG", "BRAND" ]
12-lipoxygenase is a Gene_or_gene_product, arachidonic acid is a Simple_chemical, 12-lipoxygenase is a Gene_or_gene_product, 12-hydro(pero)xyeicosatetraenoic acid is a Simple_chemical, 12-H(P)ETE is a Simple_chemical, 12-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product, pCDNA-121x is a Gene_or_gene_product, 12-H(P)ETE is a Simple_chemical, arachidonic acid is a Simple_chemical, 12-H(P)ETE is a Simple_chemical, 12-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product, 15-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product, 15-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product
233_task0
Sentence: Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. The major pathway of arachidonic acid metabolism in human platelets proceeds via a 12-lipoxygenase enzyme; however, the biological role of the product of this reaction, 12-hydro(pero)xyeicosatetraenoic acid [12-H(P)ETE], is unknown. Using a combination of the polymerase chain reaction and conventional screening procedures, we have isolated cDNA clones encoding the human platelet/human erythroleukemia (HEL) cell 12-lipoxygenase. From the deduced primary structure, human platelet/HEL 12-lipoxygenase would encode a Mr 75,000 protein consisting of 663 amino acids. The cDNA encoding the full-length protein (pCDNA-121x) under the control of the cytomegalovirus promoter was expressed in simian COS-M6 cells. Intact cells and lysed-cell supernatants were able to synthesize 12-H(P)ETE from arachidonic acid, whereas no 12-H(P)ETE synthesis was detected in mock-transfected cells. A single 2.4-kilobase mRNA was detected in erythroleukemia cells but not in several other tissues and cell lines evaluated by Northern blot analysis. Comparison of the human platelet/HEL 12-lipoxygenase sequence with that of porcine leukocyte 12-lipoxygenase and human reticulocyte 15-lipoxygenase revealed 65% amino acid identity to both enzymes. By contrast, the leukocyte 12-lipoxygenase is 86% identical to human reticulocyte 15-lipoxygenase. Sequence data and previously demonstrated immunochemical and biochemical evidence support the existence of distinct 12-lipoxygenase isoforms. The availability of cDNA probes for human platelet/HEL cell 12-lipoxygenase should facilitate elucidation of the biological role of this pathway. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Simple_chemical, Gene_or_gene_product
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. The major pathway of arachidonic acid metabolism in human platelets proceeds via a 12-lipoxygenase enzyme; however, the biological role of the product of this reaction, 12-hydro(pero)xyeicosatetraenoic acid [12-H(P)ETE], is unknown. Using a combination of the polymerase chain reaction and conventional screening procedures, we have isolated cDNA clones encoding the human platelet/human erythroleukemia (HEL) cell 12-lipoxygenase. From the deduced primary structure, human platelet/HEL 12-lipoxygenase would encode a Mr 75,000 protein consisting of 663 amino acids. The cDNA encoding the full-length protein (pCDNA-121x) under the control of the cytomegalovirus promoter was expressed in simian COS-M6 cells. Intact cells and lysed-cell supernatants were able to synthesize 12-H(P)ETE from arachidonic acid, whereas no 12-H(P)ETE synthesis was detected in mock-transfected cells. A single 2.4-kilobase mRNA was detected in erythroleukemia cells but not in several other tissues and cell lines evaluated by Northern blot analysis. Comparison of the human platelet/HEL 12-lipoxygenase sequence with that of porcine leukocyte 12-lipoxygenase and human reticulocyte 15-lipoxygenase revealed 65% amino acid identity to both enzymes. By contrast, the leukocyte 12-lipoxygenase is 86% identical to human reticulocyte 15-lipoxygenase. Sequence data and previously demonstrated immunochemical and biochemical evidence support the existence of distinct 12-lipoxygenase isoforms. The availability of cDNA probes for human platelet/HEL cell 12-lipoxygenase should facilitate elucidation of the biological role of this pathway.
[ "Molecular", "cloning", ",", "primary", "structure", ",", "and", "expression", "of", "the", "human", "platelet", "/", "erythroleukemia", "cell", "12-lipoxygenase", ".", "\n", "The", "major", "pathway", "of", "arachidonic", "acid", "metabolism", "in", "human", "platelets", "proceeds", "via", "a", "12-lipoxygenase", "enzyme", ";", "however", ",", "the", "biological", "role", "of", "the", "product", "of", "this", "reaction", ",", "12-hydro(pero)xyeicosatetraenoic", "acid", "[", "12-H(P)ETE", "]", ",", "is", "unknown", ".", "Using", "a", "combination", "of", "the", "polymerase", "chain", "reaction", "and", "conventional", "screening", "procedures", ",", "we", "have", "isolated", "cDNA", "clones", "encoding", "the", "human", "platelet", "/", "human", "erythroleukemia", "(", "HEL", ")", "cell", "12-lipoxygenase", ".", "From", "the", "deduced", "primary", "structure", ",", "human", "platelet", "/", "HEL", "12-lipoxygenase", "would", "encode", "a", "Mr", "75,000", "protein", "consisting", "of", "663", "amino", "acids", ".", "The", "cDNA", "encoding", "the", "full", "-", "length", "protein", "(", "pCDNA-121x", ")", "under", "the", "control", "of", "the", "cytomegalovirus", "promoter", "was", "expressed", "in", "simian", "COS", "-", "M6", "cells", ".", "Intact", "cells", "and", "lysed", "-", "cell", "supernatants", "were", "able", "to", "synthesize", "12-H(P)ETE", "from", "arachidonic", "acid", ",", "whereas", "no", "12-H(P)ETE", "synthesis", "was", "detected", "in", "mock", "-", "transfected", "cells", ".", "A", "single", "2.4-kilobase", "mRNA", "was", "detected", "in", "erythroleukemia", "cells", "but", "not", "in", "several", "other", "tissues", "and", "cell", "lines", "evaluated", "by", "Northern", "blot", "analysis", ".", "Comparison", "of", "the", "human", "platelet", "/", "HEL", "12-lipoxygenase", "sequence", "with", "that", "of", "porcine", "leukocyte", "12-lipoxygenase", "and", "human", "reticulocyte", "15-lipoxygenase", "revealed", "65", "%", "amino", "acid", "identity", "to", "both", "enzymes", ".", "By", "contrast", ",", "the", "leukocyte", "12-lipoxygenase", "is", "86", "%", "identical", "to", "human", "reticulocyte", "15-lipoxygenase", ".", "Sequence", "data", "and", "previously", "demonstrated", "immunochemical", "and", "biochemical", "evidence", "support", "the", "existence", "of", "distinct", "12-lipoxygenase", "isoforms", ".", "The", "availability", "of", "cDNA", "probes", "for", "human", "platelet", "/", "HEL", "cell", "12-lipoxygenase", "should", "facilitate", "elucidation", "of", "the", "biological", "role", "of", "this", "pathway", ".", "\n" ]
[ "Simple_chemical", "Gene_or_gene_product" ]
12-lipoxygenase is a Gene_or_gene_product, arachidonic acid is a Simple_chemical, 12-lipoxygenase is a Gene_or_gene_product, 12-hydro(pero)xyeicosatetraenoic acid is a Simple_chemical, 12-H(P)ETE is a Simple_chemical, 12-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product, pCDNA-121x is a Gene_or_gene_product, 12-H(P)ETE is a Simple_chemical, arachidonic acid is a Simple_chemical, 12-H(P)ETE is a Simple_chemical, 12-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product, 15-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product, 15-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product, 12-lipoxygenase is a Gene_or_gene_product
233_task1
Sentence: Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. The major pathway of arachidonic acid metabolism in human platelets proceeds via a 12-lipoxygenase enzyme; however, the biological role of the product of this reaction, 12-hydro(pero)xyeicosatetraenoic acid [12-H(P)ETE], is unknown. Using a combination of the polymerase chain reaction and conventional screening procedures, we have isolated cDNA clones encoding the human platelet/human erythroleukemia (HEL) cell 12-lipoxygenase. From the deduced primary structure, human platelet/HEL 12-lipoxygenase would encode a Mr 75,000 protein consisting of 663 amino acids. The cDNA encoding the full-length protein (pCDNA-121x) under the control of the cytomegalovirus promoter was expressed in simian COS-M6 cells. Intact cells and lysed-cell supernatants were able to synthesize 12-H(P)ETE from arachidonic acid, whereas no 12-H(P)ETE synthesis was detected in mock-transfected cells. A single 2.4-kilobase mRNA was detected in erythroleukemia cells but not in several other tissues and cell lines evaluated by Northern blot analysis. Comparison of the human platelet/HEL 12-lipoxygenase sequence with that of porcine leukocyte 12-lipoxygenase and human reticulocyte 15-lipoxygenase revealed 65% amino acid identity to both enzymes. By contrast, the leukocyte 12-lipoxygenase is 86% identical to human reticulocyte 15-lipoxygenase. Sequence data and previously demonstrated immunochemical and biochemical evidence support the existence of distinct 12-lipoxygenase isoforms. The availability of cDNA probes for human platelet/HEL cell 12-lipoxygenase should facilitate elucidation of the biological role of this pathway. Instructions: please typing these entity words according to sentence: 12-lipoxygenase, arachidonic acid, 12-lipoxygenase, 12-hydro(pero)xyeicosatetraenoic acid, 12-H(P)ETE, 12-lipoxygenase, 12-lipoxygenase, pCDNA-121x, 12-H(P)ETE, arachidonic acid, 12-H(P)ETE, 12-lipoxygenase, 12-lipoxygenase, 15-lipoxygenase, 12-lipoxygenase, 15-lipoxygenase, 12-lipoxygenase, 12-lipoxygenase Options: Simple_chemical, Gene_or_gene_product
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. The major pathway of arachidonic acid metabolism in human platelets proceeds via a 12-lipoxygenase enzyme; however, the biological role of the product of this reaction, 12-hydro(pero)xyeicosatetraenoic acid [12-H(P)ETE], is unknown. Using a combination of the polymerase chain reaction and conventional screening procedures, we have isolated cDNA clones encoding the human platelet/human erythroleukemia (HEL) cell 12-lipoxygenase. From the deduced primary structure, human platelet/HEL 12-lipoxygenase would encode a Mr 75,000 protein consisting of 663 amino acids. The cDNA encoding the full-length protein (pCDNA-121x) under the control of the cytomegalovirus promoter was expressed in simian COS-M6 cells. Intact cells and lysed-cell supernatants were able to synthesize 12-H(P)ETE from arachidonic acid, whereas no 12-H(P)ETE synthesis was detected in mock-transfected cells. A single 2.4-kilobase mRNA was detected in erythroleukemia cells but not in several other tissues and cell lines evaluated by Northern blot analysis. Comparison of the human platelet/HEL 12-lipoxygenase sequence with that of porcine leukocyte 12-lipoxygenase and human reticulocyte 15-lipoxygenase revealed 65% amino acid identity to both enzymes. By contrast, the leukocyte 12-lipoxygenase is 86% identical to human reticulocyte 15-lipoxygenase. Sequence data and previously demonstrated immunochemical and biochemical evidence support the existence of distinct 12-lipoxygenase isoforms. The availability of cDNA probes for human platelet/HEL cell 12-lipoxygenase should facilitate elucidation of the biological role of this pathway.
[ "Molecular", "cloning", ",", "primary", "structure", ",", "and", "expression", "of", "the", "human", "platelet", "/", "erythroleukemia", "cell", "12-lipoxygenase", ".", "\n", "The", "major", "pathway", "of", "arachidonic", "acid", "metabolism", "in", "human", "platelets", "proceeds", "via", "a", "12-lipoxygenase", "enzyme", ";", "however", ",", "the", "biological", "role", "of", "the", "product", "of", "this", "reaction", ",", "12-hydro(pero)xyeicosatetraenoic", "acid", "[", "12-H(P)ETE", "]", ",", "is", "unknown", ".", "Using", "a", "combination", "of", "the", "polymerase", "chain", "reaction", "and", "conventional", "screening", "procedures", ",", "we", "have", "isolated", "cDNA", "clones", "encoding", "the", "human", "platelet", "/", "human", "erythroleukemia", "(", "HEL", ")", "cell", "12-lipoxygenase", ".", "From", "the", "deduced", "primary", "structure", ",", "human", "platelet", "/", "HEL", "12-lipoxygenase", "would", "encode", "a", "Mr", "75,000", "protein", "consisting", "of", "663", "amino", "acids", ".", "The", "cDNA", "encoding", "the", "full", "-", "length", "protein", "(", "pCDNA-121x", ")", "under", "the", "control", "of", "the", "cytomegalovirus", "promoter", "was", "expressed", "in", "simian", "COS", "-", "M6", "cells", ".", "Intact", "cells", "and", "lysed", "-", "cell", "supernatants", "were", "able", "to", "synthesize", "12-H(P)ETE", "from", "arachidonic", "acid", ",", "whereas", "no", "12-H(P)ETE", "synthesis", "was", "detected", "in", "mock", "-", "transfected", "cells", ".", "A", "single", "2.4-kilobase", "mRNA", "was", "detected", "in", "erythroleukemia", "cells", "but", "not", "in", "several", "other", "tissues", "and", "cell", "lines", "evaluated", "by", "Northern", "blot", "analysis", ".", "Comparison", "of", "the", "human", "platelet", "/", "HEL", "12-lipoxygenase", "sequence", "with", "that", "of", "porcine", "leukocyte", "12-lipoxygenase", "and", "human", "reticulocyte", "15-lipoxygenase", "revealed", "65", "%", "amino", "acid", "identity", "to", "both", "enzymes", ".", "By", "contrast", ",", "the", "leukocyte", "12-lipoxygenase", "is", "86", "%", "identical", "to", "human", "reticulocyte", "15-lipoxygenase", ".", "Sequence", "data", "and", "previously", "demonstrated", "immunochemical", "and", "biochemical", "evidence", "support", "the", "existence", "of", "distinct", "12-lipoxygenase", "isoforms", ".", "The", "availability", "of", "cDNA", "probes", "for", "human", "platelet", "/", "HEL", "cell", "12-lipoxygenase", "should", "facilitate", "elucidation", "of", "the", "biological", "role", "of", "this", "pathway", ".", "\n" ]
[ "Simple_chemical", "Gene_or_gene_product" ]
12-lipoxygenase, arachidonic acid, 12-lipoxygenase, 12-hydro(pero)xyeicosatetraenoic acid, 12-H(P)ETE, 12-lipoxygenase, 12-lipoxygenase, pCDNA-121x, 12-H(P)ETE, arachidonic acid, 12-H(P)ETE, 12-lipoxygenase, 12-lipoxygenase, 15-lipoxygenase, 12-lipoxygenase, 15-lipoxygenase, 12-lipoxygenase, 12-lipoxygenase
233_task2
Sentence: Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. The major pathway of arachidonic acid metabolism in human platelets proceeds via a 12-lipoxygenase enzyme; however, the biological role of the product of this reaction, 12-hydro(pero)xyeicosatetraenoic acid [12-H(P)ETE], is unknown. Using a combination of the polymerase chain reaction and conventional screening procedures, we have isolated cDNA clones encoding the human platelet/human erythroleukemia (HEL) cell 12-lipoxygenase. From the deduced primary structure, human platelet/HEL 12-lipoxygenase would encode a Mr 75,000 protein consisting of 663 amino acids. The cDNA encoding the full-length protein (pCDNA-121x) under the control of the cytomegalovirus promoter was expressed in simian COS-M6 cells. Intact cells and lysed-cell supernatants were able to synthesize 12-H(P)ETE from arachidonic acid, whereas no 12-H(P)ETE synthesis was detected in mock-transfected cells. A single 2.4-kilobase mRNA was detected in erythroleukemia cells but not in several other tissues and cell lines evaluated by Northern blot analysis. Comparison of the human platelet/HEL 12-lipoxygenase sequence with that of porcine leukocyte 12-lipoxygenase and human reticulocyte 15-lipoxygenase revealed 65% amino acid identity to both enzymes. By contrast, the leukocyte 12-lipoxygenase is 86% identical to human reticulocyte 15-lipoxygenase. Sequence data and previously demonstrated immunochemical and biochemical evidence support the existence of distinct 12-lipoxygenase isoforms. The availability of cDNA probes for human platelet/HEL cell 12-lipoxygenase should facilitate elucidation of the biological role of this pathway. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. The major pathway of arachidonic acid metabolism in human platelets proceeds via a 12-lipoxygenase enzyme; however, the biological role of the product of this reaction, 12-hydro(pero)xyeicosatetraenoic acid [12-H(P)ETE], is unknown. Using a combination of the polymerase chain reaction and conventional screening procedures, we have isolated cDNA clones encoding the human platelet/human erythroleukemia (HEL) cell 12-lipoxygenase. From the deduced primary structure, human platelet/HEL 12-lipoxygenase would encode a Mr 75,000 protein consisting of 663 amino acids. The cDNA encoding the full-length protein (pCDNA-121x) under the control of the cytomegalovirus promoter was expressed in simian COS-M6 cells. Intact cells and lysed-cell supernatants were able to synthesize 12-H(P)ETE from arachidonic acid, whereas no 12-H(P)ETE synthesis was detected in mock-transfected cells. A single 2.4-kilobase mRNA was detected in erythroleukemia cells but not in several other tissues and cell lines evaluated by Northern blot analysis. Comparison of the human platelet/HEL 12-lipoxygenase sequence with that of porcine leukocyte 12-lipoxygenase and human reticulocyte 15-lipoxygenase revealed 65% amino acid identity to both enzymes. By contrast, the leukocyte 12-lipoxygenase is 86% identical to human reticulocyte 15-lipoxygenase. Sequence data and previously demonstrated immunochemical and biochemical evidence support the existence of distinct 12-lipoxygenase isoforms. The availability of cDNA probes for human platelet/HEL cell 12-lipoxygenase should facilitate elucidation of the biological role of this pathway.
[ "Molecular", "cloning", ",", "primary", "structure", ",", "and", "expression", "of", "the", "human", "platelet", "/", "erythroleukemia", "cell", "12-lipoxygenase", ".", "\n", "The", "major", "pathway", "of", "arachidonic", "acid", "metabolism", "in", "human", "platelets", "proceeds", "via", "a", "12-lipoxygenase", "enzyme", ";", "however", ",", "the", "biological", "role", "of", "the", "product", "of", "this", "reaction", ",", "12-hydro(pero)xyeicosatetraenoic", "acid", "[", "12-H(P)ETE", "]", ",", "is", "unknown", ".", "Using", "a", "combination", "of", "the", "polymerase", "chain", "reaction", "and", "conventional", "screening", "procedures", ",", "we", "have", "isolated", "cDNA", "clones", "encoding", "the", "human", "platelet", "/", "human", "erythroleukemia", "(", "HEL", ")", "cell", "12-lipoxygenase", ".", "From", "the", "deduced", "primary", "structure", ",", "human", "platelet", "/", "HEL", "12-lipoxygenase", "would", "encode", "a", "Mr", "75,000", "protein", "consisting", "of", "663", "amino", "acids", ".", "The", "cDNA", "encoding", "the", "full", "-", "length", "protein", "(", "pCDNA-121x", ")", "under", "the", "control", "of", "the", "cytomegalovirus", "promoter", "was", "expressed", "in", "simian", "COS", "-", "M6", "cells", ".", "Intact", "cells", "and", "lysed", "-", "cell", "supernatants", "were", "able", "to", "synthesize", "12-H(P)ETE", "from", "arachidonic", "acid", ",", "whereas", "no", "12-H(P)ETE", "synthesis", "was", "detected", "in", "mock", "-", "transfected", "cells", ".", "A", "single", "2.4-kilobase", "mRNA", "was", "detected", "in", "erythroleukemia", "cells", "but", "not", "in", "several", "other", "tissues", "and", "cell", "lines", "evaluated", "by", "Northern", "blot", "analysis", ".", "Comparison", "of", "the", "human", "platelet", "/", "HEL", "12-lipoxygenase", "sequence", "with", "that", "of", "porcine", "leukocyte", "12-lipoxygenase", "and", "human", "reticulocyte", "15-lipoxygenase", "revealed", "65", "%", "amino", "acid", "identity", "to", "both", "enzymes", ".", "By", "contrast", ",", "the", "leukocyte", "12-lipoxygenase", "is", "86", "%", "identical", "to", "human", "reticulocyte", "15-lipoxygenase", ".", "Sequence", "data", "and", "previously", "demonstrated", "immunochemical", "and", "biochemical", "evidence", "support", "the", "existence", "of", "distinct", "12-lipoxygenase", "isoforms", ".", "The", "availability", "of", "cDNA", "probes", "for", "human", "platelet", "/", "HEL", "cell", "12-lipoxygenase", "should", "facilitate", "elucidation", "of", "the", "biological", "role", "of", "this", "pathway", ".", "\n" ]
[ "Simple_chemical", "Gene_or_gene_product" ]
P sequence is a Entity, interleukin-4 is a Protein, P sequence is a Entity, interleukin-4 is a Protein, IL-4 is a Protein, P65 is a Protein, P65 is a Protein, P50 is a Protein, P65 is a Protein
8135784_task0
Sentence: Characterization of NF(P), the nuclear factor that interacts with the regulatory P sequence (5'-CGAAAATTTCC-3') of the human interleukin-4 gene: relationship to NF-kappa B and NF-AT. The P sequence of the human interleukin-4 (IL-4) gene, which was defined as a responsive element for phorbol 12-myristate 13-acetate and calcium ionophore (A23187) in Jurkat T cells, shares sequence similarity with the NF-kappa B and the NF-AT binding sites. We examined whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and NF-AT. NF-kappa B (P65 or P65/P50 heterodimer) bound to the P sequence in electrophoretic mobility shift assays (EMSA) and activated transcription through the P sequence when expression plasmids were cotransfected with P sequence-driven reporter plasmids in Jurkat T cells. In EMSAs, NF(P) binding was inhibited by the unlabeled NF-AT binding site but not by the unlabeled AP1 binding site and purified NF-AT contained an activity that bound to the P sequence. Both mobility shift and sequence specificity of NF-AT were similar to those of NF(P) and only a small amount of P65 was detected in NF(P) in crude nuclear extracts. These results indicate that the component(s) of NF-AT has the potential to reconstitute NF(P) whereas NF-kappa B alone cannot account for NF(P) in crude extracts. Unlike NF-AT, NF(P) does not contain AP1 as its DNA binding component. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Characterization of NF(P), the nuclear factor that interacts with the regulatory P sequence (5'-CGAAAATTTCC-3') of the human interleukin-4 gene: relationship to NF-kappa B and NF-AT. The P sequence of the human interleukin-4 (IL-4) gene, which was defined as a responsive element for phorbol 12-myristate 13-acetate and calcium ionophore (A23187) in Jurkat T cells, shares sequence similarity with the NF-kappa B and the NF-AT binding sites. We examined whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and NF-AT. NF-kappa B (P65 or P65/P50 heterodimer) bound to the P sequence in electrophoretic mobility shift assays (EMSA) and activated transcription through the P sequence when expression plasmids were cotransfected with P sequence-driven reporter plasmids in Jurkat T cells. In EMSAs, NF(P) binding was inhibited by the unlabeled NF-AT binding site but not by the unlabeled AP1 binding site and purified NF-AT contained an activity that bound to the P sequence. Both mobility shift and sequence specificity of NF-AT were similar to those of NF(P) and only a small amount of P65 was detected in NF(P) in crude nuclear extracts. These results indicate that the component(s) of NF-AT has the potential to reconstitute NF(P) whereas NF-kappa B alone cannot account for NF(P) in crude extracts. Unlike NF-AT, NF(P) does not contain AP1 as its DNA binding component.
[ "Characterization", "of", "NF(P", ")", ",", "the", "nuclear", "factor", "that", "interacts", "with", "the", "regulatory", "P", "sequence", "(", "5'-CGAAAATTTCC-3", "'", ")", "of", "the", "human", "interleukin-4", "gene", ":", "relationship", "to", "NF", "-", "kappa", "B", "and", "NF", "-", "AT", ".", "\n", "The", "P", "sequence", "of", "the", "human", "interleukin-4", "(", "IL-4", ")", "gene", ",", "which", "was", "defined", "as", "a", "responsive", "element", "for", "phorbol", "12-myristate", "13-acetate", "and", "calcium", "ionophore", "(", "A23187", ")", "in", "Jurkat", "T", "cells", ",", "shares", "sequence", "similarity", "with", "the", "NF", "-", "kappa", "B", "and", "the", "NF", "-", "AT", "binding", "sites", ".", "We", "examined", "whether", "NF(P", ")", ",", "a", "nuclear", "factor", "specific", "for", "the", "P", "sequence", ",", "is", "related", "to", "NF", "-", "kappa", "B", "and", "NF", "-", "AT", ".", "NF", "-", "kappa", "B", "(", "P65", "or", "P65", "/", "P50", "heterodimer", ")", "bound", "to", "the", "P", "sequence", "in", "electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "and", "activated", "transcription", "through", "the", "P", "sequence", "when", "expression", "plasmids", "were", "cotransfected", "with", "P", "sequence", "-", "driven", "reporter", "plasmids", "in", "Jurkat", "T", "cells", ".", "In", "EMSAs", ",", "NF(P", ")", "binding", "was", "inhibited", "by", "the", "unlabeled", "NF", "-", "AT", "binding", "site", "but", "not", "by", "the", "unlabeled", "AP1", "binding", "site", "and", "purified", "NF", "-", "AT", "contained", "an", "activity", "that", "bound", "to", "the", "P", "sequence", ".", "Both", "mobility", "shift", "and", "sequence", "specificity", "of", "NF", "-", "AT", "were", "similar", "to", "those", "of", "NF(P", ")", "and", "only", "a", "small", "amount", "of", "P65", "was", "detected", "in", "NF(P", ")", "in", "crude", "nuclear", "extracts", ".", "These", "results", "indicate", "that", "the", "component(s", ")", "of", "NF", "-", "AT", "has", "the", "potential", "to", "reconstitute", "NF(P", ")", "whereas", "NF", "-", "kappa", "B", "alone", "cannot", "account", "for", "NF(P", ")", "in", "crude", "extracts", ".", "Unlike", "NF", "-", "AT", ",", "NF(P", ")", "does", "not", "contain", "AP1", "as", "its", "DNA", "binding", "component", "." ]
[ "Protein", "Entity" ]
P sequence is a Entity, interleukin-4 is a Protein, P sequence is a Entity, interleukin-4 is a Protein, IL-4 is a Protein, P65 is a Protein, P65 is a Protein, P50 is a Protein, P65 is a Protein
8135784_task1
Sentence: Characterization of NF(P), the nuclear factor that interacts with the regulatory P sequence (5'-CGAAAATTTCC-3') of the human interleukin-4 gene: relationship to NF-kappa B and NF-AT. The P sequence of the human interleukin-4 (IL-4) gene, which was defined as a responsive element for phorbol 12-myristate 13-acetate and calcium ionophore (A23187) in Jurkat T cells, shares sequence similarity with the NF-kappa B and the NF-AT binding sites. We examined whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and NF-AT. NF-kappa B (P65 or P65/P50 heterodimer) bound to the P sequence in electrophoretic mobility shift assays (EMSA) and activated transcription through the P sequence when expression plasmids were cotransfected with P sequence-driven reporter plasmids in Jurkat T cells. In EMSAs, NF(P) binding was inhibited by the unlabeled NF-AT binding site but not by the unlabeled AP1 binding site and purified NF-AT contained an activity that bound to the P sequence. Both mobility shift and sequence specificity of NF-AT were similar to those of NF(P) and only a small amount of P65 was detected in NF(P) in crude nuclear extracts. These results indicate that the component(s) of NF-AT has the potential to reconstitute NF(P) whereas NF-kappa B alone cannot account for NF(P) in crude extracts. Unlike NF-AT, NF(P) does not contain AP1 as its DNA binding component. Instructions: please typing these entity words according to sentence: P sequence, interleukin-4, P sequence, interleukin-4, IL-4, P65, P65, P50, P65 Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Characterization of NF(P), the nuclear factor that interacts with the regulatory P sequence (5'-CGAAAATTTCC-3') of the human interleukin-4 gene: relationship to NF-kappa B and NF-AT. The P sequence of the human interleukin-4 (IL-4) gene, which was defined as a responsive element for phorbol 12-myristate 13-acetate and calcium ionophore (A23187) in Jurkat T cells, shares sequence similarity with the NF-kappa B and the NF-AT binding sites. We examined whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and NF-AT. NF-kappa B (P65 or P65/P50 heterodimer) bound to the P sequence in electrophoretic mobility shift assays (EMSA) and activated transcription through the P sequence when expression plasmids were cotransfected with P sequence-driven reporter plasmids in Jurkat T cells. In EMSAs, NF(P) binding was inhibited by the unlabeled NF-AT binding site but not by the unlabeled AP1 binding site and purified NF-AT contained an activity that bound to the P sequence. Both mobility shift and sequence specificity of NF-AT were similar to those of NF(P) and only a small amount of P65 was detected in NF(P) in crude nuclear extracts. These results indicate that the component(s) of NF-AT has the potential to reconstitute NF(P) whereas NF-kappa B alone cannot account for NF(P) in crude extracts. Unlike NF-AT, NF(P) does not contain AP1 as its DNA binding component.
[ "Characterization", "of", "NF(P", ")", ",", "the", "nuclear", "factor", "that", "interacts", "with", "the", "regulatory", "P", "sequence", "(", "5'-CGAAAATTTCC-3", "'", ")", "of", "the", "human", "interleukin-4", "gene", ":", "relationship", "to", "NF", "-", "kappa", "B", "and", "NF", "-", "AT", ".", "\n", "The", "P", "sequence", "of", "the", "human", "interleukin-4", "(", "IL-4", ")", "gene", ",", "which", "was", "defined", "as", "a", "responsive", "element", "for", "phorbol", "12-myristate", "13-acetate", "and", "calcium", "ionophore", "(", "A23187", ")", "in", "Jurkat", "T", "cells", ",", "shares", "sequence", "similarity", "with", "the", "NF", "-", "kappa", "B", "and", "the", "NF", "-", "AT", "binding", "sites", ".", "We", "examined", "whether", "NF(P", ")", ",", "a", "nuclear", "factor", "specific", "for", "the", "P", "sequence", ",", "is", "related", "to", "NF", "-", "kappa", "B", "and", "NF", "-", "AT", ".", "NF", "-", "kappa", "B", "(", "P65", "or", "P65", "/", "P50", "heterodimer", ")", "bound", "to", "the", "P", "sequence", "in", "electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "and", "activated", "transcription", "through", "the", "P", "sequence", "when", "expression", "plasmids", "were", "cotransfected", "with", "P", "sequence", "-", "driven", "reporter", "plasmids", "in", "Jurkat", "T", "cells", ".", "In", "EMSAs", ",", "NF(P", ")", "binding", "was", "inhibited", "by", "the", "unlabeled", "NF", "-", "AT", "binding", "site", "but", "not", "by", "the", "unlabeled", "AP1", "binding", "site", "and", "purified", "NF", "-", "AT", "contained", "an", "activity", "that", "bound", "to", "the", "P", "sequence", ".", "Both", "mobility", "shift", "and", "sequence", "specificity", "of", "NF", "-", "AT", "were", "similar", "to", "those", "of", "NF(P", ")", "and", "only", "a", "small", "amount", "of", "P65", "was", "detected", "in", "NF(P", ")", "in", "crude", "nuclear", "extracts", ".", "These", "results", "indicate", "that", "the", "component(s", ")", "of", "NF", "-", "AT", "has", "the", "potential", "to", "reconstitute", "NF(P", ")", "whereas", "NF", "-", "kappa", "B", "alone", "cannot", "account", "for", "NF(P", ")", "in", "crude", "extracts", ".", "Unlike", "NF", "-", "AT", ",", "NF(P", ")", "does", "not", "contain", "AP1", "as", "its", "DNA", "binding", "component", "." ]
[ "Protein", "Entity" ]
P sequence, interleukin-4, P sequence, interleukin-4, IL-4, P65, P65, P50, P65
8135784_task2
Sentence: Characterization of NF(P), the nuclear factor that interacts with the regulatory P sequence (5'-CGAAAATTTCC-3') of the human interleukin-4 gene: relationship to NF-kappa B and NF-AT. The P sequence of the human interleukin-4 (IL-4) gene, which was defined as a responsive element for phorbol 12-myristate 13-acetate and calcium ionophore (A23187) in Jurkat T cells, shares sequence similarity with the NF-kappa B and the NF-AT binding sites. We examined whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and NF-AT. NF-kappa B (P65 or P65/P50 heterodimer) bound to the P sequence in electrophoretic mobility shift assays (EMSA) and activated transcription through the P sequence when expression plasmids were cotransfected with P sequence-driven reporter plasmids in Jurkat T cells. In EMSAs, NF(P) binding was inhibited by the unlabeled NF-AT binding site but not by the unlabeled AP1 binding site and purified NF-AT contained an activity that bound to the P sequence. Both mobility shift and sequence specificity of NF-AT were similar to those of NF(P) and only a small amount of P65 was detected in NF(P) in crude nuclear extracts. These results indicate that the component(s) of NF-AT has the potential to reconstitute NF(P) whereas NF-kappa B alone cannot account for NF(P) in crude extracts. Unlike NF-AT, NF(P) does not contain AP1 as its DNA binding component. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Characterization of NF(P), the nuclear factor that interacts with the regulatory P sequence (5'-CGAAAATTTCC-3') of the human interleukin-4 gene: relationship to NF-kappa B and NF-AT. The P sequence of the human interleukin-4 (IL-4) gene, which was defined as a responsive element for phorbol 12-myristate 13-acetate and calcium ionophore (A23187) in Jurkat T cells, shares sequence similarity with the NF-kappa B and the NF-AT binding sites. We examined whether NF(P), a nuclear factor specific for the P sequence, is related to NF-kappa B and NF-AT. NF-kappa B (P65 or P65/P50 heterodimer) bound to the P sequence in electrophoretic mobility shift assays (EMSA) and activated transcription through the P sequence when expression plasmids were cotransfected with P sequence-driven reporter plasmids in Jurkat T cells. In EMSAs, NF(P) binding was inhibited by the unlabeled NF-AT binding site but not by the unlabeled AP1 binding site and purified NF-AT contained an activity that bound to the P sequence. Both mobility shift and sequence specificity of NF-AT were similar to those of NF(P) and only a small amount of P65 was detected in NF(P) in crude nuclear extracts. These results indicate that the component(s) of NF-AT has the potential to reconstitute NF(P) whereas NF-kappa B alone cannot account for NF(P) in crude extracts. Unlike NF-AT, NF(P) does not contain AP1 as its DNA binding component.
[ "Characterization", "of", "NF(P", ")", ",", "the", "nuclear", "factor", "that", "interacts", "with", "the", "regulatory", "P", "sequence", "(", "5'-CGAAAATTTCC-3", "'", ")", "of", "the", "human", "interleukin-4", "gene", ":", "relationship", "to", "NF", "-", "kappa", "B", "and", "NF", "-", "AT", ".", "\n", "The", "P", "sequence", "of", "the", "human", "interleukin-4", "(", "IL-4", ")", "gene", ",", "which", "was", "defined", "as", "a", "responsive", "element", "for", "phorbol", "12-myristate", "13-acetate", "and", "calcium", "ionophore", "(", "A23187", ")", "in", "Jurkat", "T", "cells", ",", "shares", "sequence", "similarity", "with", "the", "NF", "-", "kappa", "B", "and", "the", "NF", "-", "AT", "binding", "sites", ".", "We", "examined", "whether", "NF(P", ")", ",", "a", "nuclear", "factor", "specific", "for", "the", "P", "sequence", ",", "is", "related", "to", "NF", "-", "kappa", "B", "and", "NF", "-", "AT", ".", "NF", "-", "kappa", "B", "(", "P65", "or", "P65", "/", "P50", "heterodimer", ")", "bound", "to", "the", "P", "sequence", "in", "electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "and", "activated", "transcription", "through", "the", "P", "sequence", "when", "expression", "plasmids", "were", "cotransfected", "with", "P", "sequence", "-", "driven", "reporter", "plasmids", "in", "Jurkat", "T", "cells", ".", "In", "EMSAs", ",", "NF(P", ")", "binding", "was", "inhibited", "by", "the", "unlabeled", "NF", "-", "AT", "binding", "site", "but", "not", "by", "the", "unlabeled", "AP1", "binding", "site", "and", "purified", "NF", "-", "AT", "contained", "an", "activity", "that", "bound", "to", "the", "P", "sequence", ".", "Both", "mobility", "shift", "and", "sequence", "specificity", "of", "NF", "-", "AT", "were", "similar", "to", "those", "of", "NF(P", ")", "and", "only", "a", "small", "amount", "of", "P65", "was", "detected", "in", "NF(P", ")", "in", "crude", "nuclear", "extracts", ".", "These", "results", "indicate", "that", "the", "component(s", ")", "of", "NF", "-", "AT", "has", "the", "potential", "to", "reconstitute", "NF(P", ")", "whereas", "NF", "-", "kappa", "B", "alone", "cannot", "account", "for", "NF(P", ")", "in", "crude", "extracts", ".", "Unlike", "NF", "-", "AT", ",", "NF(P", ")", "does", "not", "contain", "AP1", "as", "its", "DNA", "binding", "component", "." ]
[ "Protein", "Entity" ]
hair is a Multi-tissue_structure, skin is a Organ, capillaries is a Tissue, blood vessels is a Multi-tissue_structure, skin is a Organ, hair follicle is a Multi-tissue_structure, skin is a Organ, epithelial hair bulbs is a Tissue, anagen follicles is a Multi-tissue_structure, follicular dermal papilla is a Tissue, hair follicles is a Multi-tissue_structure, endothelial cells is a Cell, hair follicle is a Multi-tissue_structure, C57BL/6 mice is a Organism, fumagillin derivative is a Drug_or_compound, mice is a Organism, murine is a Organism, skin is a Organ, hair follicle is a Multi-tissue_structure
5_task0
Sentence: Active hair growth (anagen) is associated with angiogenesis. After the completion of skin development, angiogenesis, i.e., the growth of new capillaries from pre-existing blood vessels, is held to occur in the skin only under pathologic conditions. It has long been noted, however, that hair follicle cycling is associated with prominent changes in skin perfusion, that the epithelial hair bulbs of anagen follicles display angiogenic properties, and that the follicular dermal papilla can produce angiogenic factors. Despite these suggestive observations, no formal proof is as yet available for the concept that angiogenesis is a physiologic event that occurs all over the mature mammalian integument whenever hair follicles switch from resting (telogen) to active growth (anagen). This study uses quantitative histomorphometry and double-immunohistologic detection techniques for the demarcation of proliferating endothelial cells, to show that synchronized hair follicle cycling in adolescent C57BL/6 mice is associated with substantial angiogenesis, and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice. Thus, angiogenesis is a physiologic event in normal postnatal murine skin, apparently is dictated by the hair follicle, and appears to be required for normal anagen development. Anagen-associated angiogenesis offers an attractive model for identifying the physiologic controls of cutaneous angiogenesis, and an interesting system for screening the effects of potential antiangiogenic drugs in vivo. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Organ, Organism, Drug_or_compound, Multi-tissue_structure, Cell
[ "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug_or_compound", "I-Drug_or_compound", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "B-Organ", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Active hair growth (anagen) is associated with angiogenesis. After the completion of skin development, angiogenesis, i.e., the growth of new capillaries from pre-existing blood vessels, is held to occur in the skin only under pathologic conditions. It has long been noted, however, that hair follicle cycling is associated with prominent changes in skin perfusion, that the epithelial hair bulbs of anagen follicles display angiogenic properties, and that the follicular dermal papilla can produce angiogenic factors. Despite these suggestive observations, no formal proof is as yet available for the concept that angiogenesis is a physiologic event that occurs all over the mature mammalian integument whenever hair follicles switch from resting (telogen) to active growth (anagen). This study uses quantitative histomorphometry and double-immunohistologic detection techniques for the demarcation of proliferating endothelial cells, to show that synchronized hair follicle cycling in adolescent C57BL/6 mice is associated with substantial angiogenesis, and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice. Thus, angiogenesis is a physiologic event in normal postnatal murine skin, apparently is dictated by the hair follicle, and appears to be required for normal anagen development. Anagen-associated angiogenesis offers an attractive model for identifying the physiologic controls of cutaneous angiogenesis, and an interesting system for screening the effects of potential antiangiogenic drugs in vivo.
[ "Active", "hair", "growth", "(", "anagen", ")", "is", "associated", "with", "angiogenesis", ".", "\n\n", "After", "the", "completion", "of", "skin", "development", ",", "angiogenesis", ",", "i.e", ".", ",", "the", "growth", "of", "new", "capillaries", "from", "pre", "-", "existing", "blood", "vessels", ",", "is", "held", "to", "occur", "in", "the", "skin", "only", "under", "pathologic", "conditions", ".", "It", "has", "long", "been", "noted", ",", "however", ",", "that", "hair", "follicle", "cycling", "is", "associated", "with", "prominent", "changes", "in", "skin", "perfusion", ",", "that", "the", "epithelial", "hair", "bulbs", "of", "anagen", "follicles", "display", "angiogenic", "properties", ",", "and", "that", "the", "follicular", "dermal", "papilla", "can", "produce", "angiogenic", "factors", ".", "Despite", "these", "suggestive", "observations", ",", "no", "formal", "proof", "is", "as", "yet", "available", "for", "the", "concept", "that", "angiogenesis", "is", "a", "physiologic", "event", "that", "occurs", "all", "over", "the", "mature", "mammalian", "integument", "whenever", "hair", "follicles", "switch", "from", "resting", "(", "telogen", ")", "to", "active", "growth", "(", "anagen", ")", ".", "This", "study", "uses", "quantitative", "histomorphometry", "and", "double", "-", "immunohistologic", "detection", "techniques", "for", "the", "demarcation", "of", "proliferating", "endothelial", "cells", ",", "to", "show", "that", "synchronized", "hair", "follicle", "cycling", "in", "adolescent", "C57BL/6", "mice", "is", "associated", "with", "substantial", "angiogenesis", ",", "and", "that", "inhibiting", "angiogenesis", "in", "vivo", "by", "the", "intraperitoneal", "application", "of", "a", "fumagillin", "derivative", "retards", "experimentally", "induced", "anagen", "development", "in", "these", "mice", ".", "Thus", ",", "angiogenesis", "is", "a", "physiologic", "event", "in", "normal", "postnatal", "murine", "skin", ",", "apparently", "is", "dictated", "by", "the", "hair", "follicle", ",", "and", "appears", "to", "be", "required", "for", "normal", "anagen", "development", ".", "Anagen", "-", "associated", "angiogenesis", "offers", "an", "attractive", "model", "for", "identifying", "the", "physiologic", "controls", "of", "cutaneous", "angiogenesis", ",", "and", "an", "interesting", "system", "for", "screening", "the", "effects", "of", "potential", "antiangiogenic", "drugs", "in", "vivo", ".", "\n" ]
[ "Tissue", "Drug_or_compound", "Cell", "Multi-tissue_structure", "Organism", "Organ" ]
hair is a Multi-tissue_structure, skin is a Organ, capillaries is a Tissue, blood vessels is a Multi-tissue_structure, skin is a Organ, hair follicle is a Multi-tissue_structure, skin is a Organ, epithelial hair bulbs is a Tissue, anagen follicles is a Multi-tissue_structure, follicular dermal papilla is a Tissue, hair follicles is a Multi-tissue_structure, endothelial cells is a Cell, hair follicle is a Multi-tissue_structure, C57BL/6 mice is a Organism, fumagillin derivative is a Drug_or_compound, mice is a Organism, murine is a Organism, skin is a Organ, hair follicle is a Multi-tissue_structure
5_task1
Sentence: Active hair growth (anagen) is associated with angiogenesis. After the completion of skin development, angiogenesis, i.e., the growth of new capillaries from pre-existing blood vessels, is held to occur in the skin only under pathologic conditions. It has long been noted, however, that hair follicle cycling is associated with prominent changes in skin perfusion, that the epithelial hair bulbs of anagen follicles display angiogenic properties, and that the follicular dermal papilla can produce angiogenic factors. Despite these suggestive observations, no formal proof is as yet available for the concept that angiogenesis is a physiologic event that occurs all over the mature mammalian integument whenever hair follicles switch from resting (telogen) to active growth (anagen). This study uses quantitative histomorphometry and double-immunohistologic detection techniques for the demarcation of proliferating endothelial cells, to show that synchronized hair follicle cycling in adolescent C57BL/6 mice is associated with substantial angiogenesis, and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice. Thus, angiogenesis is a physiologic event in normal postnatal murine skin, apparently is dictated by the hair follicle, and appears to be required for normal anagen development. Anagen-associated angiogenesis offers an attractive model for identifying the physiologic controls of cutaneous angiogenesis, and an interesting system for screening the effects of potential antiangiogenic drugs in vivo. Instructions: please typing these entity words according to sentence: hair, skin, capillaries, blood vessels, skin, hair follicle, skin, epithelial hair bulbs, anagen follicles, follicular dermal papilla, hair follicles, endothelial cells, hair follicle, C57BL/6 mice, fumagillin derivative, mice, murine, skin, hair follicle Options: Tissue, Organ, Organism, Drug_or_compound, Multi-tissue_structure, Cell
[ "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug_or_compound", "I-Drug_or_compound", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "B-Organ", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Active hair growth (anagen) is associated with angiogenesis. After the completion of skin development, angiogenesis, i.e., the growth of new capillaries from pre-existing blood vessels, is held to occur in the skin only under pathologic conditions. It has long been noted, however, that hair follicle cycling is associated with prominent changes in skin perfusion, that the epithelial hair bulbs of anagen follicles display angiogenic properties, and that the follicular dermal papilla can produce angiogenic factors. Despite these suggestive observations, no formal proof is as yet available for the concept that angiogenesis is a physiologic event that occurs all over the mature mammalian integument whenever hair follicles switch from resting (telogen) to active growth (anagen). This study uses quantitative histomorphometry and double-immunohistologic detection techniques for the demarcation of proliferating endothelial cells, to show that synchronized hair follicle cycling in adolescent C57BL/6 mice is associated with substantial angiogenesis, and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice. Thus, angiogenesis is a physiologic event in normal postnatal murine skin, apparently is dictated by the hair follicle, and appears to be required for normal anagen development. Anagen-associated angiogenesis offers an attractive model for identifying the physiologic controls of cutaneous angiogenesis, and an interesting system for screening the effects of potential antiangiogenic drugs in vivo.
[ "Active", "hair", "growth", "(", "anagen", ")", "is", "associated", "with", "angiogenesis", ".", "\n\n", "After", "the", "completion", "of", "skin", "development", ",", "angiogenesis", ",", "i.e", ".", ",", "the", "growth", "of", "new", "capillaries", "from", "pre", "-", "existing", "blood", "vessels", ",", "is", "held", "to", "occur", "in", "the", "skin", "only", "under", "pathologic", "conditions", ".", "It", "has", "long", "been", "noted", ",", "however", ",", "that", "hair", "follicle", "cycling", "is", "associated", "with", "prominent", "changes", "in", "skin", "perfusion", ",", "that", "the", "epithelial", "hair", "bulbs", "of", "anagen", "follicles", "display", "angiogenic", "properties", ",", "and", "that", "the", "follicular", "dermal", "papilla", "can", "produce", "angiogenic", "factors", ".", "Despite", "these", "suggestive", "observations", ",", "no", "formal", "proof", "is", "as", "yet", "available", "for", "the", "concept", "that", "angiogenesis", "is", "a", "physiologic", "event", "that", "occurs", "all", "over", "the", "mature", "mammalian", "integument", "whenever", "hair", "follicles", "switch", "from", "resting", "(", "telogen", ")", "to", "active", "growth", "(", "anagen", ")", ".", "This", "study", "uses", "quantitative", "histomorphometry", "and", "double", "-", "immunohistologic", "detection", "techniques", "for", "the", "demarcation", "of", "proliferating", "endothelial", "cells", ",", "to", "show", "that", "synchronized", "hair", "follicle", "cycling", "in", "adolescent", "C57BL/6", "mice", "is", "associated", "with", "substantial", "angiogenesis", ",", "and", "that", "inhibiting", "angiogenesis", "in", "vivo", "by", "the", "intraperitoneal", "application", "of", "a", "fumagillin", "derivative", "retards", "experimentally", "induced", "anagen", "development", "in", "these", "mice", ".", "Thus", ",", "angiogenesis", "is", "a", "physiologic", "event", "in", "normal", "postnatal", "murine", "skin", ",", "apparently", "is", "dictated", "by", "the", "hair", "follicle", ",", "and", "appears", "to", "be", "required", "for", "normal", "anagen", "development", ".", "Anagen", "-", "associated", "angiogenesis", "offers", "an", "attractive", "model", "for", "identifying", "the", "physiologic", "controls", "of", "cutaneous", "angiogenesis", ",", "and", "an", "interesting", "system", "for", "screening", "the", "effects", "of", "potential", "antiangiogenic", "drugs", "in", "vivo", ".", "\n" ]
[ "Tissue", "Drug_or_compound", "Cell", "Multi-tissue_structure", "Organism", "Organ" ]
hair, skin, capillaries, blood vessels, skin, hair follicle, skin, epithelial hair bulbs, anagen follicles, follicular dermal papilla, hair follicles, endothelial cells, hair follicle, C57BL/6 mice, fumagillin derivative, mice, murine, skin, hair follicle
5_task2
Sentence: Active hair growth (anagen) is associated with angiogenesis. After the completion of skin development, angiogenesis, i.e., the growth of new capillaries from pre-existing blood vessels, is held to occur in the skin only under pathologic conditions. It has long been noted, however, that hair follicle cycling is associated with prominent changes in skin perfusion, that the epithelial hair bulbs of anagen follicles display angiogenic properties, and that the follicular dermal papilla can produce angiogenic factors. Despite these suggestive observations, no formal proof is as yet available for the concept that angiogenesis is a physiologic event that occurs all over the mature mammalian integument whenever hair follicles switch from resting (telogen) to active growth (anagen). This study uses quantitative histomorphometry and double-immunohistologic detection techniques for the demarcation of proliferating endothelial cells, to show that synchronized hair follicle cycling in adolescent C57BL/6 mice is associated with substantial angiogenesis, and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice. Thus, angiogenesis is a physiologic event in normal postnatal murine skin, apparently is dictated by the hair follicle, and appears to be required for normal anagen development. Anagen-associated angiogenesis offers an attractive model for identifying the physiologic controls of cutaneous angiogenesis, and an interesting system for screening the effects of potential antiangiogenic drugs in vivo. Instructions: please extract entity words from the input sentence
[ "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug_or_compound", "I-Drug_or_compound", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "B-Organ", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Active hair growth (anagen) is associated with angiogenesis. After the completion of skin development, angiogenesis, i.e., the growth of new capillaries from pre-existing blood vessels, is held to occur in the skin only under pathologic conditions. It has long been noted, however, that hair follicle cycling is associated with prominent changes in skin perfusion, that the epithelial hair bulbs of anagen follicles display angiogenic properties, and that the follicular dermal papilla can produce angiogenic factors. Despite these suggestive observations, no formal proof is as yet available for the concept that angiogenesis is a physiologic event that occurs all over the mature mammalian integument whenever hair follicles switch from resting (telogen) to active growth (anagen). This study uses quantitative histomorphometry and double-immunohistologic detection techniques for the demarcation of proliferating endothelial cells, to show that synchronized hair follicle cycling in adolescent C57BL/6 mice is associated with substantial angiogenesis, and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice. Thus, angiogenesis is a physiologic event in normal postnatal murine skin, apparently is dictated by the hair follicle, and appears to be required for normal anagen development. Anagen-associated angiogenesis offers an attractive model for identifying the physiologic controls of cutaneous angiogenesis, and an interesting system for screening the effects of potential antiangiogenic drugs in vivo.
[ "Active", "hair", "growth", "(", "anagen", ")", "is", "associated", "with", "angiogenesis", ".", "\n\n", "After", "the", "completion", "of", "skin", "development", ",", "angiogenesis", ",", "i.e", ".", ",", "the", "growth", "of", "new", "capillaries", "from", "pre", "-", "existing", "blood", "vessels", ",", "is", "held", "to", "occur", "in", "the", "skin", "only", "under", "pathologic", "conditions", ".", "It", "has", "long", "been", "noted", ",", "however", ",", "that", "hair", "follicle", "cycling", "is", "associated", "with", "prominent", "changes", "in", "skin", "perfusion", ",", "that", "the", "epithelial", "hair", "bulbs", "of", "anagen", "follicles", "display", "angiogenic", "properties", ",", "and", "that", "the", "follicular", "dermal", "papilla", "can", "produce", "angiogenic", "factors", ".", "Despite", "these", "suggestive", "observations", ",", "no", "formal", "proof", "is", "as", "yet", "available", "for", "the", "concept", "that", "angiogenesis", "is", "a", "physiologic", "event", "that", "occurs", "all", "over", "the", "mature", "mammalian", "integument", "whenever", "hair", "follicles", "switch", "from", "resting", "(", "telogen", ")", "to", "active", "growth", "(", "anagen", ")", ".", "This", "study", "uses", "quantitative", "histomorphometry", "and", "double", "-", "immunohistologic", "detection", "techniques", "for", "the", "demarcation", "of", "proliferating", "endothelial", "cells", ",", "to", "show", "that", "synchronized", "hair", "follicle", "cycling", "in", "adolescent", "C57BL/6", "mice", "is", "associated", "with", "substantial", "angiogenesis", ",", "and", "that", "inhibiting", "angiogenesis", "in", "vivo", "by", "the", "intraperitoneal", "application", "of", "a", "fumagillin", "derivative", "retards", "experimentally", "induced", "anagen", "development", "in", "these", "mice", ".", "Thus", ",", "angiogenesis", "is", "a", "physiologic", "event", "in", "normal", "postnatal", "murine", "skin", ",", "apparently", "is", "dictated", "by", "the", "hair", "follicle", ",", "and", "appears", "to", "be", "required", "for", "normal", "anagen", "development", ".", "Anagen", "-", "associated", "angiogenesis", "offers", "an", "attractive", "model", "for", "identifying", "the", "physiologic", "controls", "of", "cutaneous", "angiogenesis", ",", "and", "an", "interesting", "system", "for", "screening", "the", "effects", "of", "potential", "antiangiogenic", "drugs", "in", "vivo", ".", "\n" ]
[ "Tissue", "Drug_or_compound", "Cell", "Multi-tissue_structure", "Organism", "Organ" ]
oleoyl is a compound, PON1 is a protein
DS.d399_task0
Sentence: Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies.
[ "Di", "-", "oleoyl", "phosphatidylcholine", "(", "PC-18:1", ")", "stimulates", "paraoxonase", "1", "(", "PON1", ")", "enzymatic", "and", "biological", "activities", ":", "in", "vitro", "and", "in", "vivo", "studies", "." ]
[ "compound", "protein" ]
oleoyl is a compound, PON1 is a protein
DS.d399_task1
Sentence: Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Instructions: please typing these entity words according to sentence: oleoyl, PON1 Options: compound, protein
[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies.
[ "Di", "-", "oleoyl", "phosphatidylcholine", "(", "PC-18:1", ")", "stimulates", "paraoxonase", "1", "(", "PON1", ")", "enzymatic", "and", "biological", "activities", ":", "in", "vitro", "and", "in", "vivo", "studies", "." ]
[ "compound", "protein" ]
oleoyl, PON1
DS.d399_task2
Sentence: Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies.
[ "Di", "-", "oleoyl", "phosphatidylcholine", "(", "PC-18:1", ")", "stimulates", "paraoxonase", "1", "(", "PON1", ")", "enzymatic", "and", "biological", "activities", ":", "in", "vitro", "and", "in", "vivo", "studies", "." ]
[ "compound", "protein" ]
EMSA is an assay, NF - Y is a protein, HSP - CBF is a protein, HSP70 is a protein-family, HSP40 is a protein, CCAAT box is a DNA
1.0alpha7.train.381_task0
Sentence: EMSA of NF-Y and HSP-CBF bound to the HSP70 (A) and HSP40 (B) proximal CCAAT box regions. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, assay, protein-family, protein
[ "B-assay", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O" ]
EMSA of NF-Y and HSP-CBF bound to the HSP70 (A) and HSP40 (B) proximal CCAAT box regions.
[ "EMSA", "of", "NF", "-", "Y", "and", "HSP", "-", "CBF", "bound", "to", "the", "HSP70", "(", "A", ")", "and", "HSP40", "(", "B", ")", "proximal", "CCAAT", "box", "regions", "." ]
[ "DNA", "protein", "protein-family", "assay" ]
EMSA is an assay, NF - Y is a protein, HSP - CBF is a protein, HSP70 is a protein-family, HSP40 is a protein, CCAAT box is a DNA
1.0alpha7.train.381_task1
Sentence: EMSA of NF-Y and HSP-CBF bound to the HSP70 (A) and HSP40 (B) proximal CCAAT box regions. Instructions: please typing these entity words according to sentence: EMSA, NF - Y, HSP - CBF, HSP70, HSP40, CCAAT box Options: DNA, assay, protein-family, protein
[ "B-assay", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O" ]
EMSA of NF-Y and HSP-CBF bound to the HSP70 (A) and HSP40 (B) proximal CCAAT box regions.
[ "EMSA", "of", "NF", "-", "Y", "and", "HSP", "-", "CBF", "bound", "to", "the", "HSP70", "(", "A", ")", "and", "HSP40", "(", "B", ")", "proximal", "CCAAT", "box", "regions", "." ]
[ "DNA", "protein", "protein-family", "assay" ]
EMSA, NF - Y, HSP - CBF, HSP70, HSP40, CCAAT box
1.0alpha7.train.381_task2
Sentence: EMSA of NF-Y and HSP-CBF bound to the HSP70 (A) and HSP40 (B) proximal CCAAT box regions. Instructions: please extract entity words from the input sentence
[ "B-assay", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O" ]
EMSA of NF-Y and HSP-CBF bound to the HSP70 (A) and HSP40 (B) proximal CCAAT box regions.
[ "EMSA", "of", "NF", "-", "Y", "and", "HSP", "-", "CBF", "bound", "to", "the", "HSP70", "(", "A", ")", "and", "HSP40", "(", "B", ")", "proximal", "CCAAT", "box", "regions", "." ]
[ "DNA", "protein", "protein-family", "assay" ]
Medikamenteneinnahmen is an umlsterm, Medikamenten is an umlsterm
Rechtsmedizin.90090215.ger.abstr_task0
Sentence: Die Screening " " -Stufe der Dopinganalytik erfasst ausser den zahlreichen verbotenen Dopingstoffen auch weitere Xenobiotika , die identifiziert werden muessen . Sofern diese nicht als erlaubte Medikamenteneinnahmen seitens des Probanden deklariert werden , ist sogar die Vermutung zu pruefen , ob das Dopingverbot mittels zunaechst nicht explizit verbotener Stoffe unterwandert werden soll . Nach frueheren " Grauzonen " -Faellen mit erlaubten , jedoch ohne medizinische Indikation und somit aus suspekten Motiven applizierten Medikamenten fiel 1996 in Atlanta das halblegale und inzwischen als Dopingmittel verbotene Pharmazeutikum Bromantan auf . 1997 gelang uns erstmals im Weltmassstab die massenspektrometrische Identifikation eines halblegal synthetisierten , weder regulaer toxikologisch geprueften noch registrierten Wirkstoffs , der als Designerdroge aus zwei Wirkstofftypen mit nootrop/psychotroper beziehungsweise analeptischer Wirkung anzusehen ist . Als Carphedon " " unterliegt er inzwischen explizit dem IOC-Dopingverbot . Nachweis und Identifikation der bis 1997 weitgehend unbekannten Verbindung sowie die unmittelbaren Konsequenzen werden beschrieben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Screening " " -Stufe der Dopinganalytik erfasst ausser den zahlreichen verbotenen Dopingstoffen auch weitere Xenobiotika , die identifiziert werden muessen . Sofern diese nicht als erlaubte Medikamenteneinnahmen seitens des Probanden deklariert werden , ist sogar die Vermutung zu pruefen , ob das Dopingverbot mittels zunaechst nicht explizit verbotener Stoffe unterwandert werden soll . Nach frueheren " Grauzonen " -Faellen mit erlaubten , jedoch ohne medizinische Indikation und somit aus suspekten Motiven applizierten Medikamenten fiel 1996 in Atlanta das halblegale und inzwischen als Dopingmittel verbotene Pharmazeutikum Bromantan auf . 1997 gelang uns erstmals im Weltmassstab die massenspektrometrische Identifikation eines halblegal synthetisierten , weder regulaer toxikologisch geprueften noch registrierten Wirkstoffs , der als Designerdroge aus zwei Wirkstofftypen mit nootrop/psychotroper beziehungsweise analeptischer Wirkung anzusehen ist . Als Carphedon " " unterliegt er inzwischen explizit dem IOC-Dopingverbot . Nachweis und Identifikation der bis 1997 weitgehend unbekannten Verbindung sowie die unmittelbaren Konsequenzen werden beschrieben .
[ "Die", "Screening", "\"", "\"", "-Stufe", "der", "Dopinganalytik", "erfasst", "ausser", "den", "zahlreichen", "verbotenen", "Dopingstoffen", "auch", "weitere", "Xenobiotika", ",", "die", "identifiziert", "werden", "muessen", ".", "Sofern", "diese", "nicht", "als", "erlaubte", "Medikamenteneinnahmen", "seitens", "des", "Probanden", "deklariert", "werden", ",", "ist", "sogar", "die", "Vermutung", "zu", "pruefen", ",", "ob", "das", "Dopingverbot", "mittels", "zunaechst", "nicht", "explizit", "verbotener", "Stoffe", "unterwandert", "werden", "soll", ".", "Nach", "frueheren", "\"", "Grauzonen", "\"", "-Faellen", "mit", "erlaubten", ",", "jedoch", "ohne", "medizinische", "Indikation", "und", "somit", "aus", "suspekten", "Motiven", "applizierten", "Medikamenten", "fiel", "1996", "in", "Atlanta", "das", "halblegale", "und", "inzwischen", "als", "Dopingmittel", "verbotene", "Pharmazeutikum", "Bromantan", "auf", ".", "1997", "gelang", "uns", "erstmals", "im", "Weltmassstab", "die", "massenspektrometrische", "Identifikation", "eines", "halblegal", "synthetisierten", ",", "weder", "regulaer", "toxikologisch", "geprueften", "noch", "registrierten", "Wirkstoffs", ",", "der", "als", "Designerdroge", "aus", "zwei", "Wirkstofftypen", "mit", "nootrop", "/", "psychotroper", "beziehungsweise", "analeptischer", "Wirkung", "anzusehen", "ist", ".", "Als", "Carphedon", "\"", "\"", "unterliegt", "er", "inzwischen", "explizit", "dem", "IOC", "-", "Dopingverbot", ".", "Nachweis", "und", "Identifikation", "der", "bis", "1997", "weitgehend", "unbekannten", "Verbindung", "sowie", "die", "unmittelbaren", "Konsequenzen", "werden", "beschrieben", "." ]
[ "umlsterm" ]
Medikamenteneinnahmen is an umlsterm, Medikamenten is an umlsterm
Rechtsmedizin.90090215.ger.abstr_task1
Sentence: Die Screening " " -Stufe der Dopinganalytik erfasst ausser den zahlreichen verbotenen Dopingstoffen auch weitere Xenobiotika , die identifiziert werden muessen . Sofern diese nicht als erlaubte Medikamenteneinnahmen seitens des Probanden deklariert werden , ist sogar die Vermutung zu pruefen , ob das Dopingverbot mittels zunaechst nicht explizit verbotener Stoffe unterwandert werden soll . Nach frueheren " Grauzonen " -Faellen mit erlaubten , jedoch ohne medizinische Indikation und somit aus suspekten Motiven applizierten Medikamenten fiel 1996 in Atlanta das halblegale und inzwischen als Dopingmittel verbotene Pharmazeutikum Bromantan auf . 1997 gelang uns erstmals im Weltmassstab die massenspektrometrische Identifikation eines halblegal synthetisierten , weder regulaer toxikologisch geprueften noch registrierten Wirkstoffs , der als Designerdroge aus zwei Wirkstofftypen mit nootrop/psychotroper beziehungsweise analeptischer Wirkung anzusehen ist . Als Carphedon " " unterliegt er inzwischen explizit dem IOC-Dopingverbot . Nachweis und Identifikation der bis 1997 weitgehend unbekannten Verbindung sowie die unmittelbaren Konsequenzen werden beschrieben . Instructions: please typing these entity words according to sentence: Medikamenteneinnahmen, Medikamenten Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Screening " " -Stufe der Dopinganalytik erfasst ausser den zahlreichen verbotenen Dopingstoffen auch weitere Xenobiotika , die identifiziert werden muessen . Sofern diese nicht als erlaubte Medikamenteneinnahmen seitens des Probanden deklariert werden , ist sogar die Vermutung zu pruefen , ob das Dopingverbot mittels zunaechst nicht explizit verbotener Stoffe unterwandert werden soll . Nach frueheren " Grauzonen " -Faellen mit erlaubten , jedoch ohne medizinische Indikation und somit aus suspekten Motiven applizierten Medikamenten fiel 1996 in Atlanta das halblegale und inzwischen als Dopingmittel verbotene Pharmazeutikum Bromantan auf . 1997 gelang uns erstmals im Weltmassstab die massenspektrometrische Identifikation eines halblegal synthetisierten , weder regulaer toxikologisch geprueften noch registrierten Wirkstoffs , der als Designerdroge aus zwei Wirkstofftypen mit nootrop/psychotroper beziehungsweise analeptischer Wirkung anzusehen ist . Als Carphedon " " unterliegt er inzwischen explizit dem IOC-Dopingverbot . Nachweis und Identifikation der bis 1997 weitgehend unbekannten Verbindung sowie die unmittelbaren Konsequenzen werden beschrieben .
[ "Die", "Screening", "\"", "\"", "-Stufe", "der", "Dopinganalytik", "erfasst", "ausser", "den", "zahlreichen", "verbotenen", "Dopingstoffen", "auch", "weitere", "Xenobiotika", ",", "die", "identifiziert", "werden", "muessen", ".", "Sofern", "diese", "nicht", "als", "erlaubte", "Medikamenteneinnahmen", "seitens", "des", "Probanden", "deklariert", "werden", ",", "ist", "sogar", "die", "Vermutung", "zu", "pruefen", ",", "ob", "das", "Dopingverbot", "mittels", "zunaechst", "nicht", "explizit", "verbotener", "Stoffe", "unterwandert", "werden", "soll", ".", "Nach", "frueheren", "\"", "Grauzonen", "\"", "-Faellen", "mit", "erlaubten", ",", "jedoch", "ohne", "medizinische", "Indikation", "und", "somit", "aus", "suspekten", "Motiven", "applizierten", "Medikamenten", "fiel", "1996", "in", "Atlanta", "das", "halblegale", "und", "inzwischen", "als", "Dopingmittel", "verbotene", "Pharmazeutikum", "Bromantan", "auf", ".", "1997", "gelang", "uns", "erstmals", "im", "Weltmassstab", "die", "massenspektrometrische", "Identifikation", "eines", "halblegal", "synthetisierten", ",", "weder", "regulaer", "toxikologisch", "geprueften", "noch", "registrierten", "Wirkstoffs", ",", "der", "als", "Designerdroge", "aus", "zwei", "Wirkstofftypen", "mit", "nootrop", "/", "psychotroper", "beziehungsweise", "analeptischer", "Wirkung", "anzusehen", "ist", ".", "Als", "Carphedon", "\"", "\"", "unterliegt", "er", "inzwischen", "explizit", "dem", "IOC", "-", "Dopingverbot", ".", "Nachweis", "und", "Identifikation", "der", "bis", "1997", "weitgehend", "unbekannten", "Verbindung", "sowie", "die", "unmittelbaren", "Konsequenzen", "werden", "beschrieben", "." ]
[ "umlsterm" ]
Medikamenteneinnahmen, Medikamenten
Rechtsmedizin.90090215.ger.abstr_task2
Sentence: Die Screening " " -Stufe der Dopinganalytik erfasst ausser den zahlreichen verbotenen Dopingstoffen auch weitere Xenobiotika , die identifiziert werden muessen . Sofern diese nicht als erlaubte Medikamenteneinnahmen seitens des Probanden deklariert werden , ist sogar die Vermutung zu pruefen , ob das Dopingverbot mittels zunaechst nicht explizit verbotener Stoffe unterwandert werden soll . Nach frueheren " Grauzonen " -Faellen mit erlaubten , jedoch ohne medizinische Indikation und somit aus suspekten Motiven applizierten Medikamenten fiel 1996 in Atlanta das halblegale und inzwischen als Dopingmittel verbotene Pharmazeutikum Bromantan auf . 1997 gelang uns erstmals im Weltmassstab die massenspektrometrische Identifikation eines halblegal synthetisierten , weder regulaer toxikologisch geprueften noch registrierten Wirkstoffs , der als Designerdroge aus zwei Wirkstofftypen mit nootrop/psychotroper beziehungsweise analeptischer Wirkung anzusehen ist . Als Carphedon " " unterliegt er inzwischen explizit dem IOC-Dopingverbot . Nachweis und Identifikation der bis 1997 weitgehend unbekannten Verbindung sowie die unmittelbaren Konsequenzen werden beschrieben . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Screening " " -Stufe der Dopinganalytik erfasst ausser den zahlreichen verbotenen Dopingstoffen auch weitere Xenobiotika , die identifiziert werden muessen . Sofern diese nicht als erlaubte Medikamenteneinnahmen seitens des Probanden deklariert werden , ist sogar die Vermutung zu pruefen , ob das Dopingverbot mittels zunaechst nicht explizit verbotener Stoffe unterwandert werden soll . Nach frueheren " Grauzonen " -Faellen mit erlaubten , jedoch ohne medizinische Indikation und somit aus suspekten Motiven applizierten Medikamenten fiel 1996 in Atlanta das halblegale und inzwischen als Dopingmittel verbotene Pharmazeutikum Bromantan auf . 1997 gelang uns erstmals im Weltmassstab die massenspektrometrische Identifikation eines halblegal synthetisierten , weder regulaer toxikologisch geprueften noch registrierten Wirkstoffs , der als Designerdroge aus zwei Wirkstofftypen mit nootrop/psychotroper beziehungsweise analeptischer Wirkung anzusehen ist . Als Carphedon " " unterliegt er inzwischen explizit dem IOC-Dopingverbot . Nachweis und Identifikation der bis 1997 weitgehend unbekannten Verbindung sowie die unmittelbaren Konsequenzen werden beschrieben .
[ "Die", "Screening", "\"", "\"", "-Stufe", "der", "Dopinganalytik", "erfasst", "ausser", "den", "zahlreichen", "verbotenen", "Dopingstoffen", "auch", "weitere", "Xenobiotika", ",", "die", "identifiziert", "werden", "muessen", ".", "Sofern", "diese", "nicht", "als", "erlaubte", "Medikamenteneinnahmen", "seitens", "des", "Probanden", "deklariert", "werden", ",", "ist", "sogar", "die", "Vermutung", "zu", "pruefen", ",", "ob", "das", "Dopingverbot", "mittels", "zunaechst", "nicht", "explizit", "verbotener", "Stoffe", "unterwandert", "werden", "soll", ".", "Nach", "frueheren", "\"", "Grauzonen", "\"", "-Faellen", "mit", "erlaubten", ",", "jedoch", "ohne", "medizinische", "Indikation", "und", "somit", "aus", "suspekten", "Motiven", "applizierten", "Medikamenten", "fiel", "1996", "in", "Atlanta", "das", "halblegale", "und", "inzwischen", "als", "Dopingmittel", "verbotene", "Pharmazeutikum", "Bromantan", "auf", ".", "1997", "gelang", "uns", "erstmals", "im", "Weltmassstab", "die", "massenspektrometrische", "Identifikation", "eines", "halblegal", "synthetisierten", ",", "weder", "regulaer", "toxikologisch", "geprueften", "noch", "registrierten", "Wirkstoffs", ",", "der", "als", "Designerdroge", "aus", "zwei", "Wirkstofftypen", "mit", "nootrop", "/", "psychotroper", "beziehungsweise", "analeptischer", "Wirkung", "anzusehen", "ist", ".", "Als", "Carphedon", "\"", "\"", "unterliegt", "er", "inzwischen", "explizit", "dem", "IOC", "-", "Dopingverbot", ".", "Nachweis", "und", "Identifikation", "der", "bis", "1997", "weitgehend", "unbekannten", "Verbindung", "sowie", "die", "unmittelbaren", "Konsequenzen", "werden", "beschrieben", "." ]
[ "umlsterm" ]
primosome is a Individual_protein, UL5 is a Gene, UL8 is a Gene, UL52 is a Gene
713_task0
Sentence: The Herpes simplex virus type 1 primosome consists of three subunits that are the products of the UL5, UL8, and UL52 genes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein, Gene
[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O" ]
The Herpes simplex virus type 1 primosome consists of three subunits that are the products of the UL5, UL8, and UL52 genes.
[ "The", "Herpes", "simplex", "virus", "type", "1", "primosome", "consists", "of", "three", "subunits", "that", "are", "the", "products", "of", "the", "UL5", ",", "UL8", ",", "and", "UL52", "genes", "." ]
[ "Individual_protein", "Gene" ]
primosome is a Individual_protein, UL5 is a Gene, UL8 is a Gene, UL52 is a Gene
713_task1
Sentence: The Herpes simplex virus type 1 primosome consists of three subunits that are the products of the UL5, UL8, and UL52 genes. Instructions: please typing these entity words according to sentence: primosome, UL5, UL8, UL52 Options: Individual_protein, Gene
[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O" ]
The Herpes simplex virus type 1 primosome consists of three subunits that are the products of the UL5, UL8, and UL52 genes.
[ "The", "Herpes", "simplex", "virus", "type", "1", "primosome", "consists", "of", "three", "subunits", "that", "are", "the", "products", "of", "the", "UL5", ",", "UL8", ",", "and", "UL52", "genes", "." ]
[ "Individual_protein", "Gene" ]
primosome, UL5, UL8, UL52
713_task2
Sentence: The Herpes simplex virus type 1 primosome consists of three subunits that are the products of the UL5, UL8, and UL52 genes. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O" ]
The Herpes simplex virus type 1 primosome consists of three subunits that are the products of the UL5, UL8, and UL52 genes.
[ "The", "Herpes", "simplex", "virus", "type", "1", "primosome", "consists", "of", "three", "subunits", "that", "are", "the", "products", "of", "the", "UL5", ",", "UL8", ",", "and", "UL52", "genes", "." ]
[ "Individual_protein", "Gene" ]
dominantly inherited is a Concepts_Ideas, familial adenomatous polyposis is a disease, FAP is a disease, germline mutations is a mutation, APC is a gene, 5q21-q22 is a mutation, classical is a Concepts_Ideas, FAP is a disease, hundreds to thousands of adenomatous is a Concepts_Ideas, large intestine is a body-part, colorectal cancer is a disease, CRC is a disease, extra - colonic is a body-part, FAP is a disease, Duodenal is a body-part, adenomas is a disease, carcinomas is a disease, duodenum is a body-part, FAP is a disease, patients is a cohort-patient, Patients is a cohort-patient, extra - intestinal is a body-part, tumors is a disease, desmoids is a disease, colorectal is a body-part, adenomatous polyposis is a disease, MUTYH - associated polyposis is a disease, MAP is a disease, MUTYH - associated CRC is a disease, MAP is a disease, biallelic mutations is a mutation, MUTYH is a gene, mutY homologue is a mutation, 1p32.1-p34.3 is a gene, inherited in a recessive manner is a Physiology, germline APC mutations is a mutation, FAP is a disease, families is a cohort-patient, APC is a gene, truncations is a mutation, nonsense APC mutations is a mutation, frameshifts caused by small deletions / insertions is a mutation, APC is a gene, deletions is a mutation, FAP is a disease, cases is a cohort-patient, APC is a gene, splice - site mutations is a mutation, 10–15 % is a size, FAP is a disease, patients is a cohort-patient, reduced or absent APC expression is a Physiology, patients is a cohort-patient, truncating APC mutation is a mutation, FAP is a disease, Germline APC - mutation is a mutation, FAP is a disease, patients is a cohort-patient, FAP is a disease, mutations in the central part of the APC gene is a mutation, Mutations around codon 1309 is a mutation, severe course is a Concepts_Ideas, disease is a disease, early onset is a Disorder, profuse polyposis is a Disorder, milder , attenuated form is a Concepts_Ideas, disease is a disease, AFAP is a disease, less than 100 is a Concepts_Ideas, adenomas is a disease, later onset of adenomatosis and CRC is a Disorder, mutations in the far 5 ' and 3 ' regions is a mutation, APC is a gene, in the part excluded by alternative splicing of exon 9 is a mutation
12_task0
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Background The dominantly inherited condition familial adenomatous polyposis (FAP) is caused by germline mutations in the APC gene (5q21-q22; MIM#175100) [1,2]. The classical FAP phenotype is defined by hundreds to thousands of adenomatous polyps that develop in the large intestine, conferring a high risk of colorectal cancer (CRC). A variety of extra-colonic manifestations exist in FAP. Duodenal adenomas are common and carcinomas of the duodenum are a main cause of death in FAP patients. Patients also have an increased risk of developing extra-intestinal tumors, for example, desmoids. Recently, a new type of colorectal adenomatous polyposis has been described, MUTYH-associated polyposis (MAP) [3] or MUTYH-associated CRC (MIM#608456). MAP is caused by biallelic mutations in the MUTYH (mutY homologue; MIM*604933) gene (1p32.1-p34.3) and is inherited in a recessive manner [4,5]. The majority of germline APC mutations identified in FAP families cause truncations in this multifunctional protein [6,7]. The APC truncations most often occur as the result of nonsense APC mutations or frameshifts caused by small deletions/insertions. Large APC deletions are found in a limited number of FAP cases. By using methods such as quantitative real-time PCR (polymerase chain reaction) or MLPA (multiplex ligation-dependent probe amplification) rather than conventional mutation-detection techniques, we can achieve higher detection rates of large deletions [8-12]. The number of reported characterized APC splice-site mutations is comparatively low [13-17]. Approximately 10–15% of the FAP patients could have a reduced or absent APC expression [18]. The cause of the reduced expression is not known but the patients show a similar phenotype to those with an identified truncating APC mutation [19-21]. It has been shown that a decrease of approximately 50% of the expression of an allele can result in a predisposition to FAP [20]. Germline APC-mutation mosaicism in FAP patients has been reported [22-25] but is not generally included in the mutation screening procedure provided by most labs owing to the technical difficulties encountered with these analyses. Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course of disease with early onset and profuse polyposis. The milder, attenuated form of disease (AFAP), characterized by less than 100 adenomas and later onset of adenomatosis and CRC, is often caused by mutations in the far 5' and 3' regions of the APC gene, as well as in the part excluded by alternative splicing of exon 9 [29]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: size, Concepts_Ideas, disease, cohort-patient, Physiology, body-part, Disorder, mutation, gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "I-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "B-mutation", "I-mutation", "O", "O", "B-gene", "O", "O", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "I-body-part", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "B-disease", "O", "O", "B-body-part", "O", "O", "O", "O", "O", "O", "O", "B-disease", "B-cohort-patient", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "I-disease", "O", "O", "O", "O", "B-disease", "I-disease", "I-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "O", "B-disease", "I-disease", "I-disease", "I-disease", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-mutation", "I-mutation", "O", "O", "B-gene", "O", "B-mutation", "I-mutation", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-gene", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "O", "B-Disorder", "I-Disorder", "O", "B-Disorder", "I-Disorder", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "O", "B-disease", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-gene", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Background The dominantly inherited condition familial adenomatous polyposis (FAP) is caused by germline mutations in the APC gene (5q21-q22; MIM#175100) [1,2]. The classical FAP phenotype is defined by hundreds to thousands of adenomatous polyps that develop in the large intestine, conferring a high risk of colorectal cancer (CRC). A variety of extra-colonic manifestations exist in FAP. Duodenal adenomas are common and carcinomas of the duodenum are a main cause of death in FAP patients. Patients also have an increased risk of developing extra-intestinal tumors, for example, desmoids. Recently, a new type of colorectal adenomatous polyposis has been described, MUTYH-associated polyposis (MAP) [3] or MUTYH-associated CRC (MIM#608456). MAP is caused by biallelic mutations in the MUTYH (mutY homologue; MIM*604933) gene (1p32.1-p34.3) and is inherited in a recessive manner [4,5]. The majority of germline APC mutations identified in FAP families cause truncations in this multifunctional protein [6,7]. The APC truncations most often occur as the result of nonsense APC mutations or frameshifts caused by small deletions/insertions. Large APC deletions are found in a limited number of FAP cases. By using methods such as quantitative real-time PCR (polymerase chain reaction) or MLPA (multiplex ligation-dependent probe amplification) rather than conventional mutation-detection techniques, we can achieve higher detection rates of large deletions [8-12]. The number of reported characterized APC splice-site mutations is comparatively low [13-17]. Approximately 10–15% of the FAP patients could have a reduced or absent APC expression [18]. The cause of the reduced expression is not known but the patients show a similar phenotype to those with an identified truncating APC mutation [19-21]. It has been shown that a decrease of approximately 50% of the expression of an allele can result in a predisposition to FAP [20]. Germline APC-mutation mosaicism in FAP patients has been reported [22-25] but is not generally included in the mutation screening procedure provided by most labs owing to the technical difficulties encountered with these analyses. Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course of disease with early onset and profuse polyposis. The milder, attenuated form of disease (AFAP), characterized by less than 100 adenomas and later onset of adenomatosis and CRC, is often caused by mutations in the far 5' and 3' regions of the APC gene, as well as in the part excluded by alternative splicing of exon 9 [29].
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Background", "\n\n", "The", "dominantly", "inherited", "condition", "familial", "adenomatous", "polyposis", "(", "FAP", ")", "is", "caused", "by", "germline", "mutations", "in", "the", "APC", "gene", "(", "5q21-q22", ";", "MIM#175100", ")", "[", "1,2", "]", ".", "The", "classical", "FAP", "phenotype", "is", "defined", "by", "hundreds", "to", "thousands", "of", "adenomatous", "polyps", "that", "develop", "in", "the", "large", "intestine", ",", "conferring", "a", "high", "risk", "of", "colorectal", "cancer", "(", "CRC", ")", ".", "A", "variety", "of", "extra", "-", "colonic", "manifestations", "exist", "in", "FAP", ".", "Duodenal", "adenomas", "are", "common", "and", "carcinomas", "of", "the", "duodenum", "are", "a", "main", "cause", "of", "death", "in", "FAP", "patients", ".", "Patients", "also", "have", "an", "increased", "risk", "of", "developing", "extra", "-", "intestinal", "tumors", ",", "for", "example", ",", "desmoids", ".", "Recently", ",", "a", "new", "type", "of", "colorectal", "adenomatous", "polyposis", "has", "been", "described", ",", "MUTYH", "-", "associated", "polyposis", "(", "MAP", ")", "[", "3", "]", "or", "MUTYH", "-", "associated", "CRC", "(", "MIM#608456", ")", ".", "MAP", "is", "caused", "by", "biallelic", "mutations", "in", "the", "MUTYH", "(", "mutY", "homologue", ";", "MIM*604933", ")", "gene", "(", "1p32.1-p34.3", ")", "and", "is", "inherited", "in", "a", "recessive", "manner", "[", "4,5", "]", ".", "\n\n", "The", "majority", "of", "germline", "APC", "mutations", "identified", "in", "FAP", "families", "cause", "truncations", "in", "this", "multifunctional", "protein", "[", "6,7", "]", ".", "The", "APC", "truncations", "most", "often", "occur", "as", "the", "result", "of", "nonsense", "APC", "mutations", "or", "frameshifts", "caused", "by", "small", "deletions", "/", "insertions", ".", "Large", "APC", "deletions", "are", "found", "in", "a", "limited", "number", "of", "FAP", "cases", ".", "By", "using", "methods", "such", "as", "quantitative", "real", "-", "time", "PCR", "(", "polymerase", "chain", "reaction", ")", "or", "MLPA", "(", "multiplex", "ligation", "-", "dependent", "probe", "amplification", ")", "rather", "than", "conventional", "mutation", "-", "detection", "techniques", ",", "we", "can", "achieve", "higher", "detection", "rates", "of", "large", "deletions", "[", "8", "-", "12", "]", ".", "The", "number", "of", "reported", "characterized", "APC", "splice", "-", "site", "mutations", "is", "comparatively", "low", "[", "13", "-", "17", "]", ".", "Approximately", "10–15", "%", "of", "the", "FAP", "patients", "could", "have", "a", "reduced", "or", "absent", "APC", "expression", "[", "18", "]", ".", "The", "cause", "of", "the", "reduced", "expression", "is", "not", "known", "but", "the", "patients", "show", "a", "similar", "phenotype", "to", "those", "with", "an", "identified", "truncating", "APC", "mutation", "[", "19", "-", "21", "]", ".", "It", "has", "been", "shown", "that", "a", "decrease", "of", "approximately", "50", "%", "of", "the", "expression", "of", "an", "allele", "can", "result", "in", "a", "predisposition", "to", "FAP", "[", "20", "]", ".", "Germline", "APC", "-", "mutation", "mosaicism", "in", "FAP", "patients", "has", "been", "reported", "[", "22", "-", "25", "]", "but", "is", "not", "generally", "included", "in", "the", "mutation", "screening", "procedure", "provided", "by", "most", "labs", "owing", "to", "the", "technical", "difficulties", "encountered", "with", "these", "analyses", ".", "\n\n", "Different", "genotype", "-", "phenotype", "correlations", "in", "FAP", "have", "been", "suggested", "[", "26", "-", "28", "]", ".", "The", "classic", "phenotype", "is", "primarily", "caused", "by", "mutations", "in", "the", "central", "part", "of", "the", "APC", "gene", ".", "Mutations", "around", "codon", "1309", "cause", "a", "severe", "course", "of", "disease", "with", "early", "onset", "and", "profuse", "polyposis", ".", "The", "milder", ",", "attenuated", "form", "of", "disease", "(", "AFAP", ")", ",", "characterized", "by", "less", "than", "100", "adenomas", "and", "later", "onset", "of", "adenomatosis", "and", "CRC", ",", "is", "often", "caused", "by", "mutations", "in", "the", "far", "5", "'", "and", "3", "'", "regions", "of", "the", "APC", "gene", ",", "as", "well", "as", "in", "the", "part", "excluded", "by", "alternative", "splicing", "of", "exon", "9", "[", "29", "]", ".", "\n\n" ]
[ "mutation", "Concepts_Ideas", "Disorder", "Physiology", "disease", "body-part", "gene", "cohort-patient", "size" ]
dominantly inherited is a Concepts_Ideas, familial adenomatous polyposis is a disease, FAP is a disease, germline mutations is a mutation, APC is a gene, 5q21-q22 is a mutation, classical is a Concepts_Ideas, FAP is a disease, hundreds to thousands of adenomatous is a Concepts_Ideas, large intestine is a body-part, colorectal cancer is a disease, CRC is a disease, extra - colonic is a body-part, FAP is a disease, Duodenal is a body-part, adenomas is a disease, carcinomas is a disease, duodenum is a body-part, FAP is a disease, patients is a cohort-patient, Patients is a cohort-patient, extra - intestinal is a body-part, tumors is a disease, desmoids is a disease, colorectal is a body-part, adenomatous polyposis is a disease, MUTYH - associated polyposis is a disease, MAP is a disease, MUTYH - associated CRC is a disease, MAP is a disease, biallelic mutations is a mutation, MUTYH is a gene, mutY homologue is a mutation, 1p32.1-p34.3 is a gene, inherited in a recessive manner is a Physiology, germline APC mutations is a mutation, FAP is a disease, families is a cohort-patient, APC is a gene, truncations is a mutation, nonsense APC mutations is a mutation, frameshifts caused by small deletions / insertions is a mutation, APC is a gene, deletions is a mutation, FAP is a disease, cases is a cohort-patient, APC is a gene, splice - site mutations is a mutation, 10–15 % is a size, FAP is a disease, patients is a cohort-patient, reduced or absent APC expression is a Physiology, patients is a cohort-patient, truncating APC mutation is a mutation, FAP is a disease, Germline APC - mutation is a mutation, FAP is a disease, patients is a cohort-patient, FAP is a disease, mutations in the central part of the APC gene is a mutation, Mutations around codon 1309 is a mutation, severe course is a Concepts_Ideas, disease is a disease, early onset is a Disorder, profuse polyposis is a Disorder, milder , attenuated form is a Concepts_Ideas, disease is a disease, AFAP is a disease, less than 100 is a Concepts_Ideas, adenomas is a disease, later onset of adenomatosis and CRC is a Disorder, mutations in the far 5 ' and 3 ' regions is a mutation, APC is a gene, in the part excluded by alternative splicing of exon 9 is a mutation
12_task1
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Background The dominantly inherited condition familial adenomatous polyposis (FAP) is caused by germline mutations in the APC gene (5q21-q22; MIM#175100) [1,2]. The classical FAP phenotype is defined by hundreds to thousands of adenomatous polyps that develop in the large intestine, conferring a high risk of colorectal cancer (CRC). A variety of extra-colonic manifestations exist in FAP. Duodenal adenomas are common and carcinomas of the duodenum are a main cause of death in FAP patients. Patients also have an increased risk of developing extra-intestinal tumors, for example, desmoids. Recently, a new type of colorectal adenomatous polyposis has been described, MUTYH-associated polyposis (MAP) [3] or MUTYH-associated CRC (MIM#608456). MAP is caused by biallelic mutations in the MUTYH (mutY homologue; MIM*604933) gene (1p32.1-p34.3) and is inherited in a recessive manner [4,5]. The majority of germline APC mutations identified in FAP families cause truncations in this multifunctional protein [6,7]. The APC truncations most often occur as the result of nonsense APC mutations or frameshifts caused by small deletions/insertions. Large APC deletions are found in a limited number of FAP cases. By using methods such as quantitative real-time PCR (polymerase chain reaction) or MLPA (multiplex ligation-dependent probe amplification) rather than conventional mutation-detection techniques, we can achieve higher detection rates of large deletions [8-12]. The number of reported characterized APC splice-site mutations is comparatively low [13-17]. Approximately 10–15% of the FAP patients could have a reduced or absent APC expression [18]. The cause of the reduced expression is not known but the patients show a similar phenotype to those with an identified truncating APC mutation [19-21]. It has been shown that a decrease of approximately 50% of the expression of an allele can result in a predisposition to FAP [20]. Germline APC-mutation mosaicism in FAP patients has been reported [22-25] but is not generally included in the mutation screening procedure provided by most labs owing to the technical difficulties encountered with these analyses. Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course of disease with early onset and profuse polyposis. The milder, attenuated form of disease (AFAP), characterized by less than 100 adenomas and later onset of adenomatosis and CRC, is often caused by mutations in the far 5' and 3' regions of the APC gene, as well as in the part excluded by alternative splicing of exon 9 [29]. Instructions: please typing these entity words according to sentence: dominantly inherited, familial adenomatous polyposis, FAP, germline mutations, APC, 5q21-q22, classical, FAP, hundreds to thousands of adenomatous, large intestine, colorectal cancer, CRC, extra - colonic, FAP, Duodenal, adenomas, carcinomas, duodenum, FAP, patients, Patients, extra - intestinal, tumors, desmoids, colorectal, adenomatous polyposis, MUTYH - associated polyposis, MAP, MUTYH - associated CRC, MAP, biallelic mutations, MUTYH, mutY homologue, 1p32.1-p34.3, inherited in a recessive manner, germline APC mutations, FAP, families, APC, truncations, nonsense APC mutations, frameshifts caused by small deletions / insertions, APC, deletions, FAP, cases, APC, splice - site mutations, 10–15 %, FAP, patients, reduced or absent APC expression, patients, truncating APC mutation, FAP, Germline APC - mutation, FAP, patients, FAP, mutations in the central part of the APC gene, Mutations around codon 1309, severe course, disease, early onset, profuse polyposis, milder , attenuated form, disease, AFAP, less than 100, adenomas, later onset of adenomatosis and CRC, mutations in the far 5 ' and 3 ' regions, APC, in the part excluded by alternative splicing of exon 9 Options: size, Concepts_Ideas, disease, cohort-patient, Physiology, body-part, Disorder, mutation, gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "I-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "B-mutation", "I-mutation", "O", "O", "B-gene", "O", "O", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "I-body-part", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "B-disease", "O", "O", "B-body-part", "O", "O", "O", "O", "O", "O", "O", "B-disease", "B-cohort-patient", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "I-disease", "O", "O", "O", "O", "B-disease", "I-disease", "I-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "O", "B-disease", "I-disease", "I-disease", "I-disease", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-mutation", "I-mutation", "O", "O", "B-gene", "O", "B-mutation", "I-mutation", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-gene", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "O", "B-Disorder", "I-Disorder", "O", "B-Disorder", "I-Disorder", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "O", "B-disease", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-gene", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Background The dominantly inherited condition familial adenomatous polyposis (FAP) is caused by germline mutations in the APC gene (5q21-q22; MIM#175100) [1,2]. The classical FAP phenotype is defined by hundreds to thousands of adenomatous polyps that develop in the large intestine, conferring a high risk of colorectal cancer (CRC). A variety of extra-colonic manifestations exist in FAP. Duodenal adenomas are common and carcinomas of the duodenum are a main cause of death in FAP patients. Patients also have an increased risk of developing extra-intestinal tumors, for example, desmoids. Recently, a new type of colorectal adenomatous polyposis has been described, MUTYH-associated polyposis (MAP) [3] or MUTYH-associated CRC (MIM#608456). MAP is caused by biallelic mutations in the MUTYH (mutY homologue; MIM*604933) gene (1p32.1-p34.3) and is inherited in a recessive manner [4,5]. The majority of germline APC mutations identified in FAP families cause truncations in this multifunctional protein [6,7]. The APC truncations most often occur as the result of nonsense APC mutations or frameshifts caused by small deletions/insertions. Large APC deletions are found in a limited number of FAP cases. By using methods such as quantitative real-time PCR (polymerase chain reaction) or MLPA (multiplex ligation-dependent probe amplification) rather than conventional mutation-detection techniques, we can achieve higher detection rates of large deletions [8-12]. The number of reported characterized APC splice-site mutations is comparatively low [13-17]. Approximately 10–15% of the FAP patients could have a reduced or absent APC expression [18]. The cause of the reduced expression is not known but the patients show a similar phenotype to those with an identified truncating APC mutation [19-21]. It has been shown that a decrease of approximately 50% of the expression of an allele can result in a predisposition to FAP [20]. Germline APC-mutation mosaicism in FAP patients has been reported [22-25] but is not generally included in the mutation screening procedure provided by most labs owing to the technical difficulties encountered with these analyses. Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course of disease with early onset and profuse polyposis. The milder, attenuated form of disease (AFAP), characterized by less than 100 adenomas and later onset of adenomatosis and CRC, is often caused by mutations in the far 5' and 3' regions of the APC gene, as well as in the part excluded by alternative splicing of exon 9 [29].
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Background", "\n\n", "The", "dominantly", "inherited", "condition", "familial", "adenomatous", "polyposis", "(", "FAP", ")", "is", "caused", "by", "germline", "mutations", "in", "the", "APC", "gene", "(", "5q21-q22", ";", "MIM#175100", ")", "[", "1,2", "]", ".", "The", "classical", "FAP", "phenotype", "is", "defined", "by", "hundreds", "to", "thousands", "of", "adenomatous", "polyps", "that", "develop", "in", "the", "large", "intestine", ",", "conferring", "a", "high", "risk", "of", "colorectal", "cancer", "(", "CRC", ")", ".", "A", "variety", "of", "extra", "-", "colonic", "manifestations", "exist", "in", "FAP", ".", "Duodenal", "adenomas", "are", "common", "and", "carcinomas", "of", "the", "duodenum", "are", "a", "main", "cause", "of", "death", "in", "FAP", "patients", ".", "Patients", "also", "have", "an", "increased", "risk", "of", "developing", "extra", "-", "intestinal", "tumors", ",", "for", "example", ",", "desmoids", ".", "Recently", ",", "a", "new", "type", "of", "colorectal", "adenomatous", "polyposis", "has", "been", "described", ",", "MUTYH", "-", "associated", "polyposis", "(", "MAP", ")", "[", "3", "]", "or", "MUTYH", "-", "associated", "CRC", "(", "MIM#608456", ")", ".", "MAP", "is", "caused", "by", "biallelic", "mutations", "in", "the", "MUTYH", "(", "mutY", "homologue", ";", "MIM*604933", ")", "gene", "(", "1p32.1-p34.3", ")", "and", "is", "inherited", "in", "a", "recessive", "manner", "[", "4,5", "]", ".", "\n\n", "The", "majority", "of", "germline", "APC", "mutations", "identified", "in", "FAP", "families", "cause", "truncations", "in", "this", "multifunctional", "protein", "[", "6,7", "]", ".", "The", "APC", "truncations", "most", "often", "occur", "as", "the", "result", "of", "nonsense", "APC", "mutations", "or", "frameshifts", "caused", "by", "small", "deletions", "/", "insertions", ".", "Large", "APC", "deletions", "are", "found", "in", "a", "limited", "number", "of", "FAP", "cases", ".", "By", "using", "methods", "such", "as", "quantitative", "real", "-", "time", "PCR", "(", "polymerase", "chain", "reaction", ")", "or", "MLPA", "(", "multiplex", "ligation", "-", "dependent", "probe", "amplification", ")", "rather", "than", "conventional", "mutation", "-", "detection", "techniques", ",", "we", "can", "achieve", "higher", "detection", "rates", "of", "large", "deletions", "[", "8", "-", "12", "]", ".", "The", "number", "of", "reported", "characterized", "APC", "splice", "-", "site", "mutations", "is", "comparatively", "low", "[", "13", "-", "17", "]", ".", "Approximately", "10–15", "%", "of", "the", "FAP", "patients", "could", "have", "a", "reduced", "or", "absent", "APC", "expression", "[", "18", "]", ".", "The", "cause", "of", "the", "reduced", "expression", "is", "not", "known", "but", "the", "patients", "show", "a", "similar", "phenotype", "to", "those", "with", "an", "identified", "truncating", "APC", "mutation", "[", "19", "-", "21", "]", ".", "It", "has", "been", "shown", "that", "a", "decrease", "of", "approximately", "50", "%", "of", "the", "expression", "of", "an", "allele", "can", "result", "in", "a", "predisposition", "to", "FAP", "[", "20", "]", ".", "Germline", "APC", "-", "mutation", "mosaicism", "in", "FAP", "patients", "has", "been", "reported", "[", "22", "-", "25", "]", "but", "is", "not", "generally", "included", "in", "the", "mutation", "screening", "procedure", "provided", "by", "most", "labs", "owing", "to", "the", "technical", "difficulties", "encountered", "with", "these", "analyses", ".", "\n\n", "Different", "genotype", "-", "phenotype", "correlations", "in", "FAP", "have", "been", "suggested", "[", "26", "-", "28", "]", ".", "The", "classic", "phenotype", "is", "primarily", "caused", "by", "mutations", "in", "the", "central", "part", "of", "the", "APC", "gene", ".", "Mutations", "around", "codon", "1309", "cause", "a", "severe", "course", "of", "disease", "with", "early", "onset", "and", "profuse", "polyposis", ".", "The", "milder", ",", "attenuated", "form", "of", "disease", "(", "AFAP", ")", ",", "characterized", "by", "less", "than", "100", "adenomas", "and", "later", "onset", "of", "adenomatosis", "and", "CRC", ",", "is", "often", "caused", "by", "mutations", "in", "the", "far", "5", "'", "and", "3", "'", "regions", "of", "the", "APC", "gene", ",", "as", "well", "as", "in", "the", "part", "excluded", "by", "alternative", "splicing", "of", "exon", "9", "[", "29", "]", ".", "\n\n" ]
[ "mutation", "Concepts_Ideas", "Disorder", "Physiology", "disease", "body-part", "gene", "cohort-patient", "size" ]
dominantly inherited, familial adenomatous polyposis, FAP, germline mutations, APC, 5q21-q22, classical, FAP, hundreds to thousands of adenomatous, large intestine, colorectal cancer, CRC, extra - colonic, FAP, Duodenal, adenomas, carcinomas, duodenum, FAP, patients, Patients, extra - intestinal, tumors, desmoids, colorectal, adenomatous polyposis, MUTYH - associated polyposis, MAP, MUTYH - associated CRC, MAP, biallelic mutations, MUTYH, mutY homologue, 1p32.1-p34.3, inherited in a recessive manner, germline APC mutations, FAP, families, APC, truncations, nonsense APC mutations, frameshifts caused by small deletions / insertions, APC, deletions, FAP, cases, APC, splice - site mutations, 10–15 %, FAP, patients, reduced or absent APC expression, patients, truncating APC mutation, FAP, Germline APC - mutation, FAP, patients, FAP, mutations in the central part of the APC gene, Mutations around codon 1309, severe course, disease, early onset, profuse polyposis, milder , attenuated form, disease, AFAP, less than 100, adenomas, later onset of adenomatosis and CRC, mutations in the far 5 ' and 3 ' regions, APC, in the part excluded by alternative splicing of exon 9
12_task2
Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Background The dominantly inherited condition familial adenomatous polyposis (FAP) is caused by germline mutations in the APC gene (5q21-q22; MIM#175100) [1,2]. The classical FAP phenotype is defined by hundreds to thousands of adenomatous polyps that develop in the large intestine, conferring a high risk of colorectal cancer (CRC). A variety of extra-colonic manifestations exist in FAP. Duodenal adenomas are common and carcinomas of the duodenum are a main cause of death in FAP patients. Patients also have an increased risk of developing extra-intestinal tumors, for example, desmoids. Recently, a new type of colorectal adenomatous polyposis has been described, MUTYH-associated polyposis (MAP) [3] or MUTYH-associated CRC (MIM#608456). MAP is caused by biallelic mutations in the MUTYH (mutY homologue; MIM*604933) gene (1p32.1-p34.3) and is inherited in a recessive manner [4,5]. The majority of germline APC mutations identified in FAP families cause truncations in this multifunctional protein [6,7]. The APC truncations most often occur as the result of nonsense APC mutations or frameshifts caused by small deletions/insertions. Large APC deletions are found in a limited number of FAP cases. By using methods such as quantitative real-time PCR (polymerase chain reaction) or MLPA (multiplex ligation-dependent probe amplification) rather than conventional mutation-detection techniques, we can achieve higher detection rates of large deletions [8-12]. The number of reported characterized APC splice-site mutations is comparatively low [13-17]. Approximately 10–15% of the FAP patients could have a reduced or absent APC expression [18]. The cause of the reduced expression is not known but the patients show a similar phenotype to those with an identified truncating APC mutation [19-21]. It has been shown that a decrease of approximately 50% of the expression of an allele can result in a predisposition to FAP [20]. Germline APC-mutation mosaicism in FAP patients has been reported [22-25] but is not generally included in the mutation screening procedure provided by most labs owing to the technical difficulties encountered with these analyses. Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course of disease with early onset and profuse polyposis. The milder, attenuated form of disease (AFAP), characterized by less than 100 adenomas and later onset of adenomatosis and CRC, is often caused by mutations in the far 5' and 3' regions of the APC gene, as well as in the part excluded by alternative splicing of exon 9 [29]. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "I-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "B-mutation", "I-mutation", "O", "O", "B-gene", "O", "O", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "O", "B-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "I-body-part", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "B-disease", "O", "O", "B-body-part", "O", "O", "O", "O", "O", "O", "O", "B-disease", "B-cohort-patient", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "I-disease", "O", "O", "O", "O", "B-disease", "I-disease", "I-disease", "I-disease", "O", "B-disease", "O", "O", "O", "O", "O", "B-disease", "I-disease", "I-disease", "I-disease", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-mutation", "I-mutation", "O", "O", "B-gene", "O", "B-mutation", "I-mutation", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-gene", "B-mutation", "O", "O", "O", "O", "O", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "O", "B-Disorder", "I-Disorder", "O", "B-Disorder", "I-Disorder", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "O", "B-disease", "O", "B-disease", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "B-gene", "O", "O", "O", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "O" ]
** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Background The dominantly inherited condition familial adenomatous polyposis (FAP) is caused by germline mutations in the APC gene (5q21-q22; MIM#175100) [1,2]. The classical FAP phenotype is defined by hundreds to thousands of adenomatous polyps that develop in the large intestine, conferring a high risk of colorectal cancer (CRC). A variety of extra-colonic manifestations exist in FAP. Duodenal adenomas are common and carcinomas of the duodenum are a main cause of death in FAP patients. Patients also have an increased risk of developing extra-intestinal tumors, for example, desmoids. Recently, a new type of colorectal adenomatous polyposis has been described, MUTYH-associated polyposis (MAP) [3] or MUTYH-associated CRC (MIM#608456). MAP is caused by biallelic mutations in the MUTYH (mutY homologue; MIM*604933) gene (1p32.1-p34.3) and is inherited in a recessive manner [4,5]. The majority of germline APC mutations identified in FAP families cause truncations in this multifunctional protein [6,7]. The APC truncations most often occur as the result of nonsense APC mutations or frameshifts caused by small deletions/insertions. Large APC deletions are found in a limited number of FAP cases. By using methods such as quantitative real-time PCR (polymerase chain reaction) or MLPA (multiplex ligation-dependent probe amplification) rather than conventional mutation-detection techniques, we can achieve higher detection rates of large deletions [8-12]. The number of reported characterized APC splice-site mutations is comparatively low [13-17]. Approximately 10–15% of the FAP patients could have a reduced or absent APC expression [18]. The cause of the reduced expression is not known but the patients show a similar phenotype to those with an identified truncating APC mutation [19-21]. It has been shown that a decrease of approximately 50% of the expression of an allele can result in a predisposition to FAP [20]. Germline APC-mutation mosaicism in FAP patients has been reported [22-25] but is not generally included in the mutation screening procedure provided by most labs owing to the technical difficulties encountered with these analyses. Different genotype-phenotype correlations in FAP have been suggested [26-28]. The classic phenotype is primarily caused by mutations in the central part of the APC gene. Mutations around codon 1309 cause a severe course of disease with early onset and profuse polyposis. The milder, attenuated form of disease (AFAP), characterized by less than 100 adenomas and later onset of adenomatosis and CRC, is often caused by mutations in the far 5' and 3' regions of the APC gene, as well as in the part excluded by alternative splicing of exon 9 [29].
[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Background", "\n\n", "The", "dominantly", "inherited", "condition", "familial", "adenomatous", "polyposis", "(", "FAP", ")", "is", "caused", "by", "germline", "mutations", "in", "the", "APC", "gene", "(", "5q21-q22", ";", "MIM#175100", ")", "[", "1,2", "]", ".", "The", "classical", "FAP", "phenotype", "is", "defined", "by", "hundreds", "to", "thousands", "of", "adenomatous", "polyps", "that", "develop", "in", "the", "large", "intestine", ",", "conferring", "a", "high", "risk", "of", "colorectal", "cancer", "(", "CRC", ")", ".", "A", "variety", "of", "extra", "-", "colonic", "manifestations", "exist", "in", "FAP", ".", "Duodenal", "adenomas", "are", "common", "and", "carcinomas", "of", "the", "duodenum", "are", "a", "main", "cause", "of", "death", "in", "FAP", "patients", ".", "Patients", "also", "have", "an", "increased", "risk", "of", "developing", "extra", "-", "intestinal", "tumors", ",", "for", "example", ",", "desmoids", ".", "Recently", ",", "a", "new", "type", "of", "colorectal", "adenomatous", "polyposis", "has", "been", "described", ",", "MUTYH", "-", "associated", "polyposis", "(", "MAP", ")", "[", "3", "]", "or", "MUTYH", "-", "associated", "CRC", "(", "MIM#608456", ")", ".", "MAP", "is", "caused", "by", "biallelic", "mutations", "in", "the", "MUTYH", "(", "mutY", "homologue", ";", "MIM*604933", ")", "gene", "(", "1p32.1-p34.3", ")", "and", "is", "inherited", "in", "a", "recessive", "manner", "[", "4,5", "]", ".", "\n\n", "The", "majority", "of", "germline", "APC", "mutations", "identified", "in", "FAP", "families", "cause", "truncations", "in", "this", "multifunctional", "protein", "[", "6,7", "]", ".", "The", "APC", "truncations", "most", "often", "occur", "as", "the", "result", "of", "nonsense", "APC", "mutations", "or", "frameshifts", "caused", "by", "small", "deletions", "/", "insertions", ".", "Large", "APC", "deletions", "are", "found", "in", "a", "limited", "number", "of", "FAP", "cases", ".", "By", "using", "methods", "such", "as", "quantitative", "real", "-", "time", "PCR", "(", "polymerase", "chain", "reaction", ")", "or", "MLPA", "(", "multiplex", "ligation", "-", "dependent", "probe", "amplification", ")", "rather", "than", "conventional", "mutation", "-", "detection", "techniques", ",", "we", "can", "achieve", "higher", "detection", "rates", "of", "large", "deletions", "[", "8", "-", "12", "]", ".", "The", "number", "of", "reported", "characterized", "APC", "splice", "-", "site", "mutations", "is", "comparatively", "low", "[", "13", "-", "17", "]", ".", "Approximately", "10–15", "%", "of", "the", "FAP", "patients", "could", "have", "a", "reduced", "or", "absent", "APC", "expression", "[", "18", "]", ".", "The", "cause", "of", "the", "reduced", "expression", "is", "not", "known", "but", "the", "patients", "show", "a", "similar", "phenotype", "to", "those", "with", "an", "identified", "truncating", "APC", "mutation", "[", "19", "-", "21", "]", ".", "It", "has", "been", "shown", "that", "a", "decrease", "of", "approximately", "50", "%", "of", "the", "expression", "of", "an", "allele", "can", "result", "in", "a", "predisposition", "to", "FAP", "[", "20", "]", ".", "Germline", "APC", "-", "mutation", "mosaicism", "in", "FAP", "patients", "has", "been", "reported", "[", "22", "-", "25", "]", "but", "is", "not", "generally", "included", "in", "the", "mutation", "screening", "procedure", "provided", "by", "most", "labs", "owing", "to", "the", "technical", "difficulties", "encountered", "with", "these", "analyses", ".", "\n\n", "Different", "genotype", "-", "phenotype", "correlations", "in", "FAP", "have", "been", "suggested", "[", "26", "-", "28", "]", ".", "The", "classic", "phenotype", "is", "primarily", "caused", "by", "mutations", "in", "the", "central", "part", "of", "the", "APC", "gene", ".", "Mutations", "around", "codon", "1309", "cause", "a", "severe", "course", "of", "disease", "with", "early", "onset", "and", "profuse", "polyposis", ".", "The", "milder", ",", "attenuated", "form", "of", "disease", "(", "AFAP", ")", ",", "characterized", "by", "less", "than", "100", "adenomas", "and", "later", "onset", "of", "adenomatosis", "and", "CRC", ",", "is", "often", "caused", "by", "mutations", "in", "the", "far", "5", "'", "and", "3", "'", "regions", "of", "the", "APC", "gene", ",", "as", "well", "as", "in", "the", "part", "excluded", "by", "alternative", "splicing", "of", "exon", "9", "[", "29", "]", ".", "\n\n" ]
[ "mutation", "Concepts_Ideas", "Disorder", "Physiology", "disease", "body-part", "gene", "cohort-patient", "size" ]
ecto-5'-nucleotidase is a Protein, promoter is a Entity, camp response element site is a Entity, upstream regulatory region is a Entity, 5 ' region is a Entity, ecto-5'-nucleotidase is a Protein, 5'-NT is a Protein, CAT is a Protein, reporter gene is a Entity, ecto-5'-NT is a Protein, 768-bp upstream negative regulatory region is a Entity, 244-bp deoxycytidine kinase core promoter is a Entity, DNase I is a Protein, Sp1 is a Protein, Sp1 is a Protein, binding sites is a Entity, Sp1 is a Protein, NRE-2a is a Protein, TCF-1 is a Protein, LEF-1 is a Protein, Sp1 is a Protein, binding sites is a Entity, upstream regulatory region is a Entity, CRE site is a Entity, upstream regulatory region is a Entity, Sp1 is a Protein, / AP-2 site is a Entity, CRE site is a Entity, ATF-1 is a Protein, ATF-2 is a Protein, 969-bp promoter fragments is a Entity, CRE site is a Entity, tissue - specific regulatory region is a Entity, ecto-5'-NT is a Protein, core promoter is a Entity, CRE site is a Entity, basal promoter is a Entity
515_task0
Sentence: Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region. We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established that a 969-base pair (bp) fragment confers cell-specific expression of a CAT reporter gene that correlates with the expression of endogenous ecto-5'-NT mRNA and enzymatic activity. A 768-bp upstream negative regulatory region has been identified that conferred lymphocyte-specific negative regulation in a heterologous system with a 244-bp deoxycytidine kinase core promoter. DNase I footprinting identified several protected areas including Sp1, Sp1/AP-2, and cAMP response element (CRE) binding sites within the 201-bp core promoter region and Sp1, NRE-2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the upstream regulatory region. Whereas the CRE site was essential in mediating the negative activity of the upstream regulatory region in Jurkat but not in HeLa cells, mutation of the Sp1/AP-2 site decreased promoter activity in both cell lines. Electrophoretic mobility shift assay analysis of proteins binding to the CRE site identified both ATF-1 and ATF-2 in Jurkat cells. Finally, phorbol 12-myristate 13-acetate increased the activity of both the core and the 969-bp promoter fragments, and this increase was abrogated by mutations at the CRE site. In summary, we have identified a tissue-specific regulatory region 5' of the ecto-5'-NT core promoter that requires the presence of a functional CRE site within the basal promoter for its suppressive activity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O" ]
Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region. We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established that a 969-base pair (bp) fragment confers cell-specific expression of a CAT reporter gene that correlates with the expression of endogenous ecto-5'-NT mRNA and enzymatic activity. A 768-bp upstream negative regulatory region has been identified that conferred lymphocyte-specific negative regulation in a heterologous system with a 244-bp deoxycytidine kinase core promoter. DNase I footprinting identified several protected areas including Sp1, Sp1/AP-2, and cAMP response element (CRE) binding sites within the 201-bp core promoter region and Sp1, NRE-2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the upstream regulatory region. Whereas the CRE site was essential in mediating the negative activity of the upstream regulatory region in Jurkat but not in HeLa cells, mutation of the Sp1/AP-2 site decreased promoter activity in both cell lines. Electrophoretic mobility shift assay analysis of proteins binding to the CRE site identified both ATF-1 and ATF-2 in Jurkat cells. Finally, phorbol 12-myristate 13-acetate increased the activity of both the core and the 969-bp promoter fragments, and this increase was abrogated by mutations at the CRE site. In summary, we have identified a tissue-specific regulatory region 5' of the ecto-5'-NT core promoter that requires the presence of a functional CRE site within the basal promoter for its suppressive activity.
[ "Tissue", "-", "specific", "regulation", "of", "the", "ecto-5'-nucleotidase", "promoter", ".", "Role", "of", "the", "camp", "response", "element", "site", "in", "mediating", "repression", "by", "the", "upstream", "regulatory", "region", ".", "\n", "We", "have", "isolated", "the", "5", "'", "region", "of", "the", "ecto-5'-nucleotidase", "(", "low", "K(m", ")", "5'-NT", ")", "gene", "and", "established", "that", "a", "969-base", "pair", "(", "bp", ")", "fragment", "confers", "cell", "-", "specific", "expression", "of", "a", "CAT", "reporter", "gene", "that", "correlates", "with", "the", "expression", "of", "endogenous", "ecto-5'-NT", "mRNA", "and", "enzymatic", "activity", ".", "A", "768-bp", "upstream", "negative", "regulatory", "region", "has", "been", "identified", "that", "conferred", "lymphocyte", "-", "specific", "negative", "regulation", "in", "a", "heterologous", "system", "with", "a", "244-bp", "deoxycytidine", "kinase", "core", "promoter", ".", "DNase", "I", "footprinting", "identified", "several", "protected", "areas", "including", "Sp1", ",", "Sp1", "/", "AP-2", ",", "and", "cAMP", "response", "element", "(", "CRE", ")", "binding", "sites", "within", "the", "201-bp", "core", "promoter", "region", "and", "Sp1", ",", "NRE-2a", ",", "TCF-1", "/", "LEF-1", ",", "and", "Sp1", "/", "NF", "-", "AT", "binding", "sites", "in", "the", "upstream", "regulatory", "region", ".", "Whereas", "the", "CRE", "site", "was", "essential", "in", "mediating", "the", "negative", "activity", "of", "the", "upstream", "regulatory", "region", "in", "Jurkat", "but", "not", "in", "HeLa", "cells", ",", "mutation", "of", "the", "Sp1", "/", "AP-2", "site", "decreased", "promoter", "activity", "in", "both", "cell", "lines", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "of", "proteins", "binding", "to", "the", "CRE", "site", "identified", "both", "ATF-1", "and", "ATF-2", "in", "Jurkat", "cells", ".", "Finally", ",", "phorbol", "12-myristate", "13-acetate", "increased", "the", "activity", "of", "both", "the", "core", "and", "the", "969-bp", "promoter", "fragments", ",", "and", "this", "increase", "was", "abrogated", "by", "mutations", "at", "the", "CRE", "site", ".", "In", "summary", ",", "we", "have", "identified", "a", "tissue", "-", "specific", "regulatory", "region", "5", "'", "of", "the", "ecto-5'-NT", "core", "promoter", "that", "requires", "the", "presence", "of", "a", "functional", "CRE", "site", "within", "the", "basal", "promoter", "for", "its", "suppressive", "activity", ".", "\n" ]
[ "Entity", "Protein" ]
ecto-5'-nucleotidase is a Protein, promoter is a Entity, camp response element site is a Entity, upstream regulatory region is a Entity, 5 ' region is a Entity, ecto-5'-nucleotidase is a Protein, 5'-NT is a Protein, CAT is a Protein, reporter gene is a Entity, ecto-5'-NT is a Protein, 768-bp upstream negative regulatory region is a Entity, 244-bp deoxycytidine kinase core promoter is a Entity, DNase I is a Protein, Sp1 is a Protein, Sp1 is a Protein, binding sites is a Entity, Sp1 is a Protein, NRE-2a is a Protein, TCF-1 is a Protein, LEF-1 is a Protein, Sp1 is a Protein, binding sites is a Entity, upstream regulatory region is a Entity, CRE site is a Entity, upstream regulatory region is a Entity, Sp1 is a Protein, / AP-2 site is a Entity, CRE site is a Entity, ATF-1 is a Protein, ATF-2 is a Protein, 969-bp promoter fragments is a Entity, CRE site is a Entity, tissue - specific regulatory region is a Entity, ecto-5'-NT is a Protein, core promoter is a Entity, CRE site is a Entity, basal promoter is a Entity
515_task1
Sentence: Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region. We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established that a 969-base pair (bp) fragment confers cell-specific expression of a CAT reporter gene that correlates with the expression of endogenous ecto-5'-NT mRNA and enzymatic activity. A 768-bp upstream negative regulatory region has been identified that conferred lymphocyte-specific negative regulation in a heterologous system with a 244-bp deoxycytidine kinase core promoter. DNase I footprinting identified several protected areas including Sp1, Sp1/AP-2, and cAMP response element (CRE) binding sites within the 201-bp core promoter region and Sp1, NRE-2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the upstream regulatory region. Whereas the CRE site was essential in mediating the negative activity of the upstream regulatory region in Jurkat but not in HeLa cells, mutation of the Sp1/AP-2 site decreased promoter activity in both cell lines. Electrophoretic mobility shift assay analysis of proteins binding to the CRE site identified both ATF-1 and ATF-2 in Jurkat cells. Finally, phorbol 12-myristate 13-acetate increased the activity of both the core and the 969-bp promoter fragments, and this increase was abrogated by mutations at the CRE site. In summary, we have identified a tissue-specific regulatory region 5' of the ecto-5'-NT core promoter that requires the presence of a functional CRE site within the basal promoter for its suppressive activity. Instructions: please typing these entity words according to sentence: ecto-5'-nucleotidase, promoter, camp response element site, upstream regulatory region, 5 ' region, ecto-5'-nucleotidase, 5'-NT, CAT, reporter gene, ecto-5'-NT, 768-bp upstream negative regulatory region, 244-bp deoxycytidine kinase core promoter, DNase I, Sp1, Sp1, binding sites, Sp1, NRE-2a, TCF-1, LEF-1, Sp1, binding sites, upstream regulatory region, CRE site, upstream regulatory region, Sp1, / AP-2 site, CRE site, ATF-1, ATF-2, 969-bp promoter fragments, CRE site, tissue - specific regulatory region, ecto-5'-NT, core promoter, CRE site, basal promoter Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O" ]
Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region. We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established that a 969-base pair (bp) fragment confers cell-specific expression of a CAT reporter gene that correlates with the expression of endogenous ecto-5'-NT mRNA and enzymatic activity. A 768-bp upstream negative regulatory region has been identified that conferred lymphocyte-specific negative regulation in a heterologous system with a 244-bp deoxycytidine kinase core promoter. DNase I footprinting identified several protected areas including Sp1, Sp1/AP-2, and cAMP response element (CRE) binding sites within the 201-bp core promoter region and Sp1, NRE-2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the upstream regulatory region. Whereas the CRE site was essential in mediating the negative activity of the upstream regulatory region in Jurkat but not in HeLa cells, mutation of the Sp1/AP-2 site decreased promoter activity in both cell lines. Electrophoretic mobility shift assay analysis of proteins binding to the CRE site identified both ATF-1 and ATF-2 in Jurkat cells. Finally, phorbol 12-myristate 13-acetate increased the activity of both the core and the 969-bp promoter fragments, and this increase was abrogated by mutations at the CRE site. In summary, we have identified a tissue-specific regulatory region 5' of the ecto-5'-NT core promoter that requires the presence of a functional CRE site within the basal promoter for its suppressive activity.
[ "Tissue", "-", "specific", "regulation", "of", "the", "ecto-5'-nucleotidase", "promoter", ".", "Role", "of", "the", "camp", "response", "element", "site", "in", "mediating", "repression", "by", "the", "upstream", "regulatory", "region", ".", "\n", "We", "have", "isolated", "the", "5", "'", "region", "of", "the", "ecto-5'-nucleotidase", "(", "low", "K(m", ")", "5'-NT", ")", "gene", "and", "established", "that", "a", "969-base", "pair", "(", "bp", ")", "fragment", "confers", "cell", "-", "specific", "expression", "of", "a", "CAT", "reporter", "gene", "that", "correlates", "with", "the", "expression", "of", "endogenous", "ecto-5'-NT", "mRNA", "and", "enzymatic", "activity", ".", "A", "768-bp", "upstream", "negative", "regulatory", "region", "has", "been", "identified", "that", "conferred", "lymphocyte", "-", "specific", "negative", "regulation", "in", "a", "heterologous", "system", "with", "a", "244-bp", "deoxycytidine", "kinase", "core", "promoter", ".", "DNase", "I", "footprinting", "identified", "several", "protected", "areas", "including", "Sp1", ",", "Sp1", "/", "AP-2", ",", "and", "cAMP", "response", "element", "(", "CRE", ")", "binding", "sites", "within", "the", "201-bp", "core", "promoter", "region", "and", "Sp1", ",", "NRE-2a", ",", "TCF-1", "/", "LEF-1", ",", "and", "Sp1", "/", "NF", "-", "AT", "binding", "sites", "in", "the", "upstream", "regulatory", "region", ".", "Whereas", "the", "CRE", "site", "was", "essential", "in", "mediating", "the", "negative", "activity", "of", "the", "upstream", "regulatory", "region", "in", "Jurkat", "but", "not", "in", "HeLa", "cells", ",", "mutation", "of", "the", "Sp1", "/", "AP-2", "site", "decreased", "promoter", "activity", "in", "both", "cell", "lines", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "of", "proteins", "binding", "to", "the", "CRE", "site", "identified", "both", "ATF-1", "and", "ATF-2", "in", "Jurkat", "cells", ".", "Finally", ",", "phorbol", "12-myristate", "13-acetate", "increased", "the", "activity", "of", "both", "the", "core", "and", "the", "969-bp", "promoter", "fragments", ",", "and", "this", "increase", "was", "abrogated", "by", "mutations", "at", "the", "CRE", "site", ".", "In", "summary", ",", "we", "have", "identified", "a", "tissue", "-", "specific", "regulatory", "region", "5", "'", "of", "the", "ecto-5'-NT", "core", "promoter", "that", "requires", "the", "presence", "of", "a", "functional", "CRE", "site", "within", "the", "basal", "promoter", "for", "its", "suppressive", "activity", ".", "\n" ]
[ "Entity", "Protein" ]
ecto-5'-nucleotidase, promoter, camp response element site, upstream regulatory region, 5 ' region, ecto-5'-nucleotidase, 5'-NT, CAT, reporter gene, ecto-5'-NT, 768-bp upstream negative regulatory region, 244-bp deoxycytidine kinase core promoter, DNase I, Sp1, Sp1, binding sites, Sp1, NRE-2a, TCF-1, LEF-1, Sp1, binding sites, upstream regulatory region, CRE site, upstream regulatory region, Sp1, / AP-2 site, CRE site, ATF-1, ATF-2, 969-bp promoter fragments, CRE site, tissue - specific regulatory region, ecto-5'-NT, core promoter, CRE site, basal promoter
515_task2
Sentence: Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region. We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established that a 969-base pair (bp) fragment confers cell-specific expression of a CAT reporter gene that correlates with the expression of endogenous ecto-5'-NT mRNA and enzymatic activity. A 768-bp upstream negative regulatory region has been identified that conferred lymphocyte-specific negative regulation in a heterologous system with a 244-bp deoxycytidine kinase core promoter. DNase I footprinting identified several protected areas including Sp1, Sp1/AP-2, and cAMP response element (CRE) binding sites within the 201-bp core promoter region and Sp1, NRE-2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the upstream regulatory region. Whereas the CRE site was essential in mediating the negative activity of the upstream regulatory region in Jurkat but not in HeLa cells, mutation of the Sp1/AP-2 site decreased promoter activity in both cell lines. Electrophoretic mobility shift assay analysis of proteins binding to the CRE site identified both ATF-1 and ATF-2 in Jurkat cells. Finally, phorbol 12-myristate 13-acetate increased the activity of both the core and the 969-bp promoter fragments, and this increase was abrogated by mutations at the CRE site. In summary, we have identified a tissue-specific regulatory region 5' of the ecto-5'-NT core promoter that requires the presence of a functional CRE site within the basal promoter for its suppressive activity. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O" ]
Tissue-specific regulation of the ecto-5'-nucleotidase promoter. Role of the camp response element site in mediating repression by the upstream regulatory region. We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established that a 969-base pair (bp) fragment confers cell-specific expression of a CAT reporter gene that correlates with the expression of endogenous ecto-5'-NT mRNA and enzymatic activity. A 768-bp upstream negative regulatory region has been identified that conferred lymphocyte-specific negative regulation in a heterologous system with a 244-bp deoxycytidine kinase core promoter. DNase I footprinting identified several protected areas including Sp1, Sp1/AP-2, and cAMP response element (CRE) binding sites within the 201-bp core promoter region and Sp1, NRE-2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the upstream regulatory region. Whereas the CRE site was essential in mediating the negative activity of the upstream regulatory region in Jurkat but not in HeLa cells, mutation of the Sp1/AP-2 site decreased promoter activity in both cell lines. Electrophoretic mobility shift assay analysis of proteins binding to the CRE site identified both ATF-1 and ATF-2 in Jurkat cells. Finally, phorbol 12-myristate 13-acetate increased the activity of both the core and the 969-bp promoter fragments, and this increase was abrogated by mutations at the CRE site. In summary, we have identified a tissue-specific regulatory region 5' of the ecto-5'-NT core promoter that requires the presence of a functional CRE site within the basal promoter for its suppressive activity.
[ "Tissue", "-", "specific", "regulation", "of", "the", "ecto-5'-nucleotidase", "promoter", ".", "Role", "of", "the", "camp", "response", "element", "site", "in", "mediating", "repression", "by", "the", "upstream", "regulatory", "region", ".", "\n", "We", "have", "isolated", "the", "5", "'", "region", "of", "the", "ecto-5'-nucleotidase", "(", "low", "K(m", ")", "5'-NT", ")", "gene", "and", "established", "that", "a", "969-base", "pair", "(", "bp", ")", "fragment", "confers", "cell", "-", "specific", "expression", "of", "a", "CAT", "reporter", "gene", "that", "correlates", "with", "the", "expression", "of", "endogenous", "ecto-5'-NT", "mRNA", "and", "enzymatic", "activity", ".", "A", "768-bp", "upstream", "negative", "regulatory", "region", "has", "been", "identified", "that", "conferred", "lymphocyte", "-", "specific", "negative", "regulation", "in", "a", "heterologous", "system", "with", "a", "244-bp", "deoxycytidine", "kinase", "core", "promoter", ".", "DNase", "I", "footprinting", "identified", "several", "protected", "areas", "including", "Sp1", ",", "Sp1", "/", "AP-2", ",", "and", "cAMP", "response", "element", "(", "CRE", ")", "binding", "sites", "within", "the", "201-bp", "core", "promoter", "region", "and", "Sp1", ",", "NRE-2a", ",", "TCF-1", "/", "LEF-1", ",", "and", "Sp1", "/", "NF", "-", "AT", "binding", "sites", "in", "the", "upstream", "regulatory", "region", ".", "Whereas", "the", "CRE", "site", "was", "essential", "in", "mediating", "the", "negative", "activity", "of", "the", "upstream", "regulatory", "region", "in", "Jurkat", "but", "not", "in", "HeLa", "cells", ",", "mutation", "of", "the", "Sp1", "/", "AP-2", "site", "decreased", "promoter", "activity", "in", "both", "cell", "lines", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "of", "proteins", "binding", "to", "the", "CRE", "site", "identified", "both", "ATF-1", "and", "ATF-2", "in", "Jurkat", "cells", ".", "Finally", ",", "phorbol", "12-myristate", "13-acetate", "increased", "the", "activity", "of", "both", "the", "core", "and", "the", "969-bp", "promoter", "fragments", ",", "and", "this", "increase", "was", "abrogated", "by", "mutations", "at", "the", "CRE", "site", ".", "In", "summary", ",", "we", "have", "identified", "a", "tissue", "-", "specific", "regulatory", "region", "5", "'", "of", "the", "ecto-5'-NT", "core", "promoter", "that", "requires", "the", "presence", "of", "a", "functional", "CRE", "site", "within", "the", "basal", "promoter", "for", "its", "suppressive", "activity", ".", "\n" ]
[ "Entity", "Protein" ]
Infants is a Person, postnatal vitamin D supplementation is a Procedure, prematurity is a Condition, birthweight is a Measurement, < 2500 g is a Value, poor health is a Condition, current or past is a Scope, significant disease state is a Condition, congenital abnormality is a Condition
NCT02112734_exc_task0
Sentence: Infants who have already received postnatal vitamin D supplementation prematurity (<37 weeks)/low birthweight <2500 g poor health due to a current or past significant disease state or congenital abnormality. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Procedure, Scope, Measurement
[ "B-Person", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O" ]
Infants who have already received postnatal vitamin D supplementation prematurity (<37 weeks)/low birthweight <2500 g poor health due to a current or past significant disease state or congenital abnormality.
[ "Infants", "who", "have", "already", "received", "postnatal", "vitamin", "D", "supplementation", "\n", "prematurity", "(", "<", "37", "weeks)/low", "birthweight", "<", "2500", "g", "\n", "poor", "health", "due", "to", "a", "current", "or", "past", "significant", "disease", "state", "or", "congenital", "abnormality", ".", "\n" ]
[ "Procedure", "Condition", "Scope", "Measurement", "Drug", "Person", "Value", "Temporal" ]
Infants is a Person, postnatal vitamin D supplementation is a Procedure, prematurity is a Condition, birthweight is a Measurement, < 2500 g is a Value, poor health is a Condition, current or past is a Scope, significant disease state is a Condition, congenital abnormality is a Condition
NCT02112734_exc_task1
Sentence: Infants who have already received postnatal vitamin D supplementation prematurity (<37 weeks)/low birthweight <2500 g poor health due to a current or past significant disease state or congenital abnormality. Instructions: please typing these entity words according to sentence: Infants, postnatal vitamin D supplementation, prematurity, birthweight, < 2500 g, poor health, current or past, significant disease state, congenital abnormality Options: Condition, Value, Person, Procedure, Scope, Measurement
[ "B-Person", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O" ]
Infants who have already received postnatal vitamin D supplementation prematurity (<37 weeks)/low birthweight <2500 g poor health due to a current or past significant disease state or congenital abnormality.
[ "Infants", "who", "have", "already", "received", "postnatal", "vitamin", "D", "supplementation", "\n", "prematurity", "(", "<", "37", "weeks)/low", "birthweight", "<", "2500", "g", "\n", "poor", "health", "due", "to", "a", "current", "or", "past", "significant", "disease", "state", "or", "congenital", "abnormality", ".", "\n" ]
[ "Procedure", "Condition", "Scope", "Measurement", "Drug", "Person", "Value", "Temporal" ]
Infants, postnatal vitamin D supplementation, prematurity, birthweight, < 2500 g, poor health, current or past, significant disease state, congenital abnormality
NCT02112734_exc_task2
Sentence: Infants who have already received postnatal vitamin D supplementation prematurity (<37 weeks)/low birthweight <2500 g poor health due to a current or past significant disease state or congenital abnormality. Instructions: please extract entity words from the input sentence
[ "B-Person", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O" ]
Infants who have already received postnatal vitamin D supplementation prematurity (<37 weeks)/low birthweight <2500 g poor health due to a current or past significant disease state or congenital abnormality.
[ "Infants", "who", "have", "already", "received", "postnatal", "vitamin", "D", "supplementation", "\n", "prematurity", "(", "<", "37", "weeks)/low", "birthweight", "<", "2500", "g", "\n", "poor", "health", "due", "to", "a", "current", "or", "past", "significant", "disease", "state", "or", "congenital", "abnormality", ".", "\n" ]
[ "Procedure", "Condition", "Scope", "Measurement", "Drug", "Person", "Value", "Temporal" ]
Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Diagnosen is an umlsterm
DerNervenarzt.70680259.ger.abstr_task0
Sentence: Die Untersuchungsergebnisse von 1000 Patienten , die sich in einer konsekutiven Stichprobe unter dem Verdacht einer Gedaechtnisstoerung im Alter in einer Memory-Clinic vorstellten , zeigen die Notwendigkeit einer breiten differentialdiagnostischen Kompetenz . Die Patienten wurden von einem interdisziplinaer arbeitenden Team ( Psychiater und Neurologe , Geriater , Dipl. -Psychologe , Dipl. -Geragoge ) nacheinander untersucht . Der diagnostische Weg zur Klaerung der DSM-III-R- und der ICD-10-Kriterien wird ausfuehrlich diskutiert . 49,6 % der Patienten litten tatsaechlich unter einer demenziellen Stoerung ( davon 48,2 % unter einer DAT , 31 % unter einer DVT und 10 % unter einem Mischtyp ) . Im Gesamtkollektiv fanden sich bei 31,4 % andere psychiatrische Diagnosen , die in der Haelfte der Faelle als psychotherapeutisch behandelbar eingeschaetzt wurden . 12,5 % waren internistisch erkrankt . Die Ergebnisse werden v. a. im Hinblick auf ihre Bedeutung fuer die Versorgungsrealitaet diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Untersuchungsergebnisse von 1000 Patienten , die sich in einer konsekutiven Stichprobe unter dem Verdacht einer Gedaechtnisstoerung im Alter in einer Memory-Clinic vorstellten , zeigen die Notwendigkeit einer breiten differentialdiagnostischen Kompetenz . Die Patienten wurden von einem interdisziplinaer arbeitenden Team ( Psychiater und Neurologe , Geriater , Dipl. -Psychologe , Dipl. -Geragoge ) nacheinander untersucht . Der diagnostische Weg zur Klaerung der DSM-III-R- und der ICD-10-Kriterien wird ausfuehrlich diskutiert . 49,6 % der Patienten litten tatsaechlich unter einer demenziellen Stoerung ( davon 48,2 % unter einer DAT , 31 % unter einer DVT und 10 % unter einem Mischtyp ) . Im Gesamtkollektiv fanden sich bei 31,4 % andere psychiatrische Diagnosen , die in der Haelfte der Faelle als psychotherapeutisch behandelbar eingeschaetzt wurden . 12,5 % waren internistisch erkrankt . Die Ergebnisse werden v. a. im Hinblick auf ihre Bedeutung fuer die Versorgungsrealitaet diskutiert .
[ "Die", "Untersuchungsergebnisse", "von", "1000", "Patienten", ",", "die", "sich", "in", "einer", "konsekutiven", "Stichprobe", "unter", "dem", "Verdacht", "einer", "Gedaechtnisstoerung", "im", "Alter", "in", "einer", "Memory", "-", "Clinic", "vorstellten", ",", "zeigen", "die", "Notwendigkeit", "einer", "breiten", "differentialdiagnostischen", "Kompetenz", ".", "Die", "Patienten", "wurden", "von", "einem", "interdisziplinaer", "arbeitenden", "Team", "(", "Psychiater", "und", "Neurologe", ",", "Geriater", ",", "Dipl", ".", "-Psychologe", ",", "Dipl", ".", "-Geragoge", ")", "nacheinander", "untersucht", ".", "Der", "diagnostische", "Weg", "zur", "Klaerung", "der", "DSM", "-", "III", "-", "R-", "und", "der", "ICD-10-Kriterien", "wird", "ausfuehrlich", "diskutiert", ".", "49,6", "%", "der", "Patienten", "litten", "tatsaechlich", "unter", "einer", "demenziellen", "Stoerung", "(", "davon", "48,2", "%", "unter", "einer", "DAT", ",", "31", "%", "unter", "einer", "DVT", "und", "10", "%", "unter", "einem", "Mischtyp", ")", ".", "Im", "Gesamtkollektiv", "fanden", "sich", "bei", "31,4", "%", "andere", "psychiatrische", "Diagnosen", ",", "die", "in", "der", "Haelfte", "der", "Faelle", "als", "psychotherapeutisch", "behandelbar", "eingeschaetzt", "wurden", ".", "12,5", "%", "waren", "internistisch", "erkrankt", ".", "Die", "Ergebnisse", "werden", "v.", "a.", "im", "Hinblick", "auf", "ihre", "Bedeutung", "fuer", "die", "Versorgungsrealitaet", "diskutiert", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Diagnosen is an umlsterm
DerNervenarzt.70680259.ger.abstr_task1
Sentence: Die Untersuchungsergebnisse von 1000 Patienten , die sich in einer konsekutiven Stichprobe unter dem Verdacht einer Gedaechtnisstoerung im Alter in einer Memory-Clinic vorstellten , zeigen die Notwendigkeit einer breiten differentialdiagnostischen Kompetenz . Die Patienten wurden von einem interdisziplinaer arbeitenden Team ( Psychiater und Neurologe , Geriater , Dipl. -Psychologe , Dipl. -Geragoge ) nacheinander untersucht . Der diagnostische Weg zur Klaerung der DSM-III-R- und der ICD-10-Kriterien wird ausfuehrlich diskutiert . 49,6 % der Patienten litten tatsaechlich unter einer demenziellen Stoerung ( davon 48,2 % unter einer DAT , 31 % unter einer DVT und 10 % unter einem Mischtyp ) . Im Gesamtkollektiv fanden sich bei 31,4 % andere psychiatrische Diagnosen , die in der Haelfte der Faelle als psychotherapeutisch behandelbar eingeschaetzt wurden . 12,5 % waren internistisch erkrankt . Die Ergebnisse werden v. a. im Hinblick auf ihre Bedeutung fuer die Versorgungsrealitaet diskutiert . Instructions: please typing these entity words according to sentence: Patienten, Patienten, Patienten, Diagnosen Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Untersuchungsergebnisse von 1000 Patienten , die sich in einer konsekutiven Stichprobe unter dem Verdacht einer Gedaechtnisstoerung im Alter in einer Memory-Clinic vorstellten , zeigen die Notwendigkeit einer breiten differentialdiagnostischen Kompetenz . Die Patienten wurden von einem interdisziplinaer arbeitenden Team ( Psychiater und Neurologe , Geriater , Dipl. -Psychologe , Dipl. -Geragoge ) nacheinander untersucht . Der diagnostische Weg zur Klaerung der DSM-III-R- und der ICD-10-Kriterien wird ausfuehrlich diskutiert . 49,6 % der Patienten litten tatsaechlich unter einer demenziellen Stoerung ( davon 48,2 % unter einer DAT , 31 % unter einer DVT und 10 % unter einem Mischtyp ) . Im Gesamtkollektiv fanden sich bei 31,4 % andere psychiatrische Diagnosen , die in der Haelfte der Faelle als psychotherapeutisch behandelbar eingeschaetzt wurden . 12,5 % waren internistisch erkrankt . Die Ergebnisse werden v. a. im Hinblick auf ihre Bedeutung fuer die Versorgungsrealitaet diskutiert .
[ "Die", "Untersuchungsergebnisse", "von", "1000", "Patienten", ",", "die", "sich", "in", "einer", "konsekutiven", "Stichprobe", "unter", "dem", "Verdacht", "einer", "Gedaechtnisstoerung", "im", "Alter", "in", "einer", "Memory", "-", "Clinic", "vorstellten", ",", "zeigen", "die", "Notwendigkeit", "einer", "breiten", "differentialdiagnostischen", "Kompetenz", ".", "Die", "Patienten", "wurden", "von", "einem", "interdisziplinaer", "arbeitenden", "Team", "(", "Psychiater", "und", "Neurologe", ",", "Geriater", ",", "Dipl", ".", "-Psychologe", ",", "Dipl", ".", "-Geragoge", ")", "nacheinander", "untersucht", ".", "Der", "diagnostische", "Weg", "zur", "Klaerung", "der", "DSM", "-", "III", "-", "R-", "und", "der", "ICD-10-Kriterien", "wird", "ausfuehrlich", "diskutiert", ".", "49,6", "%", "der", "Patienten", "litten", "tatsaechlich", "unter", "einer", "demenziellen", "Stoerung", "(", "davon", "48,2", "%", "unter", "einer", "DAT", ",", "31", "%", "unter", "einer", "DVT", "und", "10", "%", "unter", "einem", "Mischtyp", ")", ".", "Im", "Gesamtkollektiv", "fanden", "sich", "bei", "31,4", "%", "andere", "psychiatrische", "Diagnosen", ",", "die", "in", "der", "Haelfte", "der", "Faelle", "als", "psychotherapeutisch", "behandelbar", "eingeschaetzt", "wurden", ".", "12,5", "%", "waren", "internistisch", "erkrankt", ".", "Die", "Ergebnisse", "werden", "v.", "a.", "im", "Hinblick", "auf", "ihre", "Bedeutung", "fuer", "die", "Versorgungsrealitaet", "diskutiert", "." ]
[ "umlsterm" ]
Patienten, Patienten, Patienten, Diagnosen
DerNervenarzt.70680259.ger.abstr_task2
Sentence: Die Untersuchungsergebnisse von 1000 Patienten , die sich in einer konsekutiven Stichprobe unter dem Verdacht einer Gedaechtnisstoerung im Alter in einer Memory-Clinic vorstellten , zeigen die Notwendigkeit einer breiten differentialdiagnostischen Kompetenz . Die Patienten wurden von einem interdisziplinaer arbeitenden Team ( Psychiater und Neurologe , Geriater , Dipl. -Psychologe , Dipl. -Geragoge ) nacheinander untersucht . Der diagnostische Weg zur Klaerung der DSM-III-R- und der ICD-10-Kriterien wird ausfuehrlich diskutiert . 49,6 % der Patienten litten tatsaechlich unter einer demenziellen Stoerung ( davon 48,2 % unter einer DAT , 31 % unter einer DVT und 10 % unter einem Mischtyp ) . Im Gesamtkollektiv fanden sich bei 31,4 % andere psychiatrische Diagnosen , die in der Haelfte der Faelle als psychotherapeutisch behandelbar eingeschaetzt wurden . 12,5 % waren internistisch erkrankt . Die Ergebnisse werden v. a. im Hinblick auf ihre Bedeutung fuer die Versorgungsrealitaet diskutiert . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Untersuchungsergebnisse von 1000 Patienten , die sich in einer konsekutiven Stichprobe unter dem Verdacht einer Gedaechtnisstoerung im Alter in einer Memory-Clinic vorstellten , zeigen die Notwendigkeit einer breiten differentialdiagnostischen Kompetenz . Die Patienten wurden von einem interdisziplinaer arbeitenden Team ( Psychiater und Neurologe , Geriater , Dipl. -Psychologe , Dipl. -Geragoge ) nacheinander untersucht . Der diagnostische Weg zur Klaerung der DSM-III-R- und der ICD-10-Kriterien wird ausfuehrlich diskutiert . 49,6 % der Patienten litten tatsaechlich unter einer demenziellen Stoerung ( davon 48,2 % unter einer DAT , 31 % unter einer DVT und 10 % unter einem Mischtyp ) . Im Gesamtkollektiv fanden sich bei 31,4 % andere psychiatrische Diagnosen , die in der Haelfte der Faelle als psychotherapeutisch behandelbar eingeschaetzt wurden . 12,5 % waren internistisch erkrankt . Die Ergebnisse werden v. a. im Hinblick auf ihre Bedeutung fuer die Versorgungsrealitaet diskutiert .
[ "Die", "Untersuchungsergebnisse", "von", "1000", "Patienten", ",", "die", "sich", "in", "einer", "konsekutiven", "Stichprobe", "unter", "dem", "Verdacht", "einer", "Gedaechtnisstoerung", "im", "Alter", "in", "einer", "Memory", "-", "Clinic", "vorstellten", ",", "zeigen", "die", "Notwendigkeit", "einer", "breiten", "differentialdiagnostischen", "Kompetenz", ".", "Die", "Patienten", "wurden", "von", "einem", "interdisziplinaer", "arbeitenden", "Team", "(", "Psychiater", "und", "Neurologe", ",", "Geriater", ",", "Dipl", ".", "-Psychologe", ",", "Dipl", ".", "-Geragoge", ")", "nacheinander", "untersucht", ".", "Der", "diagnostische", "Weg", "zur", "Klaerung", "der", "DSM", "-", "III", "-", "R-", "und", "der", "ICD-10-Kriterien", "wird", "ausfuehrlich", "diskutiert", ".", "49,6", "%", "der", "Patienten", "litten", "tatsaechlich", "unter", "einer", "demenziellen", "Stoerung", "(", "davon", "48,2", "%", "unter", "einer", "DAT", ",", "31", "%", "unter", "einer", "DVT", "und", "10", "%", "unter", "einem", "Mischtyp", ")", ".", "Im", "Gesamtkollektiv", "fanden", "sich", "bei", "31,4", "%", "andere", "psychiatrische", "Diagnosen", ",", "die", "in", "der", "Haelfte", "der", "Faelle", "als", "psychotherapeutisch", "behandelbar", "eingeschaetzt", "wurden", ".", "12,5", "%", "waren", "internistisch", "erkrankt", ".", "Die", "Ergebnisse", "werden", "v.", "a.", "im", "Hinblick", "auf", "ihre", "Bedeutung", "fuer", "die", "Versorgungsrealitaet", "diskutiert", "." ]
[ "umlsterm" ]
analgesia is an umlsterm, objective is an umlsterm, risk is an umlsterm, patient is an umlsterm, myocardial infarction is an umlsterm, vessels is an umlsterm, vessels is an umlsterm, haemodynamic is an umlsterm, side effects is an umlsterm, opioids is an umlsterm, risk is an umlsterm, patients is an umlsterm, vascular surgery is an umlsterm, Methods is an umlsterm, Patients is an umlsterm, opioid is an umlsterm, buprenorphine is an umlsterm, fentanyl is an umlsterm, morphine is an umlsterm, nalbuphine is an umlsterm, pentazocine is an umlsterm, pethidine is an umlsterm, tramadol is an umlsterm, alfentanil is an umlsterm, haemodynamic is an umlsterm, blood gas is an umlsterm, opioid is an umlsterm, administration is an umlsterm, Monitoring is an umlsterm, haemodynamic is an umlsterm, blood gas is an umlsterm, evaluation is an umlsterm, ANOVA is an umlsterm, time is an umlsterm, baseline is an umlsterm, time is an umlsterm, measurement is an umlsterm, heart rate is an umlsterm, peripheral resistance is an umlsterm, values is an umlsterm, times is an umlsterm, measurements is an umlsterm, time is an umlsterm, pulmonary artery is an umlsterm, pressure is an umlsterm, capillary is an umlsterm, wedge pressure is an umlsterm, stroke volume is an umlsterm, index is an umlsterm, morphine is an umlsterm, fentanyl is an umlsterm, alfentanil is an umlsterm, tramadol is an umlsterm, nalbuphine is an umlsterm, Buprenorphine is an umlsterm, depression is an umlsterm, Pentazocine is an umlsterm, pethidine is an umlsterm, vascular resistance is an umlsterm, pethidine is an umlsterm, depression is an umlsterm, depression is an umlsterm, histamine release is an umlsterm, secretion is an umlsterm, catecholamines is an umlsterm, vasoconstriction is an umlsterm, Tramadol is an umlsterm, opioid is an umlsterm, minor is an umlsterm, side effects is an umlsterm
DerAnaesthesist.40430743.eng.abstr_task0
Sentence: Efficient analgesia may be the major objective in the cardiovascular risk patient following myocardial infarction , acute occlusion of peripheral vessels , or dissection/perforation of major abdominal vessels . It was the purpose of the study to investigate the haemodynamic and respiratory side effects of eight different opioids in 57 circulatory risk patients prior to major vascular surgery . Methods . Patients were randomly allocated to eight groups , each receiving a different opioid within a clinical , equipotent dose range ( buprenorphine , fentanyl , morphine , nalbuphine , pentazocine , pethidine , tramadol , alfentanil ) . A complete haemodynamic and blood gas status was obtained prior to as well as 5 , 10 , 15 , and 20 min following opioid administration . Monitoring included a complete invasive haemodynamic and blood gas status . Statistical evaluation was performed by 1- and 2-factorial ANOVA ( P 0.05 ) . Results . Significant time effects ( changes from baseline at the time of measurement ) were observed for heart rate and total peripheral resistance , while significant group ( group-specific differences in the course of values at the different times of measurements ) and time effects were noted for mean pulmonary artery pressure , pulmonary capillary wedge pressure , stroke volume index , and PaO2. No major effects were observed following morphine , fentanyl , alfentanil , tramadol , and nalbuphine . Buprenorphine caused distinct respiratory depression accompanied by an increase in pulmonary vascular tone . Pentazocine and pethidine caused a significant increase in MPAP and peripheral vascular resistance while pethidine also produced marked respiratory depression . Conclusions . For interpretation of the results , factors such as respiratory depression , histamine release , secretion of endogenous catecholamines , and hypoxia-induced pulmonary vasoconstriction have to be discussed . Tramadol , an opioid with moderate potency , seems to offer some advantages due to its minor cardiovascular and respiratory side effects . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Efficient analgesia may be the major objective in the cardiovascular risk patient following myocardial infarction , acute occlusion of peripheral vessels , or dissection/perforation of major abdominal vessels . It was the purpose of the study to investigate the haemodynamic and respiratory side effects of eight different opioids in 57 circulatory risk patients prior to major vascular surgery . Methods . Patients were randomly allocated to eight groups , each receiving a different opioid within a clinical , equipotent dose range ( buprenorphine , fentanyl , morphine , nalbuphine , pentazocine , pethidine , tramadol , alfentanil ) . A complete haemodynamic and blood gas status was obtained prior to as well as 5 , 10 , 15 , and 20 min following opioid administration . Monitoring included a complete invasive haemodynamic and blood gas status . Statistical evaluation was performed by 1- and 2-factorial ANOVA ( P 0.05 ) . Results . Significant time effects ( changes from baseline at the time of measurement ) were observed for heart rate and total peripheral resistance , while significant group ( group-specific differences in the course of values at the different times of measurements ) and time effects were noted for mean pulmonary artery pressure , pulmonary capillary wedge pressure , stroke volume index , and PaO2. No major effects were observed following morphine , fentanyl , alfentanil , tramadol , and nalbuphine . Buprenorphine caused distinct respiratory depression accompanied by an increase in pulmonary vascular tone . Pentazocine and pethidine caused a significant increase in MPAP and peripheral vascular resistance while pethidine also produced marked respiratory depression . Conclusions . For interpretation of the results , factors such as respiratory depression , histamine release , secretion of endogenous catecholamines , and hypoxia-induced pulmonary vasoconstriction have to be discussed . Tramadol , an opioid with moderate potency , seems to offer some advantages due to its minor cardiovascular and respiratory side effects .
[ "Efficient", "analgesia", "may", "be", "the", "major", "objective", "in", "the", "cardiovascular", "risk", "patient", "following", "myocardial", "infarction", ",", "acute", "occlusion", "of", "peripheral", "vessels", ",", "or", "dissection", "/", "perforation", "of", "major", "abdominal", "vessels", ".", "It", "was", "the", "purpose", "of", "the", "study", "to", "investigate", "the", "haemodynamic", "and", "respiratory", "side", "effects", "of", "eight", "different", "opioids", "in", "57", "circulatory", "risk", "patients", "prior", "to", "major", "vascular", "surgery", ".", "Methods", ".", "Patients", "were", "randomly", "allocated", "to", "eight", "groups", ",", "each", "receiving", "a", "different", "opioid", "within", "a", "clinical", ",", "equipotent", "dose", "range", "(", "buprenorphine", ",", "fentanyl", ",", "morphine", ",", "nalbuphine", ",", "pentazocine", ",", "pethidine", ",", "tramadol", ",", "alfentanil", ")", ".", "A", "complete", "haemodynamic", "and", "blood", "gas", "status", "was", "obtained", "prior", "to", "as", "well", "as", "5", ",", "10", ",", "15", ",", "and", "20", "min", "following", "opioid", "administration", ".", "Monitoring", "included", "a", "complete", "invasive", "haemodynamic", "and", "blood", "gas", "status", ".", "Statistical", "evaluation", "was", "performed", "by", "1-", "and", "2-factorial", "ANOVA", "(", "P", "0.05", ")", ".", "Results", ".", "Significant", "time", "effects", "(", "changes", "from", "baseline", "at", "the", "time", "of", "measurement", ")", "were", "observed", "for", "heart", "rate", "and", "total", "peripheral", "resistance", ",", "while", "significant", "group", "(", "group", "-", "specific", "differences", "in", "the", "course", "of", "values", "at", "the", "different", "times", "of", "measurements", ")", "and", "time", "effects", "were", "noted", "for", "mean", "pulmonary", "artery", "pressure", ",", "pulmonary", "capillary", "wedge", "pressure", ",", "stroke", "volume", "index", ",", "and", "PaO2", ".", "No", "major", "effects", "were", "observed", "following", "morphine", ",", "fentanyl", ",", "alfentanil", ",", "tramadol", ",", "and", "nalbuphine", ".", "Buprenorphine", "caused", "distinct", "respiratory", "depression", "accompanied", "by", "an", "increase", "in", "pulmonary", "vascular", "tone", ".", "Pentazocine", "and", "pethidine", "caused", "a", "significant", "increase", "in", "MPAP", "and", "peripheral", "vascular", "resistance", "while", "pethidine", "also", "produced", "marked", "respiratory", "depression", ".", "Conclusions", ".", "For", "interpretation", "of", "the", "results", ",", "factors", "such", "as", "respiratory", "depression", ",", "histamine", "release", ",", "secretion", "of", "endogenous", "catecholamines", ",", "and", "hypoxia", "-", "induced", "pulmonary", "vasoconstriction", "have", "to", "be", "discussed", ".", "Tramadol", ",", "an", "opioid", "with", "moderate", "potency", ",", "seems", "to", "offer", "some", "advantages", "due", "to", "its", "minor", "cardiovascular", "and", "respiratory", "side", "effects", "." ]
[ "umlsterm" ]
analgesia is an umlsterm, objective is an umlsterm, risk is an umlsterm, patient is an umlsterm, myocardial infarction is an umlsterm, vessels is an umlsterm, vessels is an umlsterm, haemodynamic is an umlsterm, side effects is an umlsterm, opioids is an umlsterm, risk is an umlsterm, patients is an umlsterm, vascular surgery is an umlsterm, Methods is an umlsterm, Patients is an umlsterm, opioid is an umlsterm, buprenorphine is an umlsterm, fentanyl is an umlsterm, morphine is an umlsterm, nalbuphine is an umlsterm, pentazocine is an umlsterm, pethidine is an umlsterm, tramadol is an umlsterm, alfentanil is an umlsterm, haemodynamic is an umlsterm, blood gas is an umlsterm, opioid is an umlsterm, administration is an umlsterm, Monitoring is an umlsterm, haemodynamic is an umlsterm, blood gas is an umlsterm, evaluation is an umlsterm, ANOVA is an umlsterm, time is an umlsterm, baseline is an umlsterm, time is an umlsterm, measurement is an umlsterm, heart rate is an umlsterm, peripheral resistance is an umlsterm, values is an umlsterm, times is an umlsterm, measurements is an umlsterm, time is an umlsterm, pulmonary artery is an umlsterm, pressure is an umlsterm, capillary is an umlsterm, wedge pressure is an umlsterm, stroke volume is an umlsterm, index is an umlsterm, morphine is an umlsterm, fentanyl is an umlsterm, alfentanil is an umlsterm, tramadol is an umlsterm, nalbuphine is an umlsterm, Buprenorphine is an umlsterm, depression is an umlsterm, Pentazocine is an umlsterm, pethidine is an umlsterm, vascular resistance is an umlsterm, pethidine is an umlsterm, depression is an umlsterm, depression is an umlsterm, histamine release is an umlsterm, secretion is an umlsterm, catecholamines is an umlsterm, vasoconstriction is an umlsterm, Tramadol is an umlsterm, opioid is an umlsterm, minor is an umlsterm, side effects is an umlsterm
DerAnaesthesist.40430743.eng.abstr_task1
Sentence: Efficient analgesia may be the major objective in the cardiovascular risk patient following myocardial infarction , acute occlusion of peripheral vessels , or dissection/perforation of major abdominal vessels . It was the purpose of the study to investigate the haemodynamic and respiratory side effects of eight different opioids in 57 circulatory risk patients prior to major vascular surgery . Methods . Patients were randomly allocated to eight groups , each receiving a different opioid within a clinical , equipotent dose range ( buprenorphine , fentanyl , morphine , nalbuphine , pentazocine , pethidine , tramadol , alfentanil ) . A complete haemodynamic and blood gas status was obtained prior to as well as 5 , 10 , 15 , and 20 min following opioid administration . Monitoring included a complete invasive haemodynamic and blood gas status . Statistical evaluation was performed by 1- and 2-factorial ANOVA ( P 0.05 ) . Results . Significant time effects ( changes from baseline at the time of measurement ) were observed for heart rate and total peripheral resistance , while significant group ( group-specific differences in the course of values at the different times of measurements ) and time effects were noted for mean pulmonary artery pressure , pulmonary capillary wedge pressure , stroke volume index , and PaO2. No major effects were observed following morphine , fentanyl , alfentanil , tramadol , and nalbuphine . Buprenorphine caused distinct respiratory depression accompanied by an increase in pulmonary vascular tone . Pentazocine and pethidine caused a significant increase in MPAP and peripheral vascular resistance while pethidine also produced marked respiratory depression . Conclusions . For interpretation of the results , factors such as respiratory depression , histamine release , secretion of endogenous catecholamines , and hypoxia-induced pulmonary vasoconstriction have to be discussed . Tramadol , an opioid with moderate potency , seems to offer some advantages due to its minor cardiovascular and respiratory side effects . Instructions: please typing these entity words according to sentence: analgesia, objective, risk, patient, myocardial infarction, vessels, vessels, haemodynamic, side effects, opioids, risk, patients, vascular surgery, Methods, Patients, opioid, buprenorphine, fentanyl, morphine, nalbuphine, pentazocine, pethidine, tramadol, alfentanil, haemodynamic, blood gas, opioid, administration, Monitoring, haemodynamic, blood gas, evaluation, ANOVA, time, baseline, time, measurement, heart rate, peripheral resistance, values, times, measurements, time, pulmonary artery, pressure, capillary, wedge pressure, stroke volume, index, morphine, fentanyl, alfentanil, tramadol, nalbuphine, Buprenorphine, depression, Pentazocine, pethidine, vascular resistance, pethidine, depression, depression, histamine release, secretion, catecholamines, vasoconstriction, Tramadol, opioid, minor, side effects Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Efficient analgesia may be the major objective in the cardiovascular risk patient following myocardial infarction , acute occlusion of peripheral vessels , or dissection/perforation of major abdominal vessels . It was the purpose of the study to investigate the haemodynamic and respiratory side effects of eight different opioids in 57 circulatory risk patients prior to major vascular surgery . Methods . Patients were randomly allocated to eight groups , each receiving a different opioid within a clinical , equipotent dose range ( buprenorphine , fentanyl , morphine , nalbuphine , pentazocine , pethidine , tramadol , alfentanil ) . A complete haemodynamic and blood gas status was obtained prior to as well as 5 , 10 , 15 , and 20 min following opioid administration . Monitoring included a complete invasive haemodynamic and blood gas status . Statistical evaluation was performed by 1- and 2-factorial ANOVA ( P 0.05 ) . Results . Significant time effects ( changes from baseline at the time of measurement ) were observed for heart rate and total peripheral resistance , while significant group ( group-specific differences in the course of values at the different times of measurements ) and time effects were noted for mean pulmonary artery pressure , pulmonary capillary wedge pressure , stroke volume index , and PaO2. No major effects were observed following morphine , fentanyl , alfentanil , tramadol , and nalbuphine . Buprenorphine caused distinct respiratory depression accompanied by an increase in pulmonary vascular tone . Pentazocine and pethidine caused a significant increase in MPAP and peripheral vascular resistance while pethidine also produced marked respiratory depression . Conclusions . For interpretation of the results , factors such as respiratory depression , histamine release , secretion of endogenous catecholamines , and hypoxia-induced pulmonary vasoconstriction have to be discussed . Tramadol , an opioid with moderate potency , seems to offer some advantages due to its minor cardiovascular and respiratory side effects .
[ "Efficient", "analgesia", "may", "be", "the", "major", "objective", "in", "the", "cardiovascular", "risk", "patient", "following", "myocardial", "infarction", ",", "acute", "occlusion", "of", "peripheral", "vessels", ",", "or", "dissection", "/", "perforation", "of", "major", "abdominal", "vessels", ".", "It", "was", "the", "purpose", "of", "the", "study", "to", "investigate", "the", "haemodynamic", "and", "respiratory", "side", "effects", "of", "eight", "different", "opioids", "in", "57", "circulatory", "risk", "patients", "prior", "to", "major", "vascular", "surgery", ".", "Methods", ".", "Patients", "were", "randomly", "allocated", "to", "eight", "groups", ",", "each", "receiving", "a", "different", "opioid", "within", "a", "clinical", ",", "equipotent", "dose", "range", "(", "buprenorphine", ",", "fentanyl", ",", "morphine", ",", "nalbuphine", ",", "pentazocine", ",", "pethidine", ",", "tramadol", ",", "alfentanil", ")", ".", "A", "complete", "haemodynamic", "and", "blood", "gas", "status", "was", "obtained", "prior", "to", "as", "well", "as", "5", ",", "10", ",", "15", ",", "and", "20", "min", "following", "opioid", "administration", ".", "Monitoring", "included", "a", "complete", "invasive", "haemodynamic", "and", "blood", "gas", "status", ".", "Statistical", "evaluation", "was", "performed", "by", "1-", "and", "2-factorial", "ANOVA", "(", "P", "0.05", ")", ".", "Results", ".", "Significant", "time", "effects", "(", "changes", "from", "baseline", "at", "the", "time", "of", "measurement", ")", "were", "observed", "for", "heart", "rate", "and", "total", "peripheral", "resistance", ",", "while", "significant", "group", "(", "group", "-", "specific", "differences", "in", "the", "course", "of", "values", "at", "the", "different", "times", "of", "measurements", ")", "and", "time", "effects", "were", "noted", "for", "mean", "pulmonary", "artery", "pressure", ",", "pulmonary", "capillary", "wedge", "pressure", ",", "stroke", "volume", "index", ",", "and", "PaO2", ".", "No", "major", "effects", "were", "observed", "following", "morphine", ",", "fentanyl", ",", "alfentanil", ",", "tramadol", ",", "and", "nalbuphine", ".", "Buprenorphine", "caused", "distinct", "respiratory", "depression", "accompanied", "by", "an", "increase", "in", "pulmonary", "vascular", "tone", ".", "Pentazocine", "and", "pethidine", "caused", "a", "significant", "increase", "in", "MPAP", "and", "peripheral", "vascular", "resistance", "while", "pethidine", "also", "produced", "marked", "respiratory", "depression", ".", "Conclusions", ".", "For", "interpretation", "of", "the", "results", ",", "factors", "such", "as", "respiratory", "depression", ",", "histamine", "release", ",", "secretion", "of", "endogenous", "catecholamines", ",", "and", "hypoxia", "-", "induced", "pulmonary", "vasoconstriction", "have", "to", "be", "discussed", ".", "Tramadol", ",", "an", "opioid", "with", "moderate", "potency", ",", "seems", "to", "offer", "some", "advantages", "due", "to", "its", "minor", "cardiovascular", "and", "respiratory", "side", "effects", "." ]
[ "umlsterm" ]
analgesia, objective, risk, patient, myocardial infarction, vessels, vessels, haemodynamic, side effects, opioids, risk, patients, vascular surgery, Methods, Patients, opioid, buprenorphine, fentanyl, morphine, nalbuphine, pentazocine, pethidine, tramadol, alfentanil, haemodynamic, blood gas, opioid, administration, Monitoring, haemodynamic, blood gas, evaluation, ANOVA, time, baseline, time, measurement, heart rate, peripheral resistance, values, times, measurements, time, pulmonary artery, pressure, capillary, wedge pressure, stroke volume, index, morphine, fentanyl, alfentanil, tramadol, nalbuphine, Buprenorphine, depression, Pentazocine, pethidine, vascular resistance, pethidine, depression, depression, histamine release, secretion, catecholamines, vasoconstriction, Tramadol, opioid, minor, side effects
DerAnaesthesist.40430743.eng.abstr_task2
Sentence: Efficient analgesia may be the major objective in the cardiovascular risk patient following myocardial infarction , acute occlusion of peripheral vessels , or dissection/perforation of major abdominal vessels . It was the purpose of the study to investigate the haemodynamic and respiratory side effects of eight different opioids in 57 circulatory risk patients prior to major vascular surgery . Methods . Patients were randomly allocated to eight groups , each receiving a different opioid within a clinical , equipotent dose range ( buprenorphine , fentanyl , morphine , nalbuphine , pentazocine , pethidine , tramadol , alfentanil ) . A complete haemodynamic and blood gas status was obtained prior to as well as 5 , 10 , 15 , and 20 min following opioid administration . Monitoring included a complete invasive haemodynamic and blood gas status . Statistical evaluation was performed by 1- and 2-factorial ANOVA ( P 0.05 ) . Results . Significant time effects ( changes from baseline at the time of measurement ) were observed for heart rate and total peripheral resistance , while significant group ( group-specific differences in the course of values at the different times of measurements ) and time effects were noted for mean pulmonary artery pressure , pulmonary capillary wedge pressure , stroke volume index , and PaO2. No major effects were observed following morphine , fentanyl , alfentanil , tramadol , and nalbuphine . Buprenorphine caused distinct respiratory depression accompanied by an increase in pulmonary vascular tone . Pentazocine and pethidine caused a significant increase in MPAP and peripheral vascular resistance while pethidine also produced marked respiratory depression . Conclusions . For interpretation of the results , factors such as respiratory depression , histamine release , secretion of endogenous catecholamines , and hypoxia-induced pulmonary vasoconstriction have to be discussed . Tramadol , an opioid with moderate potency , seems to offer some advantages due to its minor cardiovascular and respiratory side effects . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Efficient analgesia may be the major objective in the cardiovascular risk patient following myocardial infarction , acute occlusion of peripheral vessels , or dissection/perforation of major abdominal vessels . It was the purpose of the study to investigate the haemodynamic and respiratory side effects of eight different opioids in 57 circulatory risk patients prior to major vascular surgery . Methods . Patients were randomly allocated to eight groups , each receiving a different opioid within a clinical , equipotent dose range ( buprenorphine , fentanyl , morphine , nalbuphine , pentazocine , pethidine , tramadol , alfentanil ) . A complete haemodynamic and blood gas status was obtained prior to as well as 5 , 10 , 15 , and 20 min following opioid administration . Monitoring included a complete invasive haemodynamic and blood gas status . Statistical evaluation was performed by 1- and 2-factorial ANOVA ( P 0.05 ) . Results . Significant time effects ( changes from baseline at the time of measurement ) were observed for heart rate and total peripheral resistance , while significant group ( group-specific differences in the course of values at the different times of measurements ) and time effects were noted for mean pulmonary artery pressure , pulmonary capillary wedge pressure , stroke volume index , and PaO2. No major effects were observed following morphine , fentanyl , alfentanil , tramadol , and nalbuphine . Buprenorphine caused distinct respiratory depression accompanied by an increase in pulmonary vascular tone . Pentazocine and pethidine caused a significant increase in MPAP and peripheral vascular resistance while pethidine also produced marked respiratory depression . Conclusions . For interpretation of the results , factors such as respiratory depression , histamine release , secretion of endogenous catecholamines , and hypoxia-induced pulmonary vasoconstriction have to be discussed . Tramadol , an opioid with moderate potency , seems to offer some advantages due to its minor cardiovascular and respiratory side effects .
[ "Efficient", "analgesia", "may", "be", "the", "major", "objective", "in", "the", "cardiovascular", "risk", "patient", "following", "myocardial", "infarction", ",", "acute", "occlusion", "of", "peripheral", "vessels", ",", "or", "dissection", "/", "perforation", "of", "major", "abdominal", "vessels", ".", "It", "was", "the", "purpose", "of", "the", "study", "to", "investigate", "the", "haemodynamic", "and", "respiratory", "side", "effects", "of", "eight", "different", "opioids", "in", "57", "circulatory", "risk", "patients", "prior", "to", "major", "vascular", "surgery", ".", "Methods", ".", "Patients", "were", "randomly", "allocated", "to", "eight", "groups", ",", "each", "receiving", "a", "different", "opioid", "within", "a", "clinical", ",", "equipotent", "dose", "range", "(", "buprenorphine", ",", "fentanyl", ",", "morphine", ",", "nalbuphine", ",", "pentazocine", ",", "pethidine", ",", "tramadol", ",", "alfentanil", ")", ".", "A", "complete", "haemodynamic", "and", "blood", "gas", "status", "was", "obtained", "prior", "to", "as", "well", "as", "5", ",", "10", ",", "15", ",", "and", "20", "min", "following", "opioid", "administration", ".", "Monitoring", "included", "a", "complete", "invasive", "haemodynamic", "and", "blood", "gas", "status", ".", "Statistical", "evaluation", "was", "performed", "by", "1-", "and", "2-factorial", "ANOVA", "(", "P", "0.05", ")", ".", "Results", ".", "Significant", "time", "effects", "(", "changes", "from", "baseline", "at", "the", "time", "of", "measurement", ")", "were", "observed", "for", "heart", "rate", "and", "total", "peripheral", "resistance", ",", "while", "significant", "group", "(", "group", "-", "specific", "differences", "in", "the", "course", "of", "values", "at", "the", "different", "times", "of", "measurements", ")", "and", "time", "effects", "were", "noted", "for", "mean", "pulmonary", "artery", "pressure", ",", "pulmonary", "capillary", "wedge", "pressure", ",", "stroke", "volume", "index", ",", "and", "PaO2", ".", "No", "major", "effects", "were", "observed", "following", "morphine", ",", "fentanyl", ",", "alfentanil", ",", "tramadol", ",", "and", "nalbuphine", ".", "Buprenorphine", "caused", "distinct", "respiratory", "depression", "accompanied", "by", "an", "increase", "in", "pulmonary", "vascular", "tone", ".", "Pentazocine", "and", "pethidine", "caused", "a", "significant", "increase", "in", "MPAP", "and", "peripheral", "vascular", "resistance", "while", "pethidine", "also", "produced", "marked", "respiratory", "depression", ".", "Conclusions", ".", "For", "interpretation", "of", "the", "results", ",", "factors", "such", "as", "respiratory", "depression", ",", "histamine", "release", ",", "secretion", "of", "endogenous", "catecholamines", ",", "and", "hypoxia", "-", "induced", "pulmonary", "vasoconstriction", "have", "to", "be", "discussed", ".", "Tramadol", ",", "an", "opioid", "with", "moderate", "potency", ",", "seems", "to", "offer", "some", "advantages", "due", "to", "its", "minor", "cardiovascular", "and", "respiratory", "side", "effects", "." ]
[ "umlsterm" ]
metástasis is a MORFOLOGIA_NEOPLASIA, realce meníngeo is a MORFOLOGIA_NEOPLASIA, carcinomatosis is a MORFOLOGIA_NEOPLASIA, carcinomatosis is a MORFOLOGIA_NEOPLASIA, afectación ósea is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA
563_task0
Sentence: Anamnesis En la anamnesis realizada el día octavo, dificultada por alteración del lenguaje, la paciente manifiesta dolor en ala iliaca derecha y miembro ipsilateral, y disminución de la movilidad en miembros inferiores, con tendencia a la somnolencia. El día anterior precisó sondaje vesical por retención aguda de orina. En la anamnesis conjunta con los familiares se evidencia apatía y la presencia de lenguaje empobrecido. Niega de forma rotunda la ingesta, en los días o semanas previos, de productos lácteos poco procesados y de otros alimentos sospechosos. No hay familiares que presenten un cuadro clínico similar. Exploración física Temperatura de 36,2ºC, tensión arterial sistólica de 130 mm de Hg y sistólica de 80 mm de Hg, frecuencia cardiaca de 75 lpm, frecuencia respiratoria de 14 respiraciones por minuto, saturación aire ambiente del 97 %. En la exploración neurológica el día octavo, destaca la presencia de fluctuación en la atención e incapacidad para procesar órdenes sucesivas. Asocia además disfasia mixta con fluencia alterada, parafasias abundantes y dificultades de nominación. En la exploración motora, se aprecia paresia de miembro inferior izquierdo con balance muscular dos sobre cinco y aumento del área reflexógena ipsilateral. En la exploración realizada cuatro días después, se observó bajo nivel de conciencia con un Glasgow de 13 sobre quince, rigidez de nuca y presencia de signos meníngeos. Pruebas complementarias No se evidenciaron alteraciones significativas en los análisis al ingreso ni durante los primeros días en planta. Como parte de la valoración ambulatoria de la paciente se realizó al tercer día una resonancia magnética de columna completa que evidenció metástasis en varios cuerpos descartando afectación medular. Los hemocultivos diferenciales sacados durante el pico febril fueron negativos. El día octavo, coincidiendo con el inicio del deterioro clínico, se interconsultó al servicio de Neurología y se realizó TC craneal, mostrándose dudoso realce meníngeo en el tentorio y cisternas basales. Ante la sospecha de carcinomatosis meníngea vs. encefalopatía metabólica, y para descartar estatus convulsivo, se realizó un electroencefalograma urgente en el que se observaron ondas lentas evidentes de encefalopatía moderada. Con los hallazgos anteriores y ante persistencia de deterioro neurológico se realizó una RM cerebral urgente el día décimo que descartó carcinomatosis meníngea, la presencia de otras lesiones y de signos indirectos de hipertensión craneal, por lo que se realizó una punción lumbar por sospecha de meningitis. En el estudio de laboratorio del líquido cefalorraquídeo se evidenció líquido transparente, con glucosa 23 mg/dl, proteínas totales 198,2 mg/dl ADA < 8 U/l. Visualización inicial en Gram de bacilos Gram positivos con firmándose varios días después la presencia de Listeria monocytogenes sensible a ampicilina. Diagnóstico » Meningitis aguda adquirida en la comunidad por Listeria monocytogenes sensible a ampicilina. » Paresia de miembro inferior derecho, disfasia mixta y apraxia secundaria a meningitis aguda. » Mal control del dolor en relación a afectación ósea metastásica. » Adenocarcinoma de sigma estadio IV. Tratamiento Dada la presencia de síndrome febril autolimitado y asintomático el día cuarto de ingreso, y teniendo en cuenta la observación en la planta de la paciente, se decidió no comenzar tratamiento antibiótico en dicho momento. No obstante, ante la presencia de deterioro clínico durante el día octavo y la sospecha de meningitis subaguda, se inició antibioterapia empírica con ceftriaxona 2 g cada 12 horas, vancomicina 1 g cada 8 horas y ampicilina 4 g cada 4 horas asociada a dexametasona 4 mg cada 12 horas. Posteriormente se realizó tratamiento dirigido con el resultado de la tinción de Gram usando ampicilina asociada a gentamicina intravenosa durante 7 días, con reducción progresiva de corticoterapia hasta suspenderla. Más adelante, se sustituyó la gentamicina por trimetoprima/sulfametoxazol durante diez días, manteniendo la ampicilina, antes de cambiar tratamiento antibiótico a vía oral con trimetoprima/sulfametoxazol en monoterapia. Finalmente, y teniendo en cuenta el perfil de toxicidad, la paciente se fue de alta con ampicilina en monoterapia hasta cumplir al menos 8 semanas de tratamiento. También se realizó durante su ingreso en planta ajuste progresivo de la analgesia de tercer escalón asociada a coadyuvantes. Evolución Durante el ingreso, la paciente fue valorada de forma conjunta por el equipo de Oncología Médica, Oncología Radioterápica, Psicooncología, Neurología, la Unidad de Enfermedades Infecciosas, Nutrición, Paliativos, Digestivo, Cirugía General y Rehabilitación para abordar de forma multidisciplinar la meningitis, el dolor secundario a metástasis óseas, la desnutrición asociada al cáncer y la disminución de ingesta por bajo nivel de conciencia, la pérdida de la capacidad funcional y un estado de ánimo bajo reactivo así como otras complicaciones acaecidas durante el ingreso. En cuanto a la meningitis, se evidenció mejoría del nivel de conciencia ad integrum tras cuatro días de tratamiento antibiótico dirigido, con desaparición completa de los signos meníngeos y rigidez de nuca al sexto día de antibioterapia. Se realizó nueva resonancia magnética cerebral al trigésimo día de su admisión, que descartó la presencia de abscesos cerebrales que indicara la necesidad de prolongar el tratamiento. Con respecto al tratamiento del dolor, se realizó radioterapia antiálgica de la lesión localizada en ala iliaca derecha pudiendo disminuir la dosis de mórficos para control del dolor y con ello mejorar el nivel de conciencia y la tendencia a la somnolencia, síntomas que condicionaban la calidad de vida de la paciente. Como complicaciones durante el ingreso, la paciente presentó una hemorragia digestiva baja autolimitada, probablemente secundaria a isquemia intestinal de origen hemodinámico que se manejó de forma conservadora tras ser evaluada por el servicio de digestivo y de cirugía general. Desarrolló también toxicidad hematológica secundaria al tratamiento prolongado con trimetoprima/sulfametoxazol con presencia de bicitopenia (anemia G2 y leucopenia G1) que obligaron al cambio de tratamiento por ampicilina vía oral hasta cumplir al menos 8 semanas de tratamiento. La paciente fue dada de alta tras 40 días de ingreso, manteniendo tratamiento con ampicilina oral. Se facilitó una cita en Oncología para valorar retirada de antibioterapia y continuar tratamiento oncológico. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis En la anamnesis realizada el día octavo, dificultada por alteración del lenguaje, la paciente manifiesta dolor en ala iliaca derecha y miembro ipsilateral, y disminución de la movilidad en miembros inferiores, con tendencia a la somnolencia. El día anterior precisó sondaje vesical por retención aguda de orina. En la anamnesis conjunta con los familiares se evidencia apatía y la presencia de lenguaje empobrecido. Niega de forma rotunda la ingesta, en los días o semanas previos, de productos lácteos poco procesados y de otros alimentos sospechosos. No hay familiares que presenten un cuadro clínico similar. Exploración física Temperatura de 36,2ºC, tensión arterial sistólica de 130 mm de Hg y sistólica de 80 mm de Hg, frecuencia cardiaca de 75 lpm, frecuencia respiratoria de 14 respiraciones por minuto, saturación aire ambiente del 97 %. En la exploración neurológica el día octavo, destaca la presencia de fluctuación en la atención e incapacidad para procesar órdenes sucesivas. Asocia además disfasia mixta con fluencia alterada, parafasias abundantes y dificultades de nominación. En la exploración motora, se aprecia paresia de miembro inferior izquierdo con balance muscular dos sobre cinco y aumento del área reflexógena ipsilateral. En la exploración realizada cuatro días después, se observó bajo nivel de conciencia con un Glasgow de 13 sobre quince, rigidez de nuca y presencia de signos meníngeos. Pruebas complementarias No se evidenciaron alteraciones significativas en los análisis al ingreso ni durante los primeros días en planta. Como parte de la valoración ambulatoria de la paciente se realizó al tercer día una resonancia magnética de columna completa que evidenció metástasis en varios cuerpos descartando afectación medular. Los hemocultivos diferenciales sacados durante el pico febril fueron negativos. El día octavo, coincidiendo con el inicio del deterioro clínico, se interconsultó al servicio de Neurología y se realizó TC craneal, mostrándose dudoso realce meníngeo en el tentorio y cisternas basales. Ante la sospecha de carcinomatosis meníngea vs. encefalopatía metabólica, y para descartar estatus convulsivo, se realizó un electroencefalograma urgente en el que se observaron ondas lentas evidentes de encefalopatía moderada. Con los hallazgos anteriores y ante persistencia de deterioro neurológico se realizó una RM cerebral urgente el día décimo que descartó carcinomatosis meníngea, la presencia de otras lesiones y de signos indirectos de hipertensión craneal, por lo que se realizó una punción lumbar por sospecha de meningitis. En el estudio de laboratorio del líquido cefalorraquídeo se evidenció líquido transparente, con glucosa 23 mg/dl, proteínas totales 198,2 mg/dl ADA < 8 U/l. Visualización inicial en Gram de bacilos Gram positivos con firmándose varios días después la presencia de Listeria monocytogenes sensible a ampicilina. Diagnóstico » Meningitis aguda adquirida en la comunidad por Listeria monocytogenes sensible a ampicilina. » Paresia de miembro inferior derecho, disfasia mixta y apraxia secundaria a meningitis aguda. » Mal control del dolor en relación a afectación ósea metastásica. » Adenocarcinoma de sigma estadio IV. Tratamiento Dada la presencia de síndrome febril autolimitado y asintomático el día cuarto de ingreso, y teniendo en cuenta la observación en la planta de la paciente, se decidió no comenzar tratamiento antibiótico en dicho momento. No obstante, ante la presencia de deterioro clínico durante el día octavo y la sospecha de meningitis subaguda, se inició antibioterapia empírica con ceftriaxona 2 g cada 12 horas, vancomicina 1 g cada 8 horas y ampicilina 4 g cada 4 horas asociada a dexametasona 4 mg cada 12 horas. Posteriormente se realizó tratamiento dirigido con el resultado de la tinción de Gram usando ampicilina asociada a gentamicina intravenosa durante 7 días, con reducción progresiva de corticoterapia hasta suspenderla. Más adelante, se sustituyó la gentamicina por trimetoprima/sulfametoxazol durante diez días, manteniendo la ampicilina, antes de cambiar tratamiento antibiótico a vía oral con trimetoprima/sulfametoxazol en monoterapia. Finalmente, y teniendo en cuenta el perfil de toxicidad, la paciente se fue de alta con ampicilina en monoterapia hasta cumplir al menos 8 semanas de tratamiento. También se realizó durante su ingreso en planta ajuste progresivo de la analgesia de tercer escalón asociada a coadyuvantes. Evolución Durante el ingreso, la paciente fue valorada de forma conjunta por el equipo de Oncología Médica, Oncología Radioterápica, Psicooncología, Neurología, la Unidad de Enfermedades Infecciosas, Nutrición, Paliativos, Digestivo, Cirugía General y Rehabilitación para abordar de forma multidisciplinar la meningitis, el dolor secundario a metástasis óseas, la desnutrición asociada al cáncer y la disminución de ingesta por bajo nivel de conciencia, la pérdida de la capacidad funcional y un estado de ánimo bajo reactivo así como otras complicaciones acaecidas durante el ingreso. En cuanto a la meningitis, se evidenció mejoría del nivel de conciencia ad integrum tras cuatro días de tratamiento antibiótico dirigido, con desaparición completa de los signos meníngeos y rigidez de nuca al sexto día de antibioterapia. Se realizó nueva resonancia magnética cerebral al trigésimo día de su admisión, que descartó la presencia de abscesos cerebrales que indicara la necesidad de prolongar el tratamiento. Con respecto al tratamiento del dolor, se realizó radioterapia antiálgica de la lesión localizada en ala iliaca derecha pudiendo disminuir la dosis de mórficos para control del dolor y con ello mejorar el nivel de conciencia y la tendencia a la somnolencia, síntomas que condicionaban la calidad de vida de la paciente. Como complicaciones durante el ingreso, la paciente presentó una hemorragia digestiva baja autolimitada, probablemente secundaria a isquemia intestinal de origen hemodinámico que se manejó de forma conservadora tras ser evaluada por el servicio de digestivo y de cirugía general. Desarrolló también toxicidad hematológica secundaria al tratamiento prolongado con trimetoprima/sulfametoxazol con presencia de bicitopenia (anemia G2 y leucopenia G1) que obligaron al cambio de tratamiento por ampicilina vía oral hasta cumplir al menos 8 semanas de tratamiento. La paciente fue dada de alta tras 40 días de ingreso, manteniendo tratamiento con ampicilina oral. Se facilitó una cita en Oncología para valorar retirada de antibioterapia y continuar tratamiento oncológico.
[ "Anamnesis", "\n", "En", "la", "anamnesis", "realizada", "el", "día", "octavo", ",", "dificultada", "por", "alteración", "del", "lenguaje", ",", "la", "paciente", "manifiesta", "dolor", "en", "ala", "iliaca", "derecha", "y", "miembro", "ipsilateral", ",", "y", "disminución", "de", "la", "movilidad", "en", "miembros", "inferiores", ",", "con", "tendencia", "a", "la", "somnolencia", ".", "El", "día", "anterior", "precisó", "sondaje", "vesical", "por", "retención", "aguda", "de", "orina", ".", "\n", "En", "la", "anamnesis", "conjunta", "con", "los", "familiares", "se", "evidencia", "apatía", "y", "la", "presencia", "de", "lenguaje", "empobrecido", ".", "Niega", "de", "forma", "rotunda", "la", "ingesta", ",", "en", "los", "días", "o", "semanas", "previos", ",", "de", "productos", "lácteos", "poco", "procesados", "y", "de", "otros", "alimentos", "sospechosos", ".", "No", "hay", "familiares", "que", "presenten", "un", "cuadro", "clínico", "similar", ".", "\n\n", "Exploración", "física", "\n", "Temperatura", "de", "36,2ºC", ",", "tensión", "arterial", "sistólica", "de", "130", "mm", "de", "Hg", "y", "sistólica", "de", "80", "mm", "de", "Hg", ",", "frecuencia", "cardiaca", "de", "75", "lpm", ",", "frecuencia", "respiratoria", "de", "14", "respiraciones", "por", "minuto", ",", "saturación", "aire", "ambiente", "del", "97", "%", ".", "En", "la", "exploración", "neurológica", "el", "día", "octavo", ",", "destaca", "la", "presencia", "de", "fluctuación", "en", "la", "atención", "e", "incapacidad", "para", "procesar", "órdenes", "sucesivas", ".", "Asocia", "además", "disfasia", "mixta", "con", "fluencia", "alterada", ",", "parafasias", "abundantes", "y", "dificultades", "de", "nominación", ".", "En", "la", "exploración", "motora", ",", "se", "aprecia", "paresia", "de", "miembro", "inferior", "izquierdo", "con", "balance", "muscular", "dos", "sobre", "cinco", "y", "aumento", "del", "área", "reflexógena", "ipsilateral", ".", "En", "la", "exploración", "realizada", "cuatro", "días", "después", ",", "se", "observó", "bajo", "nivel", "de", "conciencia", "con", "un", "Glasgow", "de", "13", "sobre", "quince", ",", "rigidez", "de", "nuca", "y", "presencia", "de", "signos", "meníngeos", ".", "\n\n", "Pruebas", "complementarias", "\n", "No", "se", "evidenciaron", "alteraciones", "significativas", "en", "los", "análisis", "al", "ingreso", "ni", "durante", "los", "primeros", "días", "en", "planta", ".", "Como", "parte", "de", "la", "valoración", "ambulatoria", "de", "la", "paciente", "se", "realizó", "al", "tercer", "día", "una", "resonancia", "magnética", "de", "columna", "completa", "que", "evidenció", "metástasis", "en", "varios", "cuerpos", "descartando", "afectación", "medular", ".", "Los", "hemocultivos", "diferenciales", "sacados", "durante", "el", "pico", "febril", "fueron", "negativos", ".", "\n", "El", "día", "octavo", ",", "coincidiendo", "con", "el", "inicio", "del", "deterioro", "clínico", ",", "se", "interconsultó", "al", "servicio", "de", "Neurología", "y", "se", "realizó", "TC", "craneal", ",", "mostrándose", "dudoso", "realce", "meníngeo", "en", "el", "tentorio", "y", "cisternas", "basales", ".", "Ante", "la", "sospecha", "de", "carcinomatosis", "meníngea", "vs", ".", "encefalopatía", "metabólica", ",", "y", "para", "descartar", "estatus", "convulsivo", ",", "se", "realizó", "un", "electroencefalograma", "urgente", "en", "el", "que", "se", "observaron", "ondas", "lentas", "evidentes", "de", "encefalopatía", "moderada", ".", "\n", "Con", "los", "hallazgos", "anteriores", "y", "ante", "persistencia", "de", "deterioro", "neurológico", "se", "realizó", "una", "RM", "cerebral", "urgente", "el", "día", "décimo", "que", "descartó", "carcinomatosis", "meníngea", ",", "la", "presencia", "de", "otras", "lesiones", "y", "de", "signos", "indirectos", "de", "hipertensión", "craneal", ",", "por", "lo", "que", "se", "realizó", "una", "punción", "lumbar", "por", "sospecha", "de", "meningitis", ".", "En", "el", "estudio", "de", "laboratorio", "del", "líquido", "cefalorraquídeo", "se", "evidenció", "líquido", "transparente", ",", "con", "glucosa", "23", "mg", "/", "dl", ",", "proteínas", "totales", "198,2", "mg", "/", "dl", "ADA", "<", "8", "U", "/", "l.", "Visualización", "inicial", "en", "Gram", "de", "bacilos", "Gram", "positivos", "con", "firmándose", "varios", "días", "después", "la", "presencia", "de", "Listeria", "monocytogenes", "sensible", "a", "ampicilina", ".", "\n\n", "Diagnóstico", "\n", "»", "Meningitis", "aguda", "adquirida", "en", "la", "comunidad", "por", "Listeria", "monocytogenes", "sensible", "a", "ampicilina", ".", "\n", "»", "Paresia", "de", "miembro", "inferior", "derecho", ",", "disfasia", "mixta", "y", "apraxia", "secundaria", "a", "meningitis", "aguda", ".", "\n", "»", "Mal", "control", "del", "dolor", "en", "relación", "a", "afectación", "ósea", "metastásica", ".", "\n", "»", "Adenocarcinoma", "de", "sigma", "estadio", "IV", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "presencia", "de", "síndrome", "febril", "autolimitado", "y", "asintomático", "el", "día", "cuarto", "de", "ingreso", ",", "y", "teniendo", "en", "cuenta", "la", "observación", "en", "la", "planta", "de", "la", "paciente", ",", "se", "decidió", "no", "comenzar", "tratamiento", "antibiótico", "en", "dicho", "momento", ".", "No", "obstante", ",", "ante", "la", "presencia", "de", "deterioro", "clínico", "durante", "el", "día", "octavo", "y", "la", "sospecha", "de", "meningitis", "subaguda", ",", "se", "inició", "antibioterapia", "empírica", "con", "ceftriaxona", "2", "g", "cada", "12", "horas", ",", "vancomicina", "1", "g", "cada", "8", "horas", "y", "ampicilina", "4", "g", "cada", "4", "horas", "asociada", "a", "dexametasona", "4", "mg", "cada", "12", "horas", ".", "Posteriormente", "se", "realizó", "tratamiento", "dirigido", "con", "el", "resultado", "de", "la", "tinción", "de", "Gram", "usando", "ampicilina", "asociada", "a", "gentamicina", "intravenosa", "durante", "7", "días", ",", "con", "reducción", "progresiva", "de", "corticoterapia", "hasta", "suspenderla", ".", "Más", "adelante", ",", "se", "sustituyó", "la", "gentamicina", "por", "trimetoprima", "/", "sulfametoxazol", "durante", "diez", "días", ",", "manteniendo", "la", "ampicilina", ",", "antes", "de", "cambiar", "tratamiento", "antibiótico", "a", "vía", "oral", "con", "trimetoprima", "/", "sulfametoxazol", "en", "monoterapia", ".", "Finalmente", ",", "y", "teniendo", "en", "cuenta", "el", "perfil", "de", "toxicidad", ",", "la", "paciente", "se", "fue", "de", "alta", "con", "ampicilina", "en", "monoterapia", "hasta", "cumplir", "al", "menos", "8", "semanas", "de", "tratamiento", ".", "También", "se", "realizó", "durante", "su", "ingreso", "en", "planta", "ajuste", "progresivo", "de", "la", "analgesia", "de", "tercer", "escalón", "asociada", "a", "coadyuvantes", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "la", "paciente", "fue", "valorada", "de", "forma", "conjunta", "por", "el", "equipo", "de", "Oncología", "Médica", ",", "Oncología", "Radioterápica", ",", "Psicooncología", ",", "Neurología", ",", "la", "Unidad", "de", "Enfermedades", "Infecciosas", ",", "Nutrición", ",", "Paliativos", ",", "Digestivo", ",", "Cirugía", "General", "y", "Rehabilitación", "para", "abordar", "de", "forma", "multidisciplinar", "la", "meningitis", ",", "el", "dolor", "secundario", "a", "metástasis", "óseas", ",", "la", "desnutrición", "asociada", "al", "cáncer", "y", "la", "disminución", "de", "ingesta", "por", "bajo", "nivel", "de", "conciencia", ",", "la", "pérdida", "de", "la", "capacidad", "funcional", "y", "un", "estado", "de", "ánimo", "bajo", "reactivo", "así", "como", "otras", "complicaciones", "acaecidas", "durante", "el", "ingreso", ".", "\n", "En", "cuanto", "a", "la", "meningitis", ",", "se", "evidenció", "mejoría", "del", "nivel", "de", "conciencia", "ad", "integrum", "tras", "cuatro", "días", "de", "tratamiento", "antibiótico", "dirigido", ",", "con", "desaparición", "completa", "de", "los", "signos", "meníngeos", "y", "rigidez", "de", "nuca", "al", "sexto", "día", "de", "antibioterapia", ".", "Se", "realizó", "nueva", "resonancia", "magnética", "cerebral", "al", "trigésimo", "día", "de", "su", "admisión", ",", "que", "descartó", "la", "presencia", "de", "abscesos", "cerebrales", "que", "indicara", "la", "necesidad", "de", "prolongar", "el", "tratamiento", ".", "\n", "Con", "respecto", "al", "tratamiento", "del", "dolor", ",", "se", "realizó", "radioterapia", "antiálgica", "de", "la", "lesión", "localizada", "en", "ala", "iliaca", "derecha", "pudiendo", "disminuir", "la", "dosis", "de", "mórficos", "para", "control", "del", "dolor", "y", "con", "ello", "mejorar", "el", "nivel", "de", "conciencia", "y", "la", "tendencia", "a", "la", "somnolencia", ",", "síntomas", "que", "condicionaban", "la", "calidad", "de", "vida", "de", "la", "paciente", ".", "\n", "Como", "complicaciones", "durante", "el", "ingreso", ",", "la", "paciente", "presentó", "una", "hemorragia", "digestiva", "baja", "autolimitada", ",", "probablemente", "secundaria", "a", "isquemia", "intestinal", "de", "origen", "hemodinámico", "que", "se", "manejó", "de", "forma", "conservadora", "tras", "ser", "evaluada", "por", "el", "servicio", "de", "digestivo", "y", "de", "cirugía", "general", ".", "Desarrolló", "también", "toxicidad", "hematológica", "secundaria", "al", "tratamiento", "prolongado", "con", "trimetoprima", "/", "sulfametoxazol", "con", "presencia", "de", "bicitopenia", "(", "anemia", "G2", "y", "leucopenia", "G1", ")", "que", "obligaron", "al", "cambio", "de", "tratamiento", "por", "ampicilina", "vía", "oral", "hasta", "cumplir", "al", "menos", "8", "semanas", "de", "tratamiento", ".", "\n", "La", "paciente", "fue", "dada", "de", "alta", "tras", "40", "días", "de", "ingreso", ",", "manteniendo", "tratamiento", "con", "ampicilina", "oral", ".", "Se", "facilitó", "una", "cita", "en", "Oncología", "para", "valorar", "retirada", "de", "antibioterapia", "y", "continuar", "tratamiento", "oncológico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
metástasis is a MORFOLOGIA_NEOPLASIA, realce meníngeo is a MORFOLOGIA_NEOPLASIA, carcinomatosis is a MORFOLOGIA_NEOPLASIA, carcinomatosis is a MORFOLOGIA_NEOPLASIA, afectación ósea is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, cáncer is a MORFOLOGIA_NEOPLASIA
563_task1
Sentence: Anamnesis En la anamnesis realizada el día octavo, dificultada por alteración del lenguaje, la paciente manifiesta dolor en ala iliaca derecha y miembro ipsilateral, y disminución de la movilidad en miembros inferiores, con tendencia a la somnolencia. El día anterior precisó sondaje vesical por retención aguda de orina. En la anamnesis conjunta con los familiares se evidencia apatía y la presencia de lenguaje empobrecido. Niega de forma rotunda la ingesta, en los días o semanas previos, de productos lácteos poco procesados y de otros alimentos sospechosos. No hay familiares que presenten un cuadro clínico similar. Exploración física Temperatura de 36,2ºC, tensión arterial sistólica de 130 mm de Hg y sistólica de 80 mm de Hg, frecuencia cardiaca de 75 lpm, frecuencia respiratoria de 14 respiraciones por minuto, saturación aire ambiente del 97 %. En la exploración neurológica el día octavo, destaca la presencia de fluctuación en la atención e incapacidad para procesar órdenes sucesivas. Asocia además disfasia mixta con fluencia alterada, parafasias abundantes y dificultades de nominación. En la exploración motora, se aprecia paresia de miembro inferior izquierdo con balance muscular dos sobre cinco y aumento del área reflexógena ipsilateral. En la exploración realizada cuatro días después, se observó bajo nivel de conciencia con un Glasgow de 13 sobre quince, rigidez de nuca y presencia de signos meníngeos. Pruebas complementarias No se evidenciaron alteraciones significativas en los análisis al ingreso ni durante los primeros días en planta. Como parte de la valoración ambulatoria de la paciente se realizó al tercer día una resonancia magnética de columna completa que evidenció metástasis en varios cuerpos descartando afectación medular. Los hemocultivos diferenciales sacados durante el pico febril fueron negativos. El día octavo, coincidiendo con el inicio del deterioro clínico, se interconsultó al servicio de Neurología y se realizó TC craneal, mostrándose dudoso realce meníngeo en el tentorio y cisternas basales. Ante la sospecha de carcinomatosis meníngea vs. encefalopatía metabólica, y para descartar estatus convulsivo, se realizó un electroencefalograma urgente en el que se observaron ondas lentas evidentes de encefalopatía moderada. Con los hallazgos anteriores y ante persistencia de deterioro neurológico se realizó una RM cerebral urgente el día décimo que descartó carcinomatosis meníngea, la presencia de otras lesiones y de signos indirectos de hipertensión craneal, por lo que se realizó una punción lumbar por sospecha de meningitis. En el estudio de laboratorio del líquido cefalorraquídeo se evidenció líquido transparente, con glucosa 23 mg/dl, proteínas totales 198,2 mg/dl ADA < 8 U/l. Visualización inicial en Gram de bacilos Gram positivos con firmándose varios días después la presencia de Listeria monocytogenes sensible a ampicilina. Diagnóstico » Meningitis aguda adquirida en la comunidad por Listeria monocytogenes sensible a ampicilina. » Paresia de miembro inferior derecho, disfasia mixta y apraxia secundaria a meningitis aguda. » Mal control del dolor en relación a afectación ósea metastásica. » Adenocarcinoma de sigma estadio IV. Tratamiento Dada la presencia de síndrome febril autolimitado y asintomático el día cuarto de ingreso, y teniendo en cuenta la observación en la planta de la paciente, se decidió no comenzar tratamiento antibiótico en dicho momento. No obstante, ante la presencia de deterioro clínico durante el día octavo y la sospecha de meningitis subaguda, se inició antibioterapia empírica con ceftriaxona 2 g cada 12 horas, vancomicina 1 g cada 8 horas y ampicilina 4 g cada 4 horas asociada a dexametasona 4 mg cada 12 horas. Posteriormente se realizó tratamiento dirigido con el resultado de la tinción de Gram usando ampicilina asociada a gentamicina intravenosa durante 7 días, con reducción progresiva de corticoterapia hasta suspenderla. Más adelante, se sustituyó la gentamicina por trimetoprima/sulfametoxazol durante diez días, manteniendo la ampicilina, antes de cambiar tratamiento antibiótico a vía oral con trimetoprima/sulfametoxazol en monoterapia. Finalmente, y teniendo en cuenta el perfil de toxicidad, la paciente se fue de alta con ampicilina en monoterapia hasta cumplir al menos 8 semanas de tratamiento. También se realizó durante su ingreso en planta ajuste progresivo de la analgesia de tercer escalón asociada a coadyuvantes. Evolución Durante el ingreso, la paciente fue valorada de forma conjunta por el equipo de Oncología Médica, Oncología Radioterápica, Psicooncología, Neurología, la Unidad de Enfermedades Infecciosas, Nutrición, Paliativos, Digestivo, Cirugía General y Rehabilitación para abordar de forma multidisciplinar la meningitis, el dolor secundario a metástasis óseas, la desnutrición asociada al cáncer y la disminución de ingesta por bajo nivel de conciencia, la pérdida de la capacidad funcional y un estado de ánimo bajo reactivo así como otras complicaciones acaecidas durante el ingreso. En cuanto a la meningitis, se evidenció mejoría del nivel de conciencia ad integrum tras cuatro días de tratamiento antibiótico dirigido, con desaparición completa de los signos meníngeos y rigidez de nuca al sexto día de antibioterapia. Se realizó nueva resonancia magnética cerebral al trigésimo día de su admisión, que descartó la presencia de abscesos cerebrales que indicara la necesidad de prolongar el tratamiento. Con respecto al tratamiento del dolor, se realizó radioterapia antiálgica de la lesión localizada en ala iliaca derecha pudiendo disminuir la dosis de mórficos para control del dolor y con ello mejorar el nivel de conciencia y la tendencia a la somnolencia, síntomas que condicionaban la calidad de vida de la paciente. Como complicaciones durante el ingreso, la paciente presentó una hemorragia digestiva baja autolimitada, probablemente secundaria a isquemia intestinal de origen hemodinámico que se manejó de forma conservadora tras ser evaluada por el servicio de digestivo y de cirugía general. Desarrolló también toxicidad hematológica secundaria al tratamiento prolongado con trimetoprima/sulfametoxazol con presencia de bicitopenia (anemia G2 y leucopenia G1) que obligaron al cambio de tratamiento por ampicilina vía oral hasta cumplir al menos 8 semanas de tratamiento. La paciente fue dada de alta tras 40 días de ingreso, manteniendo tratamiento con ampicilina oral. Se facilitó una cita en Oncología para valorar retirada de antibioterapia y continuar tratamiento oncológico. Instructions: please typing these entity words according to sentence: metástasis, realce meníngeo, carcinomatosis, carcinomatosis, afectación ósea, metastásica, Adenocarcinoma, metástasis, cáncer Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis En la anamnesis realizada el día octavo, dificultada por alteración del lenguaje, la paciente manifiesta dolor en ala iliaca derecha y miembro ipsilateral, y disminución de la movilidad en miembros inferiores, con tendencia a la somnolencia. El día anterior precisó sondaje vesical por retención aguda de orina. En la anamnesis conjunta con los familiares se evidencia apatía y la presencia de lenguaje empobrecido. Niega de forma rotunda la ingesta, en los días o semanas previos, de productos lácteos poco procesados y de otros alimentos sospechosos. No hay familiares que presenten un cuadro clínico similar. Exploración física Temperatura de 36,2ºC, tensión arterial sistólica de 130 mm de Hg y sistólica de 80 mm de Hg, frecuencia cardiaca de 75 lpm, frecuencia respiratoria de 14 respiraciones por minuto, saturación aire ambiente del 97 %. En la exploración neurológica el día octavo, destaca la presencia de fluctuación en la atención e incapacidad para procesar órdenes sucesivas. Asocia además disfasia mixta con fluencia alterada, parafasias abundantes y dificultades de nominación. En la exploración motora, se aprecia paresia de miembro inferior izquierdo con balance muscular dos sobre cinco y aumento del área reflexógena ipsilateral. En la exploración realizada cuatro días después, se observó bajo nivel de conciencia con un Glasgow de 13 sobre quince, rigidez de nuca y presencia de signos meníngeos. Pruebas complementarias No se evidenciaron alteraciones significativas en los análisis al ingreso ni durante los primeros días en planta. Como parte de la valoración ambulatoria de la paciente se realizó al tercer día una resonancia magnética de columna completa que evidenció metástasis en varios cuerpos descartando afectación medular. Los hemocultivos diferenciales sacados durante el pico febril fueron negativos. El día octavo, coincidiendo con el inicio del deterioro clínico, se interconsultó al servicio de Neurología y se realizó TC craneal, mostrándose dudoso realce meníngeo en el tentorio y cisternas basales. Ante la sospecha de carcinomatosis meníngea vs. encefalopatía metabólica, y para descartar estatus convulsivo, se realizó un electroencefalograma urgente en el que se observaron ondas lentas evidentes de encefalopatía moderada. Con los hallazgos anteriores y ante persistencia de deterioro neurológico se realizó una RM cerebral urgente el día décimo que descartó carcinomatosis meníngea, la presencia de otras lesiones y de signos indirectos de hipertensión craneal, por lo que se realizó una punción lumbar por sospecha de meningitis. En el estudio de laboratorio del líquido cefalorraquídeo se evidenció líquido transparente, con glucosa 23 mg/dl, proteínas totales 198,2 mg/dl ADA < 8 U/l. Visualización inicial en Gram de bacilos Gram positivos con firmándose varios días después la presencia de Listeria monocytogenes sensible a ampicilina. Diagnóstico » Meningitis aguda adquirida en la comunidad por Listeria monocytogenes sensible a ampicilina. » Paresia de miembro inferior derecho, disfasia mixta y apraxia secundaria a meningitis aguda. » Mal control del dolor en relación a afectación ósea metastásica. » Adenocarcinoma de sigma estadio IV. Tratamiento Dada la presencia de síndrome febril autolimitado y asintomático el día cuarto de ingreso, y teniendo en cuenta la observación en la planta de la paciente, se decidió no comenzar tratamiento antibiótico en dicho momento. No obstante, ante la presencia de deterioro clínico durante el día octavo y la sospecha de meningitis subaguda, se inició antibioterapia empírica con ceftriaxona 2 g cada 12 horas, vancomicina 1 g cada 8 horas y ampicilina 4 g cada 4 horas asociada a dexametasona 4 mg cada 12 horas. Posteriormente se realizó tratamiento dirigido con el resultado de la tinción de Gram usando ampicilina asociada a gentamicina intravenosa durante 7 días, con reducción progresiva de corticoterapia hasta suspenderla. Más adelante, se sustituyó la gentamicina por trimetoprima/sulfametoxazol durante diez días, manteniendo la ampicilina, antes de cambiar tratamiento antibiótico a vía oral con trimetoprima/sulfametoxazol en monoterapia. Finalmente, y teniendo en cuenta el perfil de toxicidad, la paciente se fue de alta con ampicilina en monoterapia hasta cumplir al menos 8 semanas de tratamiento. También se realizó durante su ingreso en planta ajuste progresivo de la analgesia de tercer escalón asociada a coadyuvantes. Evolución Durante el ingreso, la paciente fue valorada de forma conjunta por el equipo de Oncología Médica, Oncología Radioterápica, Psicooncología, Neurología, la Unidad de Enfermedades Infecciosas, Nutrición, Paliativos, Digestivo, Cirugía General y Rehabilitación para abordar de forma multidisciplinar la meningitis, el dolor secundario a metástasis óseas, la desnutrición asociada al cáncer y la disminución de ingesta por bajo nivel de conciencia, la pérdida de la capacidad funcional y un estado de ánimo bajo reactivo así como otras complicaciones acaecidas durante el ingreso. En cuanto a la meningitis, se evidenció mejoría del nivel de conciencia ad integrum tras cuatro días de tratamiento antibiótico dirigido, con desaparición completa de los signos meníngeos y rigidez de nuca al sexto día de antibioterapia. Se realizó nueva resonancia magnética cerebral al trigésimo día de su admisión, que descartó la presencia de abscesos cerebrales que indicara la necesidad de prolongar el tratamiento. Con respecto al tratamiento del dolor, se realizó radioterapia antiálgica de la lesión localizada en ala iliaca derecha pudiendo disminuir la dosis de mórficos para control del dolor y con ello mejorar el nivel de conciencia y la tendencia a la somnolencia, síntomas que condicionaban la calidad de vida de la paciente. Como complicaciones durante el ingreso, la paciente presentó una hemorragia digestiva baja autolimitada, probablemente secundaria a isquemia intestinal de origen hemodinámico que se manejó de forma conservadora tras ser evaluada por el servicio de digestivo y de cirugía general. Desarrolló también toxicidad hematológica secundaria al tratamiento prolongado con trimetoprima/sulfametoxazol con presencia de bicitopenia (anemia G2 y leucopenia G1) que obligaron al cambio de tratamiento por ampicilina vía oral hasta cumplir al menos 8 semanas de tratamiento. La paciente fue dada de alta tras 40 días de ingreso, manteniendo tratamiento con ampicilina oral. Se facilitó una cita en Oncología para valorar retirada de antibioterapia y continuar tratamiento oncológico.
[ "Anamnesis", "\n", "En", "la", "anamnesis", "realizada", "el", "día", "octavo", ",", "dificultada", "por", "alteración", "del", "lenguaje", ",", "la", "paciente", "manifiesta", "dolor", "en", "ala", "iliaca", "derecha", "y", "miembro", "ipsilateral", ",", "y", "disminución", "de", "la", "movilidad", "en", "miembros", "inferiores", ",", "con", "tendencia", "a", "la", "somnolencia", ".", "El", "día", "anterior", "precisó", "sondaje", "vesical", "por", "retención", "aguda", "de", "orina", ".", "\n", "En", "la", "anamnesis", "conjunta", "con", "los", "familiares", "se", "evidencia", "apatía", "y", "la", "presencia", "de", "lenguaje", "empobrecido", ".", "Niega", "de", "forma", "rotunda", "la", "ingesta", ",", "en", "los", "días", "o", "semanas", "previos", ",", "de", "productos", "lácteos", "poco", "procesados", "y", "de", "otros", "alimentos", "sospechosos", ".", "No", "hay", "familiares", "que", "presenten", "un", "cuadro", "clínico", "similar", ".", "\n\n", "Exploración", "física", "\n", "Temperatura", "de", "36,2ºC", ",", "tensión", "arterial", "sistólica", "de", "130", "mm", "de", "Hg", "y", "sistólica", "de", "80", "mm", "de", "Hg", ",", "frecuencia", "cardiaca", "de", "75", "lpm", ",", "frecuencia", "respiratoria", "de", "14", "respiraciones", "por", "minuto", ",", "saturación", "aire", "ambiente", "del", "97", "%", ".", "En", "la", "exploración", "neurológica", "el", "día", "octavo", ",", "destaca", "la", "presencia", "de", "fluctuación", "en", "la", "atención", "e", "incapacidad", "para", "procesar", "órdenes", "sucesivas", ".", "Asocia", "además", "disfasia", "mixta", "con", "fluencia", "alterada", ",", "parafasias", "abundantes", "y", "dificultades", "de", "nominación", ".", "En", "la", "exploración", "motora", ",", "se", "aprecia", "paresia", "de", "miembro", "inferior", "izquierdo", "con", "balance", "muscular", "dos", "sobre", "cinco", "y", "aumento", "del", "área", "reflexógena", "ipsilateral", ".", "En", "la", "exploración", "realizada", "cuatro", "días", "después", ",", "se", "observó", "bajo", "nivel", "de", "conciencia", "con", "un", "Glasgow", "de", "13", "sobre", "quince", ",", "rigidez", "de", "nuca", "y", "presencia", "de", "signos", "meníngeos", ".", "\n\n", "Pruebas", "complementarias", "\n", "No", "se", "evidenciaron", "alteraciones", "significativas", "en", "los", "análisis", "al", "ingreso", "ni", "durante", "los", "primeros", "días", "en", "planta", ".", "Como", "parte", "de", "la", "valoración", "ambulatoria", "de", "la", "paciente", "se", "realizó", "al", "tercer", "día", "una", "resonancia", "magnética", "de", "columna", "completa", "que", "evidenció", "metástasis", "en", "varios", "cuerpos", "descartando", "afectación", "medular", ".", "Los", "hemocultivos", "diferenciales", "sacados", "durante", "el", "pico", "febril", "fueron", "negativos", ".", "\n", "El", "día", "octavo", ",", "coincidiendo", "con", "el", "inicio", "del", "deterioro", "clínico", ",", "se", "interconsultó", "al", "servicio", "de", "Neurología", "y", "se", "realizó", "TC", "craneal", ",", "mostrándose", "dudoso", "realce", "meníngeo", "en", "el", "tentorio", "y", "cisternas", "basales", ".", "Ante", "la", "sospecha", "de", "carcinomatosis", "meníngea", "vs", ".", "encefalopatía", "metabólica", ",", "y", "para", "descartar", "estatus", "convulsivo", ",", "se", "realizó", "un", "electroencefalograma", "urgente", "en", "el", "que", "se", "observaron", "ondas", "lentas", "evidentes", "de", "encefalopatía", "moderada", ".", "\n", "Con", "los", "hallazgos", "anteriores", "y", "ante", "persistencia", "de", "deterioro", "neurológico", "se", "realizó", "una", "RM", "cerebral", "urgente", "el", "día", "décimo", "que", "descartó", "carcinomatosis", "meníngea", ",", "la", "presencia", "de", "otras", "lesiones", "y", "de", "signos", "indirectos", "de", "hipertensión", "craneal", ",", "por", "lo", "que", "se", "realizó", "una", "punción", "lumbar", "por", "sospecha", "de", "meningitis", ".", "En", "el", "estudio", "de", "laboratorio", "del", "líquido", "cefalorraquídeo", "se", "evidenció", "líquido", "transparente", ",", "con", "glucosa", "23", "mg", "/", "dl", ",", "proteínas", "totales", "198,2", "mg", "/", "dl", "ADA", "<", "8", "U", "/", "l.", "Visualización", "inicial", "en", "Gram", "de", "bacilos", "Gram", "positivos", "con", "firmándose", "varios", "días", "después", "la", "presencia", "de", "Listeria", "monocytogenes", "sensible", "a", "ampicilina", ".", "\n\n", "Diagnóstico", "\n", "»", "Meningitis", "aguda", "adquirida", "en", "la", "comunidad", "por", "Listeria", "monocytogenes", "sensible", "a", "ampicilina", ".", "\n", "»", "Paresia", "de", "miembro", "inferior", "derecho", ",", "disfasia", "mixta", "y", "apraxia", "secundaria", "a", "meningitis", "aguda", ".", "\n", "»", "Mal", "control", "del", "dolor", "en", "relación", "a", "afectación", "ósea", "metastásica", ".", "\n", "»", "Adenocarcinoma", "de", "sigma", "estadio", "IV", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "presencia", "de", "síndrome", "febril", "autolimitado", "y", "asintomático", "el", "día", "cuarto", "de", "ingreso", ",", "y", "teniendo", "en", "cuenta", "la", "observación", "en", "la", "planta", "de", "la", "paciente", ",", "se", "decidió", "no", "comenzar", "tratamiento", "antibiótico", "en", "dicho", "momento", ".", "No", "obstante", ",", "ante", "la", "presencia", "de", "deterioro", "clínico", "durante", "el", "día", "octavo", "y", "la", "sospecha", "de", "meningitis", "subaguda", ",", "se", "inició", "antibioterapia", "empírica", "con", "ceftriaxona", "2", "g", "cada", "12", "horas", ",", "vancomicina", "1", "g", "cada", "8", "horas", "y", "ampicilina", "4", "g", "cada", "4", "horas", "asociada", "a", "dexametasona", "4", "mg", "cada", "12", "horas", ".", "Posteriormente", "se", "realizó", "tratamiento", "dirigido", "con", "el", "resultado", "de", "la", "tinción", "de", "Gram", "usando", "ampicilina", "asociada", "a", "gentamicina", "intravenosa", "durante", "7", "días", ",", "con", "reducción", "progresiva", "de", "corticoterapia", "hasta", "suspenderla", ".", "Más", "adelante", ",", "se", "sustituyó", "la", "gentamicina", "por", "trimetoprima", "/", "sulfametoxazol", "durante", "diez", "días", ",", "manteniendo", "la", "ampicilina", ",", "antes", "de", "cambiar", "tratamiento", "antibiótico", "a", "vía", "oral", "con", "trimetoprima", "/", "sulfametoxazol", "en", "monoterapia", ".", "Finalmente", ",", "y", "teniendo", "en", "cuenta", "el", "perfil", "de", "toxicidad", ",", "la", "paciente", "se", "fue", "de", "alta", "con", "ampicilina", "en", "monoterapia", "hasta", "cumplir", "al", "menos", "8", "semanas", "de", "tratamiento", ".", "También", "se", "realizó", "durante", "su", "ingreso", "en", "planta", "ajuste", "progresivo", "de", "la", "analgesia", "de", "tercer", "escalón", "asociada", "a", "coadyuvantes", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "la", "paciente", "fue", "valorada", "de", "forma", "conjunta", "por", "el", "equipo", "de", "Oncología", "Médica", ",", "Oncología", "Radioterápica", ",", "Psicooncología", ",", "Neurología", ",", "la", "Unidad", "de", "Enfermedades", "Infecciosas", ",", "Nutrición", ",", "Paliativos", ",", "Digestivo", ",", "Cirugía", "General", "y", "Rehabilitación", "para", "abordar", "de", "forma", "multidisciplinar", "la", "meningitis", ",", "el", "dolor", "secundario", "a", "metástasis", "óseas", ",", "la", "desnutrición", "asociada", "al", "cáncer", "y", "la", "disminución", "de", "ingesta", "por", "bajo", "nivel", "de", "conciencia", ",", "la", "pérdida", "de", "la", "capacidad", "funcional", "y", "un", "estado", "de", "ánimo", "bajo", "reactivo", "así", "como", "otras", "complicaciones", "acaecidas", "durante", "el", "ingreso", ".", "\n", "En", "cuanto", "a", "la", "meningitis", ",", "se", "evidenció", "mejoría", "del", "nivel", "de", "conciencia", "ad", "integrum", "tras", "cuatro", "días", "de", "tratamiento", "antibiótico", "dirigido", ",", "con", "desaparición", "completa", "de", "los", "signos", "meníngeos", "y", "rigidez", "de", "nuca", "al", "sexto", "día", "de", "antibioterapia", ".", "Se", "realizó", "nueva", "resonancia", "magnética", "cerebral", "al", "trigésimo", "día", "de", "su", "admisión", ",", "que", "descartó", "la", "presencia", "de", "abscesos", "cerebrales", "que", "indicara", "la", "necesidad", "de", "prolongar", "el", "tratamiento", ".", "\n", "Con", "respecto", "al", "tratamiento", "del", "dolor", ",", "se", "realizó", "radioterapia", "antiálgica", "de", "la", "lesión", "localizada", "en", "ala", "iliaca", "derecha", "pudiendo", "disminuir", "la", "dosis", "de", "mórficos", "para", "control", "del", "dolor", "y", "con", "ello", "mejorar", "el", "nivel", "de", "conciencia", "y", "la", "tendencia", "a", "la", "somnolencia", ",", "síntomas", "que", "condicionaban", "la", "calidad", "de", "vida", "de", "la", "paciente", ".", "\n", "Como", "complicaciones", "durante", "el", "ingreso", ",", "la", "paciente", "presentó", "una", "hemorragia", "digestiva", "baja", "autolimitada", ",", "probablemente", "secundaria", "a", "isquemia", "intestinal", "de", "origen", "hemodinámico", "que", "se", "manejó", "de", "forma", "conservadora", "tras", "ser", "evaluada", "por", "el", "servicio", "de", "digestivo", "y", "de", "cirugía", "general", ".", "Desarrolló", "también", "toxicidad", "hematológica", "secundaria", "al", "tratamiento", "prolongado", "con", "trimetoprima", "/", "sulfametoxazol", "con", "presencia", "de", "bicitopenia", "(", "anemia", "G2", "y", "leucopenia", "G1", ")", "que", "obligaron", "al", "cambio", "de", "tratamiento", "por", "ampicilina", "vía", "oral", "hasta", "cumplir", "al", "menos", "8", "semanas", "de", "tratamiento", ".", "\n", "La", "paciente", "fue", "dada", "de", "alta", "tras", "40", "días", "de", "ingreso", ",", "manteniendo", "tratamiento", "con", "ampicilina", "oral", ".", "Se", "facilitó", "una", "cita", "en", "Oncología", "para", "valorar", "retirada", "de", "antibioterapia", "y", "continuar", "tratamiento", "oncológico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
metástasis, realce meníngeo, carcinomatosis, carcinomatosis, afectación ósea, metastásica, Adenocarcinoma, metástasis, cáncer
563_task2
Sentence: Anamnesis En la anamnesis realizada el día octavo, dificultada por alteración del lenguaje, la paciente manifiesta dolor en ala iliaca derecha y miembro ipsilateral, y disminución de la movilidad en miembros inferiores, con tendencia a la somnolencia. El día anterior precisó sondaje vesical por retención aguda de orina. En la anamnesis conjunta con los familiares se evidencia apatía y la presencia de lenguaje empobrecido. Niega de forma rotunda la ingesta, en los días o semanas previos, de productos lácteos poco procesados y de otros alimentos sospechosos. No hay familiares que presenten un cuadro clínico similar. Exploración física Temperatura de 36,2ºC, tensión arterial sistólica de 130 mm de Hg y sistólica de 80 mm de Hg, frecuencia cardiaca de 75 lpm, frecuencia respiratoria de 14 respiraciones por minuto, saturación aire ambiente del 97 %. En la exploración neurológica el día octavo, destaca la presencia de fluctuación en la atención e incapacidad para procesar órdenes sucesivas. Asocia además disfasia mixta con fluencia alterada, parafasias abundantes y dificultades de nominación. En la exploración motora, se aprecia paresia de miembro inferior izquierdo con balance muscular dos sobre cinco y aumento del área reflexógena ipsilateral. En la exploración realizada cuatro días después, se observó bajo nivel de conciencia con un Glasgow de 13 sobre quince, rigidez de nuca y presencia de signos meníngeos. Pruebas complementarias No se evidenciaron alteraciones significativas en los análisis al ingreso ni durante los primeros días en planta. Como parte de la valoración ambulatoria de la paciente se realizó al tercer día una resonancia magnética de columna completa que evidenció metástasis en varios cuerpos descartando afectación medular. Los hemocultivos diferenciales sacados durante el pico febril fueron negativos. El día octavo, coincidiendo con el inicio del deterioro clínico, se interconsultó al servicio de Neurología y se realizó TC craneal, mostrándose dudoso realce meníngeo en el tentorio y cisternas basales. Ante la sospecha de carcinomatosis meníngea vs. encefalopatía metabólica, y para descartar estatus convulsivo, se realizó un electroencefalograma urgente en el que se observaron ondas lentas evidentes de encefalopatía moderada. Con los hallazgos anteriores y ante persistencia de deterioro neurológico se realizó una RM cerebral urgente el día décimo que descartó carcinomatosis meníngea, la presencia de otras lesiones y de signos indirectos de hipertensión craneal, por lo que se realizó una punción lumbar por sospecha de meningitis. En el estudio de laboratorio del líquido cefalorraquídeo se evidenció líquido transparente, con glucosa 23 mg/dl, proteínas totales 198,2 mg/dl ADA < 8 U/l. Visualización inicial en Gram de bacilos Gram positivos con firmándose varios días después la presencia de Listeria monocytogenes sensible a ampicilina. Diagnóstico » Meningitis aguda adquirida en la comunidad por Listeria monocytogenes sensible a ampicilina. » Paresia de miembro inferior derecho, disfasia mixta y apraxia secundaria a meningitis aguda. » Mal control del dolor en relación a afectación ósea metastásica. » Adenocarcinoma de sigma estadio IV. Tratamiento Dada la presencia de síndrome febril autolimitado y asintomático el día cuarto de ingreso, y teniendo en cuenta la observación en la planta de la paciente, se decidió no comenzar tratamiento antibiótico en dicho momento. No obstante, ante la presencia de deterioro clínico durante el día octavo y la sospecha de meningitis subaguda, se inició antibioterapia empírica con ceftriaxona 2 g cada 12 horas, vancomicina 1 g cada 8 horas y ampicilina 4 g cada 4 horas asociada a dexametasona 4 mg cada 12 horas. Posteriormente se realizó tratamiento dirigido con el resultado de la tinción de Gram usando ampicilina asociada a gentamicina intravenosa durante 7 días, con reducción progresiva de corticoterapia hasta suspenderla. Más adelante, se sustituyó la gentamicina por trimetoprima/sulfametoxazol durante diez días, manteniendo la ampicilina, antes de cambiar tratamiento antibiótico a vía oral con trimetoprima/sulfametoxazol en monoterapia. Finalmente, y teniendo en cuenta el perfil de toxicidad, la paciente se fue de alta con ampicilina en monoterapia hasta cumplir al menos 8 semanas de tratamiento. También se realizó durante su ingreso en planta ajuste progresivo de la analgesia de tercer escalón asociada a coadyuvantes. Evolución Durante el ingreso, la paciente fue valorada de forma conjunta por el equipo de Oncología Médica, Oncología Radioterápica, Psicooncología, Neurología, la Unidad de Enfermedades Infecciosas, Nutrición, Paliativos, Digestivo, Cirugía General y Rehabilitación para abordar de forma multidisciplinar la meningitis, el dolor secundario a metástasis óseas, la desnutrición asociada al cáncer y la disminución de ingesta por bajo nivel de conciencia, la pérdida de la capacidad funcional y un estado de ánimo bajo reactivo así como otras complicaciones acaecidas durante el ingreso. En cuanto a la meningitis, se evidenció mejoría del nivel de conciencia ad integrum tras cuatro días de tratamiento antibiótico dirigido, con desaparición completa de los signos meníngeos y rigidez de nuca al sexto día de antibioterapia. Se realizó nueva resonancia magnética cerebral al trigésimo día de su admisión, que descartó la presencia de abscesos cerebrales que indicara la necesidad de prolongar el tratamiento. Con respecto al tratamiento del dolor, se realizó radioterapia antiálgica de la lesión localizada en ala iliaca derecha pudiendo disminuir la dosis de mórficos para control del dolor y con ello mejorar el nivel de conciencia y la tendencia a la somnolencia, síntomas que condicionaban la calidad de vida de la paciente. Como complicaciones durante el ingreso, la paciente presentó una hemorragia digestiva baja autolimitada, probablemente secundaria a isquemia intestinal de origen hemodinámico que se manejó de forma conservadora tras ser evaluada por el servicio de digestivo y de cirugía general. Desarrolló también toxicidad hematológica secundaria al tratamiento prolongado con trimetoprima/sulfametoxazol con presencia de bicitopenia (anemia G2 y leucopenia G1) que obligaron al cambio de tratamiento por ampicilina vía oral hasta cumplir al menos 8 semanas de tratamiento. La paciente fue dada de alta tras 40 días de ingreso, manteniendo tratamiento con ampicilina oral. Se facilitó una cita en Oncología para valorar retirada de antibioterapia y continuar tratamiento oncológico. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis En la anamnesis realizada el día octavo, dificultada por alteración del lenguaje, la paciente manifiesta dolor en ala iliaca derecha y miembro ipsilateral, y disminución de la movilidad en miembros inferiores, con tendencia a la somnolencia. El día anterior precisó sondaje vesical por retención aguda de orina. En la anamnesis conjunta con los familiares se evidencia apatía y la presencia de lenguaje empobrecido. Niega de forma rotunda la ingesta, en los días o semanas previos, de productos lácteos poco procesados y de otros alimentos sospechosos. No hay familiares que presenten un cuadro clínico similar. Exploración física Temperatura de 36,2ºC, tensión arterial sistólica de 130 mm de Hg y sistólica de 80 mm de Hg, frecuencia cardiaca de 75 lpm, frecuencia respiratoria de 14 respiraciones por minuto, saturación aire ambiente del 97 %. En la exploración neurológica el día octavo, destaca la presencia de fluctuación en la atención e incapacidad para procesar órdenes sucesivas. Asocia además disfasia mixta con fluencia alterada, parafasias abundantes y dificultades de nominación. En la exploración motora, se aprecia paresia de miembro inferior izquierdo con balance muscular dos sobre cinco y aumento del área reflexógena ipsilateral. En la exploración realizada cuatro días después, se observó bajo nivel de conciencia con un Glasgow de 13 sobre quince, rigidez de nuca y presencia de signos meníngeos. Pruebas complementarias No se evidenciaron alteraciones significativas en los análisis al ingreso ni durante los primeros días en planta. Como parte de la valoración ambulatoria de la paciente se realizó al tercer día una resonancia magnética de columna completa que evidenció metástasis en varios cuerpos descartando afectación medular. Los hemocultivos diferenciales sacados durante el pico febril fueron negativos. El día octavo, coincidiendo con el inicio del deterioro clínico, se interconsultó al servicio de Neurología y se realizó TC craneal, mostrándose dudoso realce meníngeo en el tentorio y cisternas basales. Ante la sospecha de carcinomatosis meníngea vs. encefalopatía metabólica, y para descartar estatus convulsivo, se realizó un electroencefalograma urgente en el que se observaron ondas lentas evidentes de encefalopatía moderada. Con los hallazgos anteriores y ante persistencia de deterioro neurológico se realizó una RM cerebral urgente el día décimo que descartó carcinomatosis meníngea, la presencia de otras lesiones y de signos indirectos de hipertensión craneal, por lo que se realizó una punción lumbar por sospecha de meningitis. En el estudio de laboratorio del líquido cefalorraquídeo se evidenció líquido transparente, con glucosa 23 mg/dl, proteínas totales 198,2 mg/dl ADA < 8 U/l. Visualización inicial en Gram de bacilos Gram positivos con firmándose varios días después la presencia de Listeria monocytogenes sensible a ampicilina. Diagnóstico » Meningitis aguda adquirida en la comunidad por Listeria monocytogenes sensible a ampicilina. » Paresia de miembro inferior derecho, disfasia mixta y apraxia secundaria a meningitis aguda. » Mal control del dolor en relación a afectación ósea metastásica. » Adenocarcinoma de sigma estadio IV. Tratamiento Dada la presencia de síndrome febril autolimitado y asintomático el día cuarto de ingreso, y teniendo en cuenta la observación en la planta de la paciente, se decidió no comenzar tratamiento antibiótico en dicho momento. No obstante, ante la presencia de deterioro clínico durante el día octavo y la sospecha de meningitis subaguda, se inició antibioterapia empírica con ceftriaxona 2 g cada 12 horas, vancomicina 1 g cada 8 horas y ampicilina 4 g cada 4 horas asociada a dexametasona 4 mg cada 12 horas. Posteriormente se realizó tratamiento dirigido con el resultado de la tinción de Gram usando ampicilina asociada a gentamicina intravenosa durante 7 días, con reducción progresiva de corticoterapia hasta suspenderla. Más adelante, se sustituyó la gentamicina por trimetoprima/sulfametoxazol durante diez días, manteniendo la ampicilina, antes de cambiar tratamiento antibiótico a vía oral con trimetoprima/sulfametoxazol en monoterapia. Finalmente, y teniendo en cuenta el perfil de toxicidad, la paciente se fue de alta con ampicilina en monoterapia hasta cumplir al menos 8 semanas de tratamiento. También se realizó durante su ingreso en planta ajuste progresivo de la analgesia de tercer escalón asociada a coadyuvantes. Evolución Durante el ingreso, la paciente fue valorada de forma conjunta por el equipo de Oncología Médica, Oncología Radioterápica, Psicooncología, Neurología, la Unidad de Enfermedades Infecciosas, Nutrición, Paliativos, Digestivo, Cirugía General y Rehabilitación para abordar de forma multidisciplinar la meningitis, el dolor secundario a metástasis óseas, la desnutrición asociada al cáncer y la disminución de ingesta por bajo nivel de conciencia, la pérdida de la capacidad funcional y un estado de ánimo bajo reactivo así como otras complicaciones acaecidas durante el ingreso. En cuanto a la meningitis, se evidenció mejoría del nivel de conciencia ad integrum tras cuatro días de tratamiento antibiótico dirigido, con desaparición completa de los signos meníngeos y rigidez de nuca al sexto día de antibioterapia. Se realizó nueva resonancia magnética cerebral al trigésimo día de su admisión, que descartó la presencia de abscesos cerebrales que indicara la necesidad de prolongar el tratamiento. Con respecto al tratamiento del dolor, se realizó radioterapia antiálgica de la lesión localizada en ala iliaca derecha pudiendo disminuir la dosis de mórficos para control del dolor y con ello mejorar el nivel de conciencia y la tendencia a la somnolencia, síntomas que condicionaban la calidad de vida de la paciente. Como complicaciones durante el ingreso, la paciente presentó una hemorragia digestiva baja autolimitada, probablemente secundaria a isquemia intestinal de origen hemodinámico que se manejó de forma conservadora tras ser evaluada por el servicio de digestivo y de cirugía general. Desarrolló también toxicidad hematológica secundaria al tratamiento prolongado con trimetoprima/sulfametoxazol con presencia de bicitopenia (anemia G2 y leucopenia G1) que obligaron al cambio de tratamiento por ampicilina vía oral hasta cumplir al menos 8 semanas de tratamiento. La paciente fue dada de alta tras 40 días de ingreso, manteniendo tratamiento con ampicilina oral. Se facilitó una cita en Oncología para valorar retirada de antibioterapia y continuar tratamiento oncológico.
[ "Anamnesis", "\n", "En", "la", "anamnesis", "realizada", "el", "día", "octavo", ",", "dificultada", "por", "alteración", "del", "lenguaje", ",", "la", "paciente", "manifiesta", "dolor", "en", "ala", "iliaca", "derecha", "y", "miembro", "ipsilateral", ",", "y", "disminución", "de", "la", "movilidad", "en", "miembros", "inferiores", ",", "con", "tendencia", "a", "la", "somnolencia", ".", "El", "día", "anterior", "precisó", "sondaje", "vesical", "por", "retención", "aguda", "de", "orina", ".", "\n", "En", "la", "anamnesis", "conjunta", "con", "los", "familiares", "se", "evidencia", "apatía", "y", "la", "presencia", "de", "lenguaje", "empobrecido", ".", "Niega", "de", "forma", "rotunda", "la", "ingesta", ",", "en", "los", "días", "o", "semanas", "previos", ",", "de", "productos", "lácteos", "poco", "procesados", "y", "de", "otros", "alimentos", "sospechosos", ".", "No", "hay", "familiares", "que", "presenten", "un", "cuadro", "clínico", "similar", ".", "\n\n", "Exploración", "física", "\n", "Temperatura", "de", "36,2ºC", ",", "tensión", "arterial", "sistólica", "de", "130", "mm", "de", "Hg", "y", "sistólica", "de", "80", "mm", "de", "Hg", ",", "frecuencia", "cardiaca", "de", "75", "lpm", ",", "frecuencia", "respiratoria", "de", "14", "respiraciones", "por", "minuto", ",", "saturación", "aire", "ambiente", "del", "97", "%", ".", "En", "la", "exploración", "neurológica", "el", "día", "octavo", ",", "destaca", "la", "presencia", "de", "fluctuación", "en", "la", "atención", "e", "incapacidad", "para", "procesar", "órdenes", "sucesivas", ".", "Asocia", "además", "disfasia", "mixta", "con", "fluencia", "alterada", ",", "parafasias", "abundantes", "y", "dificultades", "de", "nominación", ".", "En", "la", "exploración", "motora", ",", "se", "aprecia", "paresia", "de", "miembro", "inferior", "izquierdo", "con", "balance", "muscular", "dos", "sobre", "cinco", "y", "aumento", "del", "área", "reflexógena", "ipsilateral", ".", "En", "la", "exploración", "realizada", "cuatro", "días", "después", ",", "se", "observó", "bajo", "nivel", "de", "conciencia", "con", "un", "Glasgow", "de", "13", "sobre", "quince", ",", "rigidez", "de", "nuca", "y", "presencia", "de", "signos", "meníngeos", ".", "\n\n", "Pruebas", "complementarias", "\n", "No", "se", "evidenciaron", "alteraciones", "significativas", "en", "los", "análisis", "al", "ingreso", "ni", "durante", "los", "primeros", "días", "en", "planta", ".", "Como", "parte", "de", "la", "valoración", "ambulatoria", "de", "la", "paciente", "se", "realizó", "al", "tercer", "día", "una", "resonancia", "magnética", "de", "columna", "completa", "que", "evidenció", "metástasis", "en", "varios", "cuerpos", "descartando", "afectación", "medular", ".", "Los", "hemocultivos", "diferenciales", "sacados", "durante", "el", "pico", "febril", "fueron", "negativos", ".", "\n", "El", "día", "octavo", ",", "coincidiendo", "con", "el", "inicio", "del", "deterioro", "clínico", ",", "se", "interconsultó", "al", "servicio", "de", "Neurología", "y", "se", "realizó", "TC", "craneal", ",", "mostrándose", "dudoso", "realce", "meníngeo", "en", "el", "tentorio", "y", "cisternas", "basales", ".", "Ante", "la", "sospecha", "de", "carcinomatosis", "meníngea", "vs", ".", "encefalopatía", "metabólica", ",", "y", "para", "descartar", "estatus", "convulsivo", ",", "se", "realizó", "un", "electroencefalograma", "urgente", "en", "el", "que", "se", "observaron", "ondas", "lentas", "evidentes", "de", "encefalopatía", "moderada", ".", "\n", "Con", "los", "hallazgos", "anteriores", "y", "ante", "persistencia", "de", "deterioro", "neurológico", "se", "realizó", "una", "RM", "cerebral", "urgente", "el", "día", "décimo", "que", "descartó", "carcinomatosis", "meníngea", ",", "la", "presencia", "de", "otras", "lesiones", "y", "de", "signos", "indirectos", "de", "hipertensión", "craneal", ",", "por", "lo", "que", "se", "realizó", "una", "punción", "lumbar", "por", "sospecha", "de", "meningitis", ".", "En", "el", "estudio", "de", "laboratorio", "del", "líquido", "cefalorraquídeo", "se", "evidenció", "líquido", "transparente", ",", "con", "glucosa", "23", "mg", "/", "dl", ",", "proteínas", "totales", "198,2", "mg", "/", "dl", "ADA", "<", "8", "U", "/", "l.", "Visualización", "inicial", "en", "Gram", "de", "bacilos", "Gram", "positivos", "con", "firmándose", "varios", "días", "después", "la", "presencia", "de", "Listeria", "monocytogenes", "sensible", "a", "ampicilina", ".", "\n\n", "Diagnóstico", "\n", "»", "Meningitis", "aguda", "adquirida", "en", "la", "comunidad", "por", "Listeria", "monocytogenes", "sensible", "a", "ampicilina", ".", "\n", "»", "Paresia", "de", "miembro", "inferior", "derecho", ",", "disfasia", "mixta", "y", "apraxia", "secundaria", "a", "meningitis", "aguda", ".", "\n", "»", "Mal", "control", "del", "dolor", "en", "relación", "a", "afectación", "ósea", "metastásica", ".", "\n", "»", "Adenocarcinoma", "de", "sigma", "estadio", "IV", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "presencia", "de", "síndrome", "febril", "autolimitado", "y", "asintomático", "el", "día", "cuarto", "de", "ingreso", ",", "y", "teniendo", "en", "cuenta", "la", "observación", "en", "la", "planta", "de", "la", "paciente", ",", "se", "decidió", "no", "comenzar", "tratamiento", "antibiótico", "en", "dicho", "momento", ".", "No", "obstante", ",", "ante", "la", "presencia", "de", "deterioro", "clínico", "durante", "el", "día", "octavo", "y", "la", "sospecha", "de", "meningitis", "subaguda", ",", "se", "inició", "antibioterapia", "empírica", "con", "ceftriaxona", "2", "g", "cada", "12", "horas", ",", "vancomicina", "1", "g", "cada", "8", "horas", "y", "ampicilina", "4", "g", "cada", "4", "horas", "asociada", "a", "dexametasona", "4", "mg", "cada", "12", "horas", ".", "Posteriormente", "se", "realizó", "tratamiento", "dirigido", "con", "el", "resultado", "de", "la", "tinción", "de", "Gram", "usando", "ampicilina", "asociada", "a", "gentamicina", "intravenosa", "durante", "7", "días", ",", "con", "reducción", "progresiva", "de", "corticoterapia", "hasta", "suspenderla", ".", "Más", "adelante", ",", "se", "sustituyó", "la", "gentamicina", "por", "trimetoprima", "/", "sulfametoxazol", "durante", "diez", "días", ",", "manteniendo", "la", "ampicilina", ",", "antes", "de", "cambiar", "tratamiento", "antibiótico", "a", "vía", "oral", "con", "trimetoprima", "/", "sulfametoxazol", "en", "monoterapia", ".", "Finalmente", ",", "y", "teniendo", "en", "cuenta", "el", "perfil", "de", "toxicidad", ",", "la", "paciente", "se", "fue", "de", "alta", "con", "ampicilina", "en", "monoterapia", "hasta", "cumplir", "al", "menos", "8", "semanas", "de", "tratamiento", ".", "También", "se", "realizó", "durante", "su", "ingreso", "en", "planta", "ajuste", "progresivo", "de", "la", "analgesia", "de", "tercer", "escalón", "asociada", "a", "coadyuvantes", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", ",", "la", "paciente", "fue", "valorada", "de", "forma", "conjunta", "por", "el", "equipo", "de", "Oncología", "Médica", ",", "Oncología", "Radioterápica", ",", "Psicooncología", ",", "Neurología", ",", "la", "Unidad", "de", "Enfermedades", "Infecciosas", ",", "Nutrición", ",", "Paliativos", ",", "Digestivo", ",", "Cirugía", "General", "y", "Rehabilitación", "para", "abordar", "de", "forma", "multidisciplinar", "la", "meningitis", ",", "el", "dolor", "secundario", "a", "metástasis", "óseas", ",", "la", "desnutrición", "asociada", "al", "cáncer", "y", "la", "disminución", "de", "ingesta", "por", "bajo", "nivel", "de", "conciencia", ",", "la", "pérdida", "de", "la", "capacidad", "funcional", "y", "un", "estado", "de", "ánimo", "bajo", "reactivo", "así", "como", "otras", "complicaciones", "acaecidas", "durante", "el", "ingreso", ".", "\n", "En", "cuanto", "a", "la", "meningitis", ",", "se", "evidenció", "mejoría", "del", "nivel", "de", "conciencia", "ad", "integrum", "tras", "cuatro", "días", "de", "tratamiento", "antibiótico", "dirigido", ",", "con", "desaparición", "completa", "de", "los", "signos", "meníngeos", "y", "rigidez", "de", "nuca", "al", "sexto", "día", "de", "antibioterapia", ".", "Se", "realizó", "nueva", "resonancia", "magnética", "cerebral", "al", "trigésimo", "día", "de", "su", "admisión", ",", "que", "descartó", "la", "presencia", "de", "abscesos", "cerebrales", "que", "indicara", "la", "necesidad", "de", "prolongar", "el", "tratamiento", ".", "\n", "Con", "respecto", "al", "tratamiento", "del", "dolor", ",", "se", "realizó", "radioterapia", "antiálgica", "de", "la", "lesión", "localizada", "en", "ala", "iliaca", "derecha", "pudiendo", "disminuir", "la", "dosis", "de", "mórficos", "para", "control", "del", "dolor", "y", "con", "ello", "mejorar", "el", "nivel", "de", "conciencia", "y", "la", "tendencia", "a", "la", "somnolencia", ",", "síntomas", "que", "condicionaban", "la", "calidad", "de", "vida", "de", "la", "paciente", ".", "\n", "Como", "complicaciones", "durante", "el", "ingreso", ",", "la", "paciente", "presentó", "una", "hemorragia", "digestiva", "baja", "autolimitada", ",", "probablemente", "secundaria", "a", "isquemia", "intestinal", "de", "origen", "hemodinámico", "que", "se", "manejó", "de", "forma", "conservadora", "tras", "ser", "evaluada", "por", "el", "servicio", "de", "digestivo", "y", "de", "cirugía", "general", ".", "Desarrolló", "también", "toxicidad", "hematológica", "secundaria", "al", "tratamiento", "prolongado", "con", "trimetoprima", "/", "sulfametoxazol", "con", "presencia", "de", "bicitopenia", "(", "anemia", "G2", "y", "leucopenia", "G1", ")", "que", "obligaron", "al", "cambio", "de", "tratamiento", "por", "ampicilina", "vía", "oral", "hasta", "cumplir", "al", "menos", "8", "semanas", "de", "tratamiento", ".", "\n", "La", "paciente", "fue", "dada", "de", "alta", "tras", "40", "días", "de", "ingreso", ",", "manteniendo", "tratamiento", "con", "ampicilina", "oral", ".", "Se", "facilitó", "una", "cita", "en", "Oncología", "para", "valorar", "retirada", "de", "antibioterapia", "y", "continuar", "tratamiento", "oncológico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]